podophyllotoxin profile

Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Related Flora

Flora	Rank	Flora Definition	Family	Family Definition
Podophyllum	genus	A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.[MeSH]	Berberidaceae	The Barberry plant family of the order Ranunculales, subclass Magnoliidae, class Magnoliopsida. The shrubs have spiny leaves.[MeSH]

ID Source	ID
PubMed CID	10607
CHEMBL ID	61
CHEBI ID	50305
SCHEMBL ID	42243
MeSH ID	M0017087

Synonym
BIDD:GT0123
MLS001148204
MLS002172467
bdbm50035218
(10r,11r,15r,16r)-16-hydroxy-10-(3,4,5-trimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1(9),2,7-trien-12-one
BRD-K47869605-001-05-6
MLS000069495 ,
smr000059121
NSC24818 ,
nsc-24818
furo[3',7]naphtho[2,3-d]-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, [5r-(5.alpha.,5a.beta.,8a.alpha.,9.alpha.)]-
naphtho[2,3-dioxole-6-carboxylic acid, 5,6,7,8-tetrahydro-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl-, .gamma.-lactone
DIVK1C_000292
KBIO1_000292
NCI60_001981
SDCCGMLS-0066888.P001
SPECTRUM_000199
furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5r-(5alpha,5abeta,8aalpha,9alpha))-
hsdb 7238
(5r,5ar,8ar,9r)-5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one
podophyllotoxin 7
podofilox [usan]
einecs 208-250-4
1,3,3a,4,9,9a-hexahydro-9-hydroxy-6,7-(methylenedioxy)-4-(3',4',5'-trimethoxyphenyl)benz(f)isobenzofuran-3-one
ccris 565
nsc 24818
ai3-50456
PRESTWICK_1018
cas-518-28-5
(5r,5ar,8ar,9r)-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5ah)-one
CHEBI:50305 ,
podophyllotoxin (ban)
condylox (tn)
BSPBIO_000884
D05529
podofilox (usan)
BPBIO1_000974
BCBCMAP01_000165
ccris 4391
einecs 232-546-2
podophyllum
podofillina [italian]
warticon
mayapple isolate
(5r,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-isobenzofuro[6,5-f][1,3]benzodioxol-8-one
rd4-6269
5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5ah)-one, [5r-(5.alpha.,5a.beta.,8a.alpha.,9.alpha.)]
nd-1185
condyline
podofilox
wartec
condylox
b18-5c
UPCMLD-DP035:001
UPCMLD-DP035:002
518-28-5
podophyllotoxin ,
9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(5ah)-one
podophyllotoxin, 95%
podophyllinic acid lactone
NCGC00022001-05
UPCMLD-DP035
DB01179
PRESTWICK3_000782
SMP1_000243
IDI1_000292
(-)-podophyllotoxin
NCGC00022001-09
NCGC00022001-08
KBIO2_005815
KBIO2_003247
KBIO2_000679
KBIOGR_001084
KBIOSS_000679
NINDS_000292
SPBIO_000955
SPECTRUM4_000592
SPECTRUM2_000878
SPBIO_002823
PRESTWICK1_000782
PRESTWICK0_000782
BSPBIO_002352
PRESTWICK2_000782
SPECTRUM5_001368
NCGC00022001-03
NCGC00022001-07
P-6980
HMS2093P16
AC-1656
AKOS000265559
(5r,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
CHEMBL61 ,
HMS500O14
podocon-25
podofilm
HMS1570M06
STK801918
NCGC00022001-10
NCGC00022001-11
HMS3259J19
HMS2097M06
EN300-52746
(5r,9r,5ar,8ar)-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,9,5a,8a-pentahydro-2h -isobenzofurano[5',6'-2,1]benzo[4,5-d]1,3-dioxolan-6-one
NCGC00260468-01
tox21_202922
(5r,5ar,8ar,9r)-5-oxidanyl-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one
A828801
(5r,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-isobenzofuro[5,6-f][1,3]benzodioxol-8-one
pharmakon1600-02300332
nsc759591
nsc-759591
dtxsid3045645 ,
dtxcid1025645
tox21_110874
HMS2235A23
CCG-39894
HY-15552
CS-1185
unii-l36h50f353
podophilox
l36h50f353 ,
NCGC00022001-14
podofillina
16902yvy2b ,
unii-16902yvy2b
podophyllotoxin [mi]
podofilox [orange book]
furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one, 5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-, (5r-(5.alpha.,5a.beta.,8a.alpha.,9.alpha.))-
podophyllotoxin [ep monograph]
podophyllotoxin [mart.]
podophyllotoxin [who-dd]
podofilox [hsdb]
podofilox [vandf]
BBL033695
MLS006010754
MLS006011412
NC00675
SCHEMBL42243
tox21_110874_1
NCGC00022001-13
KS-1281
YJGVMLPVUAXIQN-XVVDYKMHSA-N
(5r,5ar,8ar,9r)-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8h)-one
podophylotoxin
(5r,5ar,8ar,9r)-5,8,8a,9-tetrahydro-9-hydroxy-5-(3,4,5-trimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5ah)-one
OPERA_ID_1397
mfcd00075290
podophyllotoxin, analytical standard
sr-05000001749
SR-05000001749-2
SR-05000001749-1
(10r,11r,15r,16r)-16-hydroxy-10-(3,4,5-trimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0?,?.0??,??]hexadeca-1(9),2,7-trien-12-one
sr-01000003030
SR-01000003030-3
HMS3714M06
BCP24085
Q421193
podophyllotoxin,(s)
11016-28-7
AMY2648
BRD-K47869605-001-18-9
(10R,11R,15R,16R)-16-HYDROXY-10-(3,4,5-TRIMETHOXYPHENYL)-4,6,13-TRIOXATETRACYCLO[7.7.0.03,7.011,15]HEXADECA-1,3(7),8-TRIEN-12-ONE
P1771
Z759291658
podophyllotoxin (ep monograph)
9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro(3',4':6,7)naphtho(2,3-d)(1,3)dioxol-6(5ah)-one
(5r,5ar,8ar,9r)-9-hydroxy-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro(3',4':6,7)naphtho(2,3-d)(1,3)dioxol-6(5ah)-one
podophyllotoxin (mart.)
(5r,5ar,8ar,9r)-5,8,8a,9-tetrahydro-9-hdroxy-5-(3,4,5-trimethoxyphenyl)furo-
1-hydroxy-2-hydroxymethyl-6,7-methylenedioxy-4-(3',4',5'-trimethoxyphenyl)-1,2,3,4-tetrahydronaphthal ene-3-carboxylic acid lactone

Excerpt	Reference	Relevance
"Podophyllotoxin (PPT) is an active natural pharmaceutical component with potent anticancer activity. "	( Redox-responsive self-assembled podophyllotoxin twin drug nanoparticles for enhanced intracellular drug delivery. Chen, L; Cui, N; Deng, L; Jiang, D; Li, X; Liu, J; Ma, Y; Qiu, N; Song, Y; Zhao, X, 2023)	2.64
"Podophyllotoxin (PPT) is a highly active compound extracted from plants of the genus Podophyllum such as Dysosma versipellis (DV)."	( Nephrotoxicity assessment of podophyllotoxin-induced rats by regulating PI3K/Akt/mTOR-Nrf2/HO1 pathway in view of toxicological evidence chain (TEC) concept. Gu, C; Guo, J; He, T; Kong, J; Kong, X; Kui, H; Li, Q; Liu, C; Tian, Y, 2023)	1.92
"Podophyllotoxin (PPT) is a naturally occurring aryltetralin lignan. "	( Podophyllotoxin-mediated neurotoxicity via the microbiota-gut-brain axis in SD rats based on the toxicological evidence chain (TEC) concept. Duan, J; Jiang, T; Li, X; Liu, C; Ma, X; Sun, J; Wang, Y; Zhang, F, 2024)	4.33
"Azapodophyllotoxin is a new class of anti-tumor agent with brilliant therapeutic activity and understanding its physicochemical nature in bio-mimetic microenvironments may provide substantial importance in context of its intercellular localization, efficacy as well as delivery. "	( Entrapment in micellar assemblies switches the excimer population of potential therapeutic luminophore azapodophyllotoxin. Ganorkar, K; Ghosh, SK; Gupta, S; Kumar, A; Mukherjee, S, 2020)	1.39
"Podophyllotoxin is an antimitotic agent primarily used in the local treatment of anogenital warts. "	( Association Between Fetal Safety Outcomes and Exposure to Local Podophyllotoxin During Pregnancy. Andersen, JT; Andersson, NW, 2020)	2.24
"Podophyllotoxin (PPT) is a lignan extracted from podophyllum genera and it shows potent antitumor activity since it could effectively inhibit the assembly of microtubule in tumor cells. "	( Podophyllotoxin affects porcine oocyte maturation by inducing oxidative stress-mediated early apoptosis. Hu, LL; Jiang, WJ; Li, YH; Lu, X; Luo, XQ; Ren, YP; Xu, YN, 2020)	3.44
"Podophyllotoxin (PPT) is a naturally occurring compound obtained from the roots of Podophyllum species, indicated for a variety of malignant tumors such as breast, lung, and liver tumors. "	( Podophyllotoxin-polyacrylic acid conjugate micelles: improved anticancer efficacy against multidrug-resistant breast cancer. Disouza, JI; Kumbhar, PS; Manjappa, AS; Patil, OB; Sakate, AM, 2020)	3.44
"Podophyllotoxin is a natural lignan which possesses anticancer and antiviral activities. "	( 2, 4, 5-Trideoxyhexopyranosides Derivatives of 4'-Demethylepipodophyllotoxin: Cai, R; Li, Y; Lu, Y; Zhao, Y; Zhu, L, 2022)	2.41
"Podophyllotoxin (PPT) is an antimitotic drug used topically in the treatment of anogenital warts. "	( Novel podophyllotoxin and benzothiazole derivative induces transitional morphological and functional changes in HaCaT cells. Bialy, LP; Borensztejn, K; Czarnocki, Z; Lisiecki, K; Mlynarczuk-Bialy, I; Nieznanska, H; Strus, P; Szczepankiewicz, AA; Wojcik, C, 2021)	2.54
"Podophyllotoxin (PTOX) is an aryl-tetralin lignan of plant origin found in some species of Podophyllum such as Dysosma versipellis, Diphylleia sinensis, and Sinopodophyllum hexandrum. "	( [Research progress in biosynthesis of podophyllotoxin and its derivatives]. Li, H; Meng, Z; Tang, YJ; Yao, T; Zhao, W, 2021)	2.34
"Podophyllotoxin is a CBSI that inhibits the assembly of microtubules."	( Structure of 4'-demethylepipodophyllotoxin in complex with tubulin provides a rationale for drug design. Chen, Q; Jiang, X; Ma, L; Niu, L; Wang, C; Wang, Y; Wu, C; Yu, Y, 2017)	1.47
"Deoxypodophyllotoxin is a secondary metabolite lignan possessing potent anticancer activity with potential as a precursor for known anticancer drugs, but its use is limited by scarcity from natural sources. "	( Synthesis and Computational Studies Demonstrate the Utility of an Intramolecular Styryl Diels-Alder Reaction and Di-t-butylhydroxytoluene Assisted [1,3]-Shift to Construct Anticancer dl-Deoxypodophyllotoxin. Andrus, MB; Ess, DH; Kwon, DH; Rencher, BD; Saavedra, DI; Smith, SJ, 2018)	1.18
"Podophyllotoxin (PPT) is a chemotherapeutic agent which has shown significant activity against P-glycoprotein (P-gp) mediated multi drug resistant cancer cells. "	( A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity. Chen, X; Deng, M; Lv, S; Tang, Z; Zhang, D; Zhang, X; Zhou, H, 2018)	2.25
"Podophyllotoxin (PPT) is a chemotherapeutic agent which has shown strong activity against P-gp mediated multidrug resistant cancer cells by simultaneously inhibiting the over-expression of P-gp and the growth of cancer cells."	( A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity. Chen, X; Deng, M; Lv, S; Tang, Z; Zhang, D; Zhang, X; Zhou, H, 2018)	1.53
"Deoxypodophyllotoxin (DPT) is a naturally occurring flavolignan in Anthriscus sylvestris known as cow parsley or wild chervil, and has been reported to have inhibitory effects against several pathological processes including cancer, inflammation and infection. "	( Deoxypodophyllotoxin in Anthriscus sylvestris alleviates fat accumulation in the liver via AMP-activated protein kinase, impeding SREBP-1c signal. Ahn, SC; Baek, SY; Kim, JH; Kim, KJ; Kim, KY; Kim, SC; Kim, SH; Kim, YW; Lee, EH; Lee, SG; Oh, TW; Park, KI; Park, SG; Yu, SN, 2018)	1.51
"Podophyllotoxin is a potent cytotoxic agent and serves as a useful lead compound for the development of antitumor drugs. "	( Synthesis and anticancer activity of dimeric podophyllotoxin derivatives. Ding, ZT; Dong, FW; Hu, JM; Jiang, ZH; Li, Y; Xu, FQ; Yang, D; Yang, L; Zhou, J; Zi, CT, 2018)	2.18
"Podophyllotoxin (PPT) is a chemotherapeutic agent which has shown significant anti-cancer effects through inhibiting microtubule assembly. "	( GSH-responsive anti-mitotic cell penetrating peptide-linked podophyllotoxin conjugate for improving water solubility and targeted synergistic drug delivery. Liu, F; Sun, S; Tao, B; Wen, J, 2019)	2.2
"Deoxypodophyllotoxin (DPT) is a natural chemical that has been demonstrated to inhibit cellular viability and motility in various cancer cell types. "	( Deoxypodophyllotoxin inhibits cell viability and invasion by blocking the PI3K/Akt signaling pathway in human glioblastoma cells. Bao, Y; Gao, W; Wang, W; Zhang, D; Zhang, L; Zhao, Z, 2019)	1.54
"Deoxypodophyllotoxin (DPT) is a cyclolignan compound that exerts anti-cancer effects against various types of cancers. "	( Deoxypodophyllotoxin Exerts Anti-Cancer Effects on Colorectal Cancer Cells Through Induction of Apoptosis and Suppression of Tumorigenesis. Bae, WK; Gamage, CDB; Kim, E; Kim, H; Kim, KK; Park, SY; Shim, JH; Taş, İ; Yang, Y; Yoon, G; Zhou, R, 2019)	1.54
"Podophyllotoxin (POD) is a lignan-type toxin existing in many herbs used in folk medicine. "	( Alleviation of podophyllotoxin toxicity using coexisting flavonoids from Dysosma versipellis. Cao, W; Ding, K; Guo, CY; Jiang, RW; Jin, L; Li, J; Luo, C; Sun, H; Ye, WC; Zhang, J, 2013)	2.19
"Deoxypodophyllotoxin (DPT) is a semi-synthetic compound derived from the extract of Dysosma versipellis (Hance) M. "	( Antineoplastic effects of deoxypodophyllotoxin, a potent cytotoxic agent of plant origin, on glioblastoma U-87 MG and SF126 cells. Guerram, M; Jiang, ZZ; Sun, L; Zhang, LY; Zhu, X, 2015)	1.22
"Podophyllotoxin (PPT) is a naturally occurring antimitotic agent and an interesting lead in the development of anticancer agents. "	( Podophyllotoxin derivatives: a patent review (2012 - 2014). Ali Hussaini, SM; Kamal, A; Rahim, A; Riyaz, S, 2015)	3.3
"Podophyllotoxin (PPT) is a plant natural product that serves as a precursor for the synthesis of many well-known chemotherapeutic drugs. "	( Investigation and Expression of the Secoisolariciresinol Dehydrogenase Gene Involved in Podophyllotoxin Biosynthesis. Arneaud, SL; Porter, JR, 2015)	2.08
"Deoxypodophyllotoxin (DPT) is a natural chemical that is found to induce cancer cell death, in which the role of parthanatos is unknown."	( Deoxypodophyllotoxin triggers parthanatos in glioma cells via induction of excessive ROS. Chi, G; Feng, C; Feng, J; Ge, P; Jia, H; Lu, B; Luo, T; Luo, Y; Ma, D; Wang, C; Wang, Y, 2016)	1.4
"Podophyllotoxin acetate (PA) acts as a radiosensitizer against non-small cell lung cancer (NSCLC) in vitro and in vivo. "	( Chemosensitizing effect of podophyllotoxin acetate on topoisomerase inhibitors leads to synergistic enhancement of lung cancer cell apoptosis. Cho, JH; Hong, WG; Hwang, SG; Kim, JI; Lee, E; Lee, J; Park, JK; Um, HD, 2016)	2.17
"Deoxypodophyllotoxin (DPT) is a natural lignan product which has drawn much attention due to its pharmacological properties including antitumor effect. "	( Interspecies differences in metabolism of deoxypodophyllotoxin in hepatic microsomes from human, monkey, rat, mouse and dog. Chen, Y; Ling, Z; Liu, F; Liu, L; Liu, X; Tang, X; Wang, F; Wang, Z; Xie, Q; Zhao, K; Zhong, Z, 2016)	1.21
"Podophyllotoxin (ptox) is a therapeutically important lignan derived from Podophyllum hexandrum and is used as a precursor for the synthesis of anticancer drugs etoposide, teniposide and etopophose. "	( Transcriptome-wide identification and characterization of CAD isoforms specific for podophyllotoxin biosynthesis from Podophyllum hexandrum. Banerjee, A; Bhattacharyya, D; Chakrabarti, S; Chattopadhyay, S; Datta, R; Hazra, S; Kumar, D, 2016)	2.1
"Podophyllotoxin is an aryltetralin lignan synthesized in several plant species, which is used in chemotherapies for cancers and tumor treatment. "	( Biotechnological interventions for harnessing podophyllotoxin from plant and fungal species: current status, challenges, and opportunities for its commercialization. Kumar, S; Kumari, A; Singh, D, 2017)	2.16
"Podophyllotoxin is a naturally occurring non-alkaloid toxin isolated from the roots and rhizomes of Podophyllum peltatum and P. "	( Synthesis of some ester derivatives of 4'-demethoxyepipodophyllotoxin/2'-chloro-4'-demethoxyepipodophyllotoxin as insecticidal agents against oriental armyworm, Mythimna separata Walker. He, J; Huang, J; Li, S; Xu, H; Xu, M, 2017)	2.15
"Podophyllotoxin is an important and much sought after antimitotic natural lead compound, since it paved the way for three hemisynthetic derivatives of podophyllotoxin, e.g., etoposide, teniposide and etopophos, which are widely used as anticancer drugs and show good clinical effects against several types of neoplasms. "	( A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007. Lv, M; Tian, X; Xu, H, 2009)	2
"Podophyllotoxin is a plant-derived compound found in Podophyllum sp. "	( The role of biotechnology in the production of the anticancer compound podophyllotoxin. Lata, H; Mizuno, CS; Moraes, RM, 2009)	2.03
"Deoxypodophyllotoxin (DPT) is a bioactive compound of Anthriscus sylvestris (Apiaceae). "	( Inhibitory effects of deoxypodophyllotoxin from Anthriscus sylvestris on human CYP2C9 and CYP3A4. Jeong, SY; Jeong, TC; Jin, C; Kang, MJ; Kim, DH; Kim, Y; Lee, SH; Lee, SK; Yoo, HH, 2010)	1.17
"Deoxypodophyllotoxin (DOP) is a natural product that can be isolated from a variety of medicinal herb plants. "	( Pharmacological effect of deoxypodophyllotoxin: a medicinal agent of plant origin, on mammalian neurons. An, S; Cheng, J; Gao, R; Sun, Q; Wang, X; Xiao, H; Xu, P; Zhang, S, 2010)	1.16
"Podophyllotoxin is a natural lignan that is being used as a precursor for the semi-synthetic anti-cancer drugs etoposide, teniposide and etopophos."	( Rapid analysis of lignans from leaves of Podophyllum peltatum L. samples using UPLC-UV-MS. Avula, B; Khan, IA; Moraes, RM; Wang, YH, 2011)	1.09
"Podophyllotoxin (PTOX) is an extremely important plant-derived natural product, of which derivatives, like etoposide and teniposide, have been widely applied in therapies for cancers and venereal wart. "	( [Review on biosynthesis of podophyllotoxin]. Fu, C; Lu, W; Zhao, Y, 2011)	2.11
"Podophyllotoxin (PTOX) is a naturally occurring phenolic compound isolated as an active anti-tumor agent. "	( The effect of light on gene expression and podophyllotoxin biosynthesis in Linum album cell culture. Behmanesh, M; Ghasempour, A; Moyano, E; Palazon, J; Sharifi, M; Yousefzadi, M, 2012)	2.08
"Podophyllotoxin (POD) is a naturally occurring lignan with pronounced antineoplastic and antiviral properties. "	( Protective effects and mechanisms of curcumin on podophyllotoxin toxicity in vitro and in vivo. Cao, W; Dai, CX; Guo, CY; Jiang, RW; Jin, L; Li, J; Luo, C; Sun, H; Tian, HY; Wu, J; Ye, WC, 2012)	2.08
"Podophyllotoxin is a natural product that inhibits the polymerization of tubulin and has served as a prototype for the development of diverse antitumor agents in clinical use, such as etoposide, teniposide and etopophos. "	( Analgesic and anti-inflammatory activity of podophyllotoxin derivatives. Abad, A; Del Olmo, E; Guerrero, E; López-Pérez, JL; Montenegro, G; San Feliciano, A, 2013)	2.09
"Podophyllotoxin is an established antimitotic agent derived from podophyllum plant resin, approved for human papilloma virus (HPV)-induced genital warts."	( Er:YAG laser followed by topical podophyllotoxin for hard-to-treat palmoplantar warts. Wollina, U, 2003)	1.32
"Deoxypodophyllotoxin (Anthricin) is a medicinal herbal product isolated from Anthriscus sylvestris HOFFM. "	( Dual inhibition of cyclooxygenases-2 and 5-lipoxygenase by deoxypodophyllotoxin in mouse bone marrow-derived mast cells. Chang, HW; Choi, HG; Ju, HK; Lee, SH; Lin, CX; Moon, TC; Son, JK; Son, MJ, 2004)	1.08
"Podophyllotoxin is a well-known natural antitumor agent with severe side effects, which led us to synthesize its numerous analogs in search of product(s) of improved therapeutic potential. "	( Synthesis, spectroscopic, and biological studies of novel estolides derived from anticancer active 4-O-podophyllotoxinyl 12-hydroxyl-octadec-Z-9-enoate. Khan, IA; Khan, SI; Ma, G; Mustafa, J; Walker, LA, 2004)	1.98
"Podophyllotoxin is an antimitotic natural product. "	( Podophyllotoxin derivatives: current synthetic approaches for new anticancer agents. You, Y, 2005)	3.21
"Podophyllotoxin is a pharmaceutical compound found in leaves and rhizomes of American mayapple (P. "	( Frequency and timing of leaf removal affect growth and podophyllotoxin content of Podophyllum peltatum in full sun. Bedir, E; Cushman, KE; Gerard, PD; Khan, IA; Moraes, RM; Silva, B, 2006)	2.02
"Podophyllotoxin is a well known anti-tumor chemical, but because of its strong side effects much effort has been paid to reduce cytotoxicity by modifying its structure. "	( Seleno-podophyllotoxin derivatives induce hepatoma SMMC-7721 cell apoptosis through Bax pathway. An, L; Han, Y; Miao, R; Wang, Q; Yang, J, 2008)	2.24
"Epipodophyllotoxins are an important new class of anticancer agents which include the compounds VM-26 (teniposide) and VP-16 (etoposide). "	( Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Glisson, B; Liu, L; Ross, W; Rowe, T; Yalowich, J, 1984)	1.15
"Podophyllotoxin is a potent inhibitor of microtubule assembly in vitro, while VP16-213 has no effect in this system."	( VP16-213 and podophyllotoxin. A study on the relationship between chemical structure and biological activity. Loike, JD, 1982)	1.35
"Podophyllotoxin is a natural product isolated from Podophyllum peltatum and Podophyllum emodi and has long been known to possess medicinal properties. "	( Podophyllotoxins: current status and recent developments. Damayanthi, Y; Lown, JW, 1998)	3.19

Excerpt	Reference	Relevance
"Podophyllotoxin has been extensively used as a lead agent in the development of new anticancer drugs. "	( Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis. Kornienko, A; Magedov, IV; Manpadi, M; Przheval'skii, NM; Rogelj, S; Rozhkova, E; Slambrouck, SV; Steelant, WF, 2007)	2
"Podophyllotoxin (PPT) has been reported to have many pharmacological activities, especially its anti-tumor effects. "	( The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway. Du, R; Li, D; Wei, M; Yan, Z; Zhao, Y, 2021)	2.31
"Podophyllotoxin (PPT) has been reported to have many pharmacological activities, especially anti-tumor, but its high toxicity, poor water solubility, and serious gastrointestinal side effects limit its clinical application."	( The ester derivatives obtained by C-ring modification of podophyllotoxin-induced apoptosis and inhibited proliferation in Hemangioma Endothelial Cells via downregulation of PI3K/Akt signaling pathway. Du, R; Han, Y; Li, D; Wang, H; Yan, Z; Zhao, Y, 2022)	1.69
"Podophyllotoxin (PPT) has attracted researchers' attention because of its ability to treat various ailments. "	( Advances of podophyllotoxin and its derivatives: Patterns and mechanisms. Fan, HY; Jiang, J; Liang, XH; Shi, RJ; Tang, YL; Yu, XH, 2022)	2.54
"Podophyllotoxin derivatives have been the centre of attention of extensive chemical amendment and pharmacological investigation in modern decades."	( Podophyllotoxin derivatives as an excellent anticancer aspirant for future chemotherapy: A key current imminent needs. Asiri, AM; Manukumar, HM; Marwani, HM; Qin, HL; Rakesh, KP; Shantharam, CS; Zhang, X, 2018)	2.64
"Podophyllotoxin (1) has been known to possess anti-tumor activity and is still considered an important lead for research and development of antineoplastic agents. "	( Synthetic and application perspectives of azapodophyllotoxins: alternative scaffolds of podophyllotoxin. Alegria, AE; Kumar, A; Kumar, V; Malhotra, SV, 2011)	2.07

Excerpt	Reference	Relevance
"On podophyllotoxin treatment, most of the cells have shown blocked spindles however, depicted normal arrangement."	( Countering effects of a combination of podophyllotoxin, podophyllotoxin β-D-glucoside and rutin hydrate in minimizing radiation induced chromosomal damage, ROS and apoptosis in human blood lymphocytes. Bajaj, S; Dutta, S; Flora, SJ; Gupta, ML; Kalita, B; Ranjan, R; Singh, A; Srivastava, NN; Yashavarddhan, MH, 2016)	1.22
"Treatment with podophyllotoxin and location of lesions on partially keratinized sites were independent predictors of >50% reduction in wart area."	( A short, 8-week course of imiquimod 5% cream versus podophyllotoxin in the treatment of anogenital warts: A retrospective comparative cohort study. Bezrodnii, G; Gerodimou, M; Kanelleas, A; Nearchou, E; Nicolaidou, E; Nikolakopoulos, S; Papadopoulou-Skordou, E; Paparizos, V; Rigopoulos, D, )	0.72
"Treatment with podophyllotoxin derivatives for 6 months clearly reduced patients' RF concentrations."	( Complement activating rheumatoid factors in rheumatoid arthritis studied by haemolysis in gel: relation to antibody class and response to treatment with podophyllotoxin derivatives. Sjöholm, AG; Sturfelt, G; Truedsson, L, )	0.67

Excerpt	Reference	Relevance
" The toxic reactions and the cytostatic effect were investigated."	( [The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)]. Jankowski, RP; Vahrson, H, 1977)	0.51
" Some of these inhibitors (namely, colchicine, vinblastine, taxol, and maytansine) were found to exhibit large (between tenfold and fiftyfold) differences in their toxic and antimitotic concentrations toward various cell lines and these differences appeared to be species related inasmuch as all cell lines from a particular species showed similar sensitivities toward these inhibitors."	( Species-specific differences in toxicity of antimitotic agents toward cultured mammalian cells. Gupta, RS, 1985)	0.27
" Etoposide was much more toxic to normally oxygenated cells."	( Effect of oxygen on the cytotoxicity and antitumor activity of etoposide. Holden, SA; Rose, CM; Teicher, BA, 1985)	0.27
" Although cardiovascular toxic effects are not frequent after administration of VM 26, they should be known to the medical oncologist so that treatment of this side effect may be introduced at the first appearance of the symptoms."	( Cardiovascular toxic effects of VM26 in the treatment of acute lymphatic leukemia. Presentation of two cases. Razon-Veronesi, S, 1982)	0.26
" Inhibition of protein synthesis appeared to be a direct toxic effect of podophyllotoxin and occurred independently from that of RNA."	( Experimental podophyllotoxin (bajiaolian) poisoning: III. Biochemical bases for toxic effects. Chang, LW; Chen, CF; Deng, JF; Yang, CM, 1994)	0.89
" Within the NHL group, 21 patients were in 2nd or subsequent complete remission (CR) at transplant, 34 had sensitive disease and 11 resistant disease; 46 patients were transplanted in 1st CR due to the presence of > or = 2 adverse prognostic features at diagnosis or to a slow CR."	( BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Caballero, MD; Corral, M; del Cañizo, MC; García-Sanz, R; Gonzalez, M; Heras, I; Jean-Paul, E; León, A; Moraleda, JM; Rifon, J; Rocha, E; Rubio, V; San Miguel, JF; Vázquez, L; Vidriales, B, 1997)	0.3
"5% podofilox gel was generally well tolerated, with predominantly mild or moderate local adverse reactions occurring in the majority of patients."	( Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Barnum, G; Cherry, LK; Dromgoole, SH; Edwards, L; Greenberg, MD; Killey, FP; Kotner, S; Ramsdell, WM; Toter, T; Tyring, S; Vance, JC, 1998)	0.3
"5% podofilox gel is safe and significantly more effective than vehicle gel in the treatment of anogenital warts."	( Safety and efficacy of 0.5% podofilox gel in the treatment of anogenital warts. Barnum, G; Cherry, LK; Dromgoole, SH; Edwards, L; Greenberg, MD; Killey, FP; Kotner, S; Ramsdell, WM; Toter, T; Tyring, S; Vance, JC, 1998)	0.3
" After treatment with doses of 1/4 and 1/8 LD50 for 5 d, no significant difference on immune function of mice between GP-1 and GP-1-H was found."	( Action of free radical in podophyllic acid piperindyl hydrazone nitroxide radical on its antitumor activity and toxicity. Jia, ZP; Wang, R; Xie, JW; Xu, LT, 1999)	0.3
" Several cytostatic drugs administered in the treatment of acute leukaemia in childhood are known to cause long-term adverse effects."	( Minimising the long-term adverse effects of childhood leukaemia therapy. Langebrake, C; Reinhardt, D; Ritter, J, 2002)	0.31
" While BEAC and BEAM appears to have equal antitumour efficacy in patients with NHL, BEAM seems to be more toxic to the gastrointestinal tract."	( BEAC or BEAM for high-dose therapy in patients with non-Hodgkin's lymphoma? A single centre analysis on toxicity and efficacy. Jantunen, E; Kuittinen, T; Nousiainen, T, 2003)	0.32
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" The water-soluble salt camptothecin-sodium - introduced in early trials in the 1960s - was highly toxic in animals, whereas the semisynthetic derivatives irinotecan and topotecan did not cause haemorrhagic cystitis because of their higher physicochemical stability and solubility at lower pH values."	( Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Hartmann, JT; Lipp, HP, 2006)	0.67
" It is markedly less toxic than podophyllotoxin (IC (50) : 13 - 61 nM), but exhibits tumoricidal effects close to those of etoposide."	( Reversal of P-glycoprotein-mediated drug efflux by eudesmin from Haplophyllum perforatum and cytotoxicity pattern versus diphyllin, podophyllotoxin and etoposide. Akhmedjanova, V; Balansard, G; Barthomeuf, C; Beliveau, R; Debiton, E; Grassi, J; Lim, S, 2007)	0.83
" Both substances constitute effective and safe treatments of untreated anogenital warts in immunocompetent individuals."	( Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts. Aberer, W; Akkilic-Materna, M; Komericki, P; Strimitzer, T, 2011)	0.64
" Podophyllotoxin, a lignan is the main toxic ingredient of Bajiaolian rhizome."	( Therapeutic values, chemical constituents and toxicity of Taiwanese Dysosma pleiantha--a review. Karuppaiya, P; Tsay, HS, 2015)	1.33
" Information related to treatment with CPS and adverse effects was abstracted from medical records."	( Safety and effectiveness of cantharidin-podophylotoxin-salicylic acid in the treatment of recalcitrant plantar warts. Álvarez Castro, C; Becerro de Bengoa Vallejo, R; García Sánchez, MM; López López, D; Losa Iglesias, ME; Romero Morales, C; Vilar Fernández, JM, 2016)	0.43
" We conclude that OP administration of BEAM conditioning is safe and may offer significant advantages, including decreased length of hospitalization, reduced costs, decreased risks for severe toxicities and infectious complications, and likely improvement in patient satisfaction and quality of life."	( Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. Baran, A; Barr, PM; Becker, MW; Friedberg, JW; Liesveld, JL; Milner, LA; Phillips, GL; Reid, RM; Wedow, L, 2016)	0.43
" In-hospital major adverse events occurred in one patient (0."	( Safety and feasibility of a low frame rate protocol for percutaneous coronary intervention to chronic total occlusions: preliminary experience. Fan, B; Ge, J; Ge, L; Lu, H; Ma, J; Qian, J; Zhong, X, 2018)	0.48
"Our results provide the primary evidence that it appears to be safe and feasible to carry out the low frame rate protocol for CTO-PCI."	( Safety and feasibility of a low frame rate protocol for percutaneous coronary intervention to chronic total occlusions: preliminary experience. Fan, B; Ge, J; Ge, L; Lu, H; Ma, J; Qian, J; Zhong, X, 2018)	0.48
" In order to enhance the efficiency and reduce side effect of PPT, a polypeptide based PPT conjugate PLG-g-mPEG-PPT was developed and used for the treatment of multi drug resistant breast cancer."	( A polypeptide based podophyllotoxin conjugate for the treatment of multi drug resistant breast cancer with enhanced efficiency and minimal toxicity. Chen, X; Deng, M; Lv, S; Tang, Z; Zhang, D; Zhang, X; Zhou, H, 2018)	0.8
"3%) were the most commonly occurring adverse effects with cantharidin treatment."	( Efficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review. Chopra, R; Silverberg, JI; Silverberg, NB; Vakharia, PP, 2018)	0.48
"To investigate the association between local podophyllotoxin exposure during pregnancy and risk of adverse fetal outcomes."	( Association Between Fetal Safety Outcomes and Exposure to Local Podophyllotoxin During Pregnancy. Andersen, JT; Andersson, NW, 2020)	1.06
"Findings from this study suggest that podophyllotoxin use during pregnancy may be safe, as it did not appear to be associated with an increased risk of adverse fetal outcomes."	( Association Between Fetal Safety Outcomes and Exposure to Local Podophyllotoxin During Pregnancy. Andersen, JT; Andersson, NW, 2020)	1.07
" Whereas the toxic assessment evidence has not integrated yet, and the evaluation method has not been unanimously agreed."	( Multi modular toxicity assessment of nephrotoxicity in podophyllotoxin exposure rats on account of toxicological evidence chain (TEC) concept. He, T; Huang, J; Kong, J; Liu, C, 2022)	0.97
" Based on PPT as the main toxic constituent in DV, observe the objective toxicity impairment phenotype of animals."	( Nephrotoxicity assessment of podophyllotoxin-induced rats by regulating PI3K/Akt/mTOR-Nrf2/HO1 pathway in view of toxicological evidence chain (TEC) concept. Gu, C; Guo, J; He, T; Kong, J; Kong, X; Kui, H; Li, Q; Liu, C; Tian, Y, 2023)	1.2

Excerpt	Reference	Relevance
" As single agents, they display different dose-limiting toxicities and favourable pharmacokinetic characteristics in IP phase I trials."	( Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studies. Bugat, R; Canal, P; Chatelut, E; Chevreau, C; de Forni, M; Houin, G; Johnson, NP; Plusquellec, Y; Roche, H, 1991)	0.28
" Plasma samples were obtained during and after infusions at appropriate times for a comprehensive pharmacokinetic study of each drug."	( Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients. Evans, WE; Kavanagh, RL; Ochs, J; Rivera, GK; Rodman, JH; Sunderland, M; Yalowich, J, 1990)	0.28
" Pharmacokinetic studies, carried out in all courses, showed that the total exposure for peritoneal cavity averaged 10-fold greater than that of plasma."	( Phase I/pharmacokinetic study of intraperitoneal teniposide (VM 26). Bugat, R; Canal, P; Carton, M; Chatelut, E; Houin, G; Pinel, MC; Plusquellec, Y, 1989)	0.28
"A pharmacokinetic study of teniposide after ip administration with a 4-h dwell time was performed in patients suffering from abdominal malignant ascites."	( A pharmacokinetic model for intraperitoneal administration of drugs: application to teniposide in humans. Bugat, R; Canal, P; Chatelut, E; De Biasi, J; Houin, G; Plusquellec, Y, 1989)	0.28
" In order to study this phenomenon, plasma, urine, and dialysate levels of etoposide were determined during five treatment courses with a high-performance liquid chromatographic method combined with electrochemical detection; this proved that the pharmacokinetic curves for etoposide fit a two-compartment model."	( Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. Bakaert, AB; De Broe, ME; Holthuis, JJ; Van de Vyver, FL; van Oort, WJ; Verleun, H, 1985)	0.27
" The objectives of the trial reported here were to evaluate clinical responses and assess pharmacokinetic parameters as a determinant of outcome when VM-26 was administered as a 72-hour continuous infusion (CI) with doses escalated from 300 to 750 mg/m2 per course."	( Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. Abromowitch, M; Evans, WE; Hayes, FA; Rivera, GK; Rodman, JH; Sinkule, JA, 1987)	0.27
" In the control group plasma clearance (Clp), volume of distribution (Vd), and elimination half-life (t1/2 beta) of VP16 were, respectively, 22."	( Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cavalli, F; D'Incalci, M; Mangioni, C; Rossi, C; Sessa, C; Urso, R; Willems, Y; Zucchetti, M, 1986)	0.27
" The elimination half-life (t1/2 less than 80 min) allows autologous bone marrow transplantation 24 h after the drug administration."	( Pharmacokinetics of high-dose melphalan in children and adults. Gouyette, A; Hartmann, O; Pico, JL, 1986)	0.27
" Systemic clearance, mean residence time, and beta-phase half-life of etoposide were significantly lower in those patients who had received cisplatin prior to their Phase II etoposide trial."	( Pharmacokinetics of etoposide (VP16) in children and adolescents with refractory solid tumors. Etcubanas, E; Evans, W; Hayes, FA; Hutson, P; Sinkule, JA, 1984)	0.27
" At both of the above doses VM26 disappeared from mouse plasma biphasically, with an elimination half-life of about 70 mins."	( Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice. Broggini, M; Colombo, T; D'Incalci, M, 1983)	0.27
" At both doses the plasma elimination of half-life was around 30 min."	( Pharmacokinetics of VP16-213 in Lewis lung carcinoma bearing mice. Broggini, M; Colombo, T; D'Incalci, M; Erba, E; Torti, L, 1982)	0.26
" Pharmacokinetic parameters were calculated by both model-dependent and compartment model-independent methods."	( Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer. Crom, WR; Dow, L; Evans, WE; Look, AT; Rivera, G; Sinkule, JA, 1982)	0.26
" Subsequent pharmacokinetic analysis of one patient suggests that protein binding displacement of VP16-213 in plasma and perhaps ascites fluid increased the pharmacokinetic volume of distribution (28 l) and reduced the elimination half-life (12 h)."	( Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale? Allen, LM; Nordqvist, S; Okonmah, AD; Tejada, F, 1982)	0.54
" Pharmacodynamic studies of etoposide show that this toxicity can be modeled using a modified Hill equation and that the dose intensity of etoposide can be successfully increased by adaptive control using this model."	( Pharmacodynamics and long-term toxicity of etoposide. Kobayashi, K; Ratain, MJ, 1994)	0.29
" The overall median pharmacokinetic values were as follows (ranges are given in parentheses): mean residence time (MRT) 16."	( Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. Burk, K; Hanauske, AR; Herbst, K; Hossfeld, DK; Hüttmann, A; Manegold, C; Mross, K; Schilling, T, 1996)	0.55
" This paper describes a method for its determination using HPLC with UV detection and the determination of its pharmacokinetic parameters in rats."	( [HPLC determination of 4-[4"-(2",2",6",6"-tetramethyl-1"-piperidinyloxy) amino]-4'-demethylepipodophyllotoxin in rat plasma and studies of its pharmacokinetics]. Jia, ZP; Wang, DM; Xie, JW; Xu, LT, 1995)	0.51
" The primary objectives of this study were to determine, after both oral and intravenous administration in the same patient, the bioavailability and the pharmacokinetic profile of NK611."	( Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. Cavalli, F; D'Incalci, M; De Fusco, M; de Jong, J; Hanauske, A; Kaeser-Fröhlich, A; Pagani, O; Sessa, C; Zucchetti, M, 1996)	0.54
"We have conducted a clinical and pharmacokinetic trial of the novel podophyllotoxin derivative NK611 administered orally for 21 consecutive days."	( Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days. Hanauske, AR; Kaeser-Fröhlich, A; Rassmann, I; Rastetter, J; Schilling, T; Schrödel, H; Zucchetti, M, 1996)	0.53
" Changes in the pharmacokinetic profile or metabolism in patients with mild or severe hepatobiliary dysfunction are described and the relationships between serum levels, parameters employed for measuring hepatic function and toxic or therapeutic effects are examined."	( Pharmacokinetics of anticancer agents in patients with impaired liver function. Crosignani, A; D'Incalci, M; Donelli, MG; Munzone, E; Zucchetti, M, 1998)	0.3
" Pharmacokinetic analyses were performed in all patients."	( Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. Berdel, WE; Burk, K; Fiebig, HH; Hanauske, AR; Hüttmann, A; Kaeser-Fröhlich, A; Manegold, C; Mross, M; Rassmann, I; Thödtmann, R, )	0.38
" Clinical pharmacokinetic studies have revealed substantial interindividual variabilities regarding the area under the concentration-time curve values and steady-state concentrations for all drugs reviewed in this article."	( Camptothecin and podophyllotoxin derivatives: inhibitors of topoisomerase I and II - mechanisms of action, pharmacokinetics and toxicity profile. Hartmann, JT; Lipp, HP, 2006)	0.67

Excerpt	Reference	Relevance
" It was given in combination with cyclophosphamide or adriamycin."	( [Experiences with VP-16 in combination with cyclophosphamide or adriamycin in the anaplastic, predominantly small cell bronchogenic carcinoma]. Jungi, WF; Mayr, AC; Schmieder, HA; Senn, HJ, 1979)	0.26
"56 patients with advanced breast carcinoma, primarily or secondarily resistant to a four drug combination including Adriamycine, Vincristine, Cyclophosphamide and 5 Fluoro-Uracile, entered a phase II trial using association of VM 26, Mitomycine C and Methotrexate."	( [Effectiveness of VM 26, mitomycine C and methotrexate in advanced breast cancer refractory to a four drug combination (author's transl)]. Garcia-Giralt, E; Jouve, M; Magdelenat, H; Palangie, T; Pouillart, P, 1979)	0.26
" The majority of patients with this subtype t-AML had prior cytotoxic therapy with topoisomerase II-reactive drugs including anthracyclines, epipodophyllotoxins, or actinomycin D, combined with either an alkylating agent or cisplatin."	( Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocation. Albain, KS; Le Beau, MM; Schumacher, H; Ullirsch, R, 1990)	0.48
" A series of pilot studies showed unexplained marrow toxicity when VP-16-123 combined with vincristine was given with either methotrexate of adriamycin."	( Oral VP-16-213 in advanced bronchogenic carcinoma and toxic effects when combined with methotrexate. Anderson, G; Bowyer, F; Williams, L, 1981)	0.26
"To determine the maximum-tolerated radiation-absorbed dose (RAD) to critical organs delivered by yttrium-90 ((90)Y) ibritumomab tiuxetan in combination with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy with autologous transplantation."	( Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. Erwin, W; Evens, AM; Gordon, LI; Inwards, DJ; Mehta, J; Micallef, I; Molina, A; Patton, D; Rademaker, AW; Singhal, S; Spies, S; Tallman, MS; Weitner, BB; White, CA; Williams, SF; Winter, JN; Wiseman, G; Zimmer, M, 2009)	0.35
"Dose-escalated (90)Y ibritumomab tiuxetan may be safely combined with high-dose BEAM with autologous transplantation and has the potential to be more effective than standard-dose radioimmunotherapy."	( Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma. Erwin, W; Evens, AM; Gordon, LI; Inwards, DJ; Mehta, J; Micallef, I; Molina, A; Patton, D; Rademaker, AW; Singhal, S; Spies, S; Tallman, MS; Weitner, BB; White, CA; Williams, SF; Winter, JN; Wiseman, G; Zimmer, M, 2009)	0.35
"This study was designed to evaluate the safety and efficacy of a conventional dose of yttrium-90 ((90)Y) ibritumomab tiuxetan combined with the etoposide rabinoside acytarabine melphalan (BEAM) regimen before autologous stem cell transplantation (ASCT) in chemosensitive relapsed or refractory low-grade B-cell lymphomas."	( (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Bologna, S; Bosly, A; Bouabdallah, K; Brière, J; Coiffier, B; Decaudin, D; Delarue, R; Ghesquières, H; Gisselbrecht, C; Huynh, A; Le Gouill, S; Morschhauser, F; Mounier, N; Ribrag, V; Tilly, H, 2011)	0.37
" Our experimental data indicate that potential drug-drug interaction (DDI) might exist when PPT is co-administered with the substrates which mainly undergo CYP3A4- or CYP2C9-mediated metabolism."	( Inhibition of CYP3A4 and CYP2C9 by podophyllotoxin: implication for clinical drug-drug interactions. Chen, B; Guo, L; Ji, DH; Pu, J; Song, JH; Sun, DX; Tian, FD; Xu, J, 2011)	0.65
" The objectives of the present study were to define maximum tolerated dose and the recommended phase II dose (RPTD) of AXL1717 in combination with gemcitabine HCl and carboplatin in non-small cell lung cancer (NSCLC)."	( A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer. Bergqvist, M; Bergström, S; Brandén, E; Ekman, S; Harmenberg, J; Holgersson, G; Jerling, M; Klockare, M; Koyi, H; Larsson, O; Lundström, KL; Ringbom, M, 2015)	0.42
"The aim of this study was to determine the efficacy of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for the treatment of endometrial cancer."	( Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer. Chen, S; Lei, X; Tang, C; Xiong, YL; Xu, WJ; Zhao, KW; Zhou, Q, 2016)	0.43
"252Californium neutron intracavitary brachytherapy using a two-channel applicator combined with external beam radiotherapy was effective for treating endometrial cancer and the incidence of serious late complications related to this combination was within an acceptable range."	( Clinical assessment of 252Californium neutron intracavitary brachytherapy using a two-channel Y applicator combined with external beam radiotherapy for endometrial cancer. Chen, S; Lei, X; Tang, C; Xiong, YL; Xu, WJ; Zhao, KW; Zhou, Q, 2016)	0.43
"15% cream or imiquimod 5% cream, in combination with a three-dose regimen of qHPV or control vaccination."	( Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurr Bennett, K; Copas, AJ; Doré, CJ; Gilson, R; Haddow, LJ; Jit, M; Lacey, C; Meadows, J; Murray, ML; Nathan, M; Soldan, K; Tetlow, M, 2018)	0.69

Excerpt	Reference	Relevance
"There is no information on the effect of food or concurrent drug administration on the bioavailability of oral etoposide, despite the fact that treatment is frequently administered over several days and most often in combination with other cytotoxic agents."	( The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide. Harvey, VJ; Joel, SP; Johnston, A; Slevin, ML; Wrigley, PF, 1985)	0.27
"Following oral administration considerable variation in the bioavailability of etoposide has been reported between patients and with different formulations of the drug."	( Variable bioavailability following repeated oral doses of etoposide. Harvey, VJ; Joel, SP; Johnston, A; Slevin, ML; Smythe, MM; Wrigley, PF, 1985)	0.27
"The bioavailability of orally administered etoposide varies considerably."	( The effect of dose on the bioavailability of oral etoposide. Harvey, VJ; Joel, SP; Johnston, A; Slevin, ML; Wrigley, PF, 1986)	0.27
" Bioavailability studies on either the capsule or intravenous (i."	( Etoposide: a pharmacokinetic profile including an assessment of bioavailability. Cummings, J; Cunningham, D; Forrest, GJ; McTaggart, L; Soukop, M; Stuart, JF, 1986)	0.27
" The bioavailability of oral etoposide is about 50% but its absorption is not linear with increasing dose within the range in clinical use."	( The clinical pharmacology of etoposide and teniposide. Clark, PI; Slevin, ML, 1987)	0.27
"The absolute oral bioavailability of etoposide (VePesid) was determined in cancer patients based on a comparison of intravenous and oral administration."	( Bioavailability and pharmacokinetics of etoposide (VP-16). Comis, RL; Pfeffer, M; Scalzo, A; Smyth, RD, 1985)	0.27
"Previous studies in vitro on the influence of extracellular protein binding of Teniposide (VM26) and Etoposide (VP16-213) on subsequent cellular uptake by experimental murine tumor cells [Cancer Res 38:2549 (1978); Drug Metab Rev 8:119 (1978)] suggested that a timed-sequential combination of VM26 and VP16-213 may increase the bioavailability of VP16-213."	( Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale? Allen, LM; Nordqvist, S; Okonmah, AD; Tejada, F, 1982)	0.54
" In one cancer patient who received both an oral and an intravenous dose of 10 mg of I the bioavailability was 82% and the clearance 20."	( High-performance liquid chromatographic assay for the determination of the novel podophyllotoxin derivative dimethylaminoetoposide (NK611) in human plasma. D'Incalci, M; De Fusco, M; Fröhlich, A; Reichert, S; Sessa, C; Zucchetti, M, 1994)	0.51
" Preclinical studies have shown that NK 611 is advantageous in terms of bioavailability and of the potency of its anticancer activity."	( Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. Burk, K; Hanauske, AR; Herbst, K; Hossfeld, DK; Hüttmann, A; Manegold, C; Mross, K; Schilling, T, 1996)	0.55
"NK611 is a novel water-soluble podophyllotoxin derivative that has comparable antitumour activity but higher potency and better bioavailability in animals as compared with etoposide."	( Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. Cavalli, F; D'Incalci, M; De Fusco, M; de Jong, J; Hanauske, A; Kaeser-Fröhlich, A; Pagani, O; Sessa, C; Zucchetti, M, 1996)	0.83
" Even if its reversal activity is insufficient for clinical application, its capacity to accumulate [(3)H]-vinblastine in MDCK/MDR1 and MCF7/Dox cells suggests that eudesmin may positively affect the bioavailability and, thereby, the therapeutic potency of anticancer drugs in Pgp-overexpressing cells."	( Reversal of P-glycoprotein-mediated drug efflux by eudesmin from Haplophyllum perforatum and cytotoxicity pattern versus diphyllin, podophyllotoxin and etoposide. Akhmedjanova, V; Balansard, G; Barthomeuf, C; Beliveau, R; Debiton, E; Grassi, J; Lim, S, 2007)	0.54
" Pharmacokinetics study displays a prolonged circulation time and an increased bioavailability of PPT-LDH than PPT."	( The in vitro and in vivo anti-tumor effect of layered double hydroxides nanoparticles as delivery for podophyllotoxin. Qin, L; Sun, J; Sun, X; Wang, S; Wang, W; Xue, M; Zhang, R; Zhu, R, 2010)	0.58
" The 7-nitroquinoxalin-2-one and 5-nitroindazole scaffold derivatives 58 and 35, respectively, are particularly interesting because of their established oral bioavailability in mice."	( Discovery of nitroheterocycles active against African trypanosomes. In vitro screening and preliminary SAR studies. Arán, VJ; Dardonville, C; Kaiser, M, 2012)	0.38
" As low bioavailability limits their anticancer properties, we investigated whether conjugation with PAMAM dendrimer (D) could enhance the activity of D-EM and D-PODO by altering their release pattern."	( Comparative study of microtubule inhibitors--estramustine and natural podophyllotoxin conjugated PAMAM dendrimer on glioma cell proliferation. Dixit, D; Sen, E; Sk, UH, 2013)	0.62
" The compound was orally bioavailable and displayed good plasma and brain exposure in mice."	( Substituted 2-phenylimidazopyridines: a new class of drug leads for human African trypanosomiasis. Brun, R; Buckner, FS; Chatterjee, AK; Creason, SA; Duster, NA; Gelb, MH; Gillespie, JR; Glynne, R; Hulverson, MA; McQueen, J; Molteni, V; Nagendar, P; Nagle, A; Norcross, NR; Ranade, RM; Supek, F; Tatipaka, HB; Wenzler, T, 2014)	0.4
" Docking experiments raveled that 10 and 19 occupied the same binding pocket of paclitaxel with some difference in active site amino acids and good bioavailability of both the compounds."	( Synthesis of neolignans as microtubule stabilisers. Chanda, D; Hasanain, M; Khan, F; Konwar, R; Kumar, A; Luqman, S; Masood, N; Mitra, K; Negi, AS; Pal, A; Sarkar, J; Sathish Kumar, B; Singh, A; Singh, J; Yadav, DK, 2014)	0.4
" Pharmacokinetics analysis showed good bioavailability of PPP in lung and plasma."	( Targeting the insulin-like growth factor-1 receptor by picropodophyllin for lung cancer chemoprevention. Lubet, RA; Pan, J; Wang, Y; You, M; Zhang, Q, 2015)	0.42
"AXL1717 is an orally bioavailable IGF-1R pathway modulator that has been shown to have anti-tumoral effects."	( A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer. Bergqvist, M; Bergström, S; Brandén, E; Ekman, S; Harmenberg, J; Holgersson, G; Jerling, M; Klockare, M; Koyi, H; Larsson, O; Lundström, KL; Ringbom, M, 2015)	0.42
"Cell membrane permeability is an important determinant for oral absorption and bioavailability of a drug molecule."	( Highly predictive and interpretable models for PAMPA permeability. Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR, 2017)	0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Podophyllotoxin and its naturally occurring congeners have low bioavailability and almost all these initially discovered compounds cause systemic toxicity and development of drug resistance."	( Podophyllotoxin: History, Recent Advances and Future Prospects. Gohar, UF; Jamshed, I; Manea, R; Moga, M; Mukhtar, H; Mushtaq, A; Popovici, B; Shah, Z; Toma, SI; Zia-Ui-Haq, M, 2021)	2.97
" Additionally, an ∼85% correlation was obtained between PAMPA pH 5 permeability and in vivo oral bioavailability in mice and rats."	( Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability. Itkin, M; Kabir, M; Mathé, EA; Nguyễn, ÐT; Padilha, EC; Shah, P; Shinn, P; Siramshetty, V; Wang, AQ; Williams, J; Xu, X; Yu, KR; Zhao, T, 2022)	0.72

Excerpt	Relevance	Reference
" Complementary studies to establish its optimum dosage and administration, and its place in combination chemotherapy, are in progress."	( [Therapeutic experiences using the new podophyllotoxin derivative VP 16-213 in malignant human tumors]. Beckmann, C; Flury, R; Frei, P; Holdener, E; Jungi, WF; Senn, HJ, 1975)	0.52
" On the other side, dosage and the interval between cycles of chemotherapy appear to be a determining factor in the activity, but the limits are very narrow."	( [A study of the use of sequential chemotherapy in 176 cases of glioblastoma (author's transl)]. Buge, A; Poisson, M; Pouillart, P, 1978)	0.26
"34 patients operated on for malignant gliomas were successively treated by combination chemotherapy with VM26 and CCNU and conventional radiation therapy with an average dosage of 5,800 Rads, six months after surgery."	( Malignant gliomas treated after surgery by combination chemotherapy and delayed radiation therapy. Part II. Tolerance to irradiation after chemotherapy. Bataini, JP; Hauw, JJ; Mashaly, R; Metzger, J; Pertuiset, BF; Poisson, M; Pouillart, P, 1979)	0.26
" The dose-response curves for leukemic clonogenic cells for both agents when given by iv injection were exponential and biphasic, indicating the existence of two populations."	( Kinetics of cytotoxicity of VM-26 and VP-16-213 on L1210 leukemia and hematopoietic stem cells. Coulter, D; Kalish, R; Valeriote, FA; Vietti, TJ, 1978)	0.26
" Dianhydrogalactitol was given in a 5-day course at a dosage of 30 mg/m2/day."	( Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer. Hahn, RG; Moertel, CG; Perry, MC; Reitemeier, RJ; Schutt, AJ, 1976)	0.26
"The objective of the present study was to assess the utility of Shope rabbit papillomas as an animal model system for studying topical podofilox treatment and to evaluate dose-response relations and influence of duration of papilloma growth prior to treatment."	( Preclinical system for evaluating topical podofilox treatment of papillomas: dose-response and duration of growth prior to treatment. Christensen, ND; Christian, CB; Kreider, JW; Pickel, MD, 1992)	0.28
" The dose-response curve of GP-7 on SGC-7901 cell was similar to that of etoposide (VP-16)."	( [Antitumor activity of 4-(4''-(2'',2'',6'',6''-tetramethyl-1''-piperidinyoxy)amino)-4'- demethyl epipodophyllotoxin in vitro]. Chen, YZ; Jia, ZP; Li, JX; Liang, ZD; Tian, X; Wang, YG; Zhang, PY, 1990)	0.5
" The dose-response curve of GP-1 was a parabolic one, while that of VP-16 was a straight line."	( [Podophyllic acid piperidyl hydrazone nitroxide radical and etoposide on nucleic acids and protein metabolism of leukemia L7712 cells in vitro]. Liang, ZD; Mao, XJ; Tian, XA; Wang, JZ; Zhang, PY, 1989)	0.28
" We observed that inhibitors of both type I and II topoisomerases induced high levels of sister chromatid exchanges at 10(-6) M, and that the dose-response curves of these drugs were very similar."	( Induction of sister chromatid exchanges by inhibitors of topoisomerases. Jacobson-Kram, D; Lim, M; Liu, LF; Williams, JR, 1986)	0.27
" There may be a steep dose-response relationship, and we have explored the use of etoposide as a single agent in a high dose (1,200 mg/m2) without bone marrow transplantation, for patients with very bulky, extensive-stage disease."	( High-dose etoposide (VP-16) in small-cell lung cancer. Greco, FA; Hainsworth, JD; Hande, KR; Johnson, DH; Porter, LL; Wolff, SN, 1985)	0.27
" Multiple courses of VP-16-213 at a dosage of 200 mg/m2 X 5 days were given 1 week apart."	( Ovarian dysfunction in patients with gestational trophoblastic neoplasia treated with short intensive courses of etoposide (VP-16-213). Chan, SY; Choo, YC; Ma, HK; Wong, LC, 1985)	0.27
" VP-16 was administered via infusion at a dosage of 60-100 mg/m2 daily for 5 days, and repeated every 3 to 4 weeks."	( [A phase II study of etoposide (VP-16) injection in primary lung cancer by cooperative study group]. Hara, K; Kado, M; Kanda, T; Matsui, Y; Oshima, S; Shima, K; Shimokata, K; Takenaka, S, 1986)	0.27
" Sharp plateaus in the VpmR-5 dose-response curves for Adriamycin-induced DNA strand breaks and cytotoxicity appear to be related to interference with type II topoisomerase-mediated cleavage of DNA at high concentrations of the intercalator."	( Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target. Glisson, B; Gupta, R; Hodges, P; Ross, W, 1986)	0.52
"To evaluate postulated dose-response relationships of etoposide (VP-16) for patients with recurrent small cell carcinoma of the lung, a prospectively randomized study was undertaken."	( Randomized dose-response evaluation of etoposide in small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial. Birch, R; Greco, FA; Sarma, P; Wolff, SN, 1986)	0.27
" The interpatient pharmacokinetic variability reflected in CI and VM-26 steady state concentrations (Css), obscured any dose-response relationship."	( Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial. Abromowitch, M; Evans, WE; Hayes, FA; Rivera, GK; Rodman, JH; Sinkule, JA, 1987)	0.27
" Teniposide at this dosage and schedule is an inactive drug in CLL."	( Teniposide is not effective in chronic lymphocytic leukemia. Carbone, A; Galligioni, E; Grigoletto, E; Roncadin, M; Tirelli, U; Tumolo, S; Veronesi, A; Zagonel, V, 1986)	0.27
" The drug dosage ranged from 100 to 200 mg/m2 administered biweekly until remission was achieved, and then at 1- to 3-week intervals as maintenance therapy."	( Use of VP-16-213 in the treatment of familial erythrophagocytic lymphohistiocytosis. Alvarado, CS; Buchanan, GR; Kim, TH; Ragab, AH; Sartain, P; Zaatari, G, 1986)	0.27
" The drug combination was administered by intravenous infusion twice a week for two consecutive weeks at a dosage of 150 mg/m2 for each drug."	( [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia]. Arakawa, S; Esumi, N; Imashuku, S; Todo, S, 1986)	0.27
" The oral dosage unit was etoposide solubilized in a polyethylene glycol-based vehicle in a soft gelatin capsule formulation."	( Bioavailability and pharmacokinetics of etoposide (VP-16). Comis, RL; Pfeffer, M; Scalzo, A; Smyth, RD, 1985)	0.27
" VP 16-213 was administered orally at the dosage of 100 mg/mq for 5 consecutive days every 3 weeks."	( Phase II trial of oral VP 16-213 (etoposide) in patients with advanced head and neck cancer. Barzan, L; Carbone, A; Caruso, G; Comoretto, R; Crivellari, D; Grigoletto, E; Magri, MD; Tirelli, U; Veronesi, A, 1985)	0.27
" Such a time-qualified treatment resulted in increased long-term survival rate, highest peripheral leukocyte count at nadir, and lowest body weight loss, as compared to results from drug dosing in the activity span."	( Circadian rhythm in tolerance of mice for etoposide. Bailleul, F; Horvath, C; Lévi, F; Mathé, G; Mechkouri, M; Reinberg, A; Roulon, A, 1985)	0.27
" Vincristine dosage was the same in both arms of the study."	( Lack of potentiation of vincristine-induced neurotoxicity by VP-16-213. Cooper, MR; Jackson, DV; Muss, HB; Pope, EK; Richards, F; Spurr, CL; Stuart, JJ; Wells, HB; White, DR, 1983)	0.27
" Schedule dependency in both animal models and clinical trials has been observed; multiple dosing over three to five consecutive days is superior to weekly single dose administration."	( Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent. Sinkule, JA, )	0.42
" Recent studies in man support the dose-response relationship of etoposide."	( High-dose etoposide for refractory malignancies: a phase I study. de Vries, EG; Meinesz, AF; Mulder, NH; Postmus, PE; Sleijfer, DT; Vriesendorp, R, 1984)	0.27
" None of the esters showed higher activity than that shown by the parent molecule I when tested at the same dosage level."	( Antitumor agents LXII: synthesis and biological evaluation of podophyllotoxin esters and related derivatives. Hall, IH; Lee, KH; Levy, RK, 1983)	0.51
" Increasing the drug dosage produced proportionally higher peak plasma etoposide concentrations (27 to 114 micrograms/ml) and total areas under the concentration-time curve (9,200 to 48,000 micrograms/ml X min)."	( Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Greco, FA; Hande, KR; Noone, RM; Wedlund, PJ; Wilkinson, GR; Wolff, SN, 1984)	0.27
" Response, defined as improvement in both clinical examination and computed tomography scan in absence of glucocorticoids dosage increase, was observed in three (17%) of 18 evaluable patients, lasting greater than 21, seven, and two months, respectively."	( Etoposide (VP-16-213) in malignant brain tumors: a phase II study. Canetta, R; D'Incalci, M; Franchin, G; Galligioni, E; Grigoletto, E; Rossi, C; Tirelli, U; Trovò, MG; Tumolo, S; Veronesi, A, 1984)	0.27
"The two dosage schedules of VP16 that gave the least and the greatest efficacy in Lewis lung carcinoma of the mouse were selected for evaluation of the cytokinetic effects observable in vivo at different intervals after treatment (schedule A: 40 mg/kg IV, on day 8 after transplant; schedule B: 13 mg/kg IV, repeated on days 8, 11, and 14 after transplant)."	( Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma. Broggini, M; Colombo, T; D'Incalci, M; Erba, E; Morasca, L; Torti, L; Ubezio, P; Vaghi, M, 1983)	0.27
" Chemotherapy was given by vein twice a week for four weeks at dosage of 300 mg/m2 for ara-C and 50, 75, 110, 165, or 200 mg/m2 for VM-26."	( Combined VM-26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia. Aur, RJ; Avery, TL; Dahl, GV; Pratt, CB; Rivera, G; Wood, A, 1980)	0.26
" Since preliminary clinical information suggests that this drug is well tolerated at high doses, further development of this agent in Phase II trials with multiple dosing schedules is warranted."	( Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro. Depenbrock, H; Hanauske, AR; Kaeser-Fröhlich, A; Lehmer, A; Rastetter, J; Rotter, M; Schneider, P; Wüster, KC, 1995)	0.58
" Dose-response and time-course studies on the effects of podophyllotoxin on protein."	( Experimental podophyllotoxin (bajiaolian) poisoning: III. Biochemical bases for toxic effects. Chang, LW; Chen, CF; Deng, JF; Yang, CM, 1994)	0.9
" It was not correlated to dosage or duration of either therapy."	( Cancer morbidity in rheumatoid arthritis patients treated with Proresid or parenteral gold. Bendix, G; Bjelle, A; Holmberg, E, 1995)	0.29
" Owing to haematopoietic myeloid growth factors, dosage intensification, in the hope of overcoming the chemoresistance mechanisms responsible for the usually very temporary response, opens new and promising research lines."	( [Origin of small cell lung cancers]. Cordier, JF; Trillet-Lenoir, V, 1993)	0.29
" Therefore, the slope of the dose-response curve was very steep."	( Flow cytometric estimation on cytotoxic activity of leaf extracts from seashore plants in subtropical Japan: isolation, quantification and cytotoxic action of (-)-deoxypodophyllotoxin. Chikahisa, L; Inaba, Y; Masuda, T; Mizuguchi, S; Nakata, M; Okada, Y; Oyama, Y; Takeda, Y; Tanaka, T; Yamazaki, Y; Yonemori, S, 2002)	0.51
" rhodesiense in vivo, curing three of four infected mice dosed intraperitoneally at 5 mg/kg x 4 days."	( Synthesis and antiprotozoal activities of dicationic bis(phenoxymethyl)benzenes, bis(phenoxymethyl)naphthalenes, and bis(benzyloxy)naphthalenes. Bakunov, SA; Bakunova, SM; Barzcz, T; Brun, R; Chen, H; Jones, SK; Kumar, EV; Patrick, DA; Tidwell, RR; Wenzler, T; Werbovetz, KA, 2009)	0.35
" The expression of P-gp significantly decreased with the increasing dosage of CIP-36 examined by immunohistochemistry."	( [Anti-MDR tumor mechanism of CIP-36, a podophyllotoxin derivative]. Cao, B; Chen, H; Jiang, YG; Lü, JJ; Mei, X; Wu, KZ, 2011)	0.64
"Cidofovir cream could be a useful therapeutic alternative, although further studies are required to establish the best dosage and its cost-effectiveness."	( [Treatment of anogenital warts with topical cidofovir]. de Troya-Martín, M; Del Boz, J; Fernández-Morano, T; Frieyro-Elichegui, M; Padilla-España, L; Repiso, JB, 2013)	0.39
"Podophyllotoxin (PPT) exhibited significant activity against P-glycoprotein mediated multidrug resistant (MDR) tumor cell lines; however, due to its poor solubility and high toxicity, PPT cannot be dosed systemically, preventing its clinical use for MDR cancer."	( A highly tumor-targeted nanoparticle of podophyllotoxin penetrated tumor core and regressed multidrug resistant tumors. Ernsting, MJ; Li, SD; Roy, A; Undzys, E, 2015)	2.13
" These compounds, 4-MP-PTOX and 4-TG-PTOX, reduce the dosage and greatly improve the therapeutic effect for microtubule damage in cancer cells."	( Tubulin structure-based drug design for the development of novel 4β-sulfur-substituted podophyllum tubulin inhibitors with anti-tumor activity. Bai, JK; Chen, T; Li, HM; Tang, YJ; Zhao, W, 2015)	0.42
"This was a prospective, single-armed, open label, dose-finding phase Ia/b study with the aim of single day dosing (phase Ia) to define the starting dose for multi-day dosing (phase Ib), and phase Ib to define and confirm recommended phase II dose (RP2D) and if possible maximum tolerated dose (MTD) for repeated dosing."	( A novel oral insulin-like growth factor-1 receptor pathway modulator and its implications for patients with non-small cell lung carcinoma: A phase I clinical trial. Abrahmsen, L; Alvfors, C; Axelson, M; Bergqvist, M; Bergström, S; Ekman, S; Eksborg, S; Frödin, JE; Harmenberg, J; Hedlund, Å; Jerling, M; Larsson, O; Ståhl, B; Wassberg, C, 2016)	0.43
" Three drugs, selumetinib (a MEK inhibitor), picropodophyllin (an IGF-1R inhibitor) and LDN-193189 (a BMP2 inhibitor) were tested with dose-response design in both 2D and 3D cultures for their abilities to block net cell growth."	( Development of 3D culture models of plexiform neurofibroma and initial application for phenotypic characterization and drug screening. Chalasani, A; Kraniak, JM; Mattingly, RR; Wallace, MR, 2018)	0.48

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
keratolytic drug	A drug that softens, separates, and causes desquamation of the cornified epithelium or horny layer of skin. Keratolytic drugs are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases.
tubulin modulator	Any substance that interacts with tubulin to inhibit or promote polymerisation of microtubules.
microtubule-destabilising agent	Any substance that interacts with tubulin to inhibit polymerisation of microtubules.
antimitotic	Any compound that inhibits cell division (mitosis).
plant metabolite	Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
furonaphthodioxole
lignan	Any phenylpropanoid derived from phenylalanine via dimerization of substituted cinnamic alcohols, known as monolignols, to a dibenzylbutane skeleton. Note that while individual members of the class have names ending ...lignane, ...lignene, ...lignadiene, etc., the class names lignan, neolignan, etc., do not end with an "e".
organic heterotetracyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
podophyllotoxin glucosides metabolism	0	17

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	1.1220	0.0032	45.4673	12,589.2998	AID2517
Chain A, Beta-lactamase	Escherichia coli K-12	Potency	6.3096	0.0447	17.8581	100.0000	AID485341
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	0.0295	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
SMAD family member 2	Homo sapiens (human)	Potency	0.0535	0.1737	34.3047	61.8120	AID1346924
ATAD5 protein, partial	Homo sapiens (human)	Potency	0.0920	0.0041	10.8903	31.5287	AID504466
USP1 protein, partial	Homo sapiens (human)	Potency	31.6228	0.0316	37.5844	354.8130	AID743255
PPM1D protein	Homo sapiens (human)	Potency	0.0234	0.0052	9.4661	32.9993	AID1347411
SMAD family member 3	Homo sapiens (human)	Potency	0.0535	0.1737	34.3047	61.8120	AID1346924
TDP1 protein	Homo sapiens (human)	Potency	0.0639	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	0.0124	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	0.2490	0.0002	21.2231	8,912.5098	AID1259247; AID743035; AID743036; AID743042; AID743053; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	19.9526	0.0112	12.4002	100.0000	AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)	Homo sapiens (human)	Potency	0.0158	0.0013	7.7625	44.6684	AID914; AID915
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	0.0501	0.0010	22.6508	76.6163	AID1224838; AID1224893
progesterone receptor	Homo sapiens (human)	Potency	0.0265	0.0004	17.9460	75.1148	AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	0.4454	0.0123	7.9835	43.2770	AID1346984; AID1645841
EWS/FLI fusion protein	Homo sapiens (human)	Potency	0.0042	0.0013	10.1577	42.8575	AID1259256
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	0.0290	0.0002	14.3764	60.0339	AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	0.0302	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	0.0248	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	8.9541	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1259401
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	0.0747	0.3758	27.4851	61.6524	AID743217
pregnane X nuclear receptor	Homo sapiens (human)	Potency	5.4290	0.0054	28.0263	1,258.9301	AID1346982; AID1346985
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	0.0735	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
G	Vesicular stomatitis virus	Potency	1.5487	0.0123	8.9648	39.8107	AID1645842
67.9K protein	Vaccinia virus	Potency	18.0495	0.0001	8.4406	100.0000	AID720579; AID720580
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	0.1966	0.0010	24.5048	61.6448	AID743212
alpha-galactosidase	Homo sapiens (human)	Potency	50.1187	4.4668	18.3916	35.4813	AID1467
IDH1	Homo sapiens (human)	Potency	0.2060	0.0052	10.8652	35.4813	AID686970
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	35.4813	0.0355	20.9770	89.1251	AID504332
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	17.3477	0.0007	23.0674	1,258.9301	AID743085; AID743122
activating transcription factor 6	Homo sapiens (human)	Potency	0.0542	0.1434	27.6121	59.8106	AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	0.1140	0.0578	21.1097	61.2679	AID1159526; AID1159528
nuclear receptor subfamily 1, group I, member 2	Rattus norvegicus (Norway rat)	Potency	0.1000	0.1000	9.1916	31.6228	AID1346983
NPC intracellular cholesterol transporter 1 precursor	Homo sapiens (human)	Potency	0.5012	0.0126	2.4518	25.0177	AID485313
chromobox protein homolog 1	Homo sapiens (human)	Potency	100.0000	0.0060	26.1688	89.1251	AID540317
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	8.2379	0.0041	9.9848	25.9290	AID504444
potassium voltage-gated channel subfamily H member 2 isoform d	Homo sapiens (human)	Potency	14.1254	0.0178	9.6374	44.6684	AID588834
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	0.0244	0.0003	23.4451	159.6830	AID743065; AID743067
ras-related protein Rab-9A	Homo sapiens (human)	Potency	0.1122	0.0002	2.6215	31.4954	AID485297
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	0.0948	0.0006	27.2152	1,122.0200	AID743202; AID743219
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	11.2202	0.0501	27.0736	89.1251	AID588590
geminin	Homo sapiens (human)	Potency	0.0206	0.0046	11.3741	33.4983	AID624296; AID624297
peripheral myelin protein 22	Rattus norvegicus (Norway rat)	Potency	0.0176	0.0056	12.3677	36.1254	AID624032; AID624044
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	0.4467	0.1259	12.2344	35.4813	AID1458
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	1.9953	0.0316	10.2792	39.8107	AID884; AID885
lethal factor (plasmid)	Bacillus anthracis str. A2012	Potency	0.7943	0.0200	10.7869	31.6228	AID942
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.0299	0.8913	12.0676	28.1838	AID1487
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	0.1333	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	0.4047	0.0033	9.1582	39.8107	AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	1.5487	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	0.3349	0.0023	19.5956	74.0614	AID651631
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	0.1333	0.0015	51.7393	15,848.9004	AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	1.5487	0.0123	8.9648	39.8107	AID1645842
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	0.0155	0.0119	17.9420	71.5630	AID651632; AID720516
Ataxin-2	Homo sapiens (human)	Potency	0.0168	0.0119	12.2221	68.7989	AID651632
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	1.9953	1.0000	12.2248	31.6228	AID885
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	1.5487	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
nuclear receptor subfamily 0 group B member 1	Homo sapiens (human)	IC50 (µMol)	2.1450	0.1343	0.8646	2.1450	AID687017
steroidogenic factor 1	Homo sapiens (human)	IC50 (µMol)	67.5380	1.8730	2.9295	3.9860	AID687018
Tubulin alpha-1A chain	Sus scrofa (pig)	IC50 (µMol)	0.6733	0.0067	2.1603	10.0000	AID159533; AID1799579; AID214361; AID214687; AID257600; AID274785; AID303685; AID347582; AID362356; AID494502; AID605956; AID611278
Tubulin alpha-1A chain	Sus scrofa (pig)	Ki	2.1800	2.1800	3.9650	5.7500	AID214346
Tubulin beta chain	Sus scrofa (pig)	IC50 (µMol)	0.6220	0.0067	2.1374	10.0000	AID159533; AID214361; AID257600; AID274785; AID303685; AID347582; AID362356; AID494502; AID605956; AID611278
Tubulin beta chain	Sus scrofa (pig)	Ki	2.1800	2.1800	3.9650	5.7500	AID214346
Glucocorticoid receptor	Homo sapiens (human)	IC50 (µMol)	0.0140	0.0000	0.4953	10.0000	AID558401
Tubulin beta-4A chain	Homo sapiens (human)	IC50 (µMol)	67.1914	0.0005	1.9680	10.0000	AID1140311; AID1492876; AID214548; AID214692; AID262911; AID270966; AID494521
Prostaglandin G/H synthase 1	Ovis aries (sheep)	IC50 (µMol)	18.0000	0.0003	2.1774	10.0000	AID1802222; AID464499
Tubulin beta chain	Homo sapiens (human)	IC50 (µMol)	67.1914	0.0005	2.0529	10.0000	AID1140311; AID1492876; AID214548; AID214692; AID262911; AID270966; AID494521
Cytochrome P450 3A4	Homo sapiens (human)	IC50 (µMol)	0.6000	0.0001	1.7536	10.0000	AID625251
Tubulin alpha-3C chain	Homo sapiens (human)	IC50 (µMol)	67.1914	0.0005	1.9555	10.0000	AID1140311; AID1492876; AID214548; AID214692; AID262911; AID270966; AID494521
Cytochrome P450 2C9	Homo sapiens (human)	IC50 (µMol)	4.0000	0.0000	2.8005	10.0000	AID625248
Cytochrome P450 2C19	Homo sapiens (human)	IC50 (µMol)	5.0000	0.0000	2.3983	10.0000	AID625247
Tubulin alpha-1B chain	Homo sapiens (human)	IC50 (µMol)	67.1914	0.0005	1.9555	10.0000	AID1140311; AID1492876; AID214548; AID214692; AID262911; AID270966; AID494521
Tubulin alpha-4A chain	Homo sapiens (human)	IC50 (µMol)	67.1914	0.0005	1.9555	10.0000	AID1140311; AID1492876; AID214548; AID214692; AID262911; AID270966; AID494521
Tubulin beta-4B chain	Homo sapiens (human)	IC50 (µMol)	67.1914	0.0005	1.9680	10.0000	AID1140311; AID1492876; AID214548; AID214692; AID262911; AID270966; AID494521
Prostaglandin G/H synthase 2	Mus musculus (house mouse)	IC50 (µMol)	18.0000	0.0005	0.4008	6.2000	AID1802222; AID464500
Tubulin beta-3 chain	Homo sapiens (human)	IC50 (µMol)	67.1914	0.0005	1.8945	10.0000	AID1140311; AID1492876; AID214548; AID214692; AID262911; AID270966; AID494521
Tubulin beta-2A chain	Homo sapiens (human)	IC50 (µMol)	67.1914	0.0005	1.9680	10.0000	AID1140311; AID1492876; AID214548; AID214692; AID262911; AID270966; AID494521
Tubulin beta-8 chain	Homo sapiens (human)	IC50 (µMol)	67.1914	0.0005	1.9680	10.0000	AID1140311; AID1492876; AID214548; AID214692; AID262911; AID270966; AID494521
Calcium-activated potassium channel subunit alpha-1	Rattus norvegicus (Norway rat)	IC50 (µMol)	0.5600	0.5600	0.5600	0.5600	AID362356
Tubulin beta-2B chain	Bos taurus (cattle)	IC50 (µMol)	0.8685	0.2500	1.8838	8.7000	AID1180384; AID1188223; AID213999; AID214009; AID214013; AID214014; AID214015; AID214030; AID214033; AID214039; AID214555; AID266932; AID54295
Tubulin alpha-3E chain	Homo sapiens (human)	IC50 (µMol)	67.1914	0.0005	1.9555	10.0000	AID1140311; AID1492876; AID214548; AID214692; AID262911; AID270966; AID494521
Tubulin alpha-1A chain	Homo sapiens (human)	IC50 (µMol)	67.1914	0.0005	1.9555	10.0000	AID1140311; AID1492876; AID214548; AID214692; AID262911; AID270966; AID494521
Similar to alpha-tubulin isoform 1	Bos taurus (cattle)	IC50 (µMol)	0.9070	0.2500	1.8779	8.7000	AID1180384; AID1188223; AID213999; AID214009; AID214015; AID214030; AID214033; AID214039; AID266932; AID54295
Similar to alpha-tubulin isoform 1	Bos taurus (cattle)	IC50 (µMol)	0.7744	0.2500	1.8656	8.7000	AID1180384; AID1188223; AID213999; AID214009; AID214015; AID214030; AID214033; AID214039; AID266932
Tubulin alpha-1C chain	Homo sapiens (human)	IC50 (µMol)	67.1914	0.0005	1.9555	10.0000	AID1140311; AID1492876; AID214548; AID214692; AID262911; AID270966; AID494521
Tubulin beta-6 chain	Homo sapiens (human)	IC50 (µMol)	67.1914	0.0005	1.9680	10.0000	AID1140311; AID1492876; AID214548; AID214692; AID262911; AID270966; AID494521
Tubulin beta-2B chain	Homo sapiens (human)	IC50 (µMol)	67.1914	0.0005	1.9680	10.0000	AID1140311; AID1492876; AID214548; AID214692; AID262911; AID270966; AID494521
Tubulin beta-1 chain	Homo sapiens (human)	IC50 (µMol)	67.1914	0.0005	1.9870	10.0000	AID1140311; AID1492876; AID214548; AID214692; AID262911; AID270966; AID494521
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Tubulin alpha-1A chain	Sus scrofa (pig)	Kd	70.5000	1.0000	1.5760	3.7000	AID384951
Tubulin beta chain	Sus scrofa (pig)	Kd	70.5000	1.0000	1.5760	3.7000	AID384951
Regulatory protein E2	Human papillomavirus type 1a	Kd	206.2875	1.0500	1.0500	1.0500	AID384945; AID384946; AID384947; AID384948
Tubulin beta-4A chain	Homo sapiens (human)	Kd	21.5000	0.0580	0.6443	1.8600	AID1549930
Tubulin beta chain	Homo sapiens (human)	Kd	21.5000	0.0580	0.6443	1.8600	AID1549930
Tubulin alpha-3C chain	Homo sapiens (human)	Kd	21.5000	0.0580	0.6574	1.8600	AID1549930
Tubulin alpha-1B chain	Homo sapiens (human)	Kd	21.5000	0.0580	0.6574	1.8600	AID1549930
Tubulin alpha-4A chain	Homo sapiens (human)	Kd	21.5000	0.0580	0.6574	1.8600	AID1549930
Tubulin beta-4B chain	Homo sapiens (human)	Kd	21.5000	0.0580	0.6443	1.8600	AID1549930
Tubulin beta-3 chain	Homo sapiens (human)	Kd	21.5000	0.0580	0.6443	1.8600	AID1549930
Tubulin beta-2A chain	Homo sapiens (human)	Kd	21.5000	0.0580	0.6443	1.8600	AID1549930
Tubulin beta-8 chain	Homo sapiens (human)	Kd	21.5000	0.0580	0.6443	1.8600	AID1549930
Tubulin alpha-3E chain	Homo sapiens (human)	Kd	21.5000	0.0580	0.6574	1.8600	AID1549930
Tubulin alpha-1A chain	Homo sapiens (human)	Kd	21.5000	0.0580	0.6574	1.8600	AID1549930
Tubulin alpha-1C chain	Homo sapiens (human)	Kd	21.5000	0.0580	0.6574	1.8600	AID1549930
Tubulin beta-6 chain	Homo sapiens (human)	Kd	21.5000	0.0580	0.6443	1.8600	AID1549930
Tubulin beta-2B chain	Homo sapiens (human)	Kd	21.5000	0.0580	0.6443	1.8600	AID1549930
Tubulin beta-1 chain	Homo sapiens (human)	Kd	21.5000	0.0580	0.5894	1.8600	AID1549930
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
PAX8	Homo sapiens (human)	AC50	0.2600	0.0488	5.4354	69.1700	AID687027
Tubulin beta-4A chain	Homo sapiens (human)	Activity	23.5000	0.9000	3.3433	6.6000	AID1384281
Tubulin beta chain	Homo sapiens (human)	Activity	23.5000	0.9000	3.3433	6.6000	AID1384281
Tubulin alpha-3C chain	Homo sapiens (human)	Activity	23.5000	0.9000	3.3433	6.6000	AID1384281
Tubulin alpha-1B chain	Homo sapiens (human)	Activity	23.5000	0.9000	3.3433	6.6000	AID1384281
Tubulin alpha-4A chain	Homo sapiens (human)	Activity	23.5000	0.9000	3.3433	6.6000	AID1384281
Tubulin beta-4B chain	Homo sapiens (human)	Activity	23.5000	0.9000	3.3433	6.6000	AID1384281
Tubulin beta-3 chain	Homo sapiens (human)	Activity	23.5000	0.9000	3.3433	6.6000	AID1384281
Tubulin beta-2A chain	Homo sapiens (human)	Activity	23.5000	0.9000	3.3433	6.6000	AID1384281
Tubulin beta-8 chain	Homo sapiens (human)	Activity	23.5000	0.9000	3.3433	6.6000	AID1384281
Tubulin alpha-3E chain	Homo sapiens (human)	Activity	23.5000	0.9000	3.3433	6.6000	AID1384281
Tubulin alpha-1A chain	Homo sapiens (human)	Activity	23.5000	0.9000	3.3433	6.6000	AID1384281
Tubulin alpha-1C chain	Homo sapiens (human)	Activity	23.5000	0.9000	3.3433	6.6000	AID1384281
Tubulin beta-6 chain	Homo sapiens (human)	Activity	23.5000	0.9000	3.3433	6.6000	AID1384281
Tubulin beta-2B chain	Homo sapiens (human)	Activity	23.5000	0.9000	3.3433	6.6000	AID1384281
Tubulin beta-1 chain	Homo sapiens (human)	Activity	23.5000	0.9000	3.3433	6.6000	AID1384281
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
regulation of gluconeogenesis	Glucocorticoid receptor	Homo sapiens (human)
chromatin organization	Glucocorticoid receptor	Homo sapiens (human)
regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
chromosome segregation	Glucocorticoid receptor	Homo sapiens (human)
signal transduction	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid metabolic process	Glucocorticoid receptor	Homo sapiens (human)
gene expression	Glucocorticoid receptor	Homo sapiens (human)
microglia differentiation	Glucocorticoid receptor	Homo sapiens (human)
adrenal gland development	Glucocorticoid receptor	Homo sapiens (human)
regulation of glucocorticoid biosynthetic process	Glucocorticoid receptor	Homo sapiens (human)
synaptic transmission, glutamatergic	Glucocorticoid receptor	Homo sapiens (human)
maternal behavior	Glucocorticoid receptor	Homo sapiens (human)
intracellular glucocorticoid receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
glucocorticoid mediated signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of neuron apoptotic process	Glucocorticoid receptor	Homo sapiens (human)
negative regulation of DNA-templated transcription	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
astrocyte differentiation	Glucocorticoid receptor	Homo sapiens (human)
cell division	Glucocorticoid receptor	Homo sapiens (human)
mammary gland duct morphogenesis	Glucocorticoid receptor	Homo sapiens (human)
motor behavior	Glucocorticoid receptor	Homo sapiens (human)
cellular response to steroid hormone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to glucocorticoid stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to dexamethasone stimulus	Glucocorticoid receptor	Homo sapiens (human)
cellular response to transforming growth factor beta stimulus	Glucocorticoid receptor	Homo sapiens (human)
neuroinflammatory response	Glucocorticoid receptor	Homo sapiens (human)
positive regulation of miRNA transcription	Glucocorticoid receptor	Homo sapiens (human)
intracellular steroid hormone receptor signaling pathway	Glucocorticoid receptor	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Glucocorticoid receptor	Homo sapiens (human)
negative regulation of microtubule polymerization	Tubulin beta-4A chain	Homo sapiens (human)
microtubule cytoskeleton organization	Tubulin beta-4A chain	Homo sapiens (human)
mitotic cell cycle	Tubulin beta-4A chain	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
odontoblast differentiation	Tubulin beta chain	Homo sapiens (human)
microtubule-based process	Tubulin beta chain	Homo sapiens (human)
cytoskeleton-dependent intracellular transport	Tubulin beta chain	Homo sapiens (human)
natural killer cell mediated cytotoxicity	Tubulin beta chain	Homo sapiens (human)
regulation of synapse organization	Tubulin beta chain	Homo sapiens (human)
spindle assembly	Tubulin beta chain	Homo sapiens (human)
cell division	Tubulin beta chain	Homo sapiens (human)
microtubule cytoskeleton organization	Tubulin beta chain	Homo sapiens (human)
mitotic cell cycle	Tubulin beta chain	Homo sapiens (human)
lipid hydroxylation	Cytochrome P450 3A4	Homo sapiens (human)
lipid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
androgen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
alkaloid catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
calcitriol biosynthetic process from calciol	Cytochrome P450 3A4	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D catabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinol metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 3A4	Homo sapiens (human)
aflatoxin metabolic process	Cytochrome P450 3A4	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 3A4	Homo sapiens (human)
microtubule cytoskeleton organization	Tubulin alpha-3C chain	Homo sapiens (human)
mitotic cell cycle	Tubulin alpha-3C chain	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
cholesterol metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
estrogen metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
urea metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
monocarboxylic acid metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
amide metabolic process	Cytochrome P450 2C9	Homo sapiens (human)
icosanoid biosynthetic process	Cytochrome P450 2C9	Homo sapiens (human)
oxidative demethylation	Cytochrome P450 2C9	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C9	Homo sapiens (human)
long-chain fatty acid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
steroid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
monoterpenoid metabolic process	Cytochrome P450 2C19	Homo sapiens (human)
epoxygenase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
xenobiotic catabolic process	Cytochrome P450 2C19	Homo sapiens (human)
omega-hydroxylase P450 pathway	Cytochrome P450 2C19	Homo sapiens (human)
microtubule cytoskeleton organization	Tubulin alpha-1B chain	Homo sapiens (human)
microtubule-based process	Tubulin alpha-1B chain	Homo sapiens (human)
cytoskeleton-dependent intracellular transport	Tubulin alpha-1B chain	Homo sapiens (human)
cell division	Tubulin alpha-1B chain	Homo sapiens (human)
cellular response to interleukin-4	Tubulin alpha-1B chain	Homo sapiens (human)
mitotic cell cycle	Tubulin alpha-1B chain	Homo sapiens (human)
microtubule cytoskeleton organization	Tubulin alpha-4A chain	Homo sapiens (human)
mitotic cell cycle	Tubulin alpha-4A chain	Homo sapiens (human)
natural killer cell mediated cytotoxicity	Tubulin beta-4B chain	Homo sapiens (human)
mitotic cell cycle	Tubulin beta-4B chain	Homo sapiens (human)
microtubule cytoskeleton organization	Tubulin beta-4B chain	Homo sapiens (human)
microtubule cytoskeleton organization	Tubulin beta-3 chain	Homo sapiens (human)
axon guidance	Tubulin beta-3 chain	Homo sapiens (human)
netrin-activated signaling pathway	Tubulin beta-3 chain	Homo sapiens (human)
dorsal root ganglion development	Tubulin beta-3 chain	Homo sapiens (human)
mitotic cell cycle	Tubulin beta-3 chain	Homo sapiens (human)
cerebral cortex development	Tubulin beta-2A chain	Homo sapiens (human)
microtubule cytoskeleton organization	Tubulin beta-2A chain	Homo sapiens (human)
mitotic cell cycle	Tubulin beta-2A chain	Homo sapiens (human)
oocyte maturation	Tubulin beta-8 chain	Homo sapiens (human)
spindle assembly involved in female meiosis	Tubulin beta-8 chain	Homo sapiens (human)
microtubule cytoskeleton organization	Tubulin beta-8 chain	Homo sapiens (human)
mitotic cell cycle	Tubulin beta-8 chain	Homo sapiens (human)
microtubule-based process	Tubulin beta-2B chain	Bos taurus (cattle)
nervous system development	Tubulin beta-2B chain	Bos taurus (cattle)
positive regulation of axon guidance	Tubulin beta-2B chain	Bos taurus (cattle)
biological_process	Tubulin alpha-3E chain	Homo sapiens (human)
mitotic cell cycle	Tubulin alpha-3E chain	Homo sapiens (human)
microtubule cytoskeleton organization	Tubulin alpha-3E chain	Homo sapiens (human)
neuron migration	Tubulin alpha-1A chain	Homo sapiens (human)
startle response	Tubulin alpha-1A chain	Homo sapiens (human)
intracellular protein transport	Tubulin alpha-1A chain	Homo sapiens (human)
microtubule-based process	Tubulin alpha-1A chain	Homo sapiens (human)
centrosome cycle	Tubulin alpha-1A chain	Homo sapiens (human)
smoothened signaling pathway	Tubulin alpha-1A chain	Homo sapiens (human)
memory	Tubulin alpha-1A chain	Homo sapiens (human)
adult locomotory behavior	Tubulin alpha-1A chain	Homo sapiens (human)
visual learning	Tubulin alpha-1A chain	Homo sapiens (human)
response to mechanical stimulus	Tubulin alpha-1A chain	Homo sapiens (human)
glial cell differentiation	Tubulin alpha-1A chain	Homo sapiens (human)
gene expression	Tubulin alpha-1A chain	Homo sapiens (human)
dentate gyrus development	Tubulin alpha-1A chain	Homo sapiens (human)
cerebellar cortex morphogenesis	Tubulin alpha-1A chain	Homo sapiens (human)
pyramidal neuron differentiation	Tubulin alpha-1A chain	Homo sapiens (human)
cerebral cortex development	Tubulin alpha-1A chain	Homo sapiens (human)
cytoskeleton-dependent intracellular transport	Tubulin alpha-1A chain	Homo sapiens (human)
response to tumor necrosis factor	Tubulin alpha-1A chain	Homo sapiens (human)
locomotory exploration behavior	Tubulin alpha-1A chain	Homo sapiens (human)
microtubule polymerization	Tubulin alpha-1A chain	Homo sapiens (human)
forebrain morphogenesis	Tubulin alpha-1A chain	Homo sapiens (human)
homeostasis of number of cells within a tissue	Tubulin alpha-1A chain	Homo sapiens (human)
regulation of synapse organization	Tubulin alpha-1A chain	Homo sapiens (human)
synapse organization	Tubulin alpha-1A chain	Homo sapiens (human)
cell division	Tubulin alpha-1A chain	Homo sapiens (human)
neuron apoptotic process	Tubulin alpha-1A chain	Homo sapiens (human)
motor behavior	Tubulin alpha-1A chain	Homo sapiens (human)
cellular response to calcium ion	Tubulin alpha-1A chain	Homo sapiens (human)
organelle transport along microtubule	Tubulin alpha-1A chain	Homo sapiens (human)
neuron projection arborization	Tubulin alpha-1A chain	Homo sapiens (human)
response to L-glutamate	Tubulin alpha-1A chain	Homo sapiens (human)
microtubule cytoskeleton organization	Tubulin alpha-1A chain	Homo sapiens (human)
mitotic cell cycle	Tubulin alpha-1A chain	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
microtubule-based process	Tubulin alpha-1C chain	Homo sapiens (human)
cytoskeleton-dependent intracellular transport	Tubulin alpha-1C chain	Homo sapiens (human)
cell division	Tubulin alpha-1C chain	Homo sapiens (human)
mitotic cell cycle	Tubulin alpha-1C chain	Homo sapiens (human)
microtubule cytoskeleton organization	Tubulin alpha-1C chain	Homo sapiens (human)
mitotic cell cycle	Tubulin beta-6 chain	Homo sapiens (human)
microtubule cytoskeleton organization	Tubulin beta-6 chain	Homo sapiens (human)
neuron migration	Tubulin beta-2B chain	Homo sapiens (human)
microtubule-based process	Tubulin beta-2B chain	Homo sapiens (human)
cerebral cortex development	Tubulin beta-2B chain	Homo sapiens (human)
modulation of chemical synaptic transmission	Tubulin beta-2B chain	Homo sapiens (human)
positive regulation of axon guidance	Tubulin beta-2B chain	Homo sapiens (human)
embryonic brain development	Tubulin beta-2B chain	Homo sapiens (human)
mitotic cell cycle	Tubulin beta-2B chain	Homo sapiens (human)
microtubule cytoskeleton organization	Tubulin beta-2B chain	Homo sapiens (human)
platelet formation	Tubulin beta-1 chain	Homo sapiens (human)
thyroid gland development	Tubulin beta-1 chain	Homo sapiens (human)
microtubule polymerization	Tubulin beta-1 chain	Homo sapiens (human)
spindle assembly	Tubulin beta-1 chain	Homo sapiens (human)
thyroid hormone transport	Tubulin beta-1 chain	Homo sapiens (human)
platelet aggregation	Tubulin beta-1 chain	Homo sapiens (human)
mitotic cell cycle	Tubulin beta-1 chain	Homo sapiens (human)
microtubule cytoskeleton organization	Tubulin beta-1 chain	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
core promoter sequence-specific DNA binding	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Glucocorticoid receptor	Homo sapiens (human)
DNA-binding transcription factor activity	Glucocorticoid receptor	Homo sapiens (human)
RNA binding	Glucocorticoid receptor	Homo sapiens (human)
nuclear receptor activity	Glucocorticoid receptor	Homo sapiens (human)
nuclear glucocorticoid receptor activity	Glucocorticoid receptor	Homo sapiens (human)
steroid binding	Glucocorticoid receptor	Homo sapiens (human)
protein binding	Glucocorticoid receptor	Homo sapiens (human)
zinc ion binding	Glucocorticoid receptor	Homo sapiens (human)
TBP-class protein binding	Glucocorticoid receptor	Homo sapiens (human)
protein kinase binding	Glucocorticoid receptor	Homo sapiens (human)
identical protein binding	Glucocorticoid receptor	Homo sapiens (human)
Hsp90 protein binding	Glucocorticoid receptor	Homo sapiens (human)
steroid hormone binding	Glucocorticoid receptor	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Glucocorticoid receptor	Homo sapiens (human)
estrogen response element binding	Glucocorticoid receptor	Homo sapiens (human)
GTPase activity	Tubulin beta-4A chain	Homo sapiens (human)
calcium ion binding	Tubulin beta-4A chain	Homo sapiens (human)
protein binding	Tubulin beta-4A chain	Homo sapiens (human)
structural constituent of cytoskeleton	Tubulin beta-4A chain	Homo sapiens (human)
GTP binding	Tubulin beta-4A chain	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
GTPase activity	Tubulin beta chain	Homo sapiens (human)
structural molecule activity	Tubulin beta chain	Homo sapiens (human)
protein binding	Tubulin beta chain	Homo sapiens (human)
protein domain specific binding	Tubulin beta chain	Homo sapiens (human)
ubiquitin protein ligase binding	Tubulin beta chain	Homo sapiens (human)
GTPase activating protein binding	Tubulin beta chain	Homo sapiens (human)
MHC class I protein binding	Tubulin beta chain	Homo sapiens (human)
protein-containing complex binding	Tubulin beta chain	Homo sapiens (human)
metal ion binding	Tubulin beta chain	Homo sapiens (human)
structural constituent of cytoskeleton	Tubulin beta chain	Homo sapiens (human)
GTP binding	Tubulin beta chain	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
steroid binding	Cytochrome P450 3A4	Homo sapiens (human)
iron ion binding	Cytochrome P450 3A4	Homo sapiens (human)
protein binding	Cytochrome P450 3A4	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
retinoic acid 4-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 3A4	Homo sapiens (human)
oxygen binding	Cytochrome P450 3A4	Homo sapiens (human)
enzyme binding	Cytochrome P450 3A4	Homo sapiens (human)
heme binding	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D3 25-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
quinine 3-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
testosterone 6-beta-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 8,9 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 11,12 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
anandamide 14,15 epoxidase activity	Cytochrome P450 3A4	Homo sapiens (human)
aromatase activity	Cytochrome P450 3A4	Homo sapiens (human)
vitamin D 24-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 16-alpha-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
estrogen 2-hydroxylase activity	Cytochrome P450 3A4	Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activity	Cytochrome P450 3A4	Homo sapiens (human)
hydrolase activity	Tubulin alpha-3C chain	Homo sapiens (human)
metal ion binding	Tubulin alpha-3C chain	Homo sapiens (human)
structural constituent of cytoskeleton	Tubulin alpha-3C chain	Homo sapiens (human)
GTP binding	Tubulin alpha-3C chain	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
caffeine oxidase activity	Cytochrome P450 2C9	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C9	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C9	Homo sapiens (human)
heme binding	Cytochrome P450 2C9	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C9	Homo sapiens (human)
monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
iron ion binding	Cytochrome P450 2C19	Homo sapiens (human)
steroid hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
(S)-limonene 7-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxygen binding	Cytochrome P450 2C19	Homo sapiens (human)
enzyme binding	Cytochrome P450 2C19	Homo sapiens (human)
heme binding	Cytochrome P450 2C19	Homo sapiens (human)
(R)-limonene 6-monooxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
aromatase activity	Cytochrome P450 2C19	Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activity	Cytochrome P450 2C19	Homo sapiens (human)
arachidonic acid epoxygenase activity	Cytochrome P450 2C19	Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen	Cytochrome P450 2C19	Homo sapiens (human)
double-stranded RNA binding	Tubulin alpha-1B chain	Homo sapiens (human)
GTPase activity	Tubulin alpha-1B chain	Homo sapiens (human)
structural molecule activity	Tubulin alpha-1B chain	Homo sapiens (human)
structural constituent of cytoskeleton	Tubulin alpha-1B chain	Homo sapiens (human)
protein binding	Tubulin alpha-1B chain	Homo sapiens (human)
GTP binding	Tubulin alpha-1B chain	Homo sapiens (human)
ubiquitin protein ligase binding	Tubulin alpha-1B chain	Homo sapiens (human)
protein binding	Tubulin alpha-4A chain	Homo sapiens (human)
hydrolase activity	Tubulin alpha-4A chain	Homo sapiens (human)
protein kinase binding	Tubulin alpha-4A chain	Homo sapiens (human)
metal ion binding	Tubulin alpha-4A chain	Homo sapiens (human)
structural constituent of cytoskeleton	Tubulin alpha-4A chain	Homo sapiens (human)
GTP binding	Tubulin alpha-4A chain	Homo sapiens (human)
double-stranded RNA binding	Tubulin beta-4B chain	Homo sapiens (human)
GTPase activity	Tubulin beta-4B chain	Homo sapiens (human)
protein binding	Tubulin beta-4B chain	Homo sapiens (human)
MHC class I protein binding	Tubulin beta-4B chain	Homo sapiens (human)
metal ion binding	Tubulin beta-4B chain	Homo sapiens (human)
unfolded protein binding	Tubulin beta-4B chain	Homo sapiens (human)
structural constituent of cytoskeleton	Tubulin beta-4B chain	Homo sapiens (human)
GTP binding	Tubulin beta-4B chain	Homo sapiens (human)
GTPase activity	Tubulin beta-3 chain	Homo sapiens (human)
structural constituent of cytoskeleton	Tubulin beta-3 chain	Homo sapiens (human)
protein binding	Tubulin beta-3 chain	Homo sapiens (human)
GTP binding	Tubulin beta-3 chain	Homo sapiens (human)
peptide binding	Tubulin beta-3 chain	Homo sapiens (human)
metal ion binding	Tubulin beta-3 chain	Homo sapiens (human)
netrin receptor binding	Tubulin beta-3 chain	Homo sapiens (human)
GTPase activity	Tubulin beta-2A chain	Homo sapiens (human)
protein binding	Tubulin beta-2A chain	Homo sapiens (human)
metal ion binding	Tubulin beta-2A chain	Homo sapiens (human)
structural constituent of cytoskeleton	Tubulin beta-2A chain	Homo sapiens (human)
GTP binding	Tubulin beta-2A chain	Homo sapiens (human)
molecular_function	Tubulin beta-8 chain	Homo sapiens (human)
GTPase activity	Tubulin beta-8 chain	Homo sapiens (human)
metal ion binding	Tubulin beta-8 chain	Homo sapiens (human)
GTP binding	Tubulin beta-8 chain	Homo sapiens (human)
structural constituent of cytoskeleton	Tubulin beta-8 chain	Homo sapiens (human)
calcium-activated potassium channel activity	Calcium-activated potassium channel subunit alpha-1	Rattus norvegicus (Norway rat)
GTPase activity	Tubulin beta-2B chain	Bos taurus (cattle)
metal ion binding	Tubulin beta-2B chain	Bos taurus (cattle)
protein heterodimerization activity	Tubulin beta-2B chain	Bos taurus (cattle)
molecular_function	Tubulin alpha-3E chain	Homo sapiens (human)
protein binding	Tubulin alpha-3E chain	Homo sapiens (human)
hydrolase activity	Tubulin alpha-3E chain	Homo sapiens (human)
metal ion binding	Tubulin alpha-3E chain	Homo sapiens (human)
structural constituent of cytoskeleton	Tubulin alpha-3E chain	Homo sapiens (human)
GTP binding	Tubulin alpha-3E chain	Homo sapiens (human)
structural molecule activity	Tubulin alpha-1A chain	Homo sapiens (human)
protein binding	Tubulin alpha-1A chain	Homo sapiens (human)
hydrolase activity	Tubulin alpha-1A chain	Homo sapiens (human)
identical protein binding	Tubulin alpha-1A chain	Homo sapiens (human)
protein-containing complex binding	Tubulin alpha-1A chain	Homo sapiens (human)
metal ion binding	Tubulin alpha-1A chain	Homo sapiens (human)
protein heterodimerization activity	Tubulin alpha-1A chain	Homo sapiens (human)
GTP binding	Tubulin alpha-1A chain	Homo sapiens (human)
structural constituent of cytoskeleton	Tubulin alpha-1A chain	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
structural molecule activity	Tubulin alpha-1C chain	Homo sapiens (human)
protein binding	Tubulin alpha-1C chain	Homo sapiens (human)
hydrolase activity	Tubulin alpha-1C chain	Homo sapiens (human)
metal ion binding	Tubulin alpha-1C chain	Homo sapiens (human)
GTP binding	Tubulin alpha-1C chain	Homo sapiens (human)
structural constituent of cytoskeleton	Tubulin alpha-1C chain	Homo sapiens (human)
molecular_function	Tubulin beta-6 chain	Homo sapiens (human)
GTPase activity	Tubulin beta-6 chain	Homo sapiens (human)
protein binding	Tubulin beta-6 chain	Homo sapiens (human)
metal ion binding	Tubulin beta-6 chain	Homo sapiens (human)
structural constituent of cytoskeleton	Tubulin beta-6 chain	Homo sapiens (human)
GTP binding	Tubulin beta-6 chain	Homo sapiens (human)
GTPase activity	Tubulin beta-2B chain	Homo sapiens (human)
protein binding	Tubulin beta-2B chain	Homo sapiens (human)
metal ion binding	Tubulin beta-2B chain	Homo sapiens (human)
protein heterodimerization activity	Tubulin beta-2B chain	Homo sapiens (human)
structural constituent of cytoskeleton	Tubulin beta-2B chain	Homo sapiens (human)
GTP binding	Tubulin beta-2B chain	Homo sapiens (human)
GTPase activity	Tubulin beta-1 chain	Homo sapiens (human)
metal ion binding	Tubulin beta-1 chain	Homo sapiens (human)
structural constituent of cytoskeleton	Tubulin beta-1 chain	Homo sapiens (human)
GTP binding	Tubulin beta-1 chain	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleus	Glucocorticoid receptor	Homo sapiens (human)
nucleoplasm	Glucocorticoid receptor	Homo sapiens (human)
cytoplasm	Glucocorticoid receptor	Homo sapiens (human)
mitochondrial matrix	Glucocorticoid receptor	Homo sapiens (human)
centrosome	Glucocorticoid receptor	Homo sapiens (human)
spindle	Glucocorticoid receptor	Homo sapiens (human)
cytosol	Glucocorticoid receptor	Homo sapiens (human)
membrane	Glucocorticoid receptor	Homo sapiens (human)
nuclear speck	Glucocorticoid receptor	Homo sapiens (human)
synapse	Glucocorticoid receptor	Homo sapiens (human)
chromatin	Glucocorticoid receptor	Homo sapiens (human)
protein-containing complex	Glucocorticoid receptor	Homo sapiens (human)
nucleus	Tubulin beta-4A chain	Homo sapiens (human)
cytosol	Tubulin beta-4A chain	Homo sapiens (human)
microtubule	Tubulin beta-4A chain	Homo sapiens (human)
axoneme	Tubulin beta-4A chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin beta-4A chain	Homo sapiens (human)
internode region of axon	Tubulin beta-4A chain	Homo sapiens (human)
neuronal cell body	Tubulin beta-4A chain	Homo sapiens (human)
myelin sheath	Tubulin beta-4A chain	Homo sapiens (human)
intercellular bridge	Tubulin beta-4A chain	Homo sapiens (human)
extracellular exosome	Tubulin beta-4A chain	Homo sapiens (human)
mitotic spindle	Tubulin beta-4A chain	Homo sapiens (human)
microtubule	Tubulin beta-4A chain	Homo sapiens (human)
cytoplasm	Tubulin beta-4A chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
extracellular region	Tubulin beta chain	Homo sapiens (human)
nucleus	Tubulin beta chain	Homo sapiens (human)
nuclear envelope lumen	Tubulin beta chain	Homo sapiens (human)
cytoplasm	Tubulin beta chain	Homo sapiens (human)
cytosol	Tubulin beta chain	Homo sapiens (human)
cytoskeleton	Tubulin beta chain	Homo sapiens (human)
microtubule	Tubulin beta chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin beta chain	Homo sapiens (human)
azurophil granule lumen	Tubulin beta chain	Homo sapiens (human)
cytoplasmic ribonucleoprotein granule	Tubulin beta chain	Homo sapiens (human)
cell body	Tubulin beta chain	Homo sapiens (human)
membrane raft	Tubulin beta chain	Homo sapiens (human)
intercellular bridge	Tubulin beta chain	Homo sapiens (human)
extracellular exosome	Tubulin beta chain	Homo sapiens (human)
mitotic spindle	Tubulin beta chain	Homo sapiens (human)
protein-containing complex	Tubulin beta chain	Homo sapiens (human)
cytoplasm	Tubulin beta chain	Homo sapiens (human)
microtubule	Tubulin beta chain	Homo sapiens (human)
cytoplasm	Cytochrome P450 3A4	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 3A4	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 3A4	Homo sapiens (human)
nucleus	Tubulin alpha-3C chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin alpha-3C chain	Homo sapiens (human)
microtubule	Tubulin alpha-3C chain	Homo sapiens (human)
cytoplasm	Tubulin alpha-3C chain	Homo sapiens (human)
endoplasmic reticulum membrane	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C9	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C9	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
endoplasmic reticulum membrane	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
intracellular membrane-bounded organelle	Cytochrome P450 2C19	Homo sapiens (human)
cytoplasm	Cytochrome P450 2C19	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
microtubule cytoskeleton	Tubulin alpha-1B chain	Homo sapiens (human)
microtubule	Tubulin alpha-1B chain	Homo sapiens (human)
cytoplasmic microtubule	Tubulin alpha-1B chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin alpha-1B chain	Homo sapiens (human)
microtubule	Tubulin alpha-1B chain	Homo sapiens (human)
cytoplasm	Tubulin alpha-1B chain	Homo sapiens (human)
extracellular region	Tubulin alpha-4A chain	Homo sapiens (human)
cytosol	Tubulin alpha-4A chain	Homo sapiens (human)
cytoskeleton	Tubulin alpha-4A chain	Homo sapiens (human)
microtubule	Tubulin alpha-4A chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin alpha-4A chain	Homo sapiens (human)
extracellular exosome	Tubulin alpha-4A chain	Homo sapiens (human)
cytoplasm	Tubulin alpha-4A chain	Homo sapiens (human)
microtubule	Tubulin alpha-4A chain	Homo sapiens (human)
extracellular region	Tubulin beta-4B chain	Homo sapiens (human)
nucleus	Tubulin beta-4B chain	Homo sapiens (human)
cytosol	Tubulin beta-4B chain	Homo sapiens (human)
cytoskeleton	Tubulin beta-4B chain	Homo sapiens (human)
microtubule	Tubulin beta-4B chain	Homo sapiens (human)
axonemal microtubule	Tubulin beta-4B chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin beta-4B chain	Homo sapiens (human)
azurophil granule lumen	Tubulin beta-4B chain	Homo sapiens (human)
intercellular bridge	Tubulin beta-4B chain	Homo sapiens (human)
extracellular exosome	Tubulin beta-4B chain	Homo sapiens (human)
mitotic spindle	Tubulin beta-4B chain	Homo sapiens (human)
extracellular vesicle	Tubulin beta-4B chain	Homo sapiens (human)
microtubule	Tubulin beta-4B chain	Homo sapiens (human)
cytoplasm	Tubulin beta-4B chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin beta-3 chain	Homo sapiens (human)
nucleus	Tubulin beta-3 chain	Homo sapiens (human)
microtubule	Tubulin beta-3 chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin beta-3 chain	Homo sapiens (human)
lamellipodium	Tubulin beta-3 chain	Homo sapiens (human)
filopodium	Tubulin beta-3 chain	Homo sapiens (human)
axon	Tubulin beta-3 chain	Homo sapiens (human)
dendrite	Tubulin beta-3 chain	Homo sapiens (human)
growth cone	Tubulin beta-3 chain	Homo sapiens (human)
neuronal cell body	Tubulin beta-3 chain	Homo sapiens (human)
intercellular bridge	Tubulin beta-3 chain	Homo sapiens (human)
extracellular exosome	Tubulin beta-3 chain	Homo sapiens (human)
cell periphery	Tubulin beta-3 chain	Homo sapiens (human)
mitotic spindle	Tubulin beta-3 chain	Homo sapiens (human)
microtubule	Tubulin beta-3 chain	Homo sapiens (human)
cytoplasm	Tubulin beta-3 chain	Homo sapiens (human)
nucleus	Tubulin beta-2A chain	Homo sapiens (human)
microtubule	Tubulin beta-2A chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin beta-2A chain	Homo sapiens (human)
intercellular bridge	Tubulin beta-2A chain	Homo sapiens (human)
extracellular exosome	Tubulin beta-2A chain	Homo sapiens (human)
mitotic spindle	Tubulin beta-2A chain	Homo sapiens (human)
extracellular vesicle	Tubulin beta-2A chain	Homo sapiens (human)
cytoplasm	Tubulin beta-2A chain	Homo sapiens (human)
microtubule	Tubulin beta-2A chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin beta-8 chain	Homo sapiens (human)
intercellular bridge	Tubulin beta-8 chain	Homo sapiens (human)
extracellular exosome	Tubulin beta-8 chain	Homo sapiens (human)
mitotic spindle	Tubulin beta-8 chain	Homo sapiens (human)
meiotic spindle	Tubulin beta-8 chain	Homo sapiens (human)
microtubule	Tubulin beta-8 chain	Homo sapiens (human)
cytoplasm	Tubulin beta-8 chain	Homo sapiens (human)
plasma membrane	Calcium-activated potassium channel subunit alpha-1	Rattus norvegicus (Norway rat)
microtubule cytoskeleton	Tubulin beta-2B chain	Bos taurus (cattle)
nucleus	Tubulin alpha-3E chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin alpha-3E chain	Homo sapiens (human)
microtubule	Tubulin alpha-3E chain	Homo sapiens (human)
cytoplasm	Tubulin alpha-3E chain	Homo sapiens (human)
condensed chromosome	Tubulin alpha-1A chain	Homo sapiens (human)
nucleus	Tubulin alpha-1A chain	Homo sapiens (human)
cytosol	Tubulin alpha-1A chain	Homo sapiens (human)
microtubule	Tubulin alpha-1A chain	Homo sapiens (human)
axonemal microtubule	Tubulin alpha-1A chain	Homo sapiens (human)
plasma membrane	Tubulin alpha-1A chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin alpha-1A chain	Homo sapiens (human)
neuromuscular junction	Tubulin alpha-1A chain	Homo sapiens (human)
cytoplasmic ribonucleoprotein granule	Tubulin alpha-1A chain	Homo sapiens (human)
recycling endosome	Tubulin alpha-1A chain	Homo sapiens (human)
extracellular exosome	Tubulin alpha-1A chain	Homo sapiens (human)
microtubule	Tubulin alpha-1A chain	Homo sapiens (human)
cytoplasm	Tubulin alpha-1A chain	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
nucleus	Tubulin alpha-1C chain	Homo sapiens (human)
microtubule	Tubulin alpha-1C chain	Homo sapiens (human)
cytoplasmic microtubule	Tubulin alpha-1C chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin alpha-1C chain	Homo sapiens (human)
vesicle	Tubulin alpha-1C chain	Homo sapiens (human)
membrane raft	Tubulin alpha-1C chain	Homo sapiens (human)
microtubule	Tubulin alpha-1C chain	Homo sapiens (human)
cytoplasm	Tubulin alpha-1C chain	Homo sapiens (human)
nucleus	Tubulin beta-6 chain	Homo sapiens (human)
microtubule	Tubulin beta-6 chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin beta-6 chain	Homo sapiens (human)
intercellular bridge	Tubulin beta-6 chain	Homo sapiens (human)
extracellular exosome	Tubulin beta-6 chain	Homo sapiens (human)
mitotic spindle	Tubulin beta-6 chain	Homo sapiens (human)
cytoplasm	Tubulin beta-6 chain	Homo sapiens (human)
microtubule	Tubulin beta-6 chain	Homo sapiens (human)
nucleus	Tubulin beta-2B chain	Homo sapiens (human)
microtubule	Tubulin beta-2B chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin beta-2B chain	Homo sapiens (human)
intercellular bridge	Tubulin beta-2B chain	Homo sapiens (human)
mitotic spindle	Tubulin beta-2B chain	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Tubulin beta-2B chain	Homo sapiens (human)
microtubule	Tubulin beta-2B chain	Homo sapiens (human)
cytoplasm	Tubulin beta-2B chain	Homo sapiens (human)
cytoplasm	Tubulin beta-1 chain	Homo sapiens (human)
microtubule cytoskeleton	Tubulin beta-1 chain	Homo sapiens (human)
intercellular bridge	Tubulin beta-1 chain	Homo sapiens (human)
extracellular exosome	Tubulin beta-1 chain	Homo sapiens (human)
mitotic spindle	Tubulin beta-1 chain	Homo sapiens (human)
microtubule	Tubulin beta-1 chain	Homo sapiens (human)
cytoplasm	Tubulin beta-1 chain	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1369)

Assay ID	Title	Year	Journal	Article
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1645848	NCATS Kinetic Aqueous Solubility Profiling	2019	Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14	Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
AID1645871	NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling in pH 5 buffer	2022	Bioorganic & medicinal chemistry, 02-15, Volume: 56	Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347137	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347135	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347136	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347140	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347138	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1508591	NCATS Rat Liver Microsome Stability Profiling	2020	Scientific reports, 11-26, Volume: 10, Issue:1	Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1508612	NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Highly predictive and interpretable models for PAMPA permeability.
AID655132	Cytotoxicity against human NCI-H226 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1754702	Cytotoxicity in human A549 cells assessed as inhibition of cell proliferation measured by CCK-8 assay	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID310756	Antiproliferative activity against human MCF7 cells	2007	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24	3-(2'-Bromopropionylamino)-benzamides as novel S-phase arrest agents.
AID1432151	Inhibition of porcine brain tubulin polymerization at 5 uM measured for 1 hr by fluorescence assay relative to control
AID699779	Antimitotic activity in human A549 cells assessed as induction of microtubule depolymerization at 0.05 to 100 uM after 20 hrs by Hoechst 33342 staining-based fluorescence microscopy	2012	Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15	Synthesis and antimitotic and tubulin interaction profiles of novel pinacol derivatives of podophyllotoxins.
AID87920	Effect on cell cycle evaluated as proportion of cells in S phase of the cell cycle at 10E-6 M for 24 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1233442	Cytotoxicity against human A549 cells assessed as cell viability by SRB assay	2015	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14	Synthesis and Biological evaluation of novel 4β-[(5-substituted)-1,2,3,4-tetrazolyl] podophyllotoxins as anticancer compounds.
AID524794	Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID88037	Effect on cell cycle evaluated as proportion of cells in S phase of the cell cycle at 10E-8 M for 48 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID335776	Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 0.032 ug/mL	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID1317404	Antiproliferative activity against human HT-29 cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID655248	Cytotoxicity against human Hs 578T cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1906555	Ratio of IC50 for cytotoxicity against human HeLa cells overexpressing tubulin beta3 assessed as inhibition of cell growth measured after 48 hrs to IC50 for cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs	2022	European journal of medicinal chemistry, May-05, Volume: 235	Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy.
AID655233	Cytotoxicity against human OVCAR8 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1182196	Antimitotic microtubule destabilizing activity in Paracentrotus lividus L embryos assessed as induction of cleavage alteration	2014	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16	Comparative in vivo evaluation of polyalkoxy substituted 4H-chromenes and oxa-podophyllotoxins as microtubule destabilizing agents in the phenotypic sea urchin embryo assay.
AID347582	Inhibition of pig brain tubulin polymerization after 30 mins by turbidimetric assay	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1416605	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
AID1057258	Cytotoxicity against human KB cells assessed as cell viability after 24 hrs by MTT assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
AID214361	Tested for the inhibition of polymerization rate of tubulin microtubule assembly.	1980	Journal of medicinal chemistry, May, Volume: 23, Issue:5	Structure--antitubulin activity relationship in steganacin congeners and analogues. Inhibition of tubulin polymerization in vitro by (+/-)-isodeoxypodophyllotoxin.
AID727327	Toxicity against rat L6 cells after 72 hrs by Alamar blue assay	2013	Journal of medicinal chemistry, Feb-28, Volume: 56, Issue:4	Synthesis and in vitro antimalarial testing of neocryptolepines: SAR study for improved activity by introduction and modifications of side chains at C2 and C11 on indolo[2,3-b]quinolines.
AID1489094	Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase at 0.6 uM after 16 hrs by propidium iodide staining based flow cytometric method (Rvb = 60.19 to 60.87%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID443476	Inhibition of microtubule in human A549 cells assessed as roundish cells at 0.5 uM after 24 hrs by immunofluorescence analysis	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID1180381	Antiproliferative activity against human MiaPaCa cells after 48 hrs by SRB assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Synthesis and biological evaluation of 4-aza-2,3-dihydropyridophenanthrolines as tubulin polymerization inhibitors.
AID655134	Cytotoxicity against human NCI-H322M cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1334731	Aqueous solubility of the compound at pH 7.4 measured after 4 hrs by HPLC/UV analysis	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Novel carbazole sulfonamide derivatives of antitumor agent: Synthesis, antiproliferative activity and aqueous solubility.
AID152273	In vitro cytotoxicity against the P-388 (from DBA/2 mouse) neoplastic cell line	2004	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5	Synthesis and cytotoxicity of hydrophobic esters of podophyllotoxins.
AID1549910	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, May-15, Volume: 170	Discover 4β-NH-(6-aminoindole)-4-desoxy-podophyllotoxin with nanomolar-potency antitumor activity by improving the tubulin binding affinity on the basis of a potential binding site nearby colchicine domain.
AID1456112	Cell cycle arrest in human Bel7402/5-FU cells assessed as accumulation at S phase at 0.05 uM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 12.62%)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID359893	Cytotoxicity against human A498 cells by MTT assay	1994	Journal of natural products, Dec, Volume: 57, Issue:12	Cytotoxic cyclolignans from Koelreuteria henryi.
AID1728396	Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Design, synthesis and screening of benzimidazole containing compounds with methoxylated aryl radicals as cytotoxic molecules on (HCT-116) colon cancer cells.
AID1779356	Cytotoxicity against rat L6 cells assessed as reduction in cell viability incubated for 70 hrs by resazurin dye based fluorescence assay	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	Synthesis, in vitro antiprotozoal activity, molecular docking and molecular dynamics studies of some new monocationic guanidinobenzimidazoles.
AID1637428	Induction of ERK1/2 phosphorylation in human K562/ADR cells at 0.05 uM after 48 hrs by Western blot analysis relative to control	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID378591	Antiplasmodial activity against multi drug-resistant Plasmodium falciparum K1 in erythrocytes by [3H]hypoxanthine uptake	2000	Journal of natural products, Dec, Volume: 63, Issue:12	In vitro antiplasmodial, antiamoebic, and cytotoxic activities of some monomeric isoquinoline alkaloids.
AID1882893	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID340102	Cytotoxicity against human WRL68 cells after 24 hrs by MTT assay	2008	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14	Gallic acid-based indanone derivatives as anticancer agents.
AID655243	Cytotoxicity against human UO31 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID8624	In vitro cytotoxic activity against renal (A 498) cancer cell line.	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	9-Deoxopodophyllotoxin derivatives as anti-cancer agents.
AID87904	Effect on cell cycle evaluated as proportion of cells in G0/G1 phase of the cell cycle at 10E-6 M for 48 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1317417	Inhibition of colony formation in human T47D cells after 7 days by crystal violet staining based assay	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID1489101	Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 2 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 2.35 to 2.49%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1754715	Induction of apoptosis in human PC-3M cells assessed as late apoptotic cells at 1 nM measured after 48 hrs by Annexin V/PI staining based flow cytometry method (Rvb = 2.88%)	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID303243	Cytotoxicity against rat L6 cells	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and in vitro antiprotozoal activity of bisbenzofuran cations.
AID1142159	Binding affinity to rat brain tubulin at 37 degC after 1 to 2 mins by DEAE cellulose filter paper method	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Novel colchicine-site binders with a cyclohexanedione scaffold identified through a ligand-based virtual screening approach.
AID1193502	Cytotoxicity against rat L6 cells	2015	Bioorganic & medicinal chemistry, Apr-01, Volume: 23, Issue:7	Anti-trypanosomal cadinanes synthesized by transannular cyclization of the natural sesquiterpene lactone nobilin.
AID1504892	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence assay	2018	Journal of natural products, 01-26, Volume: 81, Issue:1	Antiprotozoal Sesquiterpene Lactones and Other Constituents from Tarchonanthus camphoratus and Schkuhria pinnata.
AID1069846	Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Synthesis of neolignans as microtubule stabilisers.
AID593184	Antimalarial activity against chloroquine-resistant erythrocytic stage of Plasmodium falciparum K1 assessed as inhibition of [3H}hypoxanthine incorporation after 24 hrs by liquid scintillation counter	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	β-Branched acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase.
AID655126	Cytotoxicity against human RPMI8226 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1491419	Inhibition of porcine brain tubulin polymerization at 5 uM measured for 1 hr by fluorescence assay relative to control	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Synthesis of thiazole linked indolyl-3-glyoxylamide derivatives as tubulin polymerization inhibitors.
AID1882950	Tmax in Sprague-Dawley rat at 10 mg/kg, iv by HPLC-MS/MS analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID214524	Percentage control on Tubulin- Dependent GTP hydrolysis was evaluated at 10 micro M concentration	1999	Bioorganic & medicinal chemistry letters, Apr-19, Volume: 9, Issue:8	A new anti-tubulin agent containing the benzo[b]thiophene ring system.
AID655230	Cytotoxicity against human OVCAR3 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID655251	Cytotoxicity against human MDA-MB-468 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1416608	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
AID1169289	Cytotoxicity against rat L6 cells	2014	Journal of natural products, Oct-24, Volume: 77, Issue:10	Antitrypanosomal quinoline alkaloids from the roots of Waltheria indica.
AID595455	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Didemnidines A and B, indole spermidine alkaloids from the New Zealand ascidian Didemnum sp.
AID628165	Inhibition of microtubule polymerization in human A549 cells assessed as total disruption of interphase microtubule network at 5 uM after 8 hrs by immunofluorescence microscopy	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID1549904	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, May-15, Volume: 170	Discover 4β-NH-(6-aminoindole)-4-desoxy-podophyllotoxin with nanomolar-potency antitumor activity by improving the tubulin binding affinity on the basis of a potential binding site nearby colchicine domain.
AID44201	Effect on cross resistance of CCRF-CEM cells resistant to vincristine expressed as log of ratio of molar concentration of compound inducing 50% growth inhibition in resistant to sensitive cells	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID273082	Antiproliferative activity against human MCF7 cells after 72 hrs	2006	Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21	Synthesis and structure-activity relationships of carbazole sulfonamides as a novel class of antimitotic agents against solid tumors.
AID384947	Binding affinity to HPV1a recombinant E2 protein hinge domain by surface plasmon resonance assay	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Podophyllotoxin directly binds a hinge domain in E2 of HPV and inhibits an E2/E7 interaction in vitro.
AID1432130	Cell cycle arrest in human DU145 cells assessed as accumulation at S phase at 400 nM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 7.91%)
AID443485	Cytotoxicity against c-myc/c-raf double transgenic mouse yA7 cells by MTS assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID1456101	Resistant factor, ratio of IC50 for human Bel7402/5-FU cells to IC50 for human Bel7402 cells	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID214711	Inhibition of colchicine binding and evaluated only when polymerization IC50 <=1 uM	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	Antitumor agents. 174. 2',3',4',5,6,7-Substituted 2-phenyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization.
AID655226	Cytotoxicity against human SK-MEL-5 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID655219	Cytotoxicity against human U251 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID270964	Cytotoxicity against proliferating RKOp27 cells after 72 hrs by Alamar Blue assay	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	[4-(imidazol-1-yl)thiazol-2-yl]phenylamines. A novel class of highly potent colchicine site binding tubulin inhibitors: synthesis and cytotoxic activity on selected human cancer cell lines.
AID1306322	Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 2 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 64.68 to 80.32%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID214013	Inhibition of tubulin polymerization	1993	Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9	Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID598808	Cytotoxicity against human KB cells after 72 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Three new cytotoxic aryltetralin lignans from Sinopodophyllum emodi.
AID359896	Cytotoxicity against human HT-29 cells by MTT assay	1994	Journal of natural products, Dec, Volume: 57, Issue:12	Cytotoxic cyclolignans from Koelreuteria henryi.
AID602111	Inhibition of purified bovine tubulin polymerization assessed as microtubule destabilization at 25 uM after 20 mins by fluorescence spectrophotometric analysis	2011	Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12	Anticancer properties of an important drug lead podophyllotoxin can be efficiently mimicked by diverse heterocyclic scaffolds accessible via one-step synthesis.
AID1628267	Binding affinity to goat brain tubulin pre-incubated for 30 mins with 5-(Quinolin-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-imidazol-2-amine before compound exposure for 30 mins by fluorescence based assay	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Novel Combretastatin-2-aminoimidazole Analogues as Potent Tubulin Assembly Inhibitors: Exploration of Unique Pharmacophoric Impact of Bridging Skeleton and Aryl Moiety.
AID1456203	Effect on E-cadherin expression in human Bel7402/5-FU cells assessed as ratio of E-cadherin to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.2 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID360831	Cytotoxicity against human KB cells by alamar blue assay	2002	Journal of natural products, Jul, Volume: 65, Issue:7	Isolation and in vitro antiplasmodial activities of alkaloids from Teclea trichocarpa: in vivo antimalarial activity and X-ray crystal structure of normelicopicine.
AID335771	Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 100 ug/mL	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID1361528	Induction of apoptosis in human MCF7 cells assessed as necrotic cells at IC50 after 24 hrs by annexin V/FITC-propidium iodide staining-based flow cytometric method (Rvb = 0.53%)	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Design, synthesis and screening of 1, 2, 4-triazinone derivatives as potential antitumor agents with apoptosis inducing activity on MCF-7 breast cancer cell line.
AID628162	Inhibition of microtubule polymerization in human A549 cells assessed as total disruption of interphase microtubule network at 0.1 uM after 8 hrs by immunofluorescence microscopy	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID1495312	Downregulation of P-gp expression in human K562/VCR cells at 0.05 uM after 48 hrs by Western blot method relative to beta-actin	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID398312	Inhibition of tubulin polymerization	1995	Journal of natural products, Apr, Volume: 58, Issue:4	Antitumor agents, 154. Cytotoxic and antimitotic flavonols from Polanisia dodecandra.
AID305850	Cytotoxicity against human HeLa cells assessed as viability at 5 uM after 48 hrs by MTT method relative to control	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Structural simplification of bioactive natural products with multicomponent synthesis: dihydropyridopyrazole analogues of podophyllotoxin.
AID355578	Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay
AID80250	In vitro cytotoxicity against human colon cancer HCT 116 cell line	1998	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11	Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents.
AID1754700	Cytotoxicity in human PC-3M cells assessed as inhibition of cell proliferation measured by CCK-8 assay	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID1317435	Induction of apoptosis in human T47D cells assessed as early apoptotic cells at 20 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.75 %)	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID1317431	Induction of apoptosis in human T47D cells assessed as early apoptotic cells at 5 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.75 %)	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID1233449	Induction of cell cycle arrest in human A549 cells assessed as accumulation at G1 phase at 5 uM after 24 hrs by flow cytometry	2015	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14	Synthesis and Biological evaluation of novel 4β-[(5-substituted)-1,2,3,4-tetrazolyl] podophyllotoxins as anticancer compounds.
AID443483	Cytotoxicity against c-myc/c-raf double transgenic mouse betaD5 cells by MTS assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID602106	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	2011	Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12	Anticancer properties of an important drug lead podophyllotoxin can be efficiently mimicked by diverse heterocyclic scaffolds accessible via one-step synthesis.
AID1317418	Antimigratory activity in human T47D cells assessed as inhibition of cell migration after 12 hrs by crystal violet staining based transwell migration assay	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID1760492	Cytotoxicity against human L02 cells	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID655206	Cytotoxicity against human NCI-H522 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID655247	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID87923	Effect on cell cycle evaluated as proportion of cells in S phase of the cell cycle at 10E-7 M for 24 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID355586	Antiproliferative activity against mouse P388 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID1233450	Induction of cell cycle arrest in human A549 cells assessed as accumulation at S phase at 5 uM after 24 hrs by flow cytometry	2015	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14	Synthesis and Biological evaluation of novel 4β-[(5-substituted)-1,2,3,4-tetrazolyl] podophyllotoxins as anticancer compounds.
AID96208	The toxicity was evaluated against KB cells	2001	Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14	Design, synthesis, and biological evaluation of a series of simple and novel potential antimalarial compounds.
AID1082996	Insecticidal activity against pre-third-instar larvae of Mythimna separata (Oriental armyworm) in wheat leaves at 1 mg/mL after 33 days by leaf-dipping method	2012	Journal of agricultural and food chemistry, Aug-29, Volume: 60, Issue:34	Synthesis and quantitative structure-activity relationship (QSAR) study of novel isoxazoline and oxime derivatives of podophyllotoxin as insecticidal agents.
AID1698822	Antimitotic activity against sea urchin embryo assessed as cleavage alteration measured 2.5 to 6 hrs post-fertilization by light microscopy analysis	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Computational modeling and target synthesis of monomethoxy-substituted o-diphenylisoxazoles with unexpectedly high antimitotic microtubule destabilizing activity.
AID403989	Antiviral activity against Murine cytomegalovirus in mouse 3T3-L1 cells at 241 nM	1998	Journal of natural products, Nov, Volume: 61, Issue:11	Antiviral activity of lignans.
AID88046	Effect on cell cycle evaluated as proportion of cells in sub-G1 phase of the cell cycle at 10E-7 M for 48 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1246960	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	One-pot synthesis of podophyllotoxin-thiourea congeners by employing NH₂SO₃H/NaI: Anticancer activity, DNA topoisomerase-II inhibition, and apoptosis inducing agents.
AID1395720	Cytotoxicity against human A431 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Antiproliferative efficacy of curcumin mimics through microtubule destabilization.
AID1306337	Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.021 to 3.8%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID103000	In vitro cytotoxic activity against melanoma (M 14) cancer cell line.	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	9-Deoxopodophyllotoxin derivatives as anti-cancer agents.
AID1154489	Cytotoxicity against mouse J774A1 cells after 72 hrs by MTT assay	2014	Journal of medicinal chemistry, Jun-26, Volume: 57, Issue:12	Antileishmanial activity of a series of N²,N⁴-disubstituted quinazoline-2,4-diamines.
AID1126160	Cytotoxicity against rat L6 cells	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Antiparasitic chaiyaphumines from entomopathogenic Xenorhabdus sp. PB61.4.
AID1091892	In vivo insecticidal activity against pre-third-instar larval stage of Mythimna separata (Oriental armyworm) in corn leaves assessed as corrected mortality rate at 1 mg/ml treated for 3 secs before larval infestation on corn leaves measured after 33 days	2010	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15	Natural products-based insecticidal agents 6. Design, semisynthesis, and insecticidal activity of novel monomethyl phthalate derivatives of podophyllotoxin against Mythimna separata Walker in vivo.
AID1760386	Antiproliferative activity against human HeLa cells incubated for 24 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID273085	Antiproliferative activity against human DND1 cells after 72 hrs	2006	Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21	Synthesis and structure-activity relationships of carbazole sulfonamides as a novel class of antimitotic agents against solid tumors.
AID1882948	MRT in Sprague-Dawley rat at 10 mg/kg, iv by HPLC-MS/MS analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID628167	Cell cycle arrest in human Jurkat cells assessed as accumulation of cells in G2/M phase at 25 nM after 24 hrs by propidium iodide staining-based flow cytometry	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID83763	In vitro cytotoxicity against HT-29 (human colon carcinoma) cell line.	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID257600	Inhibition of porcine brain tubulin polymerization by GTP-induced assembly	2005	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24	Conformationally restricted analogs of Combretastatin A-4 derived from SU5416.
AID359901	Inhibition of bovine brain tubulin polymerization by sedimentation assay	1994	Journal of natural products, Dec, Volume: 57, Issue:12	Cytotoxic cyclolignans from Koelreuteria henryi.
AID1187289	Cytotoxicity against human K562 cells after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Synthesis and evaluation of novel podophyllotoxin derivatives as potential antitumor agents.
AID298673	Induction of apoptosis in Jurkat cells after 24 hrs by flow cytometric Annexin-V/propidium iodide assay	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis.
AID464498	Inhibition of tubulin polymerization at 10 uM by fluorescence method	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID1233714	Antiproliferative activity against mouse NIH/3T3 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay	2015	Journal of natural products, Jul-24, Volume: 78, Issue:7	An Isoflavone from Leiophyllum buxifolium and Its Antiproliferative Effect.
AID1515152	Antiproliferative activity against human MCF7 cells after 48 hrs by CellTiter 96 AQueous one solution cell proliferation assay	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway.
AID1432115	Growth inhibition of human HCT15 cells after 48 hrs by MTT assay
AID1495282	Cell cycle arrest in human K562/VCR cells assessed as accumulation at G1 phase at 0.05 uM after 48 hrs by propidium iodide staining-based flow cytometric method (Rvb = 46.20%)	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID492477	Antitumor activity against human OVCAR-3 cells xenografted in mouse assessed as increase in mouse life span	2010	Journal of natural products, Mar-26, Volume: 73, Issue:3	Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.
AID1428409	Cytotoxicity against vinblastine-sensitive human MCF7 cells assessed as growth inhibition after 72 hrs by SRB assay
AID1140297	Anticancer activity against human A549 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9	Synthesis of a terphenyl substituted 4-aza-2,3-didehydropodophyllotoxin analogues as inhibitors of tubulin polymerization and apoptosis inducers.
AID115987	In vivo antitumor activity against the L1210 leukemia cell line expressed as percent increase in life span; ND means no data	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	In vivo antitumor activity of 6-benzyl-1,3-benzodioxole derivatives against the P388, L1210, B16, and M5076 murine models.
AID1754723	Induction of apoptosis in human PC-3M cells assessed as late apoptotic cells at 10 nM measured after 48 hrs by Annexin V/PI staining based flow cytometry method (Rvb = 2.88%)	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID1754717	Induction of apoptosis in human PC-3M cells assessed as viable cells at 5 nM measured after 48 hrs by Annexin V/PI staining based flow cytometry method (Rvb = 95.6%)	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID1267709	Induction of apoptosis in human K562/ADR cells assessed as necrotic cells at 0.1 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 3.57%)	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID690946	Cytotoxicity in brine shrimps larvae assessed as mortality after 24 hrs	2012	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20	Synthesis, characterization and biological evaluation of some novel 2,4-thiazolidinediones as potential cytotoxic, antimicrobial and antihyperglycemic agents.
AID618834	Cytotoxicity against human K562 cells after 2 days by MTT assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis of 4β-triazole-podophyllotoxin derivatives by azide-alkyne cycloaddition and biological evaluation as potential antitumor agents.
AID88036	Effect on cell cycle evaluated as proportion of cells in S phase of the cell cycle at 10E-8 M for 24 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1489095	Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 0.6 uM after 16 hrs by propidium iodide staining based flow cytometric method (Rvb = 29.55 to 32.22%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1637425	Induction of apoptosis in human K562/ADR cells assessed as nuclear fragmentation at 0.05 uM after 48 hrs by Hoechst 33342 staining based fluorescent microscopic analysis	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID754082	Solubility of the compound in water	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and cytotoxic activity on human cancer cells of carbamate derivatives of 4β-(1,2,3-triazol-1-yl)podophyllotoxin.
AID379325	Cytotoxicity against human Caco-2 cells	2000	Journal of natural products, Mar, Volume: 63, Issue:3	Novel extracellular diterpenoids with biological activity from the cyanobacterium Nostoc commune.
AID1495291	Induction of apoptosis in human K562/VCR cells assessed as viable cells at 0.05 uM after 48 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 91.05%)	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID694347	Cytotoxicity against mouse J774 cells	2012	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22	Antileishmanial bis-arylimidamides: DB766 analogs modified in the linker region and bis-arylimidamide structure-activity relationships.
AID608685	Cytotoxicity against human KB cells assessed as growth inhibition at 0.5 uM	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Antiplasmodial and cytotoxicity evaluation of 3-functionalized 2-azetidinone derivatives.
AID628163	Inhibition of microtubule polymerization in human A549 cells assessed as total disruption of interphase microtubule network at 0.5 uM after 8 hrs by immunofluorescence microscopy	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID655227	Cytotoxicity against human UACC257 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID311648	Cytotoxicity against rat L6 cells by Alamar blue assay	2007	Journal of natural products, Oct, Volume: 70, Issue:10	Antiprotozoal polyacetylenes from the Tanzanian medicinal plant Cussonia zimmermannii.
AID1688126	Inhibition of DNA-topoisomerase 2 in human MCF7 cells using kinetoplast DNA as substrate at 120 uM measured by ELISA	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition.
AID336478	Inhibition of COX2 at 100 uM by scintillation proximity assay	2002	Journal of natural products, Nov, Volume: 65, Issue:11	Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay.
AID1233713	Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay	2015	Journal of natural products, Jul-24, Volume: 78, Issue:7	An Isoflavone from Leiophyllum buxifolium and Its Antiproliferative Effect.
AID88047	Effect on cell cycle evaluated as proportion of cells in sub-G1 phase(apoptic cells) of the cell cycle at 10E-8 M for 72 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID695930	Cytotoxicity against human HeLa cells after 48 hrs	2012	Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21	Synthesis and biological evaluation of a series of podophyllotoxins derivatives as a class of potent antitubulin agents.
AID298656	Antiproliferative activity against human MCF7/AZ cells assessed as cell viability at 5 uM after 48 hrs by MTT assay relative to control	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis.
AID359897	Cytotoxicity against human MCF7 cells by MTT assay	1994	Journal of natural products, Dec, Volume: 57, Issue:12	Cytotoxic cyclolignans from Koelreuteria henryi.
AID1168740	Anticancer activity against human MDA-MB cells after 24 hrs by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID1200316	Antiproliferative activity against human A549 cells assessed as reduction in cell viability up to 100 uM after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells.
AID655236	Cytotoxicity against human 786-0 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1177595	Cytotoxicity against rat L6 cells	2014	Journal of natural products, Aug-22, Volume: 77, Issue:8	Xenortide Biosynthesis by Entomopathogenic Xenorhabdus nematophila.
AID655130	Cytotoxicity against human HOP62 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID657123	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and anticancer activity of 2-benzylidene indanones through inhibiting tubulin polymerization.
AID1549997	Binding affinity to alpha/beta tubulin complex (unknown origin)	2019	European journal of medicinal chemistry, May-15, Volume: 170	Discover 4β-NH-(6-aminoindole)-4-desoxy-podophyllotoxin with nanomolar-potency antitumor activity by improving the tubulin binding affinity on the basis of a potential binding site nearby colchicine domain.
AID1416606	Cytotoxicity against human B16 cells after 48 hrs by MTT assay
AID628173	Induction of apoptosis in human Jurkat cells assessed as cells with active form of caspase-3 at 50 nM after 48 hrs by annexin-V FITC/7-ADD staining-based flow cytometric analysis (Rvb = 7.1%)	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID1306332	Cytotoxicity against human A549 cells after 36 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1882896	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1489099	Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 2 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 2.36 to 2.86%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID298660	Increase in caspase 3 activation in Jurkat cells at 5 uM	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis.
AID1403417	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID336446	Antileishmanial activity against Leishmania donovani (MHOM/ET/67/L82) promastigotes	2002	Journal of natural products, Oct, Volume: 65, Issue:10	Assessment of the antiprotozoal activity of Galphimia glauca and the isolation of new nor-secofriedelanes and nor-friedelanes.
AID416486	Cytotoxicity against rat L6 cells	2009	European journal of medicinal chemistry, Feb, Volume: 44, Issue:2	Antiplasmodial and antitrypanosomal activities of aminobicyclo[2.2.2]octyl omega-aminoalkanoates.
AID1306325	Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 2 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 15.95 to 25.74%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1439848	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue staining based fluorometric assay	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	New derivatives of quinoline-4-carboxylic acid with antiplasmodial activity.
AID321843	Induction of apoptosis in human Jurkat cells assessed as viable cells at 5 uM after 48 hrs by flow cytometry relative to control	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Novel three-component synthesis and antiproliferative properties of diversely functionalized pyrrolines.
AID42665	Ability to inhibit Tubulin polymerization in Bovine brain	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID443486	Cytotoxicity against c-myc/c-raf double transgenic mouse yA3 cells by MTS assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID552696	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei s427 after 72 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and antitrypanosomal evaluation of derivatives of N-benzyl-1,2-dihydroquinolin-6-ols: Effect of core substitutions and salt formation.
AID101652	In vitro cytotoxicity against human breast cancer MDA-MB 231 cell line	1998	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11	Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents.
AID293485	Cytotoxicity against human A549 cells after 4 days	2007	Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4	Synthesis and cytotoxic evaluation of C-9 oxidized podophyllotoxin derivatives.
AID655258	Cytotoxicity against human Jurkat cells	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID386866	Cytotoxicity against human DU145 cells by sulforhodamine B assay	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Studies on novel 4beta-[(4-substituted)-1,2,3-triazol-1-yl] podophyllotoxins as potential anticancer agents.
AID1456129	Induction of apoptosis in human Bel7402/5-FU cells at 0.05 uM after 24 hrs by Hoechst 33342 staining based fluorescent microscopic method	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1489106	Induction of apoptosis in human MCF7 cells assessed as viable cells at 8 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 91.6 to 92.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID628169	Cell cycle arrest in human A549 cells assessed as accumulation of cells in G2/M phase after 24 hrs by propidium iodide staining-based flow cytometry	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID1403414	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.
AID634097	Anticancer activity against human HT-29 cells after 48 hrs by MTT assay	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and anticancer activity of 4β-alkylamidochalcone and 4β-cinnamido linked podophyllotoxins as apoptotic inducing agents.
AID277522	Cytotoxicity against androgen sensitive human LNCaP cells	2007	Journal of natural products, Feb, Volume: 70, Issue:2	Lignans from Dysosma versipellis with inhibitory effects on prostate cancer cell lines.
AID277523	Cytotoxicity against androgen-independent human PC3 cells	2007	Journal of natural products, Feb, Volume: 70, Issue:2	Lignans from Dysosma versipellis with inhibitory effects on prostate cancer cell lines.
AID1148912	Displacement of [3H]colchicine from bovine brain tubulin at 16 uM after 90 mins by liquid scintillation counting in presence of 10 uM [3H]colchicine	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Podophyllotoxin analogs. 1. Synthesis and biological evaluation of certain trans-2-aryl-trans-6-hydroxymethyl-3-cyclohexenecarboxylic acid gamma-lactones as antimitotic agents.
AID464516	Selectivity for human HEK293 cells over human HMEC	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID1112940	Insecticidal activity against pre-third-instar larvae of Mythimna separata (Oriental armyworm) assessed as corrected mortality rate at 1 mg/ml measured after 20 days by the leaf-dipping method	2013	Journal of agricultural and food chemistry, Jan-23, Volume: 61, Issue:3	Synthesis and quantitative structure-activity relationship (QSAR) study of novel 4-acyloxypodophyllotoxin derivatives modified in the A and C rings as insecticidal agents.
AID1092097	In vivo insecticidal activity against pre-third-instar larval stage of Mythimna separata (Oriental armyworm) in corn leaves assessed as corrected mortality rate at 1 mg/ml treated for 3 secs before larval infestation on corn leaves measured after 20 days	2011	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18	Natural products-based insecticidal agents 11. Synthesis and insecticidal activity of novel 4α-arylsulfonyloxybenzyloxy-2β-chloropodophyllotoxin derivatives against Mythimna separata Walker in vivo.
AID298657	Antiproliferative activity against human Jurkat cells assessed as cell viability at 5 uM after 48 hrs by MTT assay	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis.
AID115993	In vivo antitumor activity against the M5076 reticulum cell sarcoma expressed as percent increase in life span; ND means no data	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	In vivo antitumor activity of 6-benzyl-1,3-benzodioxole derivatives against the P388, L1210, B16, and M5076 murine models.
AID87922	Effect on cell cycle evaluated as proportion of cells in S phase of the cell cycle at 10E-6 M for 72 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID655234	Cytotoxicity against human NCI/ADR-RES cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID347581	Antiproliferative activity against human K562 cells after 48 hrs	2009	Journal of medicinal chemistry, Mar-12, Volume: 52, Issue:5	10-(2-oxo-2-phenylethylidene)-10H-anthracen-9-ones as highly active antimicrotubule agents: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1432112	Growth inhibition of human DU145 cells after 48 hrs by MTT assay
AID54295	Inhibition of tubulin polymerization was determined at 1.2 mg/mL concentration	2003	Journal of medicinal chemistry, Apr-24, Volume: 46, Issue:9	Synthesis, anticancer activity, and inhibition of tubulin polymerization by conformationally restricted analogues of lavendustin A.
AID1578103	Cytotoxicity against human KB cells assessed as reduction in cell viability	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID560441	Cell cycle arrest in human PHK cells assessed as accumulation at S phase at 10 times EC50 after 48 hrs by flow cytometry	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions.
AID1489086	Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 0.9 uM after 12 hrs by propidium iodide staining based flow cytometric method (Rvb = 27.63 to 32.34%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1456143	Induction of apoptosis in human Bel7402/5-FU cells assessed as early apoptotic cells at 0.05 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 5.24%)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1637446	Activation of ERK1/2 signalling in human K562/ADR cells assessed as increase in cleaved caspase-9 expression at 0.05 uM after 48 hrs by Western blot analysis relative to control	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID723350	Cytotoxicity against human A549 cells after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1	Synthesis and anticancer activity of heteroaromatic linked 4β-amido podophyllotoxins as apoptotic inducing agents.
AID84960	Minimum inhibitory concentration against herpesvirus simplex 2	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor agents. 207. Design, synthesis, and biological testing of 4beta-anilino-2-fluoro-4'-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents.
AID670483	Cytotoxicity against human A549 cells after 72 hrs by MTT assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Synthesis and biological evaluation of novel 4β-(1,3,4-oxadiazole-2-amino)-podophyllotoxin derivatives.
AID1410387	Cytotoxicity against human MG63 cells after 24 hrs by annexin-V-FITC/propidium iodide staining based flow cytometric method	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	New Hybrids Derived from Podophyllic Aldehyde and Diterpenylhydroquinones with Selectivity toward Osteosarcoma Cells.
AID1906550	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	2022	European journal of medicinal chemistry, May-05, Volume: 235	Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy.
AID321842	Induction of apoptosis in human Jurkat cells after 48 hrs at 5 uM by flow cytometry relative to control	2008	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 18, Issue:4	Novel three-component synthesis and antiproliferative properties of diversely functionalized pyrrolines.
AID1062627	Cytotoxicity against rat L6 cells assessed as cell viability after 70 hrs by Alamar blue assay	2014	Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1	Antiprotozoal activity of dicationic 3,5-diphenylisoxazoles, their prodrugs and aza-analogues.
AID481678	Antiproliferative activity against Paracentrotus lividus embryo assessed as cleavage alteration after 10 to 15 mins fertilization 45 to 60 mins before first mitotic cycle completeion	2010	European journal of medicinal chemistry, May, Volume: 45, Issue:5	Novel derivatives of 1,3,4-oxadiazoles are potent mitostatic agents featuring strong microtubule depolymerizing activity in the sea urchin embryo and cell culture assays.
AID1688050	Antiproliferative activity against human MCF-7 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition.
AID1395722	Cytotoxicity against human MCF7 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Antiproliferative efficacy of curcumin mimics through microtubule destabilization.
AID421657	Cytotoxicity against human erythrocytes	2009	Journal of natural products, Feb-27, Volume: 72, Issue:2	Okundoperoxide, a bicyclic cyclofarnesylsesquiterpene endoperoxide from Scleria striatinux with antiplasmodial activity.
AID1456231	Effect on ERK1/2 phosphorylation in human Bel7402/5-FU cells assessed as ratio of phosphorylated ERK1/2 to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.59 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1267689	Antiproliferative activity against human K562 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1395724	Inhibition of porcine brain tubulin polymerization measured every min for 1 hr	2018	European journal of medicinal chemistry, May-10, Volume: 151	Antiproliferative efficacy of curcumin mimics through microtubule destabilization.
AID1317406	Antiproliferative activity against HAF cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID1456187	Induction of apoptosis in human Bel7402/5-FU cells assessed as ratio of cleaved caspase-8 to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.17 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID560440	Cell cycle arrest in human PHK cells assessed as accumulation at G0/G1 phase at 10 times EC50 after 48 hrs by flow cytometry	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1760383	Antiproliferative activity against human A549 cells incubated for 24 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID336444	Antitrypanosomal activity against Trypanosoma brucei brucei S427 blood stream trypomastigotes	2002	Journal of natural products, Oct, Volume: 65, Issue:10	Assessment of the antiprotozoal activity of Galphimia glauca and the isolation of new nor-secofriedelanes and nor-friedelanes.
AID298659	Growth inhibition of HeLa cells after 48 hrs by MTT assay	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis.
AID101653	In vitro cytotoxicity against human breast cancer MDA-MB 435 cell line	1998	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11	Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents.
AID756583	Competitive binding affinity to pig brain tubulin colchicine binding site after 1 hr by mass spectrophotometric analysis in presence of colchicine	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Design, synthesis, and biological evaluation of (E)-N-aryl-2-arylethenesulfonamide analogues as potent and orally bioavailable microtubule-targeted anticancer agents.
AID257598	Antiproliferative activity against estrogen-dependent breast cancer MCF7 cell line by MTS assay	2005	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24	Conformationally restricted analogs of Combretastatin A-4 derived from SU5416.
AID552697	Antitrypanosomal activity against bloodstream form of Trypanosoma brucei rhodesiense STIB900 after 70 hrs by alamar blue assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and antitrypanosomal evaluation of derivatives of N-benzyl-1,2-dihydroquinolin-6-ols: Effect of core substitutions and salt formation.
AID1410383	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	New Hybrids Derived from Podophyllic Aldehyde and Diterpenylhydroquinones with Selectivity toward Osteosarcoma Cells.
AID1306349	Induction of apoptosis in human MCF7 cells assessed as viable cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 80 to 91.6%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1614009	Cytotoxicity against rat L6 cels assessed as reduction in cell viability after 72 hrs by Alamar Blue dye-based fluorometric analysis	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Design, Synthesis, and Biological Evaluation of New 1-(Aryl-1 H-pyrrolyl)(phenyl)methyl-1 H-imidazole Derivatives as Antiprotozoal Agents.
AID115986	In vivo antitumor activity against the L1210 leukemia cell line expressed as percent increase in life span; IA means inactive	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	In vivo antitumor activity of 6-benzyl-1,3-benzodioxole derivatives against the P388, L1210, B16, and M5076 murine models.
AID290173	Antiproliferative activity against human Molt3 cells	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Novel pyridinyl and pyrimidinylcarbazole sulfonamides as antiproliferative agents.
AID1639468	Cytotoxicity against rat L6 cells
AID382473	Cytotoxicity against rat L6 cells after 4 days	2008	European journal of medicinal chemistry, Jan, Volume: 43, Issue:1	Synthesis and antiprotozoal activities of simplified analogs of naphthylisoquinoline alkaloids.
AID443484	Cytotoxicity against c-myc/c-raf double transgenic mouse A2B1 cells by MTS assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID1174241	Inhibition of tubulin polymerization (unknown origin) at 5 uM measured every min for 1 hr by fluorescence-based assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Investigation of podophyllotoxin esters as potential anticancer agents: synthesis, biological studies and tubulin inhibition properties.
AID1495296	Reduction in mitochondrial membrane potential in human K562/VCR cells at 0.1 uM after 48 hrs by JC1 probe-based flow cytometric method (Rvb = 2.65%)	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID1101795	Insecticidal activity against fifth-instar larvae of Pieris rapae fed on compound treated cabbage leaf assessed as inhibition of reproduction in pupated adultoids at 250 ppm dipped for 3 secs relative to control	2002	Chemical & pharmaceutical bulletin, Mar, Volume: 50, Issue:3	Synthesis and insecticidal activity of novel 4beta-halogenated benzoylamino podophyllotoxins against Pieris rapae Linnaeus.
AID1760371	Antiproliferative activity against human BGC-823 cells incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID697853	Inhibition of horse BChE at 2 mg/ml by Ellman's method	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1306327	Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 8 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 15.95 to 25.74%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID671048	Cytotoxicity against rat L6 cells	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Discovery of nitroheterocycles active against African trypanosomes. In vitro screening and preliminary SAR studies.
AID340104	Cytotoxicity against human HEPG2 cells after 24 hrs by MTT assay	2008	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14	Gallic acid-based indanone derivatives as anticancer agents.
AID87906	Effect on cell cycle evaluated as proportion of cells in G0/G1 phase of the cell cycle at 10E-7 M for 24 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID596418	Cytotoxicity against rat L6 cells by MTT assay	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Marinoquinolines A-F, pyrroloquinolines from Ohtaekwangia kribbensis (Bacteroidetes).
AID1233712	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 72 hrs by SRB assay	2015	Journal of natural products, Jul-24, Volume: 78, Issue:7	An Isoflavone from Leiophyllum buxifolium and Its Antiproliferative Effect.
AID655128	Cytotoxicity against human A549 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID628175	Induction of apoptosis in human Jurkat cells assessed as procaspase-9 cleavage at 50 nM after 24 hrs by Western blotting	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID1637417	Induction of apoptosis in human K562/ADR cells assessed as early apoptotic cells at 0.05 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 1.99%)	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID1545817	Antiproliferative activity against human MCF7 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID95672	Toxicity of the quinacrine derivatives was determined against the KB cell line in comparison to podophyllotoxin	2001	Bioorganic & medicinal chemistry letters, Oct-08, Volume: 11, Issue:19	Antiprotozoal and cytotoxicity evaluation of sulfonamide and urea analogues of quinacrine.
AID699780	Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 0.001 to 100 uM after 20 hrs by propidium iodide staining-based flow cytometry	2012	Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15	Synthesis and antimitotic and tubulin interaction profiles of novel pinacol derivatives of podophyllotoxins.
AID214555	Inhibition of bovine tubulin polymerization	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	Antitumor agents. 174. 2',3',4',5,6,7-Substituted 2-phenyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization.
AID1743670	Cytotoxicity against rat L6 cells	2020	European journal of medicinal chemistry, Dec-01, Volume: 207	Palladium-catalysed synthesis of arylnaphthoquinones as antiprotozoal and antimycobacterial agents.
AID386869	Cytotoxicity against human HCT-15 cells by sulforhodamine B assay	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Studies on novel 4beta-[(4-substituted)-1,2,3-triazol-1-yl] podophyllotoxins as potential anticancer agents.
AID1228180	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	2015	Journal of natural products, Apr-24, Volume: 78, Issue:4	Antiplasmodial and Cytotoxic Triterpenoids from the Bark of the Cameroonian Medicinal Plant Entandrophragma congoënse.
AID1361529	Induction of apoptosis in human MCF7 cells assessed as viable cells at IC50 after 24 hrs by annexin V/FITC-propidium iodide staining-based flow cytometric method (Rvb = 96.57%)	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Design, synthesis and screening of 1, 2, 4-triazinone derivatives as potential antitumor agents with apoptosis inducing activity on MCF-7 breast cancer cell line.
AID306631	Therapeutic index, IC50 for C8166 cells to EC50 for HIV1	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Synthesis and anti-HIV-1 activities of novel podophyllotoxin derivatives.
AID655209	Cytotoxicity against human HCT116 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1148911	Displacement of [3H]colchicine from bovine brain tubulin at 8 uM after 90 mins by liquid scintillation counting in presence of 10 uM [3H]colchicine	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Podophyllotoxin analogs. 1. Synthesis and biological evaluation of certain trans-2-aryl-trans-6-hydroxymethyl-3-cyclohexenecarboxylic acid gamma-lactones as antimitotic agents.
AID359895	Cytotoxicity against human A549 cells by MTT assay	1994	Journal of natural products, Dec, Volume: 57, Issue:12	Cytotoxic cyclolignans from Koelreuteria henryi.
AID83892	Minimum inhibitory concentration against herpesvirus simplex 1	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor agents. 207. Design, synthesis, and biological testing of 4beta-anilino-2-fluoro-4'-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1140311	Inhibition of tubulin (unknown origin) polymerization measured for 1 hr by fluorescence assay	2014	Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9	Synthesis of a terphenyl substituted 4-aza-2,3-didehydropodophyllotoxin analogues as inhibitors of tubulin polymerization and apoptosis inducers.
AID1306323	Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 4 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 64.68 to 80.32%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID699777	Displacement of MTC from bovine brain tubulin colchicine binding site at 20 uM by fluorometric assay	2012	Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15	Synthesis and antimitotic and tubulin interaction profiles of novel pinacol derivatives of podophyllotoxins.
AID101632	Inhibition of the growth of MDA-MB 231 human breast cancer cells	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Inhibition of tubulin polymerization by 5,6-dihydroindolo[2,1-alpha]isoquinoline derivatives.
AID1545831	Antiproliferative activity against human HepG2 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID327981	Inhibition of bovine tubulin polymerization at 25 uM	2008	Journal of medicinal chemistry, Apr-24, Volume: 51, Issue:8	Structural simplification of bioactive natural products with multicomponent synthesis. 2. antiproliferative and antitubulin activities of pyrano[3,2-c]pyridones and pyrano[3,2-c]quinolones.
AID655231	Cytotoxicity against human OVCAR4 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1148910	Displacement of [3H]colchicine from bovine brain tubulin at 4 uM after 90 mins by liquid scintillation counting in presence of 10 uM [3H]colchicine	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Podophyllotoxin analogs. 1. Synthesis and biological evaluation of certain trans-2-aryl-trans-6-hydroxymethyl-3-cyclohexenecarboxylic acid gamma-lactones as antimitotic agents.
AID1317433	Induction of apoptosis in human T47D cells assessed as early apoptotic cells at 10 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.75 %)	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID359900	Inhibition of bovine brain tubulin polymerization by turbidity assay	1994	Journal of natural products, Dec, Volume: 57, Issue:12	Cytotoxic cyclolignans from Koelreuteria henryi.
AID300660	Growth inhibition against Leishmania donovani	2007	Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18	Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents.
AID1233444	Cytotoxicity against human MCF7 cells assessed as cell viability by SRB assay	2015	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14	Synthesis and Biological evaluation of novel 4β-[(5-substituted)-1,2,3,4-tetrazolyl] podophyllotoxins as anticancer compounds.
AID103364	In vitro cytotoxicity against human breast cancer MCF-7 ADR cell line	1998	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11	Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents.
AID443479	Cytotoxicity against c-myc/c-raf double transgenic mouse yB8 cells by MTS assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1091894	In vivo insecticidal activity against pre-third-instar larval stage of Mythimna separata (Oriental armyworm) in corn leaves assessed as corrected mortality rate at 1 mg/ml treated for 3 secs before larval infestation on corn leaves measured after 10 days	2010	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15	Natural products-based insecticidal agents 6. Design, semisynthesis, and insecticidal activity of novel monomethyl phthalate derivatives of podophyllotoxin against Mythimna separata Walker in vivo.
AID261763	Cytotoxicity against KB cell line	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Alkyl-linked bis-THTT derivatives as potent in vitro trypanocidal agents.
AID310758	Antiproliferative activity against human DU145 cells	2007	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24	3-(2'-Bromopropionylamino)-benzamides as novel S-phase arrest agents.
AID670487	Cytotoxicity against mouse L929 cells after 72 hrs by MTT assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Synthesis and biological evaluation of novel 4β-(1,3,4-oxadiazole-2-amino)-podophyllotoxin derivatives.
AID1456124	Induction of apoptosis in human Bel7402/5-FU cells assessed as morphological changes at 0.05 uM after 24 hrs by Hoechst 33342 staining based fluorescent microscopic method	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1489081	Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 0.3 uM after 12 hrs by propidium iodide staining based flow cytometric method (Rvb = 5.43 to 13.68%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1426445	Antiproliferative activity against human K562 cells after 48 hrs by Alamar blue dye based neubauer hemocytometer method	2017	Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2	N-Heterocyclic (4-Phenylpiperazin-1-yl)methanones Derived from Phenoxazine and Phenothiazine as Highly Potent Inhibitors of Tubulin Polymerization.
AID1306333	Cytotoxicity against human HeLa cells after 36 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1306331	Cytotoxicity against human MCF7 cells after 36 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID443480	Cytotoxicity against c-myc/c-raf double transgenic mouse yD12 cells by MTS assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID335784	Cytotoxicity against human LNCAP cells	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID214179	Inhibition of radiolabeled colchicine binding to tubulin	1997	Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubulin polymerization.
AID1177055	Cytotoxicity against rat L6 cells	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Hydroxamic acid based histone deacetylase inhibitors with confirmed activity against the malaria parasite.
AID1495310	Induction of apoptosis in human K562/VCR cells assessed as upregulation of cleaved PARP expression at 0.05 uM after 48 hrs by Western blot method relative to beta-actin	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID464324	Cytotoxicity against human HepG2 cells after 72 hrs by luminescence assay	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID1456189	Induction of apoptosis in human Bel7402/5-FU cells assessed as ratio of cleaved PARP to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.2 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1255396	Cytotoxicity against rat L6 cells incubated for 72 hrs by alamar blue staining based microscopy	2015	European journal of medicinal chemistry, Oct-20, Volume: 103	Discovery and optimisation studies of antimalarial phenotypic hits.
AID634096	Anticancer activity against human MCF7 cells after 48 hrs by MTT assay	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and anticancer activity of 4β-alkylamidochalcone and 4β-cinnamido linked podophyllotoxins as apoptotic inducing agents.
AID1306339	Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 8 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.021 to 3.8%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1176979	Cytotoxicity against rat L6 cells	2015	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3	Exploring in vitro and in vivo Hsp90 inhibitors activity against human protozoan parasites.
AID335772	Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 20 ug/mL	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID299202	Antiproliferative activity against human CEM cells	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Novel potent antimitotic heterocyclic ketones: synthesis, antiproliferative activity, and structure-activity relationships.
AID1906552	Cytotoxicity against human A2780AD cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	2022	European journal of medicinal chemistry, May-05, Volume: 235	Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy.
AID655250	Cytotoxicity against human T47D cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1515149	Antiproliferative activity against human PC3 cells after 48 hrs by CellTiter 96 AQueous one solution cell proliferation assay	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway.
AID1334732	Aqueous solubility of the compound at pH 2 measured after 4 hrs by HPLC/UV analysis	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Novel carbazole sulfonamide derivatives of antitumor agent: Synthesis, antiproliferative activity and aqueous solubility.
AID214548	In vitro inhibition of mammalian tubulin polymerization by 50%	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	Antitumor agents. 185. Synthesis and biological evaluation of tridemethylthiocolchicine analogues as novel topoisomerase II inhibitors.
AID1410389	Induction of apoptosis in human MG63 cells assessed as viable cells at 1 uM after 24 hrs by annexin-V-FITC/propidium iodide staining based flow cytometric analysis (Rvb = 89.58%)	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	New Hybrids Derived from Podophyllic Aldehyde and Diterpenylhydroquinones with Selectivity toward Osteosarcoma Cells.
AID1760433	Cytotoxicity against human L02 cells incubated for 24 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID464519	Half life in stimulated gastric fluid of pH 1.0	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID1699402	Cytotoxicity against hypoxia-induced human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24	Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
AID443487	Cytotoxicity against c-myc/c-raf double transgenic mouse B3 cells by MTS assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID1331344	Induction of apoptosis in mouse B16F10 cells assessed as caspase-3 activation using Ac-DEVD-pNA as substrate by spectrophotometric analysis	2017	ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1	Biological Evaluation
AID1317398	Antiproliferative activity against human MDA-MB-231 cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID1301510	Growth inhibition of human SF268 cells measured after 48 hrs by sulforhodamine B assay	2016	Journal of natural products, Mar-25, Volume: 79, Issue:3	Antineoplastic Agents. 585. Isolation of Bridelia ferruginea Anticancer Podophyllotoxins and Synthesis of 4-Aza-podophyllotoxin Structural Modifications.
AID443470	Cytotoxicity against human Caco-2 cells after 24 hrs by MTS assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID456263	Cytotoxicity against rat L6 cells	2010	Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1	Synthesis, stereoelectronic characterization and antiparasitic activity of new 1-benzenesulfonyl-2-methyl-1,2,3,4-tetrahydroquinolines.
AID1306328	Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 2 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 3.73 to 10.75%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1313993	Cytotoxicity against rat L6 cells by alamar blue assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Synthesis and potent antiprotozoal activity of mono/di amidino 2-anilinobenzimidazoles versus Plasmodium falciparum and Trypanosoma brucei rhodesiense.
AID1168744	Anticancer activity against human K562 cells after 24 hrs by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID560438	Cell cycle arrest in HPV-transformed human SiHa cells assessed as accumulation at S phase at 10 times EC50 after 48 hrs by flow cytometry	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions.
AID337714	Inhibition of microtubule assembly by turbidimetry
AID1426446	Inhibition of porcine tubulin polymerization after 45 mins by turbidometric method	2017	Journal of medicinal chemistry, 01-26, Volume: 60, Issue:2	N-Heterocyclic (4-Phenylpiperazin-1-yl)methanones Derived from Phenoxazine and Phenothiazine as Highly Potent Inhibitors of Tubulin Polymerization.
AID1487410	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	Structure-activity relationship studies on thiaplidiaquinones A and B as novel inhibitors of Plasmodium falciparum and farnesyltransferase.
AID443469	Cytotoxicity against human A549 cells after 24 hrs by MTS assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1491415	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Synthesis of thiazole linked indolyl-3-glyoxylamide derivatives as tubulin polymerization inhibitors.
AID1168738	Inhibition of rat intestinal alpha-glucosidase using p-nitrophenyl-alpha-D-glucopyranoside substrate by spectrophotometry	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID300661	Growth inhibition against Trypanosoma brucei brucei	2007	Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18	Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents.
AID1495289	Induction of apoptosis in human K562/VCR cells assessed as late apoptotic cells at 0.05 uM after 48 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 1.90%)	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID335781	Cytotoxicity against human Col2 cells	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID740950	Antileishmanial activity against Leishmania donovani	2013	Journal of natural products, Mar-22, Volume: 76, Issue:3	8,8-dialkyldihydroberberines with potent antiprotozoal activity.
AID1416614	Inhibition of porcine brain tubulin polymerization at 3 uM after 1 hr by fluorescence assay relative to control
AID605956	Inhibition of pig tubulin polymerization determined after 45 mins at 37 degC by turbidimetric analysis	2011	Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12	N-benzoylated phenoxazines and phenothiazines: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1410388	Cytotoxicity against human HT-29 cells after 24 hrs by annexin-V-FITC/propidium iodide staining based flow cytometric method	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	New Hybrids Derived from Podophyllic Aldehyde and Diterpenylhydroquinones with Selectivity toward Osteosarcoma Cells.
AID1180382	Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Synthesis and biological evaluation of 4-aza-2,3-dihydropyridophenanthrolines as tubulin polymerization inhibitors.
AID1246962	Cytotoxicity against human RWPE1 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	One-pot synthesis of podophyllotoxin-thiourea congeners by employing NH₂SO₃H/NaI: Anticancer activity, DNA topoisomerase-II inhibition, and apoptosis inducing agents.
AID273081	Antiproliferative activity against human Bel7402 cells after 72 hrs	2006	Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21	Synthesis and structure-activity relationships of carbazole sulfonamides as a novel class of antimitotic agents against solid tumors.
AID359898	Cytotoxicity against human PC3 cells by MTT assay	1994	Journal of natural products, Dec, Volume: 57, Issue:12	Cytotoxic cyclolignans from Koelreuteria henryi.
AID217565	Effective dose required to inhibit 25% of cell growth (Herpesvirus activity)	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor agents. 207. Design, synthesis, and biological testing of 4beta-anilino-2-fluoro-4'-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents.
AID634094	Anticancer activity against human A549 cells after 48 hrs by MTT assay	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and anticancer activity of 4β-alkylamidochalcone and 4β-cinnamido linked podophyllotoxins as apoptotic inducing agents.
AID1306348	Induction of apoptosis in human MCF7 cells assessed as viable cells at 1 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 80 to 91.6%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1317401	Antiproliferative activity against human PC3 cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID1180384	Inhibition of bovine brain tubulin polymerization measured for 1 hr at 1 min intervals by fluorescence assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Synthesis and biological evaluation of 4-aza-2,3-dihydropyridophenanthrolines as tubulin polymerization inhibitors.
AID628079	Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID211307	In vitro activity against mammalian topoisomerase II measured as ATP-dependent unknotting of P4 DNA compared to enzyme and DNA control; Inactive	1998	Journal of medicinal chemistry, May-21, Volume: 41, Issue:11	Antitumor agents. 185. Synthesis and biological evaluation of tridemethylthiocolchicine analogues as novel topoisomerase II inhibitors.
AID655216	Cytotoxicity against human SF539 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID214015	Inhibition of tubulin polymerization	1997	Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubulin polymerization.
AID1549911	Antiproliferative activity against human HMEC cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, May-15, Volume: 170	Discover 4β-NH-(6-aminoindole)-4-desoxy-podophyllotoxin with nanomolar-potency antitumor activity by improving the tubulin binding affinity on the basis of a potential binding site nearby colchicine domain.
AID1199925	Cytotoxicity against rat L6 cells	2015	Journal of medicinal chemistry, Feb-26, Volume: 58, Issue:4	Antiprotozoal activity and DNA binding of dicationic acridones.
AID87912	Effect on cell cycle evaluated as proportion of cells in G2/M phase of the cell cycle at 10E-6 M for 24 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1432876	Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by alamar blue assay	2017	Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7	Synthesis and activity of nucleoside-based antiprotozoan compounds.
AID1545842	Antiproliferative activity against human A549 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID290172	Cytotoxicity against human CEM cells	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Novel pyridinyl and pyrimidinylcarbazole sulfonamides as antiproliferative agents.
AID212934	In vitro minimum inhibition concentration to inhibit the regeneration of cilia in Tetrahymena pyriformis W.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Absolute structure-cytotoxic activity relationships of steganacin congeners and analogues.
AID1489108	Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 8 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 2 to 3.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID723348	Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1	Synthesis and anticancer activity of heteroaromatic linked 4β-amido podophyllotoxins as apoptotic inducing agents.
AID1882951	Cmax in Sprague-Dawley rat at 10 mg/kg, iv by HPLC-MS/MS analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID655221	Cytotoxicity against human MALME-3M cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1317434	Induction of apoptosis in human T47D cells assessed as late apoptotic cells at 10 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 2.42 %)	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID1760331	Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID415311	Cytotoxicity against human AGS cells after 72 hrs by SRB method	2009	Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8	Synthesis and biological evaluation of novel conjugates of podophyllotoxin and 5-FU as antineoplastic agents.
AID355580	Antiproliferative activity against human HT-29 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID464327	Cytotoxicity against human BJ cells after 72 hrs by luminescence assay	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID1754710	Antiproliferative activity against human PC-3M cells assessed as inhibition of cell proliferation at 1 nM measured after 9 days by Crystal violet staining based colony formation assay	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID1456232	Effect on STAT3 phosphorylation in human Bel7402/5-FU cells assessed as ratio of phosphorylated STAT3 to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.3 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1082998	Insecticidal activity against pre-third-instar larvae of Mythimna separata (Oriental armyworm) in wheat leaves at 1 mg/mL after 5 days by leaf-dipping method	2012	Journal of agricultural and food chemistry, Aug-29, Volume: 60, Issue:34	Synthesis and quantitative structure-activity relationship (QSAR) study of novel isoxazoline and oxime derivatives of podophyllotoxin as insecticidal agents.
AID338986	Inhibition of microtubule assembly after 15 mins
AID695932	Cytotoxicity against human SGC7901 cells after 48 hrs	2012	Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21	Synthesis and biological evaluation of a series of podophyllotoxins derivatives as a class of potent antitubulin agents.
AID335777	Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 0.0064 ug/mL	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID87911	Effect on cell cycle evaluated as proportion of cells in G0/G1 phase of the cell cycle at 10E-8 M for 72 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID87907	Effect on cell cycle evaluated as proportion of cells in G0/G1 phase of the cell cycle at 10E-7 M for 48 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID300657	Inhibition of Leishmania tarentolae tubulin assembly	2007	Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18	Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents.
AID384948	Binding affinity to HPV1a recombinant E2 protein DNA binding domain by surface plasmon resonance assay	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Podophyllotoxin directly binds a hinge domain in E2 of HPV and inhibits an E2/E7 interaction in vitro.
AID309303	Cytotoxicity against rat L6 cells after 72 hrs	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Marine natural products from the Turkish sponge Agelas oroides that inhibit the enoyl reductases from Plasmodium falciparum, Mycobacterium tuberculosis and Escherichia coli.
AID257597	Antiproliferative activity against androgen-independent prostate cancer PC3 cell line by MTS assay	2005	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24	Conformationally restricted analogs of Combretastatin A-4 derived from SU5416.
AID415312	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	2009	Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8	Synthesis and biological evaluation of novel conjugates of podophyllotoxin and 5-FU as antineoplastic agents.
AID670482	Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Synthesis and biological evaluation of novel 4β-(1,3,4-oxadiazole-2-amino)-podophyllotoxin derivatives.
AID326224	Cytotoxicity against human 1A9 cells	2008	Journal of medicinal chemistry, Mar-27, Volume: 51, Issue:6	Cytotoxic simplified tubulysin analogues.
AID690546	Cytotoxicity against rat L6 cells	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	2-Alkynoic fatty acids inhibit topoisomerase IB from Leishmania donovani.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID389449	Cytotoxicity against rat L6 cells	2008	Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21	Synthesis and antiprotozoal activity of cationic 2-phenylbenzofurans.
AID1751092	Antiproliferative activity against human PC-3 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID1162949	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
AID1639491	Cytotoxicity against human PC3 cells measured after 72 hrs by sulforhodamine B assay
AID524790	Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1331345	Induction of apoptosis in mouse B16F10 cells assessed as formation of organized shedding vesicles by microscopic analysis	2017	ACS medicinal chemistry letters, Jan-12, Volume: 8, Issue:1	Biological Evaluation
AID1267690	Antiproliferative activity against human K562/ADR cells assessed as growth inhibition after 72 hrs by CCK-8 assay	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID378034	Toxicity in brine shrimp after 24 hrs	2006	Journal of natural products, Aug, Volume: 69, Issue:8	Endophyte fungal isolates from Podophyllum peltatum produce podophyllotoxin.
AID1432145	Induction of mitochondrial membrane potential loss in human DU145 cells assessed as depolarized cell population at 400 nM after 24 hrs by JC-1 staining based flow cytometry (Rvb = 19.06%)
AID1331718	Binding affinity to alpha-tubulin in human A549 cells assessed as induction of microtubule depolymerization by measuring formation of abnormal type 4 spindles at 100 nM after 24 hrs by immunofluorescence microscopy	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Structural and Biochemical Characterization of the Interaction of Tubulin with Potent Natural Analogues of Podophyllotoxin.
AID1187057	Cytotoxicity against rat L6 cells	2014	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17	2-Octadecynoic acid as a dual life stage inhibitor of Plasmodium infections and plasmodial FAS-II enzymes.
AID1410384	Cytotoxicity against human MG63 cells after 72 hrs by MTT assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	New Hybrids Derived from Podophyllic Aldehyde and Diterpenylhydroquinones with Selectivity toward Osteosarcoma Cells.
AID1760384	Antiproliferative activity against human MCF7 cells incubated for 24 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID524792	Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1495288	Induction of apoptosis in human K562/VCR cells assessed as early apoptotic cells at 0.05 uM after 48 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 6.90%)	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID1495318	Induction of autophagy in human K562/VCR cells assessed as upregulation of LC3-2 expression at 0.05 uM after 48 hrs by Western blot method relative to beta-actin	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID494520	Cell growth inhibition of human K562 cells after 48 hrs	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Synthesis, antiproliferative activity and inhibition of tubulin polymerization by anthracenone-based oxime derivatives.
AID273084	Antiproliferative activity against human PC3 cells after 72 hrs	2006	Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21	Synthesis and structure-activity relationships of carbazole sulfonamides as a novel class of antimitotic agents against solid tumors.
AID655241	Cytotoxicity against human SN12C cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID443488	Cytotoxicity against c-myc/c-raf double transgenic mouse Craf/Cmyc cells by MTS assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID1306341	Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 5.92 to 9.33%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID362356	Binding affinity to pig brain tubulin at 10 uM after 15 mins relative to control	2008	Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16	Structure-activity relationship studies on a novel class of antiproliferative agents derived from Lavendustin A. Part I: Ring A modifications.
AID372586	Cytotoxicity against rat L6 cells after 72 hrs by resazurin assay	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Quinuclidine derivatives as potential antiparasitics.
AID592700	Inhibition of tubulin polymerization at 3 uM after 1 hr fluorescence analysis relative to control	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis of a new 4-aza-2,3-didehydropodophyllotoxin analogues as potent cytotoxic and antimitotic agents.
AID303266	Cytotoxicity against rat L6 cells	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Synthesis and evaluation of antiparasitic activities of new 4-[5-(4-phenoxyphenyl)-2H-pyrazol-3-yl]morpholine derivatives.
AID1760330	Antiproliferative activity against human PC3 cells incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID432049	Cytotoxicity against rat L6 cells	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiprotozoal activities of dicationic bis(phenoxymethyl)benzenes, bis(phenoxymethyl)naphthalenes, and bis(benzyloxy)naphthalenes.
AID605844	Antiproliferative activity against human K562 cells after 48 hrs by hemocytometric analysis	2011	Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12	N-benzoylated phenoxazines and phenothiazines: synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1140301	Anticancer activity against human HeLa cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9	Synthesis of a terphenyl substituted 4-aza-2,3-didehydropodophyllotoxin analogues as inhibitors of tubulin polymerization and apoptosis inducers.
AID477926	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	2010	Journal of natural products, Apr-23, Volume: 73, Issue:4	Jacaranone-derived glucosidic esters from Jacaranda glabra and their activity against Plasmodium falciparum.
AID655220	Cytotoxicity against human LOXIMVI cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID286671	Cytotoxicity against rat L6 cells	2007	Journal of medicinal chemistry, May-17, Volume: 50, Issue:10	Synthesis and in vitro antiprotozoal activities of dicationic 3,5-diphenylisoxazoles.
AID355583	Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay
AID1754722	Induction of apoptosis in human PC-3M cells assessed as early apoptotic cells at 10 nM measured after 48 hrs by Annexin V/PI staining based flow cytometry method (Rvb = 1.25%)	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID1882949	Clearance in Sprague-Dawley rat at 10 mg/kg, iv by HPLC-MS/MS analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID115982	In vivo antitumor activity against the B16 melanoma cell line expressed as percent increase in life span at 1 mg/kg dose	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	In vivo antitumor activity of 6-benzyl-1,3-benzodioxole derivatives against the P388, L1210, B16, and M5076 murine models.
AID1456188	Induction of apoptosis in human Bel7402/5-FU cells assessed as ratio of cleaved caspase-9 to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.17 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1148927	Inhibition of colony formation in mouse P815 cells assessed as percentage of colony forming cell at 50 nM after 7 days by microscopic analysis relative to control	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Podophyllotoxin analogs. 1. Synthesis and biological evaluation of certain trans-2-aryl-trans-6-hydroxymethyl-3-cyclohexenecarboxylic acid gamma-lactones as antimitotic agents.
AID1688052	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition.
AID1456211	Effect on COX1 expression in human Bel7402/5-FU cells assessed as ratio of COX1 to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.48 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1542764	Cytotoxicity against rat L6 cells measured after 72 hrs by alamar blue assay	2019	Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10	6-Bromoindolglyoxylamido derivatives as antimicrobial agents and antibiotic enhancers.
AID305856	Induction of apoptosis in human Jurkat cells at 5 uM after 48 hrs by flow cytometric annexin-V/propidium iodide assay	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Structural simplification of bioactive natural products with multicomponent synthesis: dihydropyridopyrazole analogues of podophyllotoxin.
AID655217	Cytotoxicity against human SNB19 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID273086	Antiproliferative activity against human DMS79 cells after 72 hrs	2006	Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21	Synthesis and structure-activity relationships of carbazole sulfonamides as a novel class of antimitotic agents against solid tumors.
AID1439213	Cytotoxicity against human KB cells after 72 hrs by Alamar blue assay	2017	European journal of medicinal chemistry, Mar-10, Volume: 128	Synthesis and antitrypanosomal activities of novel pyridylchalcones.
AID1395719	Cytotoxicity against human A549 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Antiproliferative efficacy of curcumin mimics through microtubule destabilization.
AID464500	Inhibition of mouse COX2	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID87918	Effect on cell cycle evaluated as proportion of cells in G2/M phase of the cell cycle at 10E-8 M for 24 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1760491	Cytotoxicity against African green monkey Vero cells	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID1317436	Induction of apoptosis in human T47D cells assessed as late apoptotic cells at 20 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 2.42 %)	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID1067817	Cytotoxicity against rat L6 cells after 48 hrs by Alamar Blue assay	2014	Journal of medicinal chemistry, Feb-13, Volume: 57, Issue:3	Substituted 2-phenylimidazopyridines: a new class of drug leads for human African trypanosomiasis.
AID1246964	Cytotoxicity against human HGC cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	One-pot synthesis of podophyllotoxin-thiourea congeners by employing NH₂SO₃H/NaI: Anticancer activity, DNA topoisomerase-II inhibition, and apoptosis inducing agents.
AID443481	Cytotoxicity against c-myc/c-raf double transgenic mouse yD1 cells by MTS assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1246963	Cytotoxicity against human LNCAP cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	One-pot synthesis of podophyllotoxin-thiourea congeners by employing NH₂SO₃H/NaI: Anticancer activity, DNA topoisomerase-II inhibition, and apoptosis inducing agents.
AID310760	Antiproliferative activity against human DND1 cells	2007	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24	3-(2'-Bromopropionylamino)-benzamides as novel S-phase arrest agents.
AID94686	In vitro cytotoxicity against human colon cancer KM 12 cell line	1998	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11	Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents.
AID1545952	Antiproliferative activity against mouse NIH/3T3 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1515166	Cell cycle arrest in human PC3 cells assessed as accumulation at sub-G1 phase at 0.12 uM after 48 hrs by RNAse/propidium iodide staining-based flow cytometric analysis (Rvb = 0.00%)	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway.
AID87919	Effect on cell cycle evaluated as proportion of cells in G2/M phase of the cell cycle at 10E-8 M for 48 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID359894	Cytotoxicity against human A431 cells by MTT assay	1994	Journal of natural products, Dec, Volume: 57, Issue:12	Cytotoxic cyclolignans from Koelreuteria henryi.
AID1317412	Selectivity index, ratio of IC50 for HAF cells to IC50 for human DU145 cells	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID1639493	Selectivity index, ratio of IC50 for human HSF30 cells to IC50 for human MCF7 cells
AID723346	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1	Synthesis and anticancer activity of heteroaromatic linked 4β-amido podophyllotoxins as apoptotic inducing agents.
AID1456172	Effect on cyclinA expression in human Bel7402/5-FU cells assessed as ratio of cyclinA to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.39 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID384944	Cytotoxicity against mouse L210 cells after 48 hrs	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Podophyllotoxin directly binds a hinge domain in E2 of HPV and inhibits an E2/E7 interaction in vitro.
AID1432129	Cell cycle arrest in human DU145 cells assessed as accumulation at G0/G1 phase at 400 nM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 66.07%)
AID335788	Cytotoxicity against human KB cells	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID1390503	Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
AID153376	Growth inhibition of P388-D1 (murine leukemia) cell line.	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Synthesis and antitumor activity of structural analogues of the epipodophyllotoxins.
AID1882947	AUC in Sprague-Dawley rat at 10 mg/kg, iv by HPLC-MS/MS analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1699419	Toxicity in BALB/c mouse xenografted with human HepG2 cells assessed as animal death at 10 mg/kg, ip administered every other day for 17 consecutive days and measured on day 17	2020	Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24	Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
AID655249	Cytotoxicity against human BT549 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID152447	Cytotoxicity against P-388 leukemia cells	2000	Bioorganic & medicinal chemistry letters, Feb-21, Volume: 10, Issue:4	4-Aza-2,3-dehydro-4-deoxypodophyllotoxins: simple aza-podophyllotoxin analogues possessing potent cytotoxicity.
AID1168748	Induction of hemolysis in human erythrocytes assessed as mean erythrocyte fragility by measuring level of hemolysis at 50% PBS at 100 ug/mL by spectrophotomtery based erythrocyte osmotic fragility assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID1403376	Cytotoxicity against HEK293 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Synthesis of podophyllotoxin linked β-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors.
AID384950	Inhibition of HPV1a E2-E7 protein interaction at 500 uM assessed as rate of E2 binding to E7 protein by surface plasmon resonance method	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Podophyllotoxin directly binds a hinge domain in E2 of HPV and inhibits an E2/E7 interaction in vitro.
AID1456149	Induction of microtubule disruption in human Bel7402/5-FU cells at 0.05 uM after 24 to 48 hrs by DAPI staining based immunofluorescence microscopic method	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1760450	Cytotoxicity against human HL7702 cells incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID1331719	Binding affinity to tubulin alpha/beta dimer (unknown origin) at 300 uM by STD-NMR method	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Structural and Biochemical Characterization of the Interaction of Tubulin with Potent Natural Analogues of Podophyllotoxin.
AID201686	In vitro cytotoxic activity against colon (SW 620) cancer cell line.	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	9-Deoxopodophyllotoxin derivatives as anti-cancer agents.
AID1148909	Displacement of [3H]colchicine from bovine brain tubulin at 2 uM after 90 mins by liquid scintillation counting in presence of 20 uM [3H]colchicine	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Podophyllotoxin analogs. 1. Synthesis and biological evaluation of certain trans-2-aryl-trans-6-hydroxymethyl-3-cyclohexenecarboxylic acid gamma-lactones as antimitotic agents.
AID273083	Antiproliferative activity against human DU145 cells after 72 hrs	2006	Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21	Synthesis and structure-activity relationships of carbazole sulfonamides as a novel class of antimitotic agents against solid tumors.
AID1637443	Activation of ERK1/2 signalling in human K562/ADR cells assessed as increase in cleaved caspase-8 expression at 0.05 uM after 48 hrs by Western blot analysis relative to control	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID404066	Cytotoxicity against human primary amnion cells assessed as morphological changes by microscopic examination	1998	Journal of natural products, Nov, Volume: 61, Issue:11	Antiviral activity of lignans.
AID1699404	Cytotoxicity against human A549 cells overexpressing NQO1 assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24	Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
AID655245	Cytotoxicity against human DU145 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID384949	Binding affinity to HPV11 recombinant E2 protein by surface plasmon resonance method	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Podophyllotoxin directly binds a hinge domain in E2 of HPV and inhibits an E2/E7 interaction in vitro.
AID1246961	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	One-pot synthesis of podophyllotoxin-thiourea congeners by employing NH₂SO₃H/NaI: Anticancer activity, DNA topoisomerase-II inhibition, and apoptosis inducing agents.
AID1182199	Cytotoxicity against human NCI60 cells	2014	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16	Comparative in vivo evaluation of polyalkoxy substituted 4H-chromenes and oxa-podophyllotoxins as microtubule destabilizing agents in the phenotypic sea urchin embryo assay.
AID1639489	Cytotoxicity against human SiHa cells measured after 72 hrs by sulforhodamine B assay
AID9039	In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line	2004	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5	Synthesis and cytotoxicity of hydrophobic esters of podophyllotoxins.
AID1639490	Cytotoxicity against human HF6 cells measured after 72 hrs by sulforhodamine B assay
AID695789	Inhibition of goat brain tubulin polymerization after 30 mins	2012	Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21	Synthesis and biological evaluation of a series of podophyllotoxins derivatives as a class of potent antitubulin agents.
AID1092098	In vivo insecticidal activity against pre-third-instar larval stage of Mythimna separata (Oriental armyworm) in corn leaves assessed as corrected mortality rate at 1 mg/ml treated for 3 secs before larval infestation on corn leaves measured after 10 days	2011	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18	Natural products-based insecticidal agents 11. Synthesis and insecticidal activity of novel 4α-arylsulfonyloxybenzyloxy-2β-chloropodophyllotoxin derivatives against Mythimna separata Walker in vivo.
AID73178	Cytotoxic effect against GLC4 (human small cell lung carcinoma cell line) using the microculture tetrazolium (MTT) assay based on continuous incubation	1995	Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12	Synthesis and cytotoxicity of novel lignans.
AID655213	Cytotoxicity against human SW620 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1281530	Induction of microtubule cytoskeleton destabilization in human MCF7 cells assessed as nuclear atypia at 250 nM after 6 hrs by Hoechst 33342 staining-based confocal fluorescence microscopy	2016	European journal of medicinal chemistry, Mar-03, Volume: 110	Novel cis-selective and non-epimerisable C3 hydroxy azapodophyllotoxins targeting microtubules in cancer cells.
AID445250	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and antiprotozoal activity of cationic 1,4-diphenyl-1H-1,2,3-triazoles.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID443472	Inhibition of bovine brain tubulin polymerization assessed as polymerized to unpolymerized ratio preincubated 15 mins before GTP addition measured after 30 mins by densitometry (Rvb= 1.82 +/- 0.06)	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID335779	Cytotoxicity against human A431 cells	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID1882894	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1306342	Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 4 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 5.92 to 9.33%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1267691	Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID655242	Cytotoxicity against human TK10 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID592701	Inhibition of tubulin polymerization in human A549 cells assessed as disrupted microtubule organization at 5 uM after 48 hrs by immunohistochemistry	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis of a new 4-aza-2,3-didehydropodophyllotoxin analogues as potent cytotoxic and antimitotic agents.
AID84936	Effective dose required to inhibit 100% against herpesvirus simplex 2	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor agents. 207. Design, synthesis, and biological testing of 4beta-anilino-2-fluoro-4'-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents.
AID1491414	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Synthesis of thiazole linked indolyl-3-glyoxylamide derivatives as tubulin polymerization inhibitors.
AID695931	Cytotoxicity against human K562 cells after 48 hrs	2012	Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21	Synthesis and biological evaluation of a series of podophyllotoxins derivatives as a class of potent antitubulin agents.
AID1754724	Induction of apoptosis in human PC-3M cells assessed as necrotic cells at 10 nM measured after 48 hrs by Annexin V/PI staining based flow cytometry method (Rvb = 0.25%)	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID655212	Cytotoxicity against human KM12 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID299203	Antiproliferative activity against human Molt3 cells	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Novel potent antimitotic heterocyclic ketones: synthesis, antiproliferative activity, and structure-activity relationships.
AID1233448	Induction of cell cycle arrest in human A549 cells assessed as accumulation at G0 phase at 5 uM after 24 hrs by flow cytometry	2015	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14	Synthesis and Biological evaluation of novel 4β-[(5-substituted)-1,2,3,4-tetrazolyl] podophyllotoxins as anticancer compounds.
AID87921	Effect on cell cycle evaluated as proportion of cells in S phase of the cell cycle at 10E-6 M for 48 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1361526	Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at IC50 after 24 hrs by annexin V/FITC-propidium iodide staining-based flow cytometric method (Rvb = 0.72%)	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Design, synthesis and screening of 1, 2, 4-triazinone derivatives as potential antitumor agents with apoptosis inducing activity on MCF-7 breast cancer cell line.
AID732423	Cytotoxicity against rat L6 cells after 72 hrs by fluorometric analysis	2013	ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1	Synthesis and antiplasmodial and antimycobacterial evaluation of new nitroimidazole and nitroimidazooxazine derivatives.
AID1334735	Antiproliferative activity against human Bel7402 assessed as reduction in cell viability measured after 48 hrs by SRB assay	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Novel carbazole sulfonamide derivatives of antitumor agent: Synthesis, antiproliferative activity and aqueous solubility.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1456098	Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK-8 assay	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID464513	Selectivity ratio for IC50 for human BJ cells to IC50 for human HepG2 cells	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID1306329	Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 4 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 3.73 to 10.75%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID305851	Cytotoxicity against human MCF7AZ cells assessed as viability at 5 uM after 48 hrs by MTT method relative to control	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Structural simplification of bioactive natural products with multicomponent synthesis: dihydropyridopyrazole analogues of podophyllotoxin.
AID274785	Inhibition of tubulin polymerization in porcine brain	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID1489098	Induction of apoptosis in human MCF7 cells assessed as viable cells at 2 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 91.6 to 92.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID214171	Effect on the binding of radiolabeled [3H]colchicine to tubulin	1991	Journal of medicinal chemistry, Aug, Volume: 34, Issue:8	Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization.
AID1760332	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID611188	Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 2 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 26.42%)	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Synthesis and biological evaluation of 4β-acrylamidopodophyllotoxin congeners as DNA damaging agents.
AID1549930	Binding affinity to tubulin (unknown origin) assessed as dissociation constant by SPR analysis	2019	European journal of medicinal chemistry, May-15, Volume: 170	Discover 4β-NH-(6-aminoindole)-4-desoxy-podophyllotoxin with nanomolar-potency antitumor activity by improving the tubulin binding affinity on the basis of a potential binding site nearby colchicine domain.
AID1846643	Cytotoxicity against rat L6 cells assessed as cell growth inhibition incubated for 70 hrs by resazurin dye based assay	2021	Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9	Synthesis and Biological Evaluation of Natural-Product-Inspired, Aminoalkyl-Substituted 1-Benzopyrans as Novel Antiplasmodial Agents.
AID694346	Antileishmanial activity against amastigote form of Leishmania amazonensis expressing beta-lactamase infected in CD1 mouse macrophages after 72 hrs by nitrocefin-based spectrophotometric analysis	2012	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22	Antileishmanial bis-arylimidamides: DB766 analogs modified in the linker region and bis-arylimidamide structure-activity relationships.
AID464873	Cytotoxicity against rat L6 cells	2010	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 20, Issue:6	Discovery of novel and potent benzhydryl-tropane trypanocides highly selective for Trypanosoma cruzi.
AID273080	Antiproliferative activity against human Molt3 cells after 72 hrs	2006	Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21	Synthesis and structure-activity relationships of carbazole sulfonamides as a novel class of antimitotic agents against solid tumors.
AID274784	Antiproliferative activity against human K562 cell line	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	9-Benzylidene-naphtho[2,3-b]thiophen-4-ones as novel antimicrotubule agents-synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID740951	Antimalarial activity against erythrocyte stage Plasmodium falciparum 3D7	2013	Journal of natural products, Mar-22, Volume: 76, Issue:3	8,8-dialkyldihydroberberines with potent antiprotozoal activity.
AID1246965	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	2015	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19	One-pot synthesis of podophyllotoxin-thiourea congeners by employing NH₂SO₃H/NaI: Anticancer activity, DNA topoisomerase-II inhibition, and apoptosis inducing agents.
AID664491	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	2012	Journal of medicinal chemistry, Apr-12, Volume: 55, Issue:7	Synthesis, biological evaluation, and structure-activity relationships of N-benzoyl-2-hydroxybenzamides as agents active against P. falciparum (K1 strain), Trypanosomes, and Leishmania.
AID1550789	Binding affinity to calf brain tubulin assessed as binding constant	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Diphenyl ether derivatives occupy the expanded binding site of cyclohexanedione compounds at the colchicine site in tubulin by movement of the αT5 loop.
AID88042	Effect on cell cycle evaluated as proportion of cells in sub-G1 phase (apoptic cells )of the cell cycle at 10E-8 M for 24 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1101802	Insecticidal activity against fifth-instar larvae of Pieris rapae fed on compound treated cabbage leaf assessed as mortality at 250 ppm dipped for 3 secs measured after 5 days (Rvb = 0%)	2002	Chemical & pharmaceutical bulletin, Mar, Volume: 50, Issue:3	Synthesis and insecticidal activity of novel 4beta-halogenated benzoylamino podophyllotoxins against Pieris rapae Linnaeus.
AID1546406	Cytotoxicity against mouse J774 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	2020	Bioorganic & medicinal chemistry letters, 01-01, Volume: 30, Issue:1	Synthesis and antileishmanial evaluation of thiazole orange analogs.
AID611185	Cell cycle arrest in human MCF7 cells assessed as accumulation at GO phase at 2 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 6.09%)	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Synthesis and biological evaluation of 4β-acrylamidopodophyllotoxin congeners as DNA damaging agents.
AID293484	Cytotoxicity against mouse P388 cells after 4 days	2007	Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4	Synthesis and cytotoxic evaluation of C-9 oxidized podophyllotoxin derivatives.
AID1637405	Antiproliferative activity against human K562/ADR cells after 72 hrs by CCK8 assay	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID80116	Inhibitory activity against human cytomegalovirus (HCMV)	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor agents. 207. Design, synthesis, and biological testing of 4beta-anilino-2-fluoro-4'-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents.
AID1617103	Cytotoxicity against rat L6 cells assessed as reduction in cell viability incubated for 72 hrs by Alamar blue staining-based fluorometric analysis	2019	Journal of natural products, 11-22, Volume: 82, Issue:11	Ealamines A-H, a Series of Naphthylisoquinolines with the Rare 7,8'-Coupling Site, from the Congolese Liana
AID1317410	Selectivity index, ratio of IC50 for HAF cells to IC50 for human T47D cells	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID355584	Antiproliferative activity against mouse P388 cells at 1 ug after 48 hrs by two-layer agar-diffusion method
AID611186	Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase at 2 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 60.5%)	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Synthesis and biological evaluation of 4β-acrylamidopodophyllotoxin congeners as DNA damaging agents.
AID1306324	Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 8 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 64.68 to 80.32%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1456221	Effect on MRP1 expression in human Bel7402/5-FU cells assessed as ratio of MRP1 to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.58 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1754720	Induction of apoptosis in human PC-3M cells assessed as necrotic cells at 5 nM measured after 48 hrs by Annexin V/PI staining based flow cytometry method (Rvb = 0.25%)	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID1489087	Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 0.9 uM after 12 hrs by propidium iodide staining based flow cytometric method (Rvb = 5.43 to 13.68%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1331704	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Structural and Biochemical Characterization of the Interaction of Tubulin with Potent Natural Analogues of Podophyllotoxin.
AID1594579	Cytotoxicity in rat L6 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue assay	2019	Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10	Synthesis and structure-activity relationships for new 6-fluoroquinoline derivatives with antiplasmodial activity.
AID403985	Antiviral activity against Sindbis virus in mouse 3T3-L1 cells at 241 nM	1998	Journal of natural products, Nov, Volume: 61, Issue:11	Antiviral activity of lignans.
AID655240	Cytotoxicity against human RXF393 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1495284	Cell cycle arrest in human K562/VCR cells assessed as accumulation at G2 phase at 0.05 uM after 48 hrs by propidium iodide staining-based flow cytometric method (Rvb = 7.78%)	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID666699	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	2012	Journal of medicinal chemistry, Mar-22, Volume: 55, Issue:6	Synthesis and structure-activity analysis of new phosphonium salts with potent activity against African trypanosomes.
AID1267706	Induction of apoptosis in human K562/ADR cells assessed as late apoptotic cells at 0.1 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 1.69%)	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID298658	Induction of apoptosis in Jurkat cells assessed as cell viability at 5 uM after 48 hrs by flow cytometry Annexin-V/propidium iodide assay	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis.
AID1456142	Induction of apoptosis in human Bel7402/5-FU cells assessed as live cells at 0.05 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 91.08%)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID299206	Antiproliferative activity against human DU145 cells	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Novel potent antimitotic heterocyclic ketones: synthesis, antiproliferative activity, and structure-activity relationships.
AID1639495	Selectivity index, ratio of IC50 for human HSF30 cells to IC50 for human HF6 cells
AID418747	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Structure-activity study of pentamidine analogues as antiprotozoal agents.
AID592704	Cell cycle arrest in human A549 cells assessed as accumulation at G1 phase at 1 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 71.6%)	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis of a new 4-aza-2,3-didehydropodophyllotoxin analogues as potent cytotoxic and antimitotic agents.
AID1489084	Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 0.6 uM after 12 hrs by propidium iodide staining based flow cytometric method (Rvb = 5.43 to 13.68%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID305854	Induction of apoptosis in human Jurkat cells at 5 uM by flow cytometric annexin-V/propidium iodide assay	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Structural simplification of bioactive natural products with multicomponent synthesis: dihydropyridopyrazole analogues of podophyllotoxin.
AID1140299	Anticancer activity against human ACHN cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9	Synthesis of a terphenyl substituted 4-aza-2,3-didehydropodophyllotoxin analogues as inhibitors of tubulin polymerization and apoptosis inducers.
AID723339	Induction of cell cycle arrest in human A549 cells assessed as G2/M phase cells at 1 uM by FACS analysis (Rvb = 9.89%)	2013	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1	Synthesis and anticancer activity of heteroaromatic linked 4β-amido podophyllotoxins as apoptotic inducing agents.
AID1639492	Cytotoxicity against human HSF30 cells measured after 72 hrs by sulforhodamine B assay
AID1489090	Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 0.6 uM after 4 hrs by propidium iodide staining based flow cytometric method (Rvb = 7.59 to 9.58%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID398313	Displacement of [3H]colchicine from tubulin at 5 uM	1995	Journal of natural products, Apr, Volume: 58, Issue:4	Antitumor agents, 154. Cytotoxic and antimitotic flavonols from Polanisia dodecandra.
AID57054	Concentration of compound at which inhibitory activity detected against DNA topoisomerase II; Not tested	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Synthesis and antitumor activity of new glycosides of epipodophyllotoxin, analogues of etoposide, and NK 611.
AID1301511	Growth inhibition of human DU145 cells measured after 48 hrs by sulforhodamine B assay	2016	Journal of natural products, Mar-25, Volume: 79, Issue:3	Antineoplastic Agents. 585. Isolation of Bridelia ferruginea Anticancer Podophyllotoxins and Synthesis of 4-Aza-podophyllotoxin Structural Modifications.
AID415314	Octanol-water partition coefficient, log P of the compound	2009	Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8	Synthesis and biological evaluation of novel conjugates of podophyllotoxin and 5-FU as antineoplastic agents.
AID762340	Cytotoxicity against rat L6 cells after 70 hrs by Alamar blue assay	2013	European journal of medicinal chemistry, Aug, Volume: 66	3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis.
AID114448	Compound was tested for Immunosuppression activity by mixed lymphocyte reaction (MLR) in murine splenocytes of mice	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Immunosuppressive cyclolignans.
AID1760369	Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID335782	Cytotoxicity against human HT cells	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID1754701	Cytotoxicity in human HMEC cells assessed as inhibition of cell proliferation measured by CCK-8 assay	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID214525	Percentage control on Tubulin- Dependent GTP hydrolysis was evaluated at 50 micro M concentration	1999	Bioorganic & medicinal chemistry letters, Apr-19, Volume: 9, Issue:8	A new anti-tubulin agent containing the benzo[b]thiophene ring system.
AID464499	Inhibition of ovine COX1	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID214039	Inhibition of bovine brain tubulin polymerization (ITP).	1998	Journal of medicinal chemistry, Mar-26, Volume: 41, Issue:7	Antitumor agents. 181. Synthesis and biological evaluation of 6,7,2',3',4'-substituted-1,2,3,4-tetrahydro-2-phenyl-4-quinolones as a new class of antimitotic antitumor agents.
AID1637419	Induction of apoptosis in human K562/ADR cells assessed as necrotic cells at 0.05 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 2.47%)	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID1515150	Antiproliferative activity against human HF6 cells after 48 hrs by CellTiter 96 AQueous one solution cell proliferation assay	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway.
AID214503	in vitro inhibitory activity against tubulin polymerization.	1998	Journal of medicinal chemistry, Nov-05, Volume: 41, Issue:23	Synthesis and antitumor activity of new glycosides of epipodophyllotoxin, analogues of etoposide, and NK 611.
AID670485	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Synthesis and biological evaluation of novel 4β-(1,3,4-oxadiazole-2-amino)-podophyllotoxin derivatives.
AID1281531	Antiproliferative activity against human MCF7 cells after 96 hrs by propidium iodide-based monolayer assay	2016	European journal of medicinal chemistry, Mar-03, Volume: 110	Novel cis-selective and non-epimerisable C3 hydroxy azapodophyllotoxins targeting microtubules in cancer cells.
AID1456145	Induction of apoptosis in human Bel7402/5-FU cells assessed as necrotic cells at 0.05 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 0.58%)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1754704	Cytotoxicity in human HepG2 cells assessed as inhibition of cell proliferation measured by CCK-8 assay	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID1754716	Induction of apoptosis in human PC-3M cells assessed as necrotic cells at 1 nM measured after 48 hrs by Annexin V/PI staining based flow cytometry method (Rvb = 0.25%)	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID481680	Cytotoxicity against Paracentrotus lividus embryo assessed as embryo spinning after 9 to 12 hrs fertilization and 0.5 to 20 hrs treatment	2010	European journal of medicinal chemistry, May, Volume: 45, Issue:5	Novel derivatives of 1,3,4-oxadiazoles are potent mitostatic agents featuring strong microtubule depolymerizing activity in the sea urchin embryo and cell culture assays.
AID464517	Selectivity ratio for IC50 for human BJ cells to IC50 for human Raji cells	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID1174231	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Investigation of podophyllotoxin esters as potential anticancer agents: synthesis, biological studies and tubulin inhibition properties.
AID1428413	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by SRB assay
AID1432113	Growth inhibition of human PC3 cells after 48 hrs by MTT assay
AID1403375	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Synthesis of podophyllotoxin linked β-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors.
AID1515151	Antiproliferative activity against human CaSki cells after 48 hrs by CellTiter 96 AQueous one solution cell proliferation assay	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway.
AID1699436	Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 70 hrs by resazurin dye based inverted microscopic analysis	2020	Journal of natural products, 11-25, Volume: 83, Issue:11	Pyridine-4(1
AID1070507	Cytotoxicity against rat L6 cells assessed as growth inhibition after 70 hrs by Alamar Blue assay	2014	Journal of natural products, Mar-28, Volume: 77, Issue:3	Indoloditerpenes from a marine-derived fungal strain of Dichotomomyces cejpii with antagonistic activity at GPR18 and cannabinoid receptors.
AID1186368	Inhibition of microtubule bundle formation in human A549 cells assessed as cell detachment at 200 ug/mL incubated for 1 hr by alpha-tubulin staining based fluorescence microscopy	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	New class of squalene-based releasable nanoassemblies of paclitaxel, podophyllotoxin, camptothecin and epothilone A.
AID1140300	Anticancer activity against human DU145 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9	Synthesis of a terphenyl substituted 4-aza-2,3-didehydropodophyllotoxin analogues as inhibitors of tubulin polymerization and apoptosis inducers.
AID340105	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	2008	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14	Gallic acid-based indanone derivatives as anticancer agents.
AID337695	Antibacterial activity against Escherichia coli ATCC 25922 at 5 ug after 48 hrs by silica gel plate-based INT-formazan method
AID1267727	Inhibition of tubulin polymerization in human K562/ADR cells assessed as microtubule disruption at 0.2 uM after 8 hrs by DAPI staining based immunofluorescence microscopy	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID115996	In vivo antitumor activity against the M5076 reticulum cell sarcoma expressed as percent increase in life span at 4 mg/kg dose	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	In vivo antitumor activity of 6-benzyl-1,3-benzodioxole derivatives against the P388, L1210, B16, and M5076 murine models.
AID655123	Cytotoxicity against human HL-60(TB) cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID232657	Ratio of inhibitory activity to inhibitory activity of colchicine	1980	Journal of medicinal chemistry, May, Volume: 23, Issue:5	Structure--antitubulin activity relationship in steganacin congeners and analogues. Inhibition of tubulin polymerization in vitro by (+/-)-isodeoxypodophyllotoxin.
AID723341	Induction of cell cycle arrest in human A549 cells assessed as S phase cells at 1 uM by FACS analysis (Rvb = 3.69%)	2013	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1	Synthesis and anticancer activity of heteroaromatic linked 4β-amido podophyllotoxins as apoptotic inducing agents.
AID1168743	Anticancer activity against human A498 cells after 24 hrs by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID697852	Inhibition of electric eel AChE at 2 mg/ml by Ellman's method	2012	Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22	Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID464512	Selectivity for Trypanosoma brucei brucei over human HMEC	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID628068	Antimitotic activity against Paracentrotus lividus embryo assessed as cleavage alteration treated 10 to 25 mins post fertilization followed by 45 to 60 mins before the first mitotic cycle completion by sea urchin embryo assay	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID57216	Compound was tested for percentage inhibition against DNA topoisomerase II	1986	Journal of medicinal chemistry, Aug, Volume: 29, Issue:8	Antitumor agents. 78. Inhibition of human DNA topoisomerase II by podophyllotoxin and alpha-peltatin analogues.
AID634095	Anticancer activity against human A375 cells after 48 hrs by MTT assay	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and anticancer activity of 4β-alkylamidochalcone and 4β-cinnamido linked podophyllotoxins as apoptotic inducing agents.
AID1057259	Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 assessed as parasite growth inhibition after 48 hrs by SYBR green-1 dye-based fluorescence assay	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
AID1101797	Insecticidal activity against fifth-instar larvae of Pieris rapae fed on compound treated cabbage leaf assessed as loss of body fluid at 250 ppm dipped for 3 secs measured after 48 hr relative to control	2002	Chemical & pharmaceutical bulletin, Mar, Volume: 50, Issue:3	Synthesis and insecticidal activity of novel 4beta-halogenated benzoylamino podophyllotoxins against Pieris rapae Linnaeus.
AID1432152	Inhibition of porcine brain tubulin polymerization measured for 1 hr by fluorescence assay
AID398314	Displacement of [3H]colchicine from tubulin at 50 uM	1995	Journal of natural products, Apr, Volume: 58, Issue:4	Antitumor agents, 154. Cytotoxic and antimitotic flavonols from Polanisia dodecandra.
AID1850579	Cytotoxicity against mouse P388 cells measured after 48 hrs by MTT assay	2022	Bioorganic & medicinal chemistry, 08-01, Volume: 67	Synthesis and medicinal chemistry of tetronamides: Promising agrochemicals and antitumoral compounds.
AID644058	Induction of apoptosis in human A549 cells assessed as nuclear condensation at 0.5 uM after 24 hrs by Hoechst 33258 staining based fluorescence microscopy	2012	European journal of medicinal chemistry, Mar, Volume: 49	Synthesis and biological evaluation of conjugates of deoxypodophyllotoxin and 5-FU as inducer of caspase-3 and -7.
AID710592	Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by inverted microscopy	2012	Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23	Conjugation of quinones with natural polyamines: toward an expanded antitrypanosomatid profile.
AID611278	Inhibition of pig brain tubulin polymerization after 30 mins by turbidimetry analysis	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Phenylimino-10H-anthracen-9-ones as novel antimicrotubule agents-synthesis, antiproliferative activity and inhibition of tubulin polymerization.
AID1882898	Cytotoxicity against human A549/TxR cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID628179	Induction of apoptosis in human Jurkat cells assessed as reduction in procaspase-8 levels at 50 nM after 48 hrs by Western blotting	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID272984	Cytotoxicity against KB cell line	2006	Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20	Evaluation of azasterols as anti-parasitics.
AID655224	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID274747	Cytotoxicity against rat L6 cells	2007	Journal of natural products, Jan, Volume: 70, Issue:1	Limonoid orthoacetates and antiprotozoal compounds from the roots of Pseudocedrela kotschyi.
AID1188221	Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 48 hrs by SRB assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Synthesis and biological evaluation of podophyllotoxin congeners as tubulin polymerization inhibitors.
AID1489089	Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 0.6 uM after 4 hrs by propidium iodide staining based flow cytometric method (Rvb = 29.55 to 32.22%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID655211	Cytotoxicity against human HT-29 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID303685	Inhibition of porcine brain tubulin polymerization	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID628081	Cytotoxicity against human Jurkat cells assessed as cell viability after 48 hrs by trypan blue exclusion assay	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID1776168	Cytotoxicity against rat L6 cells measured after 72 hrs by alamar blue dye based fluorometric analysis	2021	Journal of natural products, 04-23, Volume: 84, Issue:4	Spirombandakamine A
AID536815	Cytotoxicity against rat L6 cells	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	QSAR guided synthesis of simplified antiplasmodial analogs of naphthylisoquinoline alkaloids.
AID1489104	Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 4 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 2 to 3.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1126573	Cytotoxicity against brine shrimps larvae assessed as mortality after 24 hrs	2014	European journal of medicinal chemistry, May-06, Volume: 78	Synthesis and biological evaluation of N-dehydrodipeptidyl-N,N'-dicyclohexylurea analogs.
AID404065	Antiviral activity against HSV1 infected in human primary amnion cells assessed as inhibition of virus-induced pathogenic effect	1998	Journal of natural products, Nov, Volume: 61, Issue:11	Antiviral activity of lignans.
AID57731	In vitro cytotoxic activity against prostate (DU-145) cancer cell line.	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	9-Deoxopodophyllotoxin derivatives as anti-cancer agents.
AID1317411	Selectivity index, ratio of IC50 for HAF cells to IC50 for human PC3 cells	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID1495316	Induction of autophagy in human K562/VCR cells assessed as upregulation of beclin-1 expression at 0.05 uM after 48 hrs by Western blot method relative to beta-actin	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID360862	Cytotoxicity against human KB cells	2001	Journal of natural products, Jun, Volume: 64, Issue:6	New prenylated bi- and tricyclic phloroglucinol derivatives from Hypericum papuanum.
AID1410390	Induction of apoptosis in human MG63 cells assessed as total apoptotic cells at 1 uM after 24 hrs by annexin-V-FITC/propidium iodide staining based flow cytometric analysis (Rvb = 10.42%)	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	New Hybrids Derived from Podophyllic Aldehyde and Diterpenylhydroquinones with Selectivity toward Osteosarcoma Cells.
AID1515176	Induction of apoptosis in human PC3 cells assessed as chromatin condensation at 0.005 uM after 48 hrs by acridine orange/ethidium bromide staining-based epifluorescence microscopic analysis	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway.
AID753998	Cytotoxicity against rat L6 cells assessed as growth inhibition after 70 hrs by Alamar blue staining-based inverted microscopic analysis	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and antimalarial testing of neocryptolepine analogues: addition of ester function in SAR study of 2,11-disubstituted indolo[2,3-b]quinolines.
AID1317442	Antitumor activity against human T47D cells xenografted in nude mouse assessed as tumor volume at 5 mg/kg/day, ip administered daily for 18 days measured every 3 days during compound dosing (Rvb = 1220 +/- 127 mm3)	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID150680	Tested in vitro for antineoplastic activity against P-388 (lymphoid neoplasm from DBA/2 mouse) tumor cell line	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID723345	Induction of cell cycle arrest in human A549 cells assessed as sub G1 phase cells at 1 uM by FACS analysis (Rvb = 1.08%)	2013	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1	Synthesis and anticancer activity of heteroaromatic linked 4β-amido podophyllotoxins as apoptotic inducing agents.
AID1628264	Binding affinity to goat brain tubulin assessed as reduction in binding of 5-(Quinolin-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-imidazol-2-amine to tubulin incubated for 15 mins by fluorescence based assay	2016	Journal of medicinal chemistry, Apr-14, Volume: 59, Issue:7	Novel Combretastatin-2-aminoimidazole Analogues as Potent Tubulin Assembly Inhibitors: Exploration of Unique Pharmacophoric Impact of Bridging Skeleton and Aryl Moiety.
AID337694	Antibacterial activity against Bacillus subtilis ATCC 6633 at 5 ug after 48 hrs by silica gel plate-based INT-formazan method
AID87916	Effect on cell cycle evaluated as proportion of cells in G2/M phase of the cell cycle at 10E-7 M for 48 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID644055	Induction of apoptosis in human A549 cells assessed as membrane blebbing at 0.5 uM after 24 hrs by Hoechst 33258 staining based fluorescence microscopy	2012	European journal of medicinal chemistry, Mar, Volume: 49	Synthesis and biological evaluation of conjugates of deoxypodophyllotoxin and 5-FU as inducer of caspase-3 and -7.
AID723347	Cytotoxicity against human ACHN cells after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1	Synthesis and anticancer activity of heteroaromatic linked 4β-amido podophyllotoxins as apoptotic inducing agents.
AID1101796	Insecticidal activity against fifth-instar larvae of Pieris rapae fed on compound treated cabbage leaf assessed as immobilization at 250 ppm dipped for 3 secs measured after 48 hr relative to control	2002	Chemical & pharmaceutical bulletin, Mar, Volume: 50, Issue:3	Synthesis and insecticidal activity of novel 4beta-halogenated benzoylamino podophyllotoxins against Pieris rapae Linnaeus.
AID85223	In vitro cytotoxicity against human breast cancer Hs 578.T cell line	1998	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11	Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents.
AID1728397	Inhibition of beta-tubulin polymerization in human HCT116 cells at IC50 incubated for 18 to 24 hrs and measured by spectrophotometric analysis	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Design, synthesis and screening of benzimidazole containing compounds with methoxylated aryl radicals as cytotoxic molecules on (HCT-116) colon cancer cells.
AID213999	Concentration inhibiting tubulin polymerization (ITP)	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor agents. 196. Substituted 2-thienyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization.
AID655125	Cytotoxicity against human MOLT4 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID657132	Inhibition of tubulin polymerization after 1 hr by spectrophotometric analysis	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and anticancer activity of 2-benzylidene indanones through inhibiting tubulin polymerization.
AID536767	Inhibition of tubulin polymerization at 3 uM	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis and cytotoxicity evaluation of novel 1,4-disubstituted 1,2,3-triazoles via CuI catalysed 1,3-dipolar cycloaddition.
AID1317447	Acute toxicity in nude mouse xenografted with human T47D cells assessed as mortality at 5 to 40 mg/kg/day, ip administered daily for 18 days measured on day 18 post last dose	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID699778	Inhibition of bovine brain tubulin polymerization at 1 uM after 30 mins by spectrophotometric analysis	2012	Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15	Synthesis and antimitotic and tubulin interaction profiles of novel pinacol derivatives of podophyllotoxins.
AID628164	Inhibition of microtubule polymerization in human A549 cells assessed as total disruption of interphase microtubule network at 1 uM after 8 hrs by immunofluorescence microscopy	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID303684	Antiproliferative activity against human K562 cells after 48 hrs	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Sulfonate derivatives of naphtho[2,3-b]thiophen-4(9H)-one and 9(10H)-anthracenone as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID628178	Induction of apoptosis in human Jurkat cells assessed as procaspase-2 cleavage at 50 nM after 48 hrs by Western blotting	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID290177	Antiproliferative activity against human PC3 cells	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Novel pyridinyl and pyrimidinylcarbazole sulfonamides as antiproliferative agents.
AID464326	Cytotoxicity against human Raji cells after 72 hrs by luminescence assay	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID1168742	Cytotoxic activity against HEK293 cells after 24 hrs by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID87915	Effect on cell cycle evaluated as proportion of cells in G2/M phase of the cell cycle at 10E-7 M for 24 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1489103	Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 4 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 2.36 to 2.86%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID494521	Inhibition of tubulin polymerization in human K562 cells	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Synthesis, antiproliferative activity and inhibition of tubulin polymerization by anthracenone-based oxime derivatives.
AID628171	Induction of apoptosis in human Jurkat cells assessed as hypodyploid cells at 50 nM after 48 hrs by annexin-V FITC/7-ADD staining-based flow cytometric analysis (Rvb = 12.2%)	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID1637418	Induction of apoptosis in human K562/ADR cells assessed as late apoptotic cells at 0.05 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 3.89%)	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID1301505	Growth inhibition of human NCI-H460 cells measured after 48 hrs by sulforhodamine B assay	2016	Journal of natural products, Mar-25, Volume: 79, Issue:3	Antineoplastic Agents. 585. Isolation of Bridelia ferruginea Anticancer Podophyllotoxins and Synthesis of 4-Aza-podophyllotoxin Structural Modifications.
AID1317415	Selectivity index, ratio of IC50 for HAF cells to IC50 for human HL60 cells	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID262911	Inhibition of tubulin polymerization	2006	Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7	Benzoylphenylurea sulfur analogues with potent antitumor activity.
AID384946	Binding affinity to HPV1a recombinant E2 protein activator domain by surface plasmon resonance assay	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Podophyllotoxin directly binds a hinge domain in E2 of HPV and inhibits an E2/E7 interaction in vitro.
AID1317408	Selectivity index, ratio of IC50 for HAF cells to IC50 for human MDA-MB-231 cells	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID1637434	Activation of ERK1/2 signalling in human K562/ADR cells assessed as suppression of CDK1 protein expression at 0.05 uM after 48 hrs by Western blot analysis relative to control	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID1456153	Reduction in microtubule density in human Bel7402/5-FU cells at 0.05 uM after 24 to 48 hrs by DAPI staining based immunofluorescence microscopic method	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1148922	Inhibition of colony formation in BDF1 mouse bone marrow cells assessed as percentage of colony forming cell at 50 nM after 7 days by microscopic analysis relative to control	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Podophyllotoxin analogs. 1. Synthesis and biological evaluation of certain trans-2-aryl-trans-6-hydroxymethyl-3-cyclohexenecarboxylic acid gamma-lactones as antimitotic agents.
AID1174232	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Investigation of podophyllotoxin esters as potential anticancer agents: synthesis, biological studies and tubulin inhibition properties.
AID1306343	Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 8 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 5.92 to 9.33%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1334730	Antiproliferative activity against human HepG2 assessed as reduction in cell viability measured after 48 hrs by SRB assay	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Novel carbazole sulfonamide derivatives of antitumor agent: Synthesis, antiproliferative activity and aqueous solubility.
AID1233445	Inhibition of bovine brain tubulin polymerization assessed as increase in fluorescence intensity at 5 uM relative to control	2015	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14	Synthesis and Biological evaluation of novel 4β-[(5-substituted)-1,2,3,4-tetrazolyl] podophyllotoxins as anticancer compounds.
AID335773	Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 4 ug/mL	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID398416	Cytotoxicity against human A549 cells	1995	Journal of natural products, Jun, Volume: 58, Issue:6	Methyl ethers of podophyllotoxin-related cyclolignans.
AID1495314	Downregulation of MRP-1 expression in human K562/VCR cells at 0.05 uM after 48 hrs by Western blot method relative to beta-actin	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID1306334	Cytotoxicity against HEK293T cells after 36 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID159533	In vitro inhibition of maximum porcine tubulin assembly rate after 20 min at 37 degrees C	2003	Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15	Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID310757	Antiproliferative activity against human Bel7402 cells	2007	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24	3-(2'-Bromopropionylamino)-benzamides as novel S-phase arrest agents.
AID1233443	Cytotoxicity against human HeLa cells assessed as cell viability by SRB assay	2015	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14	Synthesis and Biological evaluation of novel 4β-[(5-substituted)-1,2,3,4-tetrazolyl] podophyllotoxins as anticancer compounds.
AID300105	Cytotoxicity against human KB cells	2007	Bioorganic & medicinal chemistry, Aug-15, Volume: 15, Issue:16	Anti-malarial activity of N6-modified purine analogues.
AID1267724	Inhibition of tubulin polymerization in human K562/ADR cells assessed as reduction in microtubule density at 0.2 uM after 8 hrs by DAPI staining based immunofluorescence microscopy	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1728298	Cytotoxicity against rat L6 cells after 70 hrs by Alamar blue assay	2021	European journal of medicinal chemistry, Jan-15, Volume: 210	Preparation of new 1,3-dibenzyl tetrahydropyridinylidene ammonium salts and their antimicrobial and anticellular activities.
AID272983	Antimalarial activity against Plasmodium falciparum K1	2006	Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20	Evaluation of azasterols as anti-parasitics.
AID1489075	Cytotoxicity against human HeLa cells after 24 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID725214	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	2013	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 23, Issue:2	Discovery and preliminary structure-activity relationship analysis of 1,14-sperminediphenylacetamides as potent and selective antimalarial lead compounds.
AID1403418	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.
AID1456157	Antimigratory activity in human Bel7402/5-FU cells at 0.05 uM after 24 hrs by wound healing assay	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID441747	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Antitrypanosomal activity of 1,2-dihydroquinolin-6-ols and their ester derivatives.
AID415313	Cytotoxicity against human A549 cells after 72 hrs by SRB method	2009	Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8	Synthesis and biological evaluation of novel conjugates of podophyllotoxin and 5-FU as antineoplastic agents.
AID1699416	Induction of apoptosis in human HepG2 cells assessed as late apoptotic cells at 50 nM incubated for 24 hrs by annexin V-FITC and propidium iodide based flow cytometry analysis (Rvb = 1.56 %)	2020	Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24	Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
AID338987	Displacement of [3H]colchicine from tubulin at inhibitor and colchicine ratio 1:1 after 10 mins relative to control
AID1637407	Resistance factor, ratio of IC50 for human K562/ADR cells to IC50 for human K562 cells	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID1162946	Antiplasmodial activity against Plasmodium falciparum 3D7 asexual blood stages after 3 days by HRP2 detection based ELISA method	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
AID398417	Cytotoxicity against human HT-29 cells	1995	Journal of natural products, Jun, Volume: 58, Issue:6	Methyl ethers of podophyllotoxin-related cyclolignans.
AID235703	Selectivity index is the ratio of IC50 of P-388 cell line to that of HT-29	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID310759	Antiproliferative activity against human PC3 cells	2007	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24	3-(2'-Bromopropionylamino)-benzamides as novel S-phase arrest agents.
AID1489092	Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 0.6 uM after 8 hrs by propidium iodide staining based flow cytometric method (Rvb = 29.55 to 32.22%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1432146	Induction of mitochondrial membrane potential loss in human DU145 cells assessed as cell population with intact membrane potential at 400 nM after 24 hrs by JC-1 staining based flow cytometry (Rvb = 80.92%)
AID1405624	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Biological evaluation and structure-activity relationships of imidazole-based compounds as antiprotozoal agents.
AID1489112	Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 12 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 2 to 3.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1489080	Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 0.3 uM after 12 hrs by propidium iodide staining based flow cytometric method (Rvb = 27.63 to 32.34%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1317400	Antiproliferative activity against human T47D cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID602117	Antimitotic activity in human HeLa cells assessed as disruption of interphase microtubule organization at 10 uM after 3 hrs by inverted microscopic analysis	2011	Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12	Anticancer properties of an important drug lead podophyllotoxin can be efficiently mimicked by diverse heterocyclic scaffolds accessible via one-step synthesis.
AID736389	Cytotoxicity against rat L6 cells after 70 hrs by microscopic analysis	2013	Journal of natural products, Jan-25, Volume: 76, Issue:1	Antibacterial and antiplasmodial constituents of Beilschmiedia cryptocaryoides.
AID1306350	Induction of apoptosis in human MCF7 cells assessed as viable cells at 4 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 80 to 91.6%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID655238	Cytotoxicity against human ACHN cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1188223	Inhibition of bovine brain tubulin polymerization by fluorescence analysis	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Synthesis and biological evaluation of podophyllotoxin congeners as tubulin polymerization inhibitors.
AID1410385	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	New Hybrids Derived from Podophyllic Aldehyde and Diterpenylhydroquinones with Selectivity toward Osteosarcoma Cells.
AID1267692	Antiproliferative activity against human A549 cells assessed as growth inhibition after 72 hrs by CCK-8 assay	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1495302	Induction of JNK phosphorylation in human K562/VCR cells at 0.05 uM after 48 hrs by Western blot method relative to beta-actin	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID497464	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	2010	Journal of natural products, Aug-27, Volume: 73, Issue:8	Antiprotozoal steroidal saponins from the marine sponge Pandaros acanthifolium.
AID1549907	Antiproliferative activity against human H8 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, May-15, Volume: 170	Discover 4β-NH-(6-aminoindole)-4-desoxy-podophyllotoxin with nanomolar-potency antitumor activity by improving the tubulin binding affinity on the basis of a potential binding site nearby colchicine domain.
AID1754714	Induction of apoptosis in human PC-3M cells assessed as early apoptotic cells at 1 nM measured after 48 hrs by Annexin V/PI staining based flow cytometry method (Rvb = 1.25%)	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID400477	Cytotoxicity against african green monkey Vero cells assessed as cell rounding at 1 uM
AID87924	Effect on cell cycle evaluated as proportion of cells in S phase of the cell cycle at 10E-7 M for 48 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1306336	Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 1 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.021 to 3.8%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID655127	Cytotoxicity against human SR cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID597078	Cytotoxicity against rat L6 cells after 72 hrs by microplate fluorimetry	2011	Journal of natural products, Apr-25, Volume: 74, Issue:4	Antiparasitic compounds from Cupania cinerea with activities against Plasmodium falciparum and Trypanosoma brucei rhodesiense.
AID1456173	Effect on cyclinB1 expression in human Bel7402/5-FU cells assessed as ratio of cyclinB1 to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.53 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID310755	Antiproliferative activity against human Molt3 cells	2007	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 17, Issue:24	3-(2'-Bromopropionylamino)-benzamides as novel S-phase arrest agents.
AID592702	Inhibition of tubulin polymerization in human A549 cells assessed as disrupted microtubule organization at 1 uM after 48 hrs by immunohistochemistry	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis of a new 4-aza-2,3-didehydropodophyllotoxin analogues as potent cytotoxic and antimitotic agents.
AID1148913	Displacement of [3H]colchicine from bovine brain tubulin at 20 uM after 90 mins by liquid scintillation counting in presence of 10 uM [3H]colchicine	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Podophyllotoxin analogs. 1. Synthesis and biological evaluation of certain trans-2-aryl-trans-6-hydroxymethyl-3-cyclohexenecarboxylic acid gamma-lactones as antimitotic agents.
AID338988	Displacement of [3H]colchicine from tubulin at inhibitor and colchicine ratio 10:1 after 10 mins relative to control
AID655246	Cytotoxicity against human MCF7 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1541619	Cytotoxicity against rat L6 cells measured after 72 hrs by alamar blue dye based fluorimetry analysis	2019	Journal of natural products, 12-27, Volume: 82, Issue:12	Structure, Biosynthesis, and Bioactivity of Photoditritide from
AID1545943	Antiproliferative activity against human PC3 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID1637437	Activation of ERK1/2 signalling in human K562/ADR cells assessed as suppression of CyclinB1 protein expression at 0.05 uM after 48 hrs by Western blot analysis relative to control	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID1515167	Cell cycle arrest in human PC3 cells assessed as accumulation at G1 phase at 0.12 uM after 48 hrs by RNAse/propidium iodide staining-based flow cytometric analysis (Rvb = 55.6%)	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway.
AID723349	Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1	Synthesis and anticancer activity of heteroaromatic linked 4β-amido podophyllotoxins as apoptotic inducing agents.
AID1306351	Induction of apoptosis in human MCF7 cells assessed as viable cells at 8 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 80 to 91.6%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID214176	Inhibition of colchicine binding to tubulin was evaluated only when polymerization IC50 <=1.0 uM	1994	Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20	Antitumor agents. 155. Synthesis and biological evaluation of 3',6,7-substituted 2-phenyl-4-quinolones as antimicrotubule agents.
AID1182197	Antimitotic microtubule destabilizing activity in Paracentrotus lividus L embryos assessed as induction of cleavage arrest	2014	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16	Comparative in vivo evaluation of polyalkoxy substituted 4H-chromenes and oxa-podophyllotoxins as microtubule destabilizing agents in the phenotypic sea urchin embryo assay.
AID266615	Cytotoxicity against rat L6 cells	2006	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 16, Issue:14	Design, synthesis and evaluation of novel uracil amino acid conjugates for the inhibition of Trypanosoma cruzi dUTPase.
AID1456113	Cell cycle arrest in human Bel7402/5-FU cells assessed as accumulation at G2 phase at 0.05 uM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 35.16%)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1162947	Antiplasmodial activity against Plasmodium falciparum Dd2 asexual blood stages after 3 days by HRP2 detection based ELISA method	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
AID404379	Cytotoxicity against rat L6 cells	2008	Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12	Synthesis and in vitro antiprotozoal activities of water-soluble, inexpensive 3,7-bis(dialkylamino)phenoxazin-5-ium derivatives.
AID1186366	Inhibition of microtubule bundle formation in human A549 cells assessed as cell shrinking at 200 ug/mL incubated for 1 hr by alpha-tubulin staining based fluorescence microscopy	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	New class of squalene-based releasable nanoassemblies of paclitaxel, podophyllotoxin, camptothecin and epothilone A.
AID1172520	Cytotoxicity in brine shrimps larvae assessed as mortality after 24 hrs	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: Potential anticancer agents.
AID618833	Cytotoxicity against human HeLa cells after 2 days by MTT assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis of 4β-triazole-podophyllotoxin derivatives by azide-alkyne cycloaddition and biological evaluation as potential antitumor agents.
AID80367	In vitro cytotoxicity against human colon cancer HCT 15 cell line	1998	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11	Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents.
AID386868	Cytotoxicity against human SF295 cells by sulforhodamine B assay	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Studies on novel 4beta-[(4-substituted)-1,2,3-triazol-1-yl] podophyllotoxins as potential anticancer agents.
AID655124	Cytotoxicity against human K562 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1186372	Cytotoxicity against human A549 cells after 48 hrs by SRB assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	New class of squalene-based releasable nanoassemblies of paclitaxel, podophyllotoxin, camptothecin and epothilone A.
AID670481	Cytotoxicity against human DU145 cells after 72 hrs by MTT assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Synthesis and biological evaluation of novel 4β-(1,3,4-oxadiazole-2-amino)-podophyllotoxin derivatives.
AID1267181	Displacement of [3H]-colchicine from biotinylated porcine tubulin after 2 hrs by competitive binding assay	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer.
AID1448630	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	2017	Journal of medicinal chemistry, 06-22, Volume: 60, Issue:12	Antimalarial Inhibitors Targeting Serine Hydroxymethyltransferase (SHMT) with in Vivo Efficacy and Analysis of their Binding Mode Based on X-ray Cocrystal Structures.
AID214346	Binding affinity against tubulin using [3H]colchicine as radioligand	1980	Journal of medicinal chemistry, May, Volume: 23, Issue:5	Structure--antitubulin activity relationship in steganacin congeners and analogues. Inhibition of tubulin polymerization in vitro by (+/-)-isodeoxypodophyllotoxin.
AID1428412	Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 72 hrs by SRB assay
AID1751117	Inhibition of tubulin polymerization in human A549 cells assessed as disruption of microtubule network at 2 uM measured after 48 hrs by confocal microscopic analysis
AID748432	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	2013	ACS medicinal chemistry letters, Jun-13, Volume: 4, Issue:6	New Promising Compounds with in Vitro Nanomolar Activity against Trypanosoma cruzi.
AID1456186	Induction of apoptosis in human Bel7402/5-FU cells assessed as ratio of cleaved caspase-3 to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.19 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1906527	Cytotoxicity against human HeLa cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	2022	European journal of medicinal chemistry, May-05, Volume: 235	Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy.
AID655210	Cytotoxicity against human HCT15 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1495280	Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID1361531	Inhibition of tubulin beta polymerization in human MCF7 cells at IC50 after 18 to 24 hrs by spectrophotometric method relative to control	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Design, synthesis and screening of 1, 2, 4-triazinone derivatives as potential antitumor agents with apoptosis inducing activity on MCF-7 breast cancer cell line.
AID400479	Antiviral activity against measles virus infected in african green monkey Vero cells assessed as cell rounding at 1 uM
AID723343	Induction of cell cycle arrest in human A549 cells assessed as G1 phase cells at 1 uM by FACS analysis (Rvb = 85.33%)	2013	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 23, Issue:1	Synthesis and anticancer activity of heteroaromatic linked 4β-amido podophyllotoxins as apoptotic inducing agents.
AID1331705	Cytotoxicity against human A2780 cells assessed as decrease in cell viability after 48 hrs by MTT assay	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Structural and Biochemical Characterization of the Interaction of Tubulin with Potent Natural Analogues of Podophyllotoxin.
AID378966	Antitrypanosomal activity against Trypanosoma brucei brucei MITat 1.2 variant 221 after 72 hrs	2006	Journal of natural products, Jan, Volume: 69, Issue:1	Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1698824	Antimitotic activity against sea urchin embryo assessed as embryo spinning measured 2.5 to 6 hrs post-fertilization observed after 15 min to 20 hrs of treatment by light microscopy analysis	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Computational modeling and target synthesis of monomethoxy-substituted o-diphenylisoxazoles with unexpectedly high antimitotic microtubule destabilizing activity.
AID1495308	Induction of apoptosis in human K562/VCR cells assessed as downregulation of CDK2 expression at 0.05 uM after 48 hrs by Western blot method relative to beta-actin	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID1637449	Activation of ERK1/2 signalling in human K562/ADR cells assessed as suppression of P-gp expression at 0.05 uM after 48 hrs by Western blot analysis relative to control	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID403984	Therapeutic index, ratio of MTC for human primary amnion cells to lowest drug level causing inhibition of HSV1	1998	Journal of natural products, Nov, Volume: 61, Issue:11	Antiviral activity of lignans.
AID1699405	Cytotoxicity against NQO1-deficient human L02 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24	Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
AID1306347	Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 8 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 2.45 to 6.92%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1483955	Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay	2017	Journal of natural products, 02-24, Volume: 80, Issue:2	Dioncophyllines C
AID115979	In vivo antitumor activity against the B16 melanoma cell line expressed as percent increase in life span; IA means inactive	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	In vivo antitumor activity of 6-benzyl-1,3-benzodioxole derivatives against the P388, L1210, B16, and M5076 murine models.
AID214030	Inhibition of bovine tubulin polymerization	2000	Journal of medicinal chemistry, Nov-16, Volume: 43, Issue:23	6-Alkylamino- and 2,3-dihydro-3'-methoxy-2-phenyl-4-quinazolinones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization.
AID1403374	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Synthesis of podophyllotoxin linked β-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors.
AID628080	Cytotoxicity against mouse P388 cells assessed as cell viability after 48 hrs by trypan blue exclusion assay	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID340103	Cytotoxicity against human CaCO2 cells after 24 hrs by MTT assay	2008	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14	Gallic acid-based indanone derivatives as anticancer agents.
AID1549908	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, May-15, Volume: 170	Discover 4β-NH-(6-aminoindole)-4-desoxy-podophyllotoxin with nanomolar-potency antitumor activity by improving the tubulin binding affinity on the basis of a potential binding site nearby colchicine domain.
AID1092096	In vivo insecticidal activity against pre-third-instar larval stage of Mythimna separata (Oriental armyworm) in corn leaves assessed as corrected mortality rate at 1 mg/ml treated for 3 secs before larval infestation on corn leaves measured after 35 days	2011	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18	Natural products-based insecticidal agents 11. Synthesis and insecticidal activity of novel 4α-arylsulfonyloxybenzyloxy-2β-chloropodophyllotoxin derivatives against Mythimna separata Walker in vivo.
AID655122	Cytotoxicity against human CCRF-CEM cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID290174	Antiproliferative activity against human Bel-7402 cells	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Novel pyridinyl and pyrimidinylcarbazole sulfonamides as antiproliferative agents.
AID1515148	Cytotoxicity against human BJ cells after 48 hrs by CellTiter 96 AQueous one solution cell proliferation assay	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway.
AID270965	Cytotoxicity against cell cycle arrested RKOp27 cells after 72 hrs by alamar blue assay	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	[4-(imidazol-1-yl)thiazol-2-yl]phenylamines. A novel class of highly potent colchicine site binding tubulin inhibitors: synthesis and cytotoxic activity on selected human cancer cell lines.
AID1317844	Antiproliferative activity against drug-resistant human A549 cells up to 100 uM after 48 to 96 hrs by MTT assay relative to control	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	5,10b-Ethanophenanthridine amaryllidaceae alkaloids inspire the discovery of novel bicyclic ring systems with activity against drug resistant cancer cells.
AID1545844	Antiproliferative activity against human HeLa cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID379324	Cytotoxicity against human KB cells	2000	Journal of natural products, Mar, Volume: 63, Issue:3	Novel extracellular diterpenoids with biological activity from the cyanobacterium Nostoc commune.
AID1456220	Effect on P-gp expression in human Bel7402/5-FU cells assessed as ratio of P-gp to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.59 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID290178	Antiproliferative activity against human DND1 cells	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Novel pyridinyl and pyrimidinylcarbazole sulfonamides as antiproliferative agents.
AID1432114	Growth inhibition of human A549 cells after 48 hrs by MTT assay
AID527279	Cytotoxicity against rat L6 cells after 72 hrs by microplate fluorometric analysis	2010	Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21	2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.
AID1180388	Inhibition of tubulin polymerization in human HeLa cells assessed as increase of tubulin soluble fraction at 5 uM after 24 hrs by immunoblot analysis	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Synthesis and biological evaluation of 4-aza-2,3-dihydropyridophenanthrolines as tubulin polymerization inhibitors.
AID670484	Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Synthesis and biological evaluation of novel 4β-(1,3,4-oxadiazole-2-amino)-podophyllotoxin derivatives.
AID441774	Cytotoxicity against human HT-29 cells after 72 hrs by SRB assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and biological evaluation of new podophyllic aldehyde derivatives with cytotoxic and apoptosis-inducing activities.
AID1182198	Antimitotic microtubule destabilizing activity in Paracentrotus lividus L embryos assessed as induction of embryo spinning	2014	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 24, Issue:16	Comparative in vivo evaluation of polyalkoxy substituted 4H-chromenes and oxa-podophyllotoxins as microtubule destabilizing agents in the phenotypic sea urchin embryo assay.
AID337715	Displacement of [3H]colchicine from tubulin after 10 mins relative to control
AID384951	Binding affinity to HPV16 recombinant E2 protein by surface plasmon resonance method	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Podophyllotoxin directly binds a hinge domain in E2 of HPV and inhibits an E2/E7 interaction in vitro.
AID1489109	Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 8 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 2.35 to 2.49%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID401641	Cytotoxicity against rat L6 cells	2005	Journal of natural products, May, Volume: 68, Issue:5	Isoneocryptolepine, a synthetic indoloquinoline alkaloid, as an antiplasmodial lead compound.
AID1355406	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	2018	Journal of natural products, 06-22, Volume: 81, Issue:6	Phytochemical Study of Salvia leriifolia Roots: Rearranged Abietane Diterpenoids with Antiprotozoal Activity.
AID1101798	Insecticidal activity against fifth-instar larvae of Pieris rapae fed on compound treated cabbage leaf assessed as paralysis at 250 ppm dipped for 3 secs measured after 48 hr relative to control	2002	Chemical & pharmaceutical bulletin, Mar, Volume: 50, Issue:3	Synthesis and insecticidal activity of novel 4beta-halogenated benzoylamino podophyllotoxins against Pieris rapae Linnaeus.
AID400913	Cytotoxicity against human KB cells	2004	Journal of natural products, Apr, Volume: 67, Issue:4	New chromanone acids with antibacterial activity from Calophyllum brasiliense.
AID346047	Cytotoxicity against african green monkey Vero cells after 3 days by tetrazolium dye based colorimetric assay	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Redox-active dinitrodiphenylthioethers against Leishmania: synthesis, structure-activity relationships and mechanism of action studies.
AID1489077	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1545927	Antiproliferative activity against human DU145 cells by MTT assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
AID214687	Inhibition of tubulin polymerization. (ITP)	2001	Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23	Antitumor Agents. 211. Fluorinated 2-phenyl-4-quinolone derivatives as antimitotic antitumor agents.
AID1168741	Anticancer activity against human HeLa cells after 24 hrs by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID305852	Cytotoxicity against human Jurkat cells assessed as viability at 5 uM after 48 hrs by MTT method relative to control	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Structural simplification of bioactive natural products with multicomponent synthesis: dihydropyridopyrazole analogues of podophyllotoxin.
AID386870	Cytotoxicity against human 502713 cells by sulforhodamine B assay	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Studies on novel 4beta-[(4-substituted)-1,2,3-triazol-1-yl] podophyllotoxins as potential anticancer agents.
AID1495279	Antiproliferative activity against human K562/VCR cells after 72 hrs by CCK8 assay	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID443478	Cytotoxicity against c-myc/c-raf double transgenic mouse A2C12 cells by MTS assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID1637406	Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID592706	Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 1 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 23.1%)	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis of a new 4-aza-2,3-didehydropodophyllotoxin analogues as potent cytotoxic and antimitotic agents.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1663650	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability	2020	Bioorganic & medicinal chemistry letters, 07-15, Volume: 30, Issue:14	Vinyl sulfone-based inhibitors of trypanosomal cysteine protease rhodesain with improved antitrypanosomal activities.
AID298655	Antiproliferative activity against HeLa cells assessed as cell viability at 5 uM after 48 hrs by MTT assay relative to control	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis.
AID378967	Cytotoxicity against african green monkey Vero cells	2006	Journal of natural products, Jan, Volume: 69, Issue:1	Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities.
AID1188220	Antiproliferative activity against human MIAPaCa2 cells assessed as growth inhibition after 48 hrs by SRB assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Synthesis and biological evaluation of podophyllotoxin congeners as tubulin polymerization inhibitors.
AID95485	In vitro effective dose to inhibit KB cell growth from a human epidermoid carcinoma.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Absolute structure-cytotoxic activity relationships of steganacin congeners and analogues.
AID551374	Cytotoxicity against human HOP62 assessed as inhibition of cell growth	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	An efficient one-pot synthesis of benzothiazolo-4β-anilino-podophyllotoxin congeners: DNA topoisomerase-II inhibition and anticancer activity.
AID732345	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	2013	Journal of medicinal chemistry, Apr-11, Volume: 56, Issue:7	Discovery and structure-activity relationships of pyrrolone antimalarials.
AID87913	Effect on cell cycle evaluated as proportion of cells in G2/M phase of the cell cycle at 10E-6 M for 48 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1751091	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID1500568	Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 measured after 72 hrs by SYBR green 1 dye based fluorescence assay
AID1515177	Induction of apoptosis in human PC3 cells assessed as plasma membrane blebbing at 0.005 uM after 48 hrs by acridine orange/ethidium bromide staining-based epifluorescence microscopic analysis	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway.
AID88045	Effect on cell cycle evaluated as proportion of cells in sub-G1 phase (apoptic cells)of the cell cycle at 10E-8 M for 48 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID560439	Cell cycle arrest in HPV-transformed human SiHa cells assessed as accumulation at G2/M phase at 10 times EC50 after 48 hrs by flow cytometry	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions.
AID1500569	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay
AID1906551	Cytotoxicity against human A2780 cells assessed as inhibition of cell growth measured after 48 hrs by MTT assay	2022	European journal of medicinal chemistry, May-05, Volume: 235	Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy.
AID1267700	Induction of apoptosis in human K562/ADR cells assessed as viable cells at 0.1 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 93.25%)	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1403416	Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.
AID1549903	Antiproliferative activity against human HL7702 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, May-15, Volume: 170	Discover 4β-NH-(6-aminoindole)-4-desoxy-podophyllotoxin with nanomolar-potency antitumor activity by improving the tubulin binding affinity on the basis of a potential binding site nearby colchicine domain.
AID611190	Induction of apoptosis in human MCF7 cells assessed as double-strand DNA breaks at 2 uM after 24 hrs measured as phosphorylation at ser-139 on H2AX protein by immunostaining relative to control	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Synthesis and biological evaluation of 4β-acrylamidopodophyllotoxin congeners as DNA damaging agents.
AID298668	Effect on apoptosis in Jurkat cells assessed as cleavage of PARP at 5 uM	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis.
AID524791	Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID355582	Antiproliferative activity against human HT-29 cells at 0.01 ug after 48 hrs by two-layer agar-diffusion method
AID335787	Cytotoxicity against human ZR-75-1 cells	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID1489107	Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 8 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 2.36 to 2.86%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1639488	Cytotoxicity against human MCF7 cells measured after 72 hrs by sulforhodamine B assay
AID1760489	Antiproliferative activity against human Calu-1 cells incubated for 24 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID1489085	Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase at 0.9 uM after 12 hrs by propidium iodide staining based flow cytometric method (Rvb = 58.69 to 62.23%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID290176	Antiproliferative activity against human DU145 cells	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Novel pyridinyl and pyrimidinylcarbazole sulfonamides as antiproliferative agents.
AID1760432	Cytotoxicity against PBMC (unknown origin) incubated for 24 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID644056	Induction of apoptosis in human A549 cells assessed as cell shrinkage at 0.5 uM after 24 hrs by Hoechst 33258 staining based fluorescence microscopy	2012	European journal of medicinal chemistry, Mar, Volume: 49	Synthesis and biological evaluation of conjugates of deoxypodophyllotoxin and 5-FU as inducer of caspase-3 and -7.
AID655218	Cytotoxicity against human SNB75 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1515169	Cell cycle arrest in human PC3 cells assessed as accumulation at G2/M phase at 0.12 uM after 48 hrs by RNAse/propidium iodide staining-based flow cytometric analysis (Rvb = 24.9%)	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway.
AID1462703	Cytotoxicity against rat L6 cells assessed as cell viability after 72 hrs by Alamar blue assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Lead selection of antiparasitic compounds from a focused library of benzenesulfonyl derivatives of heterocycles.
AID1688053	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition.
AID378593	Cytotoxicity against human KB cells after 72 hrs	2000	Journal of natural products, Dec, Volume: 63, Issue:12	In vitro antiplasmodial, antiamoebic, and cytotoxic activities of some monomeric isoquinoline alkaloids.
AID408415	Inhibition of pig brain tubulin polymerization assessed as ratio of unpolymerized to polymerized tubulin at 10 uM	2008	Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11	Inhibitors of tubulin polymerization: synthesis and biological evaluation of hybrids of vindoline, anhydrovinblastine and vinorelbine with thiocolchicine, podophyllotoxin and baccatin III.
AID1306904	Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 72 hrs by Alamar blue assay	2016	Bioorganic & medicinal chemistry, 08-15, Volume: 24, Issue:16	Antiprotozoal activity of bicycles featuring a dimethylamino group at their bridgehead.
AID1428410	Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine free medium assessed as growth inhibition after 72 hrs by SRB assay
AID23271	Partition coefficient (logD7.4)	1990	Journal of medicinal chemistry, Jul, Volume: 33, Issue:7	Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1174229	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Investigation of podophyllotoxin esters as potential anticancer agents: synthesis, biological studies and tubulin inhibition properties.
AID1317432	Induction of apoptosis in human T47D cells assessed as late apoptotic cells at 5 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 2.42 %)	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID235867	Non cytotoxic IM activity index which is the ratio of IC50 of LcV to IC50 of MLR	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Immunosuppressive cyclolignans.
AID1317403	Antiproliferative activity against human HCT116 cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID1156603	Cytotoxicity against rat L6 cells after 3 days by Alamar blue assay	2014	European journal of medicinal chemistry, Aug-18, Volume: 83	Synthesis and antiparasitic activity of new bis-arylimidamides: DB766 analogs modified in the terminal groups.
AID214170	Concentration inhibiting [3H]colchicine binding to tubulin, at a concentration of 5 uM	1999	Journal of medicinal chemistry, Oct-07, Volume: 42, Issue:20	Antitumor agents. 196. Substituted 2-thienyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID655225	Cytotoxicity against human SK-MEL-28 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1082997	Insecticidal activity against pre-third-instar larvae of Mythimna separata (Oriental armyworm) in wheat leaves at 1 mg/mL after 20 days by leaf-dipping method	2012	Journal of agricultural and food chemistry, Aug-29, Volume: 60, Issue:34	Synthesis and quantitative structure-activity relationship (QSAR) study of novel isoxazoline and oxime derivatives of podophyllotoxin as insecticidal agents.
AID1101794	Insecticidal activity against fifth-instar larvae of Pieris rapae fed on compound treated cabbage leaf assessed as delay in metamorophosis at 250 ppm dipped for 3 secs relative to control	2002	Chemical & pharmaceutical bulletin, Mar, Volume: 50, Issue:3	Synthesis and insecticidal activity of novel 4beta-halogenated benzoylamino podophyllotoxins against Pieris rapae Linnaeus.
AID415310	Cytotoxicity against human K562 cells after 48 hrs by MTT assay	2009	Bioorganic & medicinal chemistry, Apr-15, Volume: 17, Issue:8	Synthesis and biological evaluation of novel conjugates of podophyllotoxin and 5-FU as antineoplastic agents.
AID635849	Cytotoxicity against rat L6 cells after 72 hrs by resazurin-based spectrophotometric assay	2011	Bioorganic & medicinal chemistry, Dec-15, Volume: 19, Issue:24	Bis(oxyphenylene)benzimidazoles: a novel class of anti-Plasmodium falciparum agents.
AID1186370	Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	New class of squalene-based releasable nanoassemblies of paclitaxel, podophyllotoxin, camptothecin and epothilone A.
AID362551	Cytotoxicity against rat L6 cells	2008	Journal of natural products, Sep, Volume: 71, Issue:9	Antiprotozoal activities of heterocyclic-substituted xanthones from the marine-derived fungus Chaetomium sp.
AID655237	Cytotoxicity against human A498 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1331717	Inhibition of 2-methoxy-5-(2,3,4-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one binding to colchicine binding site of tubulin (unknown origin) by fluorescence spectroscopic analysis	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Structural and Biochemical Characterization of the Interaction of Tubulin with Potent Natural Analogues of Podophyllotoxin.
AID73177	Cytotoxic effect against GLC4 (human small cell lung carcinoma cell line) using the microculture tetrazolium (MTT) assay based on 2 hr incubation	1995	Journal of medicinal chemistry, Jun-09, Volume: 38, Issue:12	Synthesis and cytotoxicity of novel lignans.
AID1361519	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Design, synthesis and screening of 1, 2, 4-triazinone derivatives as potential antitumor agents with apoptosis inducing activity on MCF-7 breast cancer cell line.
AID524793	Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1395723	Cytotoxicity against human DLD1 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Antiproliferative efficacy of curcumin mimics through microtubule destabilization.
AID1391621	Cytotoxicity against human HepG2 cells assessed as decrease in cell viability after 72 hrs by MTT assay	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Discovery of a quinoline-based phenyl sulfone derivative as an antitrypanosomal agent.
AID1361540	Upregulation of caspase3/7 level in human MCF7 cells at IC50 assessed as caspase 3/7 green fluorescence incubated for 24 hrs by green flow cytometric analysis (Rvb = 0.49%)	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Design, synthesis and screening of 1, 2, 4-triazinone derivatives as potential antitumor agents with apoptosis inducing activity on MCF-7 breast cancer cell line.
AID608686	Cytotoxicity against human KB cells assessed as growth inhibition	2011	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 21, Issue:15	Antiplasmodial and cytotoxicity evaluation of 3-functionalized 2-azetidinone derivatives.
AID1187290	Cytotoxicity against human K562/A02 cells after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Synthesis and evaluation of novel podophyllotoxin derivatives as potential antitumor agents.
AID1410117	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	2018	Journal of natural products, 04-27, Volume: 81, Issue:4	Mbandakamine-Type Naphthylisoquinoline Dimers and Related Alkaloids from the Central African Liana Ancistrocladus ealaensis with Antiparasitic and Antileukemic Activities.
AID1728398	Inhibition of human topoisomerase-1 beta incubated for 2 hrs by ELISA	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Design, synthesis and screening of benzimidazole containing compounds with methoxylated aryl radicals as cytotoxic molecules on (HCT-116) colon cancer cells.
AID1688122	Inhibition of bovine brain tubulin polymerisation measured by turbidometric method	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition.
AID1267715	Induction of apoptosis in human K562/ADR cells assessed as nuclear fragmentation at 0.1 uM after 48 hrs by Hoechst 33342 staining based fluorescence microscopy	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1168747	Cytotoxicty against rat NRK cells after 24 hrs by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID1428411	Cytotoxicity against multidrug resistant human MCF7 cells cultured in vinblastine containing medium assessed as growth inhibition after 72 hrs by SRB assay
AID1456144	Induction of apoptosis in human Bel7402/5-FU cells assessed as late apoptotic cells at 0.05 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 3%)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1637431	Effect on total ERK1/2 protein expression level in human K562/ADR cells at 0.05 uM after 48 hrs by Western blot analysis relative to control	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID1361520	Antiproliferative activity against human Hs 371.T cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Design, synthesis and screening of 1, 2, 4-triazinone derivatives as potential antitumor agents with apoptosis inducing activity on MCF-7 breast cancer cell line.
AID355581	Antiproliferative activity against human HT-29 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method
AID140792	Compound was tested for Cytotoxic activity by lymphocyte viability assay	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Immunosuppressive cyclolignans.
AID1699406	Cytotoxicity against hypoxia-induced human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24	Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
AID1456201	Effect on VEGFR2 expression in human Bel7402/5-FU cells assessed as ratio of VEGFR2 to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.25 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1719381	Cytotoxicity against rat L6 cells assessed as reduction in cell viability incubated for 70 hrs by resazurin dye based fluorescence assay	2021	Bioorganic & medicinal chemistry, 03-01, Volume: 33	Quest for a potent antimalarial drug lead: Synthesis and evaluation of 6,7-dimethoxyquinazoline-2,4-diamines.
AID1233446	Induction of cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 5 uM after 24 hrs by flow cytometry	2015	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14	Synthesis and Biological evaluation of novel 4β-[(5-substituted)-1,2,3,4-tetrazolyl] podophyllotoxins as anticancer compounds.
AID202655	In vitro cytotoxic activity against Ovarian (SK-OV3) cell line.	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	9-Deoxopodophyllotoxin derivatives as anti-cancer agents.
AID1639496	Selectivity index, ratio of IC50 for human HSF30 cells to IC50 for human PC3 cells
AID298672	Induction of apoptosis in human whole blood lymphocytes after 24 hrs by flow cytometric Annexin-V/propidium iodide assay	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis.
AID1148926	Inhibition of colony formation in mouse P815 cells assessed as percentage of colony forming cell at 5 nM after 7 days by microscopic analysis relative to control	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Podophyllotoxin analogs. 1. Synthesis and biological evaluation of certain trans-2-aryl-trans-6-hydroxymethyl-3-cyclohexenecarboxylic acid gamma-lactones as antimitotic agents.
AID86025	Effective dose required to inhibit 100% against herpesvirus simplex 1	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor agents. 207. Design, synthesis, and biological testing of 4beta-anilino-2-fluoro-4'-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents.
AID87909	Effect on cell cycle evaluated as proportion of cells in G0/G1 phase of the cell cycle at 10E-8 M for 24 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID338805	Cytotoxicity against human HeLa cells after 4 days by trypan blue assay	1992	Journal of natural products, Jan, Volume: 55, Issue:1	Isolation, purification, and cytotoxicity of 5-methoxypodophyllotoxin, a lignan from a root culture of Linum flavum.
AID441773	Cytotoxicity against human A549 cells after 72 hrs by SRB assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and biological evaluation of new podophyllic aldehyde derivatives with cytotoxic and apoptosis-inducing activities.
AID558401	Inhibition of human glucocorticoid receptor	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Trypanothione reductase high-throughput screening campaign identifies novel classes of inhibitors with antiparasitic activity.
AID1699403	Cytotoxicity against human HepG2 cells overexpressing NQO1 assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24	Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
AID304045	Cytotoxicity against rat L6 cells	2007	Journal of medicinal chemistry, Nov-29, Volume: 50, Issue:24	Synthesis and pharmacological evaluation of fluorescent and photoactivatable analogues of antiplasmodial naphthylisoquinolines.
AID1501233	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	2017	Journal of natural products, 09-22, Volume: 80, Issue:9	Antiprotozoal Linear Furanosesterterpenoids from the Marine Sponge Ircinia oros.
AID464515	Selectivity ratio for IC50 for human BJ cells to IC50 for human HEK293 cells	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID552695	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Synthesis and antitrypanosomal evaluation of derivatives of N-benzyl-1,2-dihydroquinolin-6-ols: Effect of core substitutions and salt formation.
AID214713	Inhibition of colchicine binding to tubulin	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Inhibition of tubulin polymerization by 5,6-dihydroindolo[2,1-alpha]isoquinoline derivatives.
AID299207	Antiproliferative activity against human PC3 cells	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Novel potent antimitotic heterocyclic ketones: synthesis, antiproliferative activity, and structure-activity relationships.
AID441772	Cytotoxicity against human MDA-MB-231 cells after 72 hrs by SRB assay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and biological evaluation of new podophyllic aldehyde derivatives with cytotoxic and apoptosis-inducing activities.
AID765718	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	2013	European journal of medicinal chemistry, Sep, Volume: 67	Synthesis and antiprotozoal activities of benzyl phenyl ether diamidine derivatives.
AID1495299	Inhibition of alpha-tubulin polymerization in human K562/VCR cells assessed as disruption of microtubule organization at 0.05 uM after 24 hrs by DAPI staining-based immunofluorescence assay	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID214009	Inhibition of tubulin polymerization using isolated calf brain	1997	Journal of medicinal chemistry, Oct-24, Volume: 40, Issue:22	Inhibition of tubulin polymerization by 5,6-dihydroindolo[2,1-alpha]isoquinoline derivatives.
AID644057	Induction of apoptosis in human A549 cells assessed as cell detachment at 0.5 uM after 24 hrs by Hoechst 33258 staining based fluorescence microscopy	2012	European journal of medicinal chemistry, Mar, Volume: 49	Synthesis and biological evaluation of conjugates of deoxypodophyllotoxin and 5-FU as inducer of caspase-3 and -7.
AID1639494	Selectivity index, ratio of IC50 for human HSF30 cells to IC50 for human SiHa cells
AID1140298	Anticancer activity against human HT-29 cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9	Synthesis of a terphenyl substituted 4-aza-2,3-didehydropodophyllotoxin analogues as inhibitors of tubulin polymerization and apoptosis inducers.
AID257599	Antiproliferative activity against estrogen-independent breast cancer MDA-MB-231 cell line by MTS assay	2005	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24	Conformationally restricted analogs of Combretastatin A-4 derived from SU5416.
AID359899	Cytotoxicity against human SK-MEL-5 cells by MTT assay	1994	Journal of natural products, Dec, Volume: 57, Issue:12	Cytotoxic cyclolignans from Koelreuteria henryi.
AID1334733	Antiproliferative activity against human MIAPaCa2 assessed as reduction in cell viability measured after 48 hrs by SRB assay	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Novel carbazole sulfonamide derivatives of antitumor agent: Synthesis, antiproliferative activity and aqueous solubility.
AID655223	Cytotoxicity against human MDA-MB-435 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID551373	Cytotoxicity against human COLO205 assessed as inhibition of cell growth	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	An efficient one-pot synthesis of benzothiazolo-4β-anilino-podophyllotoxin congeners: DNA topoisomerase-II inhibition and anticancer activity.
AID88038	Effect on cell cycle evaluated as proportion of cells in S phase of the cell cycle at 10E-8 M for 72 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1301507	Growth inhibition of mouse P388 cells measured after 48 hrs by sulforhodamine B assay	2016	Journal of natural products, Mar-25, Volume: 79, Issue:3	Antineoplastic Agents. 585. Isolation of Bridelia ferruginea Anticancer Podophyllotoxins and Synthesis of 4-Aza-podophyllotoxin Structural Modifications.
AID1489078	Cytotoxicity against human L02 cells after 24 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1550788	Inhibition of human tubulin polymerization in HMEC1 cells assessed as induction of tubulin polymerization destabilization at 30 uM incubated for 3 hrs and measured after 90 mins by turbidimetric assay	2019	European journal of medicinal chemistry, Jun-01, Volume: 171	Diphenyl ether derivatives occupy the expanded binding site of cyclohexanedione compounds at the colchicine site in tubulin by movement of the αT5 loop.
AID443482	Cytotoxicity against c-myc/c-raf double transgenic mouse betaD10 cells by MTS assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID1906544	Binding affinity to microtubule polymerization (unknown origin) assessed as formation of microtubule at 27.5 uM measured for 2 hrs by plate reader method	2022	European journal of medicinal chemistry, May-05, Volume: 235	Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy.
AID1495281	Resistance factor, ratio of IC50 for human K562/VCR cells to IC50 for human K562 cells	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID1317399	Antiproliferative activity against human MCF7 cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID1754721	Induction of apoptosis in human PC-3M cells assessed as viable cells at 10 nM measured after 48 hrs by Annexin V/PI staining based flow cytometry method (Rvb = 95.6%)	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID1101799	Insecticidal activity against fifth-instar larvae of Pieris rapae fed on compound treated cabbage leaf assessed as change in spontaneous movement at 250 ppm dipped for 3 secs measured after 24 hr relative to control	2002	Chemical & pharmaceutical bulletin, Mar, Volume: 50, Issue:3	Synthesis and insecticidal activity of novel 4beta-halogenated benzoylamino podophyllotoxins against Pieris rapae Linnaeus.
AID1403415	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.
AID1403372	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Synthesis of podophyllotoxin linked β-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors.
AID1317413	Selectivity index, ratio of IC50 for HAF cells to IC50 for human HCT116 cells	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID1148928	Inhibition of colony formation in mouse P815 cells assessed as percentage of colony forming cell at 0.5 uM after 7 days by microscopic analysis relative to control	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Podophyllotoxin analogs. 1. Synthesis and biological evaluation of certain trans-2-aryl-trans-6-hydroxymethyl-3-cyclohexenecarboxylic acid gamma-lactones as antimitotic agents.
AID1186371	Cytotoxicity against human MCF7 cells in presence of 10 mM DTT after 48 hrs by SRB assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	New class of squalene-based releasable nanoassemblies of paclitaxel, podophyllotoxin, camptothecin and epothilone A.
AID494502	Inhibition of pig brain tubulin polymerization after 30 mins by turbidimetry	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Synthesis, antiproliferative activity and inhibition of tubulin polymerization by 1,5- and 1,8-disubstituted 10H-anthracen-9-ones bearing a 10-benzylidene or 10-(2-oxo-2-phenylethylidene) moiety.
AID293487	Cytotoxicity against human MEL28 cells after 4 days	2007	Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4	Synthesis and cytotoxic evaluation of C-9 oxidized podophyllotoxin derivatives.
AID1403371	Cytotoxicity against human A549 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Synthesis of podophyllotoxin linked β-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors.
AID87905	Effect on cell cycle evaluated as proportion of cells in G0/G1 phase of the cell cycle at 10E-6 M for 72 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1882900	Resistance index, ratio of IC50 for human A549/TxR cells to IC50 for human A549 cells	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID355585	Antiproliferative activity against mouse P388 cells at 0.1 ug after 48 hrs by two-layer agar-diffusion method
AID551376	Cytotoxicity against human DWD assessed as inhibition of cell growth	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	An efficient one-pot synthesis of benzothiazolo-4β-anilino-podophyllotoxin congeners: DNA topoisomerase-II inhibition and anticancer activity.
AID1299556	Cytotoxicity against rat L6 cells after 72 hrs by AlamarBlue dye based fluorimetric method	2016	Journal of natural products, Feb-26, Volume: 79, Issue:2	Abietane-Type Diterpenoid Amides with Highly Potent and Selective Activity against Leishmania donovani and Trypanosoma cruzi.
AID655133	Cytotoxicity against human NCI-H23 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1317445	Toxicity in nude mouse xenografted with human T47D cells assessed as organ damage at 5 mg/kg/day, ip administered daily for 18 days	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID756886	Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay	2013	Journal of medicinal chemistry, Jul-11, Volume: 56, Issue:13	Synthesis and antiprotozoal activity of dicationic m-terphenyl and 1,3-dipyridylbenzene derivatives.
AID774784	Cytotoxicity against rat L6 cells	2013	Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18	Natural product derived antiprotozoal agents: synthesis, biological evaluation, and structure-activity relationships of novel chromene and chromane derivatives.
AID1456170	Effect on CDK1 expression in human Bel7402/5-FU cells assessed as ratio of CDK1 to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.33 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID79771	In vitro cytotoxicity against human colon cancer HCC 2998 cell line	1998	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11	Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents.
AID699782	Growth inhibition of human HT-29 cells after 72 hrs by SRB assay	2012	Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15	Synthesis and antimitotic and tubulin interaction profiles of novel pinacol derivatives of podophyllotoxins.
AID1306345	Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 2.45 to 6.92%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID655239	Cytotoxicity against human CAKI-1 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID677566	Cytotoxicity against rat L6 cells	2012	Journal of medicinal chemistry, Jun-14, Volume: 55, Issue:11	Novel 3-nitro-1H-1,2,4-triazole-based amides and sulfonamides as potential antitrypanosomal agents.
AID628070	Antimitotic activity against Paracentrotus lividus embryo assessed as embryo spinning treated 10 to 25 mins post fertilization followed by 45 to 60 mins before the first mitotic cycle completion by sea urchin embryo assay	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID1188222	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 48 hrs by SRB assay	2014	Bioorganic & medicinal chemistry, Oct-01, Volume: 22, Issue:19	Synthesis and biological evaluation of podophyllotoxin congeners as tubulin polymerization inhibitors.
AID1456233	Effect on AKT phosphorylation in human Bel7402/5-FU cells assessed as ratio of phosphorylated AKT to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.39 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1500567	Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 measured after 72 hrs by SYBR green 1 dye based fluorescence assay
AID655135	Cytotoxicity against human NCI-H460 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID637703	Cytotoxicity against rat L6 cells after 72 hrs by resazurin assay	2012	European journal of medicinal chemistry, Feb, Volume: 48	Synthesis and anti-protozoal activity of novel dihydropyrrolo[3,4-d][1,2,3]triazoles.
AID1456125	Induction of apoptosis in human Bel7402/5-FU cells assessed as condensed nuclei at 0.05 uM after 24 hrs by Hoechst 33342 staining based fluorescent microscopic method	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID694345	Antileishmanial activity against amastigote form of Leishmania donovani LV82 expressing beta-lactamase infected in CD1 mouse macrophages after 72 hrs by nitrocefin-based spectrophotometric analysis	2012	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 22, Issue:22	Antileishmanial bis-arylimidamides: DB766 analogs modified in the linker region and bis-arylimidamide structure-activity relationships.
AID655244	Cytotoxicity against human PC3 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID403994	Antiviral activity against VSV infected in BHK cells assessed as inhibition of plaque formation	1998	Journal of natural products, Nov, Volume: 61, Issue:11	Antiviral activity of lignans.
AID378592	Antiamnesic activity against Entamoeba histolytica NIH 200 after 72 hrs by microdilution technique	2000	Journal of natural products, Dec, Volume: 63, Issue:12	In vitro antiplasmodial, antiamoebic, and cytotoxic activities of some monomeric isoquinoline alkaloids.
AID299208	Antiproliferative activity against human DND1 cells	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Novel potent antimitotic heterocyclic ketones: synthesis, antiproliferative activity, and structure-activity relationships.
AID1882892	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1906554	Ratio of IC50 for cytotoxicity against human A2780D cells assessed as inhibition of cell growth measured after 48 hrs to IC50 for cytotoxicity against human A2780 cells assessed as inhibition of cell growth measured after 48 hrs	2022	European journal of medicinal chemistry, May-05, Volume: 235	Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy.
AID1549909	Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, May-15, Volume: 170	Discover 4β-NH-(6-aminoindole)-4-desoxy-podophyllotoxin with nanomolar-potency antitumor activity by improving the tubulin binding affinity on the basis of a potential binding site nearby colchicine domain.
AID333842	Cytotoxicity against human KB cells
AID1760367	Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay	2020	European journal of medicinal chemistry, Dec-15, Volume: 208	Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
AID1586762	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	2018	Journal of natural products, 12-28, Volume: 81, Issue:12	Antiprotozoal Isoprenoids from Salvia hydrangea.
AID83615	In vitro cytotoxicity against the HT-29 (human colon carcinoma) neoplastic cell line	2004	Bioorganic & medicinal chemistry letters, Mar-08, Volume: 14, Issue:5	Synthesis and cytotoxicity of hydrophobic esters of podophyllotoxins.
AID103732	In vitro cytotoxicity against human breast cancer MCF-7 cell line	1998	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11	Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID655129	Cytotoxicity against human EKVX cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID766747	Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay	2013	Bioorganic & medicinal chemistry, Sep-15, Volume: 21, Issue:18	Investigation of acyclic uridine amide and 5'-amido nucleoside analogues as potential inhibitors of the Plasmodium falciparum dUTPase.
AID464323	Antitrypanosomal activity against Trypanosoma brucei brucei after 48 hrs by luminescence assay	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID92128	Cytotoxic effect in human tumor cell lines, tested by the National Cancer Institute	1997	Journal of medicinal chemistry, Jul-04, Volume: 40, Issue:14	Antitumor agents. 174. 2',3',4',5,6,7-Substituted 2-phenyl-1,8-naphthyridin-4-ones: their synthesis, cytotoxicity, and inhibition of tubulin polymerization.
AID1349093	Inhibition of NAE in human Caco2 cells assessed as increase in p53 protein levels at 1 to 10 uM after 16 hrs by Western blot analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Structure-based identification of a NEDD8-activating enzyme inhibitor via drug repurposing.
AID760424	Cytotoxicity against rat L6 cells after 70 hrs by Alamar Blue assay	2013	ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7	Design, Synthesis, and Antiplasmodial Activity of Hybrid Compounds Based on (2R,3S)-N-Benzoyl-3-phenylisoserine.
AID720848	Cytotoxicity against rat L6 cells after 70 hrs by resazurin reduction assay	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Aminoalkyl derivatives of guanidine diaromatic minor groove binders with antiprotozoal activity.
AID628069	Antimitotic activity against Paracentrotus lividus embryo assessed as cleavage arrest treated 10 to 25 mins post fertilization followed by 45 to 60 mins before the first mitotic cycle completion by sea urchin embryo assay	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID290175	Antiproliferative activity against human MCF7 cells	2007	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5	Novel pyridinyl and pyrimidinylcarbazole sulfonamides as antiproliferative agents.
AID740949	Antitrypanosomal activity against Trypanosoma brucei brucei blood-stream forms	2013	Journal of natural products, Mar-22, Volume: 76, Issue:3	8,8-dialkyldihydroberberines with potent antiprotozoal activity.
AID273079	Antiproliferative activity against human CEM cells after 72 hrs	2006	Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21	Synthesis and structure-activity relationships of carbazole sulfonamides as a novel class of antimitotic agents against solid tumors.
AID598807	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Three new cytotoxic aryltetralin lignans from Sinopodophyllum emodi.
AID1069845	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Synthesis of neolignans as microtubule stabilisers.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID453258	Toxicity against rat L6 cells	2009	Bioorganic & medicinal chemistry, Oct-15, Volume: 17, Issue:20	Structure-activity relationship of antiparasitic and cytotoxic indoloquinoline alkaloids, and their tricyclic and bicyclic analogues.
AID655222	Cytotoxicity against human M14 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1267712	Induction of apoptosis in human K562/ADR cells assessed as induction of cell shrinkage at 0.1 uM after 48 hrs by Hoechst 33342 staining based fluorescence microscopy	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID87908	Effect on cell cycle evaluated as proportion of cells in G0/G1 phase of the cell cycle at 10E-7 M for 72 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID214033	Inhibition of bovine tubulin polymerization	1994	Journal of medicinal chemistry, Sep-30, Volume: 37, Issue:20	Antitumor agents. 155. Synthesis and biological evaluation of 3',6,7-substituted 2-phenyl-4-quinolones as antimicrotubule agents.
AID101493	In vitro inhibitory concentration against human chronic myelogenous leukemia K562 cell growth; Not determined	2003	Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15	Novel benzylidene-9(10H)-anthracenones as highly active antimicrotubule agents. Synthesis, antiproliferative activity, and inhibition of tubulin polymerization.
AID87910	Effect on cell cycle evaluated as proportion of cells in G0/G1 phase of the cell cycle at 10E-8 M for 48 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1267718	Induction of apoptosis in human K562/ADR cells assessed as nuclear condensation at 0.1 uM after 48 hrs by Hoechst 33342 staining based fluorescence microscopy	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID88043	Effect on cell cycle evaluated as proportion of cells in sub-G1 phase (apoptic cells) of the cell cycle at 10E-6 M for 24 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1754718	Induction of apoptosis in human PC-3M cells assessed as early apoptotic cells at 5 nM measured after 48 hrs by Annexin V/PI staining based flow cytometry method (Rvb = 1.25%)	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID1515178	Induction of apoptosis in human PC3 cells assessed as formation of apoptotic bodies at 0.005 uM after 48 hrs by acridine orange/ethidium bromide staining-based epifluorescence microscopic analysis	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway.
AID282997	Cytotoxicity against human KB cells by Alamar blue assay	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate.
AID1317443	Toxicity in nude mouse xenografted with human T47D cells assessed as body weight loss at 5 mg/kg/day, ip administered daily for 18 days measured every 3 days during compound dosing	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID335770	Cytotoxicity in mouse P388 cells	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID606847	Cytotoxicity at rat L6 cells after 72 hrs by microplate alamar blue assay	2011	Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13	Antimalarial pyrido[1,2-a]benzimidazoles.
AID1489083	Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 0.6 uM after 12 hrs by propidium iodide staining based flow cytometric method (Rvb = 27.63 to 32.34%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1236507	Cytotoxicity against mouse J774A.1 cells assessed as inhibition of cell viability after 72 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16	SAR refinement of antileishmanial N(2),N(4)-disubstituted quinazoline-2,4-diamines.
AID1180383	Antiproliferative activity against human HeLa cells after 48 hrs by SRB assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Synthesis and biological evaluation of 4-aza-2,3-dihydropyridophenanthrolines as tubulin polymerization inhibitors.
AID1181600	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	2014	Journal of medicinal chemistry, Aug-14, Volume: 57, Issue:15	Pyridyl benzamides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei.
AID386872	Cytotoxicity against human A549 cells by sulforhodamine B assay	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Studies on novel 4beta-[(4-substituted)-1,2,3-triazol-1-yl] podophyllotoxins as potential anticancer agents.
AID464514	Selectivity for human HepG2 cells over human HMEC	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID9244	GI values against A549 cells (lung cancer)	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor agents. 207. Design, synthesis, and biological testing of 4beta-anilino-2-fluoro-4'-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents.
AID1679083	Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 70 hrs by Alamar blue dye-based fluorometric analysis	2020	RSC medicinal chemistry, Dec-17, Volume: 11, Issue:12	Investigation of thiazolyl-benzothiophenamides as potential agents for African sleeping sickness.
AID611267	Antiproliferative activity against human K562 cells after 48 hrs by hemocytometer	2011	Bioorganic & medicinal chemistry, Jul-15, Volume: 19, Issue:14	Phenylimino-10H-anthracen-9-ones as novel antimicrotubule agents-synthesis, antiproliferative activity and inhibition of tubulin polymerization.
AID1140203	Cytotoxicity against rat L6 cells after 70 hrs by Alamar Blue assay	2014	Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9	Synthesis, β-haematin inhibition, and in vitro antimalarial testing of isocryptolepine analogues: SAR study of indolo[3,2-c]quinolines with various substituents at C2, C6, and N11.
AID88048	Effect on cell cycle evaluated as proportion of cells in sub-G1 (apoptic cells) phase of the cell cycle at 10E-6 M for 48 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID270966	Inhibition of [3H]colchicine binding to beta tubulin	2006	Journal of medicinal chemistry, Sep-21, Volume: 49, Issue:19	[4-(imidazol-1-yl)thiazol-2-yl]phenylamines. A novel class of highly potent colchicine site binding tubulin inhibitors: synthesis and cytotoxic activity on selected human cancer cell lines.
AID655235	Cytotoxicity against human SKOV3 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID214692	Inhibitory concentration required against tubulin polymerization in the antimicrotubule activity test	2001	Bioorganic & medicinal chemistry letters, May-07, Volume: 11, Issue:9	Antitumor agents. Part 204: synthesis and biological evaluation of substituted 2-aryl quinazolinones.
AID301313	Induction of tubulin depolymerization after 16 hrs	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Replacement of the lactone moiety on podophyllotoxin and steganacin analogues with a 1,5-disubstituted 1,2,3-triazole via ruthenium-catalyzed click chemistry.
AID1456202	Effect on MMP2 expression in human Bel7402/5-FU cells assessed as ratio of MMP2 to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.3 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1306330	Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 8 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 3.73 to 10.75%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1112941	Insecticidal activity against pre-third-instar larvae of Mythimna separata (Oriental armyworm) assessed as corrected mortality rate at 1 mg/ml measured after 10 days by the leaf-dipping method	2013	Journal of agricultural and food chemistry, Jan-23, Volume: 61, Issue:3	Synthesis and quantitative structure-activity relationship (QSAR) study of novel 4-acyloxypodophyllotoxin derivatives modified in the A and C rings as insecticidal agents.
AID306629	Cytotoxicity against C8166 cells assessed as reduction in total cell number	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Synthesis and anti-HIV-1 activities of novel podophyllotoxin derivatives.
AID1317402	Antiproliferative activity against human DU145 cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID299204	Antiproliferative activity against human Bel7402 cells	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Novel potent antimitotic heterocyclic ketones: synthesis, antiproliferative activity, and structure-activity relationships.
AID760220	Cytotoxicity against human KB cells after 72 hrs by Alamar blue assay	2013	ACS medicinal chemistry letters, Jul-11, Volume: 4, Issue:7	Synthesis, Antiplasmodial Activity, and β-Hematin Inhibition of Hydroxypyridone-Chloroquine Hybrids.
AID1495283	Cell cycle arrest in human K562/VCR cells assessed as accumulation at S phase at 0.05 uM after 48 hrs by propidium iodide staining-based flow cytometric method (Rvb = 46.02%)	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID1489100	Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 2 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 2 to 3.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1489096	Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 0.6 uM after 16 hrs by propidium iodide staining based flow cytometric method (Rvb = 7.59 to 9.58%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1882899	Resistance index, ratio of IC50 for human MCF7/TxR cells to IC50 for human MCF7 cells	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID267896	Cytotoxicity against rat L6 cells	2006	Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14	Acyclic nucleoside analogues as inhibitors of Plasmodium falciparum dUTPase.
AID419752	Cytotoxicity against rat L6 cells after 70 hrs by alamar blue assay	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Synthesis and antiprotozoal activity of pyridyl analogues of pentamidine.
AID1489093	Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 0.6 uM after 8 hrs by propidium iodide staining based flow cytometric method (Rvb = 7.59 to 9.58%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1455944	Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay
AID1336738	Cytotoxicity against rat L6 cells assessed as growth inhibition after 70 hrs by alamar blue assay	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	New derivatives of 7-chloroquinolin-4-amine with antiprotozoal activity.
AID336445	Cytotoxicity against human KB cells	2002	Journal of natural products, Oct, Volume: 65, Issue:10	Assessment of the antiprotozoal activity of Galphimia glauca and the isolation of new nor-secofriedelanes and nor-friedelanes.
AID1143880	Cytotoxicity against rat L6 cells	2014	European journal of medicinal chemistry, Jun-23, Volume: 81	Antiprotozoal activity and DNA binding of N-substituted N-phenylbenzamide and 1,3-diphenylurea bisguanidines.
AID87917	Effect on cell cycle evaluated as proportion of cells in G2/M phase of the cell cycle at 10E-7 M for 72 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID266932	Inhibition of tubulin polymerization in bovine brain by tubulin assembly assay	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Synthesis and biological evaluation of 2-amino-3-(3',4',5'-trimethoxybenzoyl)-5-aryl thiophenes as a new class of potent antitubulin agents.
AID655215	Cytotoxicity against human SF295 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID592708	Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 1 uM after 48 hrs using propidium iodide staining by flow cytometry (Rvb = 5.2%)	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis of a new 4-aza-2,3-didehydropodophyllotoxin analogues as potent cytotoxic and antimitotic agents.
AID1456099	Antiproliferative activity against human Bel7402/5-FU cells after 72 hrs by CCK-8 assay	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1741960	Cytotoxicity against rat L6 cells assessed as reduction in cell viability incubated for 70 hrs by resazurin staining based inverted microscopic analysis	2020	European journal of medicinal chemistry, Nov-01, Volume: 205	(±)-trans-2-phenyl-2,3-dihydrobenzofurans as leishmanicidal agents: Synthesis, in vitro evaluation and SAR analysis.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1495306	Induction of apoptosis in human K562/VCR cells assessed as downregulation of CDK1 expression at 0.05 uM after 48 hrs by Western blot method relative to beta-actin	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID335769	Toxicity in brine shrimp	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID1688054	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition.
AID1456171	Effect on CDK2 expression in human Bel7402/5-FU cells assessed as ratio of CDK2 to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.43 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID301310	Cytotoxicity against SH-SY5Y cells assessed as cell viability after 48 hrs by MTT method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Replacement of the lactone moiety on podophyllotoxin and steganacin analogues with a 1,5-disubstituted 1,2,3-triazole via ruthenium-catalyzed click chemistry.
AID1410386	Cytotoxicity against human MCF7 cells after 24 hrs by annexin-V-FITC/propidium iodide staining based flow cytometric method	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	New Hybrids Derived from Podophyllic Aldehyde and Diterpenylhydroquinones with Selectivity toward Osteosarcoma Cells.
AID300662	Toxicity against monkey Vero cells	2007	Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18	Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents.
AID87903	Effect on cell cycle evaluated as proportion of cells in G0/G1 phase of the cell cycle at 10E-6 M for 24 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID359892	Cytotoxicity against human SKOV3 cells by MTT assay	1994	Journal of natural products, Dec, Volume: 57, Issue:12	Cytotoxic cyclolignans from Koelreuteria henryi.
AID340101	Cytotoxicity against human KB403 cells after 24 hrs by MTT assay	2008	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14	Gallic acid-based indanone derivatives as anticancer agents.
AID443475	Inhibition of microtubule in human A549 cells assessed as network disappearane at 0.5 uM after 1 hr by immunofluorescence analysis	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID1489076	Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID400482	Antiviral activity against HSV1 infected in african green monkey Vero cells assessed as plaque formation at 1 uM after 4 days by neutral red assay relative to control
AID1390501	Cytotoxicity against human DU145 cells assessed as cell growth inhibition after 48 hrs by MTT assay
AID1699407	Cytotoxicity against taxol-resistant human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2020	Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24	Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
AID386867	Cytotoxicity against human PC-3 cells by sulforhodamine B assay	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Studies on novel 4beta-[(4-substituted)-1,2,3-triazol-1-yl] podophyllotoxins as potential anticancer agents.
AID1751093	Antiproliferative activity against human DU-145 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
AID1489105	Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 4 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 2.35 to 2.49%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID592737	Induction of apoptosis in human A549 cells assessed as activation of caspase 3 at 1 uM after 48 hrs by fluorimetric assay relative to control	2011	Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7	Synthesis of a new 4-aza-2,3-didehydropodophyllotoxin analogues as potent cytotoxic and antimitotic agents.
AID336443	Antiprotozoal activity against Plasmodium falciparum K1	2002	Journal of natural products, Oct, Volume: 65, Issue:10	Assessment of the antiprotozoal activity of Galphimia glauca and the isolation of new nor-secofriedelanes and nor-friedelanes.
AID1168746	Anticancer activity against human WRL68 cells after 24 hrs by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID1489091	Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase at 0.6 uM after 8 hrs by propidium iodide staining based flow cytometric method (Rvb = 60.19 to 60.87%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1174230	Cytotoxicity against human DU145 cells after 48 hrs by MTT assay	2015	European journal of medicinal chemistry, Jan-07, Volume: 89	Investigation of podophyllotoxin esters as potential anticancer agents: synthesis, biological studies and tubulin inhibition properties.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1162950	Selectivity index, ratio of IC50 for rat L6 cells to IC50 for Plasmodium falciparum 3D7 asexual blood stages	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
AID1301506	Growth inhibition of human KM20L2 cells measured after 48 hrs by sulforhodamine B assay	2016	Journal of natural products, Mar-25, Volume: 79, Issue:3	Antineoplastic Agents. 585. Isolation of Bridelia ferruginea Anticancer Podophyllotoxins and Synthesis of 4-Aza-podophyllotoxin Structural Modifications.
AID580717	Cytotoxicity against rat L6 cells	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Compounds structurally related to ellagic acid show improved antiplasmodial activity.
AID1331715	Inhibition of tubulin assembly (unknown origin) assessed as decrease in pelleted microtubules up to 40 uM after 20 mins	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Structural and Biochemical Characterization of the Interaction of Tubulin with Potent Natural Analogues of Podophyllotoxin.
AID551375	Cytotoxicity against human HT1080 assessed as inhibition of cell growth	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	An efficient one-pot synthesis of benzothiazolo-4β-anilino-podophyllotoxin congeners: DNA topoisomerase-II inhibition and anticancer activity.
AID1416607	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
AID1187291	Resistance index, ratio of IC50 for human K562/A02 cells to IC50 for human K562 cells	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Synthesis and evaluation of novel podophyllotoxin derivatives as potential antitumor agents.
AID1317444	Toxicity in nude mouse xenografted with human T47D cells assessed as diarrhoea at 5 mg/kg/day, ip administered daily for 18 days	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID366960	Cytotoxicity against human KB cells after 48 hrs by alamar blue assay	2008	European journal of medicinal chemistry, Sep, Volume: 43, Issue:9	Synthesis and structure-activity relationship of 3-phenylquinoxaline 1,4-di-N-oxide derivatives as antimalarial agents.
AID1698823	Antimitotic activity against sea urchin embryo assessed as cleavage arrest measured 2.5 to 6 hrs post-fertilization by light microscopy analysis	2020	Bioorganic & medicinal chemistry letters, 12-01, Volume: 30, Issue:23	Computational modeling and target synthesis of monomethoxy-substituted o-diphenylisoxazoles with unexpectedly high antimitotic microtubule destabilizing activity.
AID655131	Cytotoxicity against human HOP92 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID400480	Antiviral activity against measles virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect at 1 uM
AID628174	Induction of apoptosis in human Jurkat cells assessed as PARP cleavage at 50 nM after 48 hrs by annexin-V FITC/7-ADD staining-based flow cytometric analysis (Rvb = 6.5%)	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID1348064	Cytotoxicity against rat L6 cells after 70 hrs by Alamar blue staining-based fluorometric analysis	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Synthesis of new 1-benzyl tetrahydropyridinylidene ammonium salts and their antimicrobial and anticellular activities.
AID78724	In vitro cytotoxic activity against lung (H 522) cancer cell line.	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	9-Deoxopodophyllotoxin derivatives as anti-cancer agents.
AID88040	Effect on cell cycle evaluated as proportion of cells in sub-G1 (apoptic cells) phase of the cell cycle at 10E-6 M for 72 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1491416	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Synthesis of thiazole linked indolyl-3-glyoxylamide derivatives as tubulin polymerization inhibitors.
AID1612298	Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 72 hrs by Alamar blue staining-based fluorometric analysis	2018	Journal of natural products, 10-26, Volume: 81, Issue:10	Methionine-Containing Rhabdopeptide/Xenortide-like Peptides from Heterologous Expression of the Biosynthetic Gene Cluster kj12ABC in Escherichia coli.
AID1306338	Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 4 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.021 to 3.8%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID560437	Cell cycle arrest in HPV-transformed human SiHa cells assessed as accumulation at G0/G1 phase at 10 times EC50 after 48 hrs by flow cytometry	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions.
AID602107	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	2011	Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12	Anticancer properties of an important drug lead podophyllotoxin can be efficiently mimicked by diverse heterocyclic scaffolds accessible via one-step synthesis.
AID524795	Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID384954	Binding affinity to pig brain tubulin	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Podophyllotoxin directly binds a hinge domain in E2 of HPV and inhibits an E2/E7 interaction in vitro.
AID306630	Antiviral activity against HIV1 in C8166 cells assessed as inhibition of syncytia formation	2007	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 17, Issue:7	Synthesis and anti-HIV-1 activities of novel podophyllotoxin derivatives.
AID378968	Cytotoxicity against human PC3 cells	2006	Journal of natural products, Jan, Volume: 69, Issue:1	Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities.
AID1489079	Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase at 0.3 uM after 12 hrs by propidium iodide staining based flow cytometric method (Rvb = 58.69 to 62.23%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1057257	Therapeutic index, ratio of IC50 for human KB cells to IC50 for chloroquine-resistant Plasmodium falciparum K1	2013	Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23	Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
AID1688051	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth measured after 48 hrs by SRB assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Antiproliferative activity of diarylnaphthylpyrrolidine derivative via dual target inhibition.
AID721432	Toxicity against rat L6 cells after 72 hrs by Alamar blue assay	2013	European journal of medicinal chemistry, Feb, Volume: 60	Asymmetric synthesis and anti-protozoal activity of the 8,4'-oxyneolignans virolin, surinamensin and analogues.
AID85442	In vitro cytotoxicity against human colon cancer HT 29 cell line	1998	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11	Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents.
AID1123832	Inhibition of chicken brain microtubule polymerization after 30 mins	1979	Journal of medicinal chemistry, Mar, Volume: 22, Issue:3	Conformational analysis of podophyllotoxin and its congeners. Structure--activity relationship in microtubule assembly.
AID1489113	Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 12 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 2.35 to 2.49%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID335778	Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 0.00128 ug/mL	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID1267703	Induction of apoptosis in human K562/ADR cells assessed as early apoptotic cells at 0.1 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 1.49%)	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID618835	Cytotoxicity against human K562/A02 cells after 2 days by MTT assay	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Synthesis of 4β-triazole-podophyllotoxin derivatives by azide-alkyne cycloaddition and biological evaluation as potential antitumor agents.
AID1233441	Cytotoxicity against human SK-N-SH cells assessed as cell viability by SRB assay	2015	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 25, Issue:14	Synthesis and Biological evaluation of novel 4β-[(5-substituted)-1,2,3,4-tetrazolyl] podophyllotoxins as anticancer compounds.
AID1287492	Cytotoxicity against human HCT116	2016	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7	Anticancer activity studies of cubebin isolated from Piper cubeba and its synthetic derivatives.
AID1306346	Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 4 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 2.45 to 6.92%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID398415	Cytotoxicity against mouse P388 cells	1995	Journal of natural products, Jun, Volume: 58, Issue:6	Methyl ethers of podophyllotoxin-related cyclolignans.
AID1306326	Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 4 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 15.95 to 25.74%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1699414	Induction of apoptosis in human HepG2 cells assessed as viable cells at 50 nM incubated for 24 hrs by annexin V-FITC and propidium iodide based flow cytometry analysis (Rvb = 95.66 %)	2020	Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24	Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
AID1091893	In vivo insecticidal activity against pre-third-instar larval stage of Mythimna separata (Oriental armyworm) in corn leaves assessed as corrected mortality rate at 1 mg/ml treated for 3 secs before larval infestation on corn leaves measured after 20 days	2010	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15	Natural products-based insecticidal agents 6. Design, semisynthesis, and insecticidal activity of novel monomethyl phthalate derivatives of podophyllotoxin against Mythimna separata Walker in vivo.
AID1515168	Cell cycle arrest in human PC3 cells assessed as accumulation at S phase at 0.12 uM after 48 hrs by RNAse/propidium iodide staining-based flow cytometric analysis (Rvb = 19.7%)	2019	Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1	Design, synthesis and QSAR study of 2'-hydroxy-4'-alkoxy chalcone derivatives that exert cytotoxic activity by the mitochondrial apoptotic pathway.
AID1331706	Cell cycle arrest in human A549 cells assessed as accumulation at G2/M phase at 100 nM after 20 hrs by propidium iodide staining based flow cytometry	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Structural and Biochemical Characterization of the Interaction of Tubulin with Potent Natural Analogues of Podophyllotoxin.
AID386871	Cytotoxicity against human HEP2 cells by sulforhodamine B assay	2008	European journal of medicinal chemistry, Oct, Volume: 43, Issue:10	Studies on novel 4beta-[(4-substituted)-1,2,3-triazol-1-yl] podophyllotoxins as potential anticancer agents.
AID695812	Cytotoxicity against human HepG2 cells after 48 hrs	2012	Bioorganic & medicinal chemistry, Nov-01, Volume: 20, Issue:21	Synthesis and biological evaluation of a series of podophyllotoxins derivatives as a class of potent antitubulin agents.
AID1637415	Cell cycle arrest in human K562/ADR cells assessed as accumulation in S phase at 0.05 uM after 48 hrs by propidium iodide staining based flow cytometry	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID1168739	Anticancer activity against human MCF7 cells after 24 hrs by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID1653744	Cytotoxicity against rat L6 cells assessed as reduction in cell viability measured after 72 hrs by Alamar blue based inverted microscopy analysis	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Synthesis, in-vitro antiprotozoal activity and molecular docking study of isothiocyanate derivatives.
AID1148921	Inhibition of colony formation in BDF1 mouse bone marrow cells assessed as percentage of colony forming cell at 5 nM after 7 days by microscopic analysis relative to control	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Podophyllotoxin analogs. 1. Synthesis and biological evaluation of certain trans-2-aryl-trans-6-hydroxymethyl-3-cyclohexenecarboxylic acid gamma-lactones as antimitotic agents.
AID88041	Effect on cell cycle evaluated as proportion of cells in sub-G1 (apoptic cells) phase of the cell cycle at 10E-7 M for 72 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1306340	Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 1 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 5.92 to 9.33%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID355597	Inhibition of microtubule polymerization
AID1200315	Antiproliferative activity against human U87 cells assessed as reduction in cell viability up to 100 uM after 48 hrs by MTT assay	2015	Journal of medicinal chemistry, Mar-12, Volume: 58, Issue:5	Activity of 2-aryl-2-(3-indolyl)acetohydroxamates against drug-resistant cancer cells.
AID644369	Cytotoxicity against rat L6 myoblasts after 72 hrs by alamar blue assay	2012	Bioorganic & medicinal chemistry, Feb-15, Volume: 20, Issue:4	Synthesis and antimalarial and antituberculosis activities of a series of natural and unnatural 4-methoxy-6-styryl-pyran-2-ones, dihydro analogues and photo-dimers.
AID8688	In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID655229	Cytotoxicity against human IGROV1 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1428414	Cytotoxicity against human HCT15 cells assessed as growth inhibition after 72 hrs by SRB assay
AID655208	Cytotoxicity against human HCC2998 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1489110	Induction of apoptosis in human MCF7 cells assessed as viable cells at 12 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 91.6 to 92.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID335775	Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 0.16 ug/mL	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID1390500	Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
AID403993	Antiviral activity against HSV1 infected in monkey CV-1 cells assessed as inhibition of plaque formation	1998	Journal of natural products, Nov, Volume: 61, Issue:11	Antiviral activity of lignans.
AID1317439	Antitumor activity against human T47D cells xenografted in nude mouse assessed as tumor weight at 5 mg/kg/day, ip administered daily for 18 days measured every 3 days during compound dosing (Rvb = 882 +/- 149 mg)	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID214187	Percentage inhibition of colchicine binding(1:1 ratio of inhibitor: colchicine) to tubulin	1993	Journal of medicinal chemistry, Apr-30, Volume: 36, Issue:9	Synthesis and cytotoxicity of 1,6,7,8-substituted 2-(4'-substituted phenyl)-4-quinolones and related compounds: identification as antimitotic agents interacting with tubulin.
AID1298168	Cytotoxicity against rat L6 cells measured after 70 hrs by alamar blue staining based fluorescence analysis	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	Synthesis of novel amide and urea derivatives of thiazol-2-ethylamines and their activity against Trypanosoma brucei rhodesiense.
AID1491417	Antiproliferative activity against human HCT15 cells after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Synthesis of thiazole linked indolyl-3-glyoxylamide derivatives as tubulin polymerization inhibitors.
AID464518	Selectivity for human Raji cells over human HMEC	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID103762	In vitro cytotoxic activity against ADR resistant breast cancer (MCF-7-ADR) cell line.	1999	Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15	9-Deoxopodophyllotoxin derivatives as anti-cancer agents.
AID1492876	Inhibition of tubulin polymerization (unknown origin) preincubated for 10 mins followed by GTP addition measured after 20 mins by Coomassie blue staining based SDS-PAGE analysis	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Triazolopyridinyl-acrylonitrile derivatives as antimicrotubule agents: Synthesis, in vitro and in silico characterization of antiproliferative activity, inhibition of tubulin polymerization and binding thermodynamics.
AID299205	Antiproliferative activity against human MCF7 cells	2007	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13	Novel potent antimitotic heterocyclic ketones: synthesis, antiproliferative activity, and structure-activity relationships.
AID464511	Selectivity ratio for IC50 for human BJ cells to IC50 for Trypanosoma brucei brucei	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID214014	Inhibition of tubulin polymerization	1994	Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8	Antitumor agents. 150. 2',3',4',5',5,6,7-substituted 2-phenyl-4-quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization.
AID1101800	Insecticidal activity against fifth-instar larvae of Pieris rapae fed on compound treated cabbage leaf assessed as mortality at 250 ppm dipped for 3 secs measured after 15 days (Rvb = 10 1.22%)	2002	Chemical & pharmaceutical bulletin, Mar, Volume: 50, Issue:3	Synthesis and insecticidal activity of novel 4beta-halogenated benzoylamino podophyllotoxins against Pieris rapae Linnaeus.
AID1384281	Inhibition of tubulin polymerization (unknown origin) in glycerol-assembly buffer assessed as critical concentration of tubulin required for assembly at 27.5 uM measured every 30 secs for 2 hrs in presence of GTP (Rvb = 9 +/- 2 uM)	2018	European journal of medicinal chemistry, Apr-25, Volume: 150	Effects on tubulin polymerization and down-regulation of c-Myc, hTERT and VEGF genes by colchicine haloacetyl and haloaroyl derivatives.
AID481679	Antimitotic activity against Paracentrotus lividus embryo assessed as cleavage arrest after 10 to 15 mins fertilization 45 to 60 mins before first mitotic cycle completeion	2010	European journal of medicinal chemistry, May, Volume: 45, Issue:5	Novel derivatives of 1,3,4-oxadiazoles are potent mitostatic agents featuring strong microtubule depolymerizing activity in the sea urchin embryo and cell culture assays.
AID1549934	Inhibition of tubulin polymerization in human HeLa cells assessed as contracted and rounded cells with disordered abnormal spindles and chromosomal misalignment at 500 nM after 24 hrs by immunofluorescence based confocal microscopy	2019	European journal of medicinal chemistry, May-15, Volume: 170	Discover 4β-NH-(6-aminoindole)-4-desoxy-podophyllotoxin with nanomolar-potency antitumor activity by improving the tubulin binding affinity on the basis of a potential binding site nearby colchicine domain.
AID1240908	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue assay	2015	Journal of medicinal chemistry, Aug-27, Volume: 58, Issue:16	2-Phenoxy-1,4-naphthoquinones: From a Multitarget Antitrypanosomal to a Potential Antitumor Profile.
AID9253	Growth inhibition of A549 (human lung carcinoma) cell line.	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Synthesis and antitumor activity of structural analogues of the epipodophyllotoxins.
AID1334734	Antiproliferative activity against human MCF7 assessed as reduction in cell viability measured after 48 hrs by SRB assay	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Novel carbazole sulfonamide derivatives of antitumor agent: Synthesis, antiproliferative activity and aqueous solubility.
AID611187	Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 2 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 6.99%)	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Synthesis and biological evaluation of 4β-acrylamidopodophyllotoxin congeners as DNA damaging agents.
AID1267697	Cell cycle arrest in human K562/ADR cells assessed as accumulation in G2/M phase at 0.1 uM after 48 hrs by propidium iodide staining-based flow cytometry (Rvb = 8.32 +/- 0.81%)	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID628177	Induction of apoptosis in human Jurkat cells assessed as procaspase-2 cleavage at 50 nM after 24 hrs by Western blotting	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID1456100	Antiproliferative activity against human LO2 cells after 72 hrs by CCK-8 assay	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID400478	Cytotoxicity against african green monkey Vero cells assessed as cell viability at 1 uM by trypan blue exclusion assay
AID1267695	Resistance factor, ratio of IC50 for human K562/ADR cells to IC50 for human K562 cells	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID87914	Effect on cell cycle evaluated as proportion of cells in G2/M phase of the cell cycle at 10E-6 M for 72 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1432128	Cell cycle arrest in human DU145 cells assessed as accumulation at subG1 phase at 400 nM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 1.91%)
AID1495304	Inhibition of AKT phosphorylation in human K562/VCR cells at 0.05 uM after 48 hrs by Western blot method relative to beta-actin	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID92265	In vitro antitumor activity against NCI 's human tumor cell lines	1997	Journal of medicinal chemistry, Sep-12, Volume: 40, Issue:19	Antitumor agents. 178. Synthesis and biological evaluation of substituted 2-aryl-1,8-naphthyridin-4(1H)-ones as antitumor agents that inhibit tubulin polymerization.
AID335774	Antimitotic activity in rat ASK cells assessed as reversal of astrocyte formation at 0.8 ug/mL	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID105226	In vitro cytotoxicity against human breast cancer MDA-N cell line	1998	Bioorganic & medicinal chemistry letters, Jun-02, Volume: 8, Issue:11	Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents.
AID116434	Percent increase in life span (ILS) was measured on P388 cells which were inoculated intraperitoneally in CD2F1 mice at 8 mg/kg	1987	Journal of medicinal chemistry, Oct, Volume: 30, Issue:10	In vivo antitumor activity of 6-benzyl-1,3-benzodioxole derivatives against the P388, L1210, B16, and M5076 murine models.
AID1403419	Antiproliferative activity against human HT-29 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	4β-amidotriazole linked podophyllotoxin congeners: DNA topoisomerase-IIα inhibition and potential anticancer agents for prostate cancer.
AID214173	In vitro inhibition of binding of [3H]colchicine to tubulin (10 uM) at compound concentration of 5 mM	1998	Journal of medicinal chemistry, Jun-18, Volume: 41, Issue:13	Structure-activity requirements for flavone cytotoxicity and binding to tubulin.
AID699781	Growth inhibition of human A549 cells after 72 hrs by SRB assay	2012	Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15	Synthesis and antimitotic and tubulin interaction profiles of novel pinacol derivatives of podophyllotoxins.
AID1754703	Cytotoxicity in human MCF7 cells assessed as inhibition of cell proliferation measured by CCK-8 assay	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID1380021	Cytotoxicity in rat L6 cells assessed as reduction in cell viability incubated for 72 hrs by alamar blue dye based assay	2017	European journal of medicinal chemistry, Nov-10, Volume: 140	Synthesis and antimalarial evaluation of artesunate-polyamine and trioxolane-polyamine conjugates.
AID317959	Cytotoxicity against human KB cells by alamar blue assay	2008	Journal of medicinal chemistry, Mar-13, Volume: 51, Issue:5	Antimalarial dual drugs based on potent inhibitors of glutathione reductase from Plasmodium falciparum.
AID1168745	Anticancer activity against human SH-SY5Y cells after 24 hrs by MTT assay	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	Synthesis of cyclic 1,9-acetal derivatives of forskolin and their bioactivity evaluation.
AID1416615	Induction of apoptosis in human HeLa cells assessed as caspase-3 activation at 0.5 uM after 48 hrs by fluorimetric method relative to control
AID1637440	Activation of ERK1/2 signalling in human K562/ADR cells assessed as increase in cleaved caspase-3 expression at 0.05 uM after 48 hrs by Western blot analysis relative to control	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID560442	Cell cycle arrest in human PHK cells assessed as accumulation at G2/M phase at 10 times EC50 after 48 hrs by flow cytometry	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	GS-9191 is a novel topical prodrug of the nucleotide analog 9-(2-phosphonylmethoxyethyl)guanine with antiproliferative activity and possible utility in the treatment of human papillomavirus lesions.
AID1727701	Cytotoxicity against rat L6 cells assessed as reduction in cell viability measured after 70 hrs by Alamar blue assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	The discovery of novel antitrypanosomal 4-phenyl-6-(pyridin-3-yl)pyrimidines.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1301508	Growth inhibition of human BxPC3 cells measured after 48 hrs by sulforhodamine B assay	2016	Journal of natural products, Mar-25, Volume: 79, Issue:3	Antineoplastic Agents. 585. Isolation of Bridelia ferruginea Anticancer Podophyllotoxins and Synthesis of 4-Aza-podophyllotoxin Structural Modifications.
AID492478	Displacement of [3H]colchicine from tubulin	2010	Journal of natural products, Mar-26, Volume: 73, Issue:3	Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach.
AID1754713	Induction of apoptosis in human PC-3M cells assessed as viable cells at 1 nM measured after 48 hrs by Annexin V/PI staining based flow cytometry method (Rvb = 95.6%)	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID1699415	Induction of apoptosis in human HepG2 cells assessed as early apoptotic cells at 50 nM incubated for 24 hrs by annexin V-FITC and propidium iodide based flow cytometry analysis (Rvb = 1.84 %)	2020	Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24	Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
AID626320	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	2011	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 21, Issue:21	Biological evaluation of glycosyl-isoindigo derivatives against the pathogenic agents of tropical diseases (malaria, Chagas disease, leishmaniasis and human African trypanosomiasis).
AID1361527	Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at IC50 after 24 hrs by annexin V/FITC-propidium iodide staining-based flow cytometric method (Rvb = 0.34%)	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Design, synthesis and screening of 1, 2, 4-triazinone derivatives as potential antitumor agents with apoptosis inducing activity on MCF-7 breast cancer cell line.
AID266933	Inhibition of [3H]colchicine binding to tubulin at 1 uM	2006	Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13	Synthesis and biological evaluation of 2-amino-3-(3',4',5'-trimethoxybenzoyl)-5-aryl thiophenes as a new class of potent antitubulin agents.
AID670486	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Synthesis and biological evaluation of novel 4β-(1,3,4-oxadiazole-2-amino)-podophyllotoxin derivatives.
AID88039	Effect on cell cycle evaluated as proportion of cells in S phase of the cell cycleG2/M at 10E-8 M for 72 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID217897	Minimum inhibitory concentration for cell growth inhibition (Herpesvirus activity)	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor agents. 207. Design, synthesis, and biological testing of 4beta-anilino-2-fluoro-4'-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents.
AID214353	Ratio of binding affinity to that of colchicine	1980	Journal of medicinal chemistry, May, Volume: 23, Issue:5	Structure--antitubulin activity relationship in steganacin congeners and analogues. Inhibition of tubulin polymerization in vitro by (+/-)-isodeoxypodophyllotoxin.
AID628176	Induction of apoptosis in human Jurkat cells assessed as procaspase-9 cleavage at 50 nM after 48 hrs by Western blotting	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Polyalkoxybenzenes from plants. 5. Parsley seed extract in synthesis of azapodophyllotoxins featuring strong tubulin destabilizing activity in the sea urchin embryo and cell culture assays.
AID1517602	Cytotoxicity against rat L6 cells measured after 72 hrs by alamar blue assay	2019	European journal of medicinal chemistry, Dec-01, Volume: 183	Exploration of the antibiotic potentiating activity of indolglyoxylpolyamines.
AID1331714	Inhibition of 2-methoxy-5-(2,3,4-trimethoxyphenyl)-2,4,6-cycloheptatrien-1-one binding to colchicine binding site of tubulin (unknown origin) at 10 uM by fluorescence assay	2016	Journal of natural products, 08-26, Volume: 79, Issue:8	Structural and Biochemical Characterization of the Interaction of Tubulin with Potent Natural Analogues of Podophyllotoxin.
AID1162948	Gametocytocidal activity against transgenic Plasmodium falciparum NF54-pfs16-GFP late stage gametocytes after 72 hrs by mitotracker red CM-H2XRos dye based confocal imaging assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Blood schizontocidal and gametocytocidal activity of 3-hydroxy-N'-arylidenepropanehydrazonamides: a new class of antiplasmodial compounds.
AID1489088	Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase at 0.6 uM after 4 hrs by propidium iodide staining based flow cytometric method (Rvb = 60.19 to 60.87%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1317405	Antiproliferative activity against human HL60 cells after 96 hrs by SRB assay	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID293486	Cytotoxicity against human HT29 cells after 4 days	2007	Bioorganic & medicinal chemistry, Feb-15, Volume: 15, Issue:4	Synthesis and cytotoxic evaluation of C-9 oxidized podophyllotoxin derivatives.
AID670488	Cytotoxicity against african green monkey Vero cells after 72 hrs by MTT assay	2012	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 22, Issue:14	Synthesis and biological evaluation of novel 4β-(1,3,4-oxadiazole-2-amino)-podophyllotoxin derivatives.
AID1301509	Growth inhibition of human MCF7 cells measured after 48 hrs by sulforhodamine B assay	2016	Journal of natural products, Mar-25, Volume: 79, Issue:3	Antineoplastic Agents. 585. Isolation of Bridelia ferruginea Anticancer Podophyllotoxins and Synthesis of 4-Aza-podophyllotoxin Structural Modifications.
AID1456123	Induction of apoptosis in human Bel7402/5-FU cells assessed as reduction in cell number at 0.05 uM after 24 hrs by Hoechst 33342 staining based fluorescent microscopic method	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID640957	Toxicity against Brine shrimp nauplii after 24 hrs	2012	Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2	Synthesis, characterization and in vitro biological evaluation of some novel diarylsulfonylureas as potential cytotoxic and antimicrobial agents.
AID1069844	Cytotoxicity against human HEK293 cells after 24 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Feb-15, Volume: 22, Issue:4	Synthesis of neolignans as microtubule stabilisers.
AID621155	Cytotoxicity against rat L6 cells	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis and in vitro antiprotozoal activities of 5-phenyliminobenzo[a]phenoxazine derivatives.
AID1101801	Insecticidal activity against fifth-instar larvae of Pieris rapae fed on compound treated cabbage leaf assessed as mortality at 250 ppm dipped for 3 secs measured after 10 days (Rvb = 6.67 1.56%)	2002	Chemical & pharmaceutical bulletin, Mar, Volume: 50, Issue:3	Synthesis and insecticidal activity of novel 4beta-halogenated benzoylamino podophyllotoxins against Pieris rapae Linnaeus.
AID655207	Cytotoxicity against human COLO205 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1395721	Cytotoxicity against human WRL68 cells preincubated for 4 hrs followed by incubation in compound free media for 24 hrs by MTT assay	2018	European journal of medicinal chemistry, May-10, Volume: 151	Antiproliferative efficacy of curcumin mimics through microtubule destabilization.
AID1281533	Induction of microtubule cytoskeleton destabilization in human MCF7 cells assessed as pyknosis at 250 nM after 6 hrs by Hoechst 33342 staining-based confocal fluorescence microscopy	2016	European journal of medicinal chemistry, Mar-03, Volume: 110	Novel cis-selective and non-epimerisable C3 hydroxy azapodophyllotoxins targeting microtubules in cancer cells.
AID1140310	Inhibition of tubulin (unknown origin) polymerization at 3 uM measured for 1 hr by fluorescence assay relative to control	2014	Bioorganic & medicinal chemistry, May-01, Volume: 22, Issue:9	Synthesis of a terphenyl substituted 4-aza-2,3-didehydropodophyllotoxin analogues as inhibitors of tubulin polymerization and apoptosis inducers.
AID1503758	Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence assay	2017	Journal of natural products, 10-27, Volume: 80, Issue:10	Jozilebomines A and B, Naphthylisoquinoline Dimers from the Congolese Liana Ancistrocladus ileboensis, with Antiausterity Activities against the PANC-1 Human Pancreatic Cancer Cell Line.
AID335783	Cytotoxicity against human KBV1 cells	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID771677	Cytotoxicity against rat L6 cells assessed as growth inhibition after 72 hrs by fluorometric analysis	2013	Journal of medicinal chemistry, Oct-10, Volume: 56, Issue:19	Design, synthesis, and biological and crystallographic evaluation of novel inhibitors of Plasmodium falciparum enoyl-ACP-reductase (PfFabI).
AID1698782	Inhibition of wild type human topoisomerase-2alpha expressed in Saccharomyces cerevisiae JEL1deltatop1 assessed as inhibition of supercoiled DNA relaxation at 100 to 200 uM using negatively supercoiled pBRDNA as substrate incubated for 15 mins in presence	2020	Bioorganic & medicinal chemistry, 11-15, Volume: 28, Issue:22	Synthesis and evaluation of etoposide and podophyllotoxin analogs against topoisomerase IIα and HCT-116 cells.
AID1489074	Cytotoxicity against human A549 cells after 24 hrs by MTT assay	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1489082	Cell cycle arrest in human MCF7 cells assessed as accumulation at G1 phase at 0.6 uM after 12 hrs by propidium iodide staining based flow cytometric method (Rvb = 58.69 to 62.23%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1906553	Cytotoxicity against human HeLa cells overexpressing tubulin beta3 assessed as inhibition of cell growth measured after 48 hrs by MTT assay	2022	European journal of medicinal chemistry, May-05, Volume: 235	Design and synthesis of multifunctional microtubule targeting agents endowed with dual pro-apoptotic and anti-autophagic efficacy.
AID357845	Binding affinity to calf thymus DNA assessed as reduction in DNA peak by pre-incubation method
AID1754719	Induction of apoptosis in human PC-3M cells assessed as late apoptotic cells at 5 nM measured after 48 hrs by Annexin V/PI staining based flow cytometry method (Rvb = 2.88%)	2021	Bioorganic & medicinal chemistry letters, 08-15, Volume: 46	The ester derivatives obtained by C-ring modification of podophyllotoxin induce apoptosis and inhibited proliferation in PC-3M cells via down-regulation of PI3K/Akt signaling pathway.
AID357846	Binding affinity to yeast tRNA assessed as reduction in tRNA peak by pre-incubation method
AID262912	Inhibition of [3H]colchicine binding to tubulin at 5 uM	2006	Journal of medicinal chemistry, Apr-06, Volume: 49, Issue:7	Benzoylphenylurea sulfur analogues with potent antitumor activity.
AID378965	Antileishmanial activity against Leishmania donovani MHOM/SD/62/IS-CL2D axenic amastigotes after 3 days	2006	Journal of natural products, Jan, Volume: 69, Issue:1	Isoflavonoids and other compounds from Psorothamnus arborescens with antiprotozoal activities.
AID1428415	Cytotoxicity against human HCT116 cells assessed as growth inhibition after 72 hrs by SRB assay
AID1456213	Effect on iNOS expression in human Bel7402/5-FU cells assessed as ratio of iNOS to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.13 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1456212	Effect on COX2 expression in human Bel7402/5-FU cells assessed as ratio of COX2 to beta-actin level at 0.05 uM after 48 hrs by Western blot analysis (Rvb = 0.36 No_unit)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID1382778	Inhibition of calf brain tubulin polymerization at 30 uM measured for 6000 secs by spectrophotometric method	2018	European journal of medicinal chemistry, Mar-25, Volume: 148	Conformational mimetics of the α-methyl chalcone TUB091 binding tubulin: Design, synthesis and antiproliferative activity.
AID524796	Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID84091	Growth inhibition of HT-29 (human colon adenocarcinoma) cell line.	1991	Journal of medicinal chemistry, Mar, Volume: 34, Issue:3	Synthesis and antitumor activity of structural analogues of the epipodophyllotoxins.
AID611184	Cytotoxicity against human MCF7 cells at 2 to 4 uM after 24 hrs by MTT assay	2011	Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15	Synthesis and biological evaluation of 4β-acrylamidopodophyllotoxin congeners as DNA damaging agents.
AID655228	Cytotoxicity against human UACC62 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1267693	Antiproliferative activity against human HeLa cells assessed as growth inhibition after 72 hrs by CCK-8 assay	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID400481	Antiviral activity against measles virus infected in african green monkey Vero cells assessed as plaque formation at 1 uM after 5 days by neutral red assay relative to control
AID740948	Cytotoxicity against african green monkey Vero cells	2013	Journal of natural products, Mar-22, Volume: 76, Issue:3	8,8-dialkyldihydroberberines with potent antiprotozoal activity.
AID464325	Cytotoxicity against HEK293 cells after 72 hrs by luminescence assay	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID1578102	Cytotoxicity against rat L6 cells assessed as reduction in cell viability	2019	Bioorganic & medicinal chemistry letters, 10-15, Volume: 29, Issue:20	Antiprotozoal alkaloid principles of the plant family Amaryllidaceae.
AID42742	GI values against CAKI-1 cells(renal carcinoma)	2001	Journal of medicinal chemistry, Apr-26, Volume: 44, Issue:9	Antitumor agents. 207. Design, synthesis, and biological testing of 4beta-anilino-2-fluoro-4'-demethylpodophyllotoxin analogues as cytotoxic and antiviral agents.
AID464501	Half life in mouse plasma by UPLC-MS analysis	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Podophyllotoxin analogues active versus Trypanosoma brucei.
AID384953	Inhibition of HPV1a E2-E7 protein interaction at 250 uM assessed as rate of E2 binding to E7 protein by surface plasmon resonance method	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Podophyllotoxin directly binds a hinge domain in E2 of HPV and inhibits an E2/E7 interaction in vitro.
AID335786	Cytotoxicity against human U373 cells	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID1187288	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	2014	European journal of medicinal chemistry, Oct-06, Volume: 85	Synthesis and evaluation of novel podophyllotoxin derivatives as potential antitumor agents.
AID1489102	Induction of apoptosis in human MCF7 cells assessed as viable cells at 4 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 91.6 to 92.7%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID1267721	Inhibition of P-glycoprotein in human K562/ADR cells at 0.1 uM after 48 hrs by Western blot analysis	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID1699417	Induction of apoptosis in human HepG2 cells assessed as necrotic cells at 50 nM incubated for 24 hrs by annexin V-FITC and propidium iodide based flow cytometry analysis (Rvb = 0.94 %)	2020	Bioorganic & medicinal chemistry, 12-15, Volume: 28, Issue:24	Synthesis and biological evaluation of NQO1-activated prodrugs of podophyllotoxin as antitumor agents.
AID214163	Inhibition of colchicine binding to tubulin isolated from bovine brain tissue	1994	Journal of medicinal chemistry, Apr-15, Volume: 37, Issue:8	Antitumor agents. 150. 2',3',4',5',5,6,7-substituted 2-phenyl-4-quinolones and related compounds: their synthesis, cytotoxicity, and inhibition of tubulin polymerization.
AID1317409	Selectivity index, ratio of IC50 for HAF cells to IC50 for human MCF7 cells	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID332920	Cytotoxicity against human KB cells after 72 hrs	1994	Journal of natural products, Jan, Volume: 57, Issue:1	Cytotoxic and antibacterial dihydrochalcones from Piper aduncum.
AID298666	Effect on apoptosis in Jurkat cells assessed as cleavage of procaspase 3 to active enzyme at 5 uM	2007	Journal of medicinal chemistry, Oct-18, Volume: 50, Issue:21	Discovery and investigation of antiproliferative and apoptosis-inducing properties of new heterocyclic podophyllotoxin analogues accessible by a one-step multicomponent synthesis.
AID443471	Cytotoxicity against human HepG2 cells after 24 hrs by MTS assay	2010	European journal of medicinal chemistry, Jan, Volume: 45, Issue:1	Synthesis and biological evaluation of novel thiocolchicine-podophyllotoxin conjugates.
AID1882897	Cytotoxicity against human MCF7/TxR cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1605626	Cytotoxicity against rat L6 cells incubated for 70 hrs by resazurin dye based assay	2020	Journal of medicinal chemistry, 03-26, Volume: 63, Issue:6	Discovery and Optimization of a Compound Series Active against
AID1403373	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Jan-20, Volume: 144	Synthesis of podophyllotoxin linked β-carboline congeners as potential anticancer agents and DNA topoisomerase II inhibitors.
AID1549906	Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	European journal of medicinal chemistry, May-15, Volume: 170	Discover 4β-NH-(6-aminoindole)-4-desoxy-podophyllotoxin with nanomolar-potency antitumor activity by improving the tubulin binding affinity on the basis of a potential binding site nearby colchicine domain.
AID1112939	Insecticidal activity against pre-third-instar larvae of Mythimna separata (Oriental armyworm) assessed as corrected mortality rate at 1 mg/ml measured after 35 days by the leaf-dipping method	2013	Journal of agricultural and food chemistry, Jan-23, Volume: 61, Issue:3	Synthesis and quantitative structure-activity relationship (QSAR) study of novel 4-acyloxypodophyllotoxin derivatives modified in the A and C rings as insecticidal agents.
AID1541168	Cytotoxicity against rat L6 cells assessed as reduction in cell viability after 72 hrs by Alamar blue dye-based fluorometric analysis
AID384952	Inhibition of HPV1a recombinant E2 protein-DNA interaction by electron mobility shift assay	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Podophyllotoxin directly binds a hinge domain in E2 of HPV and inhibits an E2/E7 interaction in vitro.
AID616292	Cytotoxicity against rat L6 cells incubated for 72 hrs by Alamar Blue staining based fluorometric assay	2011	Journal of natural products, Sep-23, Volume: 74, Issue:9	Antimalarial β-carbolines from the New Zealand ascidian Pseudodistoma opacum.
AID373526	Cytotoxicity against rat L6 cells by alamar blue assay	2009	European journal of medicinal chemistry, May, Volume: 44, Issue:5	Synthesis and antiparasitic and antifungal evaluation of 2'-arylsubstituted-1H,1'H-[2,5']bisbenzimidazolyl-5-carboxamidines.
AID655232	Cytotoxicity against human OVCAR5 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID655214	Cytotoxicity against human SF268 cells after 48 hrs by trypan blue dye exclusion assay	2012	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7	Synthesis and comparative evaluation of 4-oxa- and 4-aza-podophyllotoxins as antiproliferative microtubule destabilizing agents.
AID1306344	Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 1 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 2.45 to 6.92%)	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1495300	Induction of reactive oxygen species formation in human K562/VCR cells at 0.05 uM after 24 hrs by DCFH-DA staining-based flow cytometric method (Rvb = 0.41%)	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID602109	Induction of apoptosis in human Jurkat cells assessed as cleavage of caspase 3 substrate DEVD-p-nitroanaline 2 hrs by spectrophotometric analysis	2011	Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12	Anticancer properties of an important drug lead podophyllotoxin can be efficiently mimicked by diverse heterocyclic scaffolds accessible via one-step synthesis.
AID419683	Cytotoxicity against rat L6 cells	2009	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11	Privileged structure-guided synthesis of quinazoline derivatives as inhibitors of trypanothione reductase.
AID1410393	Cell cycle arrest in human MG63 cells assessed as increase in accumulation at G2/M phase at 1 uM after 24 hrs by propidium iodide staining based flow cytometric analysis relative to control	2018	ACS medicinal chemistry letters, Apr-12, Volume: 9, Issue:4	New Hybrids Derived from Podophyllic Aldehyde and Diterpenylhydroquinones with Selectivity toward Osteosarcoma Cells.
AID1361532	Inhibition of human DNA topoisomerase 2beta after 2 hrs by ELISA	2018	European journal of medicinal chemistry, Aug-05, Volume: 156	Design, synthesis and screening of 1, 2, 4-triazinone derivatives as potential antitumor agents with apoptosis inducing activity on MCF-7 breast cancer cell line.
AID300658	Inhibition of porcine tubulin assembly	2007	Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18	Synthesis, biological evaluation, and molecular modeling of 3,5-substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents.
AID1637427	Induction of apoptosis in human K562/ADR cells assessed as chromatin condensation at 0.05 uM after 48 hrs by Hoechst 33342 staining based fluorescent microscopic analysis	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID335780	Cytotoxicity against human BC1 cells	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID1148923	Inhibition of colony formation in BDF1 mouse bone marrow cells assessed as percentage of colony forming cell at 0.5 uM after 7 days by microscopic analysis relative to control	1976	Journal of medicinal chemistry, Jan, Volume: 19, Issue:1	Podophyllotoxin analogs. 1. Synthesis and biological evaluation of certain trans-2-aryl-trans-6-hydroxymethyl-3-cyclohexenecarboxylic acid gamma-lactones as antimitotic agents.
AID1489111	Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 12 uM after 24 hrs by Annexin-V-FITC/propidium iodide staining based flow cytometric method (Rvb = 2.36 to 2.86%)	2017	Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17	Design and synthesis of piperazine acetate podophyllotoxin ester derivatives targeting tubulin depolymerization as new anticancer agents.
AID247402	Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program	2005	Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5	CHMIS-C: a comprehensive herbal medicine information system for cancer.
AID384945	Binding affinity to HPV1a recombinant E2 protein by surface plasmon resonance method	2008	Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10	Podophyllotoxin directly binds a hinge domain in E2 of HPV and inhibits an E2/E7 interaction in vitro.
AID338804	Cytotoxicity against mouse EAT cells after 4 days by trypan blue assay	1992	Journal of natural products, Jan, Volume: 55, Issue:1	Isolation, purification, and cytotoxicity of 5-methoxypodophyllotoxin, a lignan from a root culture of Linum flavum.
AID1267694	Antiproliferative activity against HUVEC assessed as growth inhibition after 72 hrs by CCK-8 assay	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	Synthesis and biological evaluation of a novel artesunate-podophyllotoxin conjugate as anticancer agent.
AID494501	Antiproliferative activity against human K562 cells after 48 hrs	2010	European journal of medicinal chemistry, Aug, Volume: 45, Issue:8	Synthesis, antiproliferative activity and inhibition of tubulin polymerization by 1,5- and 1,8-disubstituted 10H-anthracen-9-ones bearing a 10-benzylidene or 10-(2-oxo-2-phenylethylidene) moiety.
AID1882895	Cytotoxicity against human HeLa cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1882946	Half-life in Sprague-Dawley rat at 10 mg/kg, iv by HPLC-MS/MS analysis	2022	European journal of medicinal chemistry, Jul-05, Volume: 237	Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID602116	Antimitotic activity in human HeLa cells assessed as visible deffect in mitotic spindle formation at 10 uM after 3 hrs by inverted microscopic analysis	2011	Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12	Anticancer properties of an important drug lead podophyllotoxin can be efficiently mimicked by diverse heterocyclic scaffolds accessible via one-step synthesis.
AID1495290	Induction of apoptosis in human K562/VCR cells assessed as necrotic cells at 0.05 uM after 48 hrs by annexin-V-FITC/propidium iodide staining-based flow cytometric method (Rvb = 0.15%)	2018	Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10	Design, synthesis and antineoplastic activity of novel hybrids of podophyllotoxin and indirubin against human leukaemia cancer cells as multifunctional anti-MDR agents.
AID634098	Anticancer activity against human ACHN cells after 48 hrs by MTT assay	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Synthesis and anticancer activity of 4β-alkylamidochalcone and 4β-cinnamido linked podophyllotoxins as apoptotic inducing agents.
AID1317414	Selectivity index, ratio of IC50 for HAF cells to IC50 for human HT-29 cells	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	Synthesis of novel diterpenoid analogs with in-vivo antitumor activity.
AID644059	Induction of apoptosis in human A549 cells assessed as nuclear fragmentation at 0.5 uM after 24 hrs by Hoechst 33258 staining based fluorescence microscopy	2012	European journal of medicinal chemistry, Mar, Volume: 49	Synthesis and biological evaluation of conjugates of deoxypodophyllotoxin and 5-FU as inducer of caspase-3 and -7.
AID87925	Effect on cell cycle evaluated as proportion of cells in S phase of the cell cycle at 10E-7 M for 72 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID1432131	Cell cycle arrest in human DU145 cells assessed as accumulation at G2/M phase at 400 nM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 24.71%)
AID1402133	Cytotoxicity against rat L6 cells after 70 hrs by Alamar Blue-based assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Primaquine hybrids as promising antimycobacterial and antimalarial agents.
AID1637416	Induction of apoptosis in human K562/ADR cells assessed as live cells at 0.05 uM after 48 hrs by Annexin V-APC/7-AAD staining based flow cytometry (Rvb = 91.65%)	2016	Bioorganic & medicinal chemistry letters, 09-15, Volume: 26, Issue:18	Design, synthesis and evaluation of the multidrug resistance-reversing activity of pyridine acid esters of podophyllotoxin in human leukemia cells.
AID1456111	Cell cycle arrest in human Bel7402/5-FU cells assessed as accumulation at G1 phase at 0.05 uM after 48 hrs by propidium iodide staining based flow cytometry (Rvb = 52.21%)	2017	European journal of medicinal chemistry, May-05, Volume: 131	Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
AID88044	Effect on cell cycle evaluated as proportion of cells in sub-G1 phase (apoptic cells) of the cell cycle at 10E-7 M for 24 hr in HeLa cells	2004	Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5	Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin.
AID335785	Cytotoxicity against human Lu1 cells	1993	Journal of natural products, Oct, Volume: 56, Issue:10	Cytotoxic constituents from Hyptis verticillata.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1802222	COX Enzyme Inhibition Assay (Table 1) from Article 10.1021/acschembio.6b00560: \\Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors.\\	2016	ACS chemical biology, 11-18, Volume: 11, Issue:11	Antitumor Activity of Cytotoxic Cyclooxygenase-2 Inhibitors.
AID1799579	In Vitro Activity Assay from Article 10.1111/j.1747-0285.2008.00729.x: \\Inhibitors of tubulin assembly identified through screening a compound library.\\	2008	Chemical biology & drug design, Dec, Volume: 72, Issue:6	Inhibitors of tubulin assembly identified through screening a compound library.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1224864	HCS microscopy assay (F508del-CFTR)	2016	PloS one, , Volume: 11, Issue:10	Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1269 (42.77)	18.7374
1990's	348 (11.73)	18.2507
2000's	483 (16.28)	29.6817
2010's	716 (24.13)	24.3611
2020's	151 (5.09)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	226 (7.25%)	5.53%
Reviews	239 (7.66%)	6.00%
Case Studies	127 (4.07%)	4.05%
Observational	0 (0.00%)	0.25%
Other	2,527 (81.02%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (138)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma [NCT00027846]	Phase 2	378 participants (Actual)	Interventional	2003-08-31	Completed
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC [NCT04092283]	Phase 3	660 participants (Anticipated)	Interventional	2020-04-29	Active, not recruiting
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC) [NCT03382561]	Phase 2	160 participants (Actual)	Interventional	2018-05-02	Active, not recruiting
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer [NCT01642251]	Phase 1/Phase 2	156 participants (Actual)	Interventional	2012-09-28	Completed
Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors [NCT00379340]	Phase 3	395 participants (Actual)	Interventional	2007-02-26	Active, not recruiting
A Phase I Study of Azacitidine Combined With Mitoxantrone and Etoposide (A-NOVE) Chemotherapy for Patients' Age ≥ 60 With Poor Prognosis Acute Myeloid Leukemia (AML) [NCT01260714]	Phase 1	13 participants (Actual)	Interventional	2010-12-31	Terminated(stopped due to Inadequate accrual rate)
A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) as Front-Line Therapy for Adults With Acute Lymphoblastic Leukemia/Lymphoma [NCT03023046]	Phase 2	54 participants (Actual)	Interventional	2017-02-23	Completed
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse [NCT04546399]	Phase 2	550 participants (Anticipated)	Interventional	2020-12-04	Suspended(stopped due to Other - FDA Partial Clinical Hold)
Phase I Study of the Combination of Midostaurin, Bortezomib, and Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia [NCT01174888]	Phase 1	34 participants (Actual)	Interventional	2010-08-31	Completed
A Phase I Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Escalating Doses of Inotuzumab Ozogamicin (DA-EPOCH-InO) in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia [NCT03991884]	Phase 1	24 participants (Actual)	Interventional	2019-09-24	Completed
Phase II Trial of Standard Platinum Doublet Chemotherapy + Various Proton Beam Therapy (PBT) Doses in Order to Determine the Optimal Dose of PBT for Unresectable Stage 2/3 Non-Small Cell Lung Cancer [NCT03132532]	Phase 2	18 participants (Actual)	Interventional	2017-07-31	Active, not recruiting
A Randomized Phase II Study: Sequencing Topoisomerase Inhibitors for Extensive Stage Small Cell Lung Cancer (SCLC): Topotecan Sequenced With Etoposide/Cisplatin, and Irinotecan/Cisplatin Sequenced With Etoposide [NCT00057837]	Phase 2	140 participants (Actual)	Interventional	2004-07-14	Completed
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations [NCT04293562]	Phase 3	1,400 participants (Anticipated)	Interventional	2020-07-21	Recruiting
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years [NCT01096368]	Phase 3	479 participants (Actual)	Interventional	2010-05-07	Active, not recruiting
Phase II Study of Combination of Hyper-CVAD and Dasatinib (NSC-732517) With or Without Allogeneic Stem Cell Transplant in Patients With Philadelphia (Ph) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL) (A BMT Study) [NCT00792948]	Phase 2	97 participants (Actual)	Interventional	2009-09-01	Active, not recruiting
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer [NCT00334815]	Phase 2	29 participants (Actual)	Interventional	2006-06-15	Active, not recruiting
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma [NCT01798004]	Phase 1	150 participants (Actual)	Interventional	2013-04-08	Active, not recruiting
Combination Chemotherapy With or Without Maintenance Sunitinib Malate (NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study [NCT00453154]	Phase 1/Phase 2	156 participants (Actual)	Interventional	2007-03-15	Completed
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen [NCT02481310]	Phase 1/Phase 2	38 participants (Actual)	Interventional	2015-10-28	Active, not recruiting
A Pilot Study to Estimate the Safety and Tolerability of the Combination of Polatuzumab Vedotin With Dose Adjusted Rituximab, Etoposide, Cyclophosphamide, and Doxorubicin (DA-EPCH-PR) for Upfront Treatment of Aggressive B-Cell Non-Hodgkin Lymphomas [NCT04231877]	Phase 1	50 participants (Anticipated)	Interventional	2020-10-27	Recruiting
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults [NCT02003222]	Phase 3	488 participants (Actual)	Interventional	2014-05-19	Active, not recruiting
Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived CAR-NK Cells Combined With High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-Cell Lymphoma [NCT03579927]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2019-10-03	Withdrawn(stopped due to Lack of Funding)
Phase I/II Study of Carboplatin, Melphalan and Etoposide Phosphate in Conjunction With Osmotic Opening of the Blood-Brain Barrier and Delayed Intravenous Sodium Thiosulfate Chemoprotection, in Previously Treated Subjects With Anaplastic Oligodendroglioma [NCT00303849]	Phase 1/Phase 2	33 participants (Actual)	Interventional	2005-09-15	Completed
A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL) [NCT01979536]	Phase 2	137 participants (Actual)	Interventional	2013-11-13	Active, not recruiting
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) [NCT02112916]	Phase 3	847 participants (Actual)	Interventional	2014-10-04	Active, not recruiting
Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas [NCT03220022]	Phase 1	54 participants (Anticipated)	Interventional	2018-03-16	Recruiting
Intravitreal Melphalan for Intraocular Retinoblastoma [NCT05504291]	Phase 2	28 participants (Anticipated)	Interventional	2022-11-04	Recruiting
A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor [NCT04684368]	Phase 2	160 participants (Anticipated)	Interventional	2021-07-13	Recruiting
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) [NCT04322318]	Phase 2	221 participants (Anticipated)	Interventional	2020-10-19	Recruiting
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) [NCT03533582]	Phase 2/Phase 3	537 participants (Anticipated)	Interventional	2018-05-24	Recruiting
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors [NCT03067181]	Phase 3	2,059 participants (Anticipated)	Interventional	2017-05-25	Recruiting
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones [NCT03007147]	Phase 3	475 participants (Anticipated)	Interventional	2017-08-08	Recruiting
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) [NCT02101853]	Phase 3	669 participants (Actual)	Interventional	2014-12-17	Active, not recruiting
A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma [NCT01193842]	Phase 1/Phase 2	107 participants (Actual)	Interventional	2010-10-06	Completed
A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age [NCT02017964]	Phase 2	26 participants (Actual)	Interventional	2013-12-24	Completed
A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease [NCT00025259]	Phase 3	1,734 participants (Actual)	Interventional	2002-09-30	Completed
A Phase I Study of Bortezomib in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML) [NCT01127009]	Phase 1	3 participants (Actual)	Interventional	2010-07-31	Completed
NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer [NCT04989283]	Phase 2	0 participants (Actual)	Interventional	2021-09-09	Withdrawn(stopped due to Due to no accrual)
A Phase 1 Study of Lenalidomide in Combination With EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) [NCT04301076]	Phase 1	30 participants (Anticipated)	Interventional	2021-08-31	Recruiting
Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult P [NCT02153580]	Phase 1	37 participants (Actual)	Interventional	2014-09-24	Active, not recruiting
A Phase I/II Trial of PARP Inhibition, Radiation, and Immunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - PRIO Trial [NCT04728230]	Phase 1/Phase 2	63 participants (Anticipated)	Interventional	2021-01-05	Recruiting
Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma [NCT03077828]	Phase 2	43 participants (Actual)	Interventional	2017-04-21	Active, not recruiting
A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD [NCT01371981]	Phase 3	1,645 participants (Actual)	Interventional	2011-06-20	Active, not recruiting
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma [NCT06172296]	Phase 3	478 participants (Anticipated)	Interventional	2024-02-14	Not yet recruiting
A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma [NCT03749018]	Phase 2	30 participants (Anticipated)	Interventional	2019-01-02	Active, not recruiting
CASPIAN-RT Trial: Hypofractionated Consolidative Radiation Therapy After Durvalumab (MEDI4736) Plus Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer [NCT05161533]	Phase 2	0 participants (Actual)	Interventional	2023-10-19	Withdrawn(stopped due to Closed per SRC Low Accrual Policy. Study closed prior to any participants enrolled.)
A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Asparaginase (DA-EPOCH-A) for Adults With Acute Lymphoblastic Leukemia/Lymphoma [NCT02538926]	Phase 2	0 participants (Actual)	Interventional	2018-07-01	Withdrawn(stopped due to Drugs unavailable)
Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults [NCT03420963]	Phase 1	38 participants (Anticipated)	Interventional	2018-08-31	Recruiting
Phase I/ II Trial of Carboplatin and Etoposide Plus LBH589 for Previously Untreated Extensive Stage Small Cell Lung Cancer [NCT00958022]	Phase 1	7 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to Based on the tolerabilty challenges of the combination)
Atezolizumab With Platinum and Etoposide Chemotherapy Followed by Cystectomy for Patients With Localized Small Cell Neuroendocrine Bladder Cancer [NCT05312671]	Phase 2	63 participants (Anticipated)	Interventional	2022-06-27	Recruiting
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer [NCT00887159]	Phase 2	168 participants (Actual)	Interventional	2009-07-16	Completed
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma [NCT05675410]	Phase 3	1,875 participants (Anticipated)	Interventional	2023-05-11	Recruiting
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Study of Hyloris Developments' Podofilox Topical Gel 0.5% Compared to Allergan's Condylox® Gel 0.5% in Male and Female Patients With External Anogenital Warts. [NCT03532776]	Phase 3	466 participants (Actual)	Interventional	2018-04-20	Completed
Phase II Study of Maintenance Therapy With Decitabine (NSC #127716) Following Standard Induction and Cytogenetic Risk-Adapted Intensification in Previously Untreated Patients With AML < 60 Years [NCT00416598]	Phase 2	546 participants (Actual)	Interventional	2006-11-15	Completed
A Phase 1/2 Study of the Bromodomain Inhibitor Molibresib in Combination With Etoposide/Platinum in Patients With NUT Carcinoma [NCT04116359]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2020-09-18	Withdrawn(stopped due to Other - Protocol moved to Disapproved)
A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Chemotherapy for Patients With High Risk Diffuse Large B-Cell Lymphoma [NCT02636322]	Phase 2	60 participants (Actual)	Interventional	2016-03-29	Completed
Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate [NCT03582475]	Phase 1	15 participants (Actual)	Interventional	2018-12-20	Completed
A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma [NCT00554788]	Phase 3	60 participants (Actual)	Interventional	2008-02-04	Active, not recruiting
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome [NCT02521493]	Phase 3	312 participants (Anticipated)	Interventional	2015-12-23	Active, not recruiting
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma [NCT02306161]	Phase 3	312 participants (Actual)	Interventional	2014-12-12	Active, not recruiting
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma [NCT02176967]	Phase 3	621 participants (Anticipated)	Interventional	2014-08-08	Active, not recruiting
Mobilization of Autologous Peripheral Blood Stem Cells (PBSC) in CD20+ Lymphoma Patients Using RICE, G-CSF (Granulocyte-Colony Stimulating Factor), and Plerixafor [NCT01097057]	Phase 2	20 participants (Actual)	Interventional	2010-11-09	Completed
A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma [NCT03786783]	Phase 2	42 participants (Actual)	Interventional	2019-01-14	Active, not recruiting
A Phase 2 Study of Polatuzumab Vedotin With Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma [NCT04665765]	Phase 2	41 participants (Actual)	Interventional	2021-01-18	Active, not recruiting
Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer [NCT02402920]	Phase 1	83 participants (Actual)	Interventional	2015-07-22	Active, not recruiting
Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma [NCT00567567]	Phase 3	665 participants (Actual)	Interventional	2007-11-05	Completed
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults [NCT02166463]	Phase 3	600 participants (Actual)	Interventional	2015-03-19	Active, not recruiting
Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) [NCT00720109]	Phase 2/Phase 3	63 participants (Actual)	Interventional	2008-07-14	Completed
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC [NCT01993810]	Phase 3	330 participants (Actual)	Interventional	2014-02-03	Active, not recruiting
Bortezomib (Velcade®) and Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoid Malignancies [NCT00439556]	Phase 2	40 participants (Actual)	Interventional	2007-02-13	Completed
A Multicenter Phase II Study Incorporating DOXIL® and Rituximab Into the Magrath Regimen for HIV-Negative and HIV-Positive Patients With Newly Diagnosed Burkitt's and Burkitt-like Lymphoma [NCT00392990]	Phase 2	25 participants (Actual)	Interventional	2007-02-06	Completed
A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma [NCT02561273]	Phase 1/Phase 2	54 participants (Actual)	Interventional	2015-09-28	Completed
A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial) [NCT03583710]	Phase 3	240 participants (Anticipated)	Interventional	2018-08-20	Recruiting
A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells [NCT02797470]	Phase 1/Phase 2	11 participants (Actual)	Interventional	2016-06-23	Active, not recruiting
A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MD [NCT02029950]	Phase 1	50 participants (Actual)	Interventional	2013-12-16	Completed
Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation [NCT00653068]	Phase 3	70 participants (Actual)	Interventional	2008-12-08	Active, not recruiting
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer [NCT05624996]	Phase 3	474 participants (Anticipated)	Interventional	2023-05-10	Recruiting
Lead-In and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL) [NCT03136146]	Phase 2	42 participants (Anticipated)	Interventional	2017-08-09	Recruiting
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype [NCT02443077]	Phase 3	302 participants (Anticipated)	Interventional	2016-10-12	Active, not recruiting
Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia or Relapsed/Refractory Acute Lymphoblastic Leukemia [NCT02199184]	Phase 2	6 participants (Actual)	Interventional	2015-01-14	Completed
Bortezomib* and Vorinostat as Maintenance Therapy After Autologous Transplant for Non-Hodgkin Lymphoma Using R-BEAM or BEAM Conditioning Transplant Regimen [NCT00992446]	Phase 2	27 participants (Actual)	Interventional	2010-09-02	Completed
Loncastuximab Tesirine in Combination With BEAM (Carmustine, Etoposide, Ara-C, Melphalan) Conditioning Regimen Prior to Autologous Stem Cell Transplant (ASCT) and for Maintenance Therapy in Diffuse Large B-Cell Lymphoma (DLBCL) [NCT05228249]	Phase 1	0 participants (Actual)	Interventional	2023-04-30	Withdrawn(stopped due to PI left institution and funding sponsor closed study. Study did not open to accrual, and no participants were enrolled.)
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab [NCT03811002]	Phase 3	545 participants (Anticipated)	Interventional	2019-07-26	Recruiting
Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma [NCT01035463]	Phase 1/Phase 2	74 participants (Actual)	Interventional	2009-11-12	Completed
Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and II Classical Hodgkin Lymphoma (HL) [NCT01390584]	Phase 2	6 participants (Actual)	Interventional	2013-05-24	Terminated(stopped due to slow accrual)
A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) [NCT00557193]	Phase 3	218 participants (Actual)	Interventional	2008-01-15	Active, not recruiting
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer [NCT02899728]	Phase 2	9 participants (Actual)	Interventional	2018-03-30	Terminated(stopped due to Inadequate accrual rate)
A Randomized, Open-label, Phase I, Crossover Study to Assess the Effect of Food on the Bioavailability of AXL1717, in Patients With Advanced Malignant Tumors [NCT01725555]	Phase 1	13 participants (Actual)	Interventional	2012-10-31	Completed
A Randomized Pilot Study of Human Lysozyme Goat Milk in Recipients of Standard Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation [NCT04177004]	Phase 1	36 participants (Anticipated)	Interventional	2021-04-30	Recruiting
A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody NSC # 742460]) in Combination With Intensive Multi-agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma [NCT01055314]	Phase 2	175 participants (Actual)	Interventional	2010-01-31	Completed
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas [NCT03984448]	Phase 2/Phase 3	363 participants (Anticipated)	Interventional	2019-10-22	Active, not recruiting
A Phase Ib Open-Label Study of LB-100 in Combination With Carboplatin/Etoposide/Atezolizumab in Untreated Extensive-Stage Small Cell Lung Carcinoma [NCT04560972]	Phase 1	21 participants (Anticipated)	Interventional	2021-05-28	Recruiting
Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia [NCT01008462]	Phase 2	16 participants (Actual)	Interventional	2010-03-18	Completed
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue vs. [NCT00336024]	Phase 3	91 participants (Actual)	Interventional	2007-08-06	Active, not recruiting
Adaptive-Dose to Mediastinum With Immunotherapy (Durvalumab MEDI4736) and Radiation in Locally-Advanced Non-Small Cell Lung Cancer [NCT04372927]	Phase 2	1 participants (Actual)	Interventional	2021-12-10	Terminated(stopped due to Terminated due to slow accrual)
A Phase II Trial of Lamivudine in Combination With Chemoimmunotherapy in Patients With Extensive Stage SCLC [NCT04696575]	Phase 2	28 participants (Anticipated)	Interventional	2021-07-02	Recruiting
A Phase I/II Trial of Venetoclax and BEAM Conditioning Followed by Autologous Stem Cell Transplantation for Patients With Primary Refractory Non-Hodgkin Lymphoma [NCT03583424]	Phase 1/Phase 2	19 participants (Actual)	Interventional	2018-09-10	Active, not recruiting
Randomized Phase III Trial of Chemotherapy vs. Pembrolizumab Plus Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma [NCT05711628]	Phase 3	0 participants (Actual)	Interventional	2023-08-10	Withdrawn(stopped due to Other - Protocol moved to Withdrawn)
A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma [NCT01231906]	Phase 3	642 participants (Actual)	Interventional	2010-11-22	Active, not recruiting
Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study [NCT00304070]	Phase 3	78 participants (Actual)	Interventional	2007-05-03	Completed
SPECTRA: SupraPhysiological Androgen to Enhance Chemotherapy TReatment Activity [NCT06039371]	Phase 2	46 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
A Phase II Trial of Response-Adapted Second-Line Therapy for Hodgkin Lymphoma Using Anti-PD-1 Antibody Nivolumab ? ICE Chemotherapy as a Bridge to Autologous Hematopoietic Cell Transplant (NICE Trial) [NCT03016871]	Phase 2	78 participants (Actual)	Interventional	2017-04-24	Active, not recruiting
A Phase I Study Combining Ibrutinib With Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients With Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [NCT02219737]	Phase 1	26 participants (Actual)	Interventional	2014-09-12	Completed
Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) [NCT05058651]	Phase 2/Phase 3	189 participants (Anticipated)	Interventional	2022-06-28	Recruiting
High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases [NCT00716066]	Phase 2	80 participants (Anticipated)	Interventional	2008-06-30	Recruiting
Phase I/Ib Study of Carfilzomib Plus Rituximab Plus Ifosfamide Plus Carboplatin Plus Etoposide (C-R-ICE) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [NCT01959698]	Phase 1	29 participants (Actual)	Interventional	2014-04-17	Active, not recruiting
A Randomized Phase II Study of Bortezomib Plus ICE (BICE) Versus Standard ICE for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma [NCT00967369]	Phase 2	20 participants (Actual)	Interventional	2009-08-24	Completed
Feasibility and PhaseI/II Trial of Preoperative Proton Beam Radiotherapy With Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus NSCLC [NCT01076231]	Phase 1/Phase 2	34 participants (Actual)	Interventional	2010-01-31	Completed
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming With Decitabine in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase 1/2 Study [NCT01729845]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2012-12-20	Completed
Phase I Study of Romidepsin (ISTODAX®) Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma [NCT01590732]	Phase 1	22 participants (Actual)	Interventional	2012-10-29	Completed
A Multicenter, Open-Label Feasibility Study of Daratumumab With Dose-Adjusted EPOCH in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV [NCT04139304]	Early Phase 1	15 participants (Anticipated)	Interventional	2021-05-24	Recruiting
Response-Adapted Therapy for Aggressive Non-Hodgkin's Lymphomas Based on Early [18F] FDG-PET Scanning [NCT00274924]	Phase 2	100 participants (Actual)	Interventional	2006-09-26	Completed
A Randomized Phase III Trial of ABVD Versus Stanford V (+/-) Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease [NCT00003389]	Phase 3	854 participants (Actual)	Interventional	1999-06-17	Completed
Evaluation of Pretargeted Anti-CD20 Radioimmunotherapy Combined With BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk B-Cell Malignancies [NCT02483000]	Phase 1	3 participants (Actual)	Interventional	2017-02-01	Terminated(stopped due to Closed early due to lack of funding)
Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma [NCT03019640]	Phase 2	22 participants (Actual)	Interventional	2017-10-10	Completed
A Phase I Study of Subcutaneous Rituximab Hyaluronidase Combined With Local Standard-of-Care Chemotherapy for the Treatment of Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma or as Monotherapy for Kaposi Sarcoma Herpesvirus Associated Multicentric Castlem [NCT03864419]	Phase 1	40 participants (Anticipated)	Interventional	2019-10-24	Recruiting
A Phase II Trial of Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma [NCT05821088]	Phase 2	37 participants (Anticipated)	Interventional	2023-06-29	Recruiting
A Phase 2 Trial of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy (aTac-BEAM) Conditioning for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients With Primary Refractory or Relapsed Hodgkin Lymphoma [NCT04871607]	Phase 2	33 participants (Anticipated)	Interventional	2021-11-02	Recruiting
A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas [NCT03113500]	Phase 2	48 participants (Actual)	Interventional	2017-05-25	Active, not recruiting
Phase 2 Trial of Response-Based Radiation Therapy for Patients With Localized Central Nervous System Germ Cell Tumors (CNS GCT) [NCT01602666]	Phase 2	262 participants (Actual)	Interventional	2012-05-29	Active, not recruiting
A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-operative Chemotherapy [NCT00134030]	Phase 3	1,334 participants (Actual)	Interventional	2005-11-14	Completed
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC) [NCT01822496]	Phase 2	59 participants (Actual)	Interventional	2013-11-04	Terminated
A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies [NCT01921387]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2013-10-09	Completed
A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric and Adolescent-Young Adults Patients With High Risk Solid Tumors [NCT04530487]	Phase 2	40 participants (Anticipated)	Interventional	2020-08-19	Recruiting
A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE) [NCT02227199]	Phase 1/Phase 2	45 participants (Actual)	Interventional	2014-10-10	Active, not recruiting
LS1781: Phase 2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed / Refractory Lymphoma and Patients With Clonal Cytopenia of Undetermined Significance [NCT03418038]	Phase 2	55 participants (Anticipated)	Interventional	2018-03-23	Recruiting
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations [NCT02883049]	Phase 3	5,937 participants (Actual)	Interventional	2012-02-29	Active, not recruiting
A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination With Etoposide/Platinum in Patients With NUT Carcinoma [NCT05019716]	Phase 1/Phase 2	55 participants (Anticipated)	Interventional	2022-07-13	Recruiting
A Phase 2 Study of Loncastuximab Tesirine and Rituximab (Lonca-R) Followed by DA-EPOCH-R in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma [NCT05600686]	Phase 2	24 participants (Anticipated)	Interventional	2023-05-24	Recruiting
Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL) [NCT02628405]	Phase 1/Phase 2	63 participants (Actual)	Interventional	2016-05-20	Active, not recruiting
Autologous Transplant as Treatment for Favorable or Intermediate Risk MRD-Negative AML Patients After Initial Induction Therapy [NCT03515707]	Phase 2	0 participants (Actual)	Interventional	2018-07-10	Withdrawn(stopped due to PI recommended closure)
A Randomized Pilot Study of Human Lysozyme Goat Milk in Recipients of Standard Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation [NCT03531281]	Phase 1	0 participants (Actual)	Interventional	2018-12-30	Withdrawn(stopped due to Administratively withdrawn)
A Phase I/II Study of Autologous Stem Cell Transplantation Followed by Nonmyeloablative Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Lymphoma - A Multi-center Trial [NCT00005803]	Phase 1/Phase 2	76 participants (Actual)	Interventional	1999-09-30	Completed
Phase I/II Study of Intravenous (IV) Busulfan and Etoposide (VP-16) Combined With Escalated Doses of Large Field Image-Guided Intensity Modulated Radiation Therapy (IMRT) Using Helical Tomotherapy as a Preparative Regimen for Allogeneic Hematopoietic Stem [NCT00540995]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2007-06-11	Terminated(stopped due to Unable to safely escalate to TMLI doses that were hypothesized to be effective and less toxic than FTBI. Likely due to the giving of Busulfan prior to radiation delivery. Therefore, the study was abandoned and no further patients were accrued.)
A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients With Relapsed High-Risk Multiple Myeloma [NCT02504359]	Phase 1	11 participants (Actual)	Interventional	2015-07-20	Completed
A Phase 1 Study of Entinostat in Combination With Atezolizumab / Carboplatin / Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer [NCT04631029]	Phase 1	3 participants (Actual)	Interventional	2021-04-27	Completed
A Pilot Study of Allogeneic Hematopoietic Cell Transplantation for Patients With High Grade Central Nervous System Malignancies [NCT04521946]	Phase 1	0 participants (Actual)	Interventional	2021-01-14	Withdrawn(stopped due to No participants enrolled.)
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) +/- Rituximab (R) + Tafasitamab-cxix for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative (Ph-) B-cell Lymphoblastic Lymphoma/Leuke [NCT05453500]	Phase 2	30 participants (Anticipated)	Interventional	2023-03-27	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00003389 (3) [back to overview]	Incidence of Second Cancers
NCT00003389 (3) [back to overview]	Failure-free Survival at 5 Years
NCT00003389 (3) [back to overview]	5-year Overall Survival
NCT00005803 (4) [back to overview]	Progression Free-survival (PFS)
NCT00005803 (4) [back to overview]	Engraftment of HLA Identical PBSC Allografts
NCT00005803 (4) [back to overview]	Non-Relapse Mortality
NCT00005803 (4) [back to overview]	Overall Survival (OS)
NCT00025259 (4) [back to overview]	Disease Response Assessed by Modified RECIST Criteria
NCT00025259 (4) [back to overview]	Event-free Survival
NCT00025259 (4) [back to overview]	Grade 3 or 4 Non-hematologic Toxicity
NCT00025259 (4) [back to overview]	Overall Survival
NCT00027846 (6) [back to overview]	Event-free Survival
NCT00027846 (6) [back to overview]	Event-free Survival (EFS)
NCT00027846 (6) [back to overview]	Event-free Survival (EFS)
NCT00027846 (6) [back to overview]	Overall Survival
NCT00027846 (6) [back to overview]	Rate of Gross-total or Near-total Resection and Second Surgery After Chemotherapy
NCT00027846 (6) [back to overview]	Local Control and Patterns of Failure
NCT00057837 (3) [back to overview]	Proportion of Patients With Objective Response by Solid Tumor Response Criteria (RECIST)
NCT00057837 (3) [back to overview]	Overall Survival
NCT00057837 (3) [back to overview]	Duration of Response
NCT00134030 (3) [back to overview]	Event-free Survival (EFS)
NCT00134030 (3) [back to overview]	Toxicity as Measured by Common Terminology Criteria for Adverse Events (CTCAE) v3.0
NCT00134030 (3) [back to overview]	Percentage of Patients With Overall Survival
NCT00274924 (2) [back to overview]	5-year Overall Survival
NCT00274924 (2) [back to overview]	2-year Progression-Free Survival (PFS)
NCT00304070 (7) [back to overview]	Five Year Event-free Survival (EFS)
NCT00304070 (7) [back to overview]	Complications Associated With Radical Adrenalectomy and RLND
NCT00304070 (7) [back to overview]	Toxicity Associated With Chemotherapy Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
NCT00304070 (7) [back to overview]	Molecular Alterations and Embryonal Markers in Children With ACT - A43 del33bp Mutation of (Beta)-Catenin.
NCT00304070 (7) [back to overview]	Frequency of Tumor Spillage at the Time of Tumor Resection
NCT00304070 (7) [back to overview]	Frequency of Lymph Node Involvement by Imaging.
NCT00304070 (7) [back to overview]	Incidence and Type of Germline TP53 Mutations in Non-Brazilian Children and Children From Southern Brazil by Deoxyribonucleic Acid (DNA) Sequencing and Affymetrix Gene Chip Analysis.
NCT00334815 (4) [back to overview]	Overall Survival
NCT00334815 (4) [back to overview]	Response Rate (Confirmed or Unconfirmed Partial Response)
NCT00334815 (4) [back to overview]	Adverse Events
NCT00334815 (4) [back to overview]	Progression-free Survival
NCT00336024 (10) [back to overview]	Rates of Nutritional Toxicities
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Primary Hypothyroidism/Subclinical Compensatory HypothyroidismHypothyroidism/Subclinical Compensatory Hypothyroidism
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Diabetes Insipidus
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Low Somatomedin C
NCT00336024 (10) [back to overview]	Number of Participants With Secondary Malignancies
NCT00336024 (10) [back to overview]	Percentage of Participants With Any Acute Adverse Events
NCT00336024 (10) [back to overview]	Median/Range of Patients for Total Quality of Life (QOL) Score, Intelligence Quotient (IQ) and Processing Speed Index (PSI).
NCT00336024 (10) [back to overview]	Rates of Gastrointestinal Toxicities
NCT00336024 (10) [back to overview]	Percentage of Participants With Event Free Survival (EFS)
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Central Hypothyroidism
NCT00379340 (4) [back to overview]	Event Free Survival Associated With the Burden of Pulmonary Metastatic Disease
NCT00379340 (4) [back to overview]	Event Free Survival Probability
NCT00379340 (4) [back to overview]	Event Free Survival Probability
NCT00379340 (4) [back to overview]	Event Free Survival (EFS) Probability
NCT00392990 (4) [back to overview]	Progression Free Survival (PFS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen
NCT00392990 (4) [back to overview]	Overall Survival (OS) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen
NCT00392990 (4) [back to overview]	Safety of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen (Addition of Rituximab, Subsitution of Adriamycin for Doxil and Using Lower Dose of Methotrexate)
NCT00392990 (4) [back to overview]	Overall Response Rate (ORR) of Patients With Burkitt's and Burkitt-like Lymphoma/Leukemia Treated With Modified Magrath Regimen
NCT00416598 (2) [back to overview]	Disease-free Survival (DFS) Rate at 1 Year
NCT00416598 (2) [back to overview]	Number of Participants Who Completed Maintenance Decitabine.
NCT00439556 (2) [back to overview]	Number of Participants With Dose Limiting Toxicity (DLT)
NCT00439556 (2) [back to overview]	Disease-free Survival
NCT00453154 (4) [back to overview]	Maximum Tolerated of Sunitinib Combined With Cisplatin and Etoposide (Phase I)
NCT00453154 (4) [back to overview]	Overall Survival
NCT00453154 (4) [back to overview]	Progression-free Survival (Phase II)
NCT00453154 (4) [back to overview]	Number of Participants With Overall Tumor Response
NCT00540995 (1) [back to overview]	Maximum Tolerated Dose (MTD) of Intensity-modulated Radiation Therapy (Phase I)
NCT00554788 (3) [back to overview]	Event-free Survival (EFS)
NCT00554788 (3) [back to overview]	Response Rate to the Induction Phase of the Regimen
NCT00554788 (3) [back to overview]	Percentage of Participants With Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
NCT00557193 (10) [back to overview]	Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2
NCT00557193 (10) [back to overview]	Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy
NCT00557193 (10) [back to overview]	Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)
NCT00557193 (10) [back to overview]	Percent Probability for Event-free Survival (EFS) for Patients on Arm A
NCT00557193 (10) [back to overview]	Number of Patients Who Experienced Lestaurtinib-related Dose Limiting Toxicity (DLT)
NCT00557193 (10) [back to overview]	Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]	Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00567567 (14) [back to overview]	Proportion of Patients With a Polymorphism
NCT00567567 (14) [back to overview]	Peak Serum Concentration of Isotretinoin in Patients Enrolled on Either A3973, ANBL0032, ANBL0931, ANBL0532 and Future High Risk Studies
NCT00567567 (14) [back to overview]	OS in Patients 12-18 Months, Stage 4, MYCN Nonamplified Tumor/Unfavorable Histopathology/Diploid DNA Content/Indeterminant Histology/Ploidy and Patients > 547 Days, Stage 3, MYCN Nonamplified Tumor AND Unfavorable Histopathology/Indeterminant Histology
NCT00567567 (14) [back to overview]	Intraspinal Extension
NCT00567567 (14) [back to overview]	Incidence Rate of Local Recurrence
NCT00567567 (14) [back to overview]	Event-free Survival Rate
NCT00567567 (14) [back to overview]	EFS Pts Non-randomly Assigned to Single CEM (12-18 Mths, Stg. 4, MYCN Nonamplified Tumor/Unfavorable or Indeterminant Histopathology/Diploid DNA Content & Pts>547 Days, Stg.3, MYCN Nonamplified Tumor AND Unfavorable or Indeterminant Histopathology).
NCT00567567 (14) [back to overview]	Duration of Greater Than or Equal to Grade 3 Thrombocytopenia
NCT00567567 (14) [back to overview]	Duration of Greater Than or Equal to Grade 3 Neutropenia
NCT00567567 (14) [back to overview]	Enumeration of Peripheral Blood Cluster of Differentiation (CD)3, CD4, and CD8 Cells
NCT00567567 (14) [back to overview]	Type of Surgical or Radiotherapy Complication
NCT00567567 (14) [back to overview]	Topotecan Systemic Clearance
NCT00567567 (14) [back to overview]	Surgical Response
NCT00567567 (14) [back to overview]	Response After Induction Therapy
NCT00653068 (4) [back to overview]	Toxic Death
NCT00653068 (4) [back to overview]	Non-hematological Toxicity Associated With Chemotherapy: Grade 3 or Higher During Protocol Therapy
NCT00653068 (4) [back to overview]	Overall Survival (OS)
NCT00653068 (4) [back to overview]	Event-free Survival
NCT00720109 (5) [back to overview]	Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy
NCT00720109 (5) [back to overview]	Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events
NCT00720109 (5) [back to overview]	Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)
NCT00720109 (5) [back to overview]	Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation
NCT00720109 (5) [back to overview]	Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy
NCT00792948 (3) [back to overview]	Relapse-free Survival (RFS) After Allogeneic Stem Cell Transplantation
NCT00792948 (3) [back to overview]	Overall Survival (OS)
NCT00792948 (3) [back to overview]	Continuous Complete Remission (CCR) Rate
NCT00887159 (4) [back to overview]	Progression-free Survival (PFS)
NCT00887159 (4) [back to overview]	Overall Survival (OS)
NCT00887159 (4) [back to overview]	PFS
NCT00887159 (4) [back to overview]	Response Rate
NCT00967369 (4) [back to overview]	Overall Response After 3 Cycles of Botezomib Plus ICE (BICE) Versus Ifosfamide, Carboplatin, Etoposide (ICE) in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
NCT00967369 (4) [back to overview]	Progression Free Survival (PFS) Rate at 12 Months
NCT00967369 (4) [back to overview]	Overall Survival (OS) Rate at 24 Months
NCT00967369 (4) [back to overview]	PET Scan Response After 3 Cycles of BICE Versus ICE Chemotherapy.
NCT00992446 (4) [back to overview]	Median Time to Disease Progression
NCT00992446 (4) [back to overview]	Overall Survival
NCT00992446 (4) [back to overview]	Event-free Survival
NCT00992446 (4) [back to overview]	Toxicity of Vorinostat Bortezomib Maintenance Therapy After Autologous Transplant
NCT01008462 (7) [back to overview]	Number of Patients Who Had Infections
NCT01008462 (7) [back to overview]	Number of Patients Who Engrafted
NCT01008462 (7) [back to overview]	Overall Survival
NCT01008462 (7) [back to overview]	Number of Patients With Grade II-IV Acute Graft-versus-Host-Disease and/or Chronic Extensive Graft-versus-Host-Disease
NCT01008462 (7) [back to overview]	Event-Free Survival (EFS)
NCT01008462 (7) [back to overview]	Non-relapse Mortality (NRM)
NCT01008462 (7) [back to overview]	Number of Patients With Relapsed/Progressive Disease
NCT01035463 (3) [back to overview]	Event-free Survival
NCT01035463 (3) [back to overview]	Overall Survival
NCT01035463 (3) [back to overview]	Maximum Tolerated Dose of Lenalidomide (Phase I)
NCT01055314 (5) [back to overview]	Incidence of Adverse Events Assessed by Common Terminology Criteria for Adverse Events Version 4.0
NCT01055314 (5) [back to overview]	Feasibility of the Addition of Temozolomide to Chemotherapy Determined by Patient Enrollment
NCT01055314 (5) [back to overview]	Feasibility of the Addition of Cixutumumab to Chemotherapy Determined by Patient Enrollment
NCT01055314 (5) [back to overview]	Event-Free Survival
NCT01055314 (5) [back to overview]	Response Rate (CR + PR)
NCT01076231 (4) [back to overview]	Dose-limiting Toxicity
NCT01076231 (4) [back to overview]	Late Toxicity
NCT01076231 (4) [back to overview]	Number of Participants Deemed Feasible to Receive Intervention
NCT01076231 (4) [back to overview]	Pathologic CR Rate
NCT01096368 (10) [back to overview]	OS in Children With Incomplete Resection After Initial Surgery Who Then Achieved CR After Induction Chemotherapy or GTR/NTR After Second Surgery and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only
NCT01096368 (10) [back to overview]	OS of Children With Incompletely Resected Ependymoma Who Are Unable to Achieve a Complete Response (CR) by Post-operative Induction Chemotherapy or by Second Surgery and Who Are Non-randomly Assigned to Receive Maintenance Chemotherapy
NCT01096368 (10) [back to overview]	OS of Children With Supratentorial Classic Ependymoma Who Achieve Complete Resection at First or Second Surgery or Children Who Achieve Complete Response (CR) After Induction Chemo and Who Are Non-randomly Assigned to Observation
NCT01096368 (10) [back to overview]	Overall Survival (OS) in Children Who Have Completely Resected Ependymoma or Achieved CR and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only
NCT01096368 (10) [back to overview]	EFS With Incomplete Resection After Initial Surgery, Then Achieved CR After Induction Chemotherapy or GTR/NTR After Second Surgery and Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only
NCT01096368 (10) [back to overview]	EFS in Children Who Have Completely Resected Ependymoma at Initial Surgery and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only
NCT01096368 (10) [back to overview]	EFS of Children With Incompletely Resected Ependymoma Who Are Unable to Achieve a Complete Response (CR) by Post-operative Induction Chemotherapy or by Second Surgery and Who Are Non-randomly Assigned to Receive Maintenance Chemotherapy
NCT01096368 (10) [back to overview]	EFS of Children With Supratentorial Classic Ependymoma Who Achieve Complete Resection at First or Second Surgery or Children Who Achieve Complete Response (CR) After Induction Chemo and Who Are Non-randomly Assigned to Observation
NCT01096368 (10) [back to overview]	Event-free Survival (EFS) in Children Who Have Completely Resected Ependymoma or Achieved CR and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only
NCT01096368 (10) [back to overview]	OS in Children Who Have Completely Resected Ependymoma at Initial Surgery and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only.
NCT01097057 (4) [back to overview]	Number of Participants Requiring One or Two Apheresis Collection Days to Reach ≥5 x 10^6 CD34 Cells/kg
NCT01097057 (4) [back to overview]	Total Number of Participants Who Did Not Collect ≥5 x 10^6 CD34 Cells/kg in a Maximum of Four Apheresis Days
NCT01097057 (4) [back to overview]	Number of Patients Who Achieved ≥5 x 10^6 CD34 Cells/kg in ≤4 Apheresis Days
NCT01097057 (4) [back to overview]	Number of Patients to Mobilize ≥5 x 10^6 CD34 Cells/kg Autologous PBSC (Efficacy)
NCT01193842 (14) [back to overview]	Changes in Human Herpes Virus (HHV)-8 Viral Load
NCT01193842 (14) [back to overview]	Event-free Survival (EFS) (Phase II)
NCT01193842 (14) [back to overview]	Tumor Response (Phase I)
NCT01193842 (14) [back to overview]	Pharmacokinetic Clearance (Phase I)
NCT01193842 (14) [back to overview]	Percentage of Participant Experiencing Adverse Events (AEs) for Each Treatment Arm as Assessed by Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase II)
NCT01193842 (14) [back to overview]	Changes in Human Immunodeficiency Virus (HIV) Viral Load
NCT01193842 (14) [back to overview]	Changes in Human Herpes Virus (HHV)-8 Viral Load
NCT01193842 (14) [back to overview]	Changes in Epstein-Barr Virus (EBV) Viral Load
NCT01193842 (14) [back to overview]	Changes in Absolute CD4 Cell Counts (Phase I)
NCT01193842 (14) [back to overview]	Change in Plasma Associated Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) (Phase I)
NCT01193842 (14) [back to overview]	Change in CD8 Cell Counts (Phase I)
NCT01193842 (14) [back to overview]	Recommended Phase II Dose of Vorinostat Determined According to Dose-limiting Toxicities Graded Using Common Terminology Criteria for Adverse Events Version 4.0 (CTCAE v4.0) (Phase I)
NCT01193842 (14) [back to overview]	Percentage of Participants With Complete Response (CR) as Assessed by Response Evaluation Criteria in Solid Tumors (Phase II)
NCT01193842 (14) [back to overview]	Overall Survival (OS) (Phase II)
NCT01231906 (1) [back to overview]	Event-Free Survival
NCT01371981 (18) [back to overview]	EFS for Patients on Arm C, Cohort 1
NCT01371981 (18) [back to overview]	Change in Ejection Fraction
NCT01371981 (18) [back to overview]	OS for Patients on Arm C, Cohort 3
NCT01371981 (18) [back to overview]	EFS for Patients on Arm C, Cohort 3
NCT01371981 (18) [back to overview]	Event-free Survival (EFS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations
NCT01371981 (18) [back to overview]	OS for Patients on Arm C, Cohort 1
NCT01371981 (18) [back to overview]	OS for Patients on Arm C, Cohort 2
NCT01371981 (18) [back to overview]	Total Scale Score From Parent-reported Cancer Module
NCT01371981 (18) [back to overview]	Change in Shortening Fraction
NCT01371981 (18) [back to overview]	Overall Survival (OS) for Patients Without High Allelic Ratio FLT3/ITD+ Mutations
NCT01371981 (18) [back to overview]	Proportion of Patients Experiencing Grade 3 or Higher Non-hematologic Toxicities and Infections While on Protocol Therapy
NCT01371981 (18) [back to overview]	Relapse Rate for Patients Without High Allelic Ratio FLT3/ITD+ Mutations
NCT01371981 (18) [back to overview]	Sorafenib Steady State Concentration
NCT01371981 (18) [back to overview]	Total Scale Score From Parent-reported Multidimensional Fatigue Scale Module
NCT01371981 (18) [back to overview]	Proportion of High Risk Children Without HR FLT3/ITD+ Converting From Positive MRD at End of Induction I to Negative MRD at the End of Induction II
NCT01371981 (18) [back to overview]	Bortezomib Clearance
NCT01371981 (18) [back to overview]	Total Scale Score From Parent-reported Pediatric Quality of Life Inventory Module
NCT01371981 (18) [back to overview]	EFS for Patients on Arm C, Cohort 2
NCT01390584 (5) [back to overview]	Complete Response (CR) Rate After Induction Treatment
NCT01390584 (5) [back to overview]	Overall Survival
NCT01390584 (5) [back to overview]	Proportion of Patients Who Are PET Negative After Induction Treatment
NCT01390584 (5) [back to overview]	Progression-free Survival at 36 Months Among Patients Who Are PET Positive After Induction Treatment
NCT01390584 (5) [back to overview]	Progression-free Survival Rate
NCT01602666 (6) [back to overview]	Estimation of the OS Distribution of Patients With Localized Germinoma Patients and CSF Serum hCGbeta of 50 mIU/mL or Less or CSF Serum hCGbeta Greater Than 50 mIU/mL and Less Than or Equal to 100 mIU/mL
NCT01602666 (6) [back to overview]	3-year Progression-free Survival (PFS) Rate of Patients With Nongerminomatous Germ Cell Tumor (NGGCT) Who Were Treated With Reduced Dose Whole Ventricular-field Irradiation
NCT01602666 (6) [back to overview]	Estimation of the PFS Distribution of Patients With Localized Germinoma Patients and Cerebrospinal Fluid (CSF) Serum hCGbeta of 50 mIU/mL or Less or CSF Serum hCGbeta Greater Than 50 mIU/mL and Less Than or Equal to 100 mIU/mL
NCT01602666 (6) [back to overview]	Estimation of the PFS Distribution of Patients With NGGCT Treated With Involved-field Radiation Therapy (IFR)
NCT01602666 (6) [back to overview]	3-year PFS Rate of Patients With Localized CNS Germinoma Who Were Treated With Reduced Dose Radiation Therapy
NCT01602666 (6) [back to overview]	Estimation of the Overall Survival (OS) Distribution of Patients With NGGCT Treated With IFR Assessed
NCT01642251 (5) [back to overview]	Neurotoxicity Total Score Change Between Baseline and 3 Months After Treatment Start
NCT01642251 (5) [back to overview]	Progression Free Survival (Phase II)
NCT01642251 (5) [back to overview]	Recommended Phase II Dose (Phase I)
NCT01642251 (5) [back to overview]	Overall Survival (OS)
NCT01642251 (5) [back to overview]	Overall Response Rate (ORR)
NCT01729845 (4) [back to overview]	Remission Rate Including CR and CRp
NCT01729845 (4) [back to overview]	Most Efficacious and Tolerated Dosage of Decitabine (Period 1)
NCT01729845 (4) [back to overview]	Duration of Relapse-free Survival (for Patients Achieving CR or CRp)
NCT01729845 (4) [back to overview]	Overall Survival
NCT01798004 (1) [back to overview]	The Tolerability of BuMel Regimen
NCT01822496 (6) [back to overview]	Overall Survival
NCT01822496 (6) [back to overview]	Number of Patients With Grade 3-5 Adverse Events
NCT01822496 (6) [back to overview]	Local-regional Progression-free Survival
NCT01822496 (6) [back to overview]	Distant Progression-free Survival
NCT01822496 (6) [back to overview]	Progression-free Survival
NCT01822496 (6) [back to overview]	Percentage of Patients With Complete or Partial Response
NCT01921387 (4) [back to overview]	The Lowest Antibody (Yttrium 90-BC8-DOTA) Dose (mg/kg) That is Consistent With a Favorable Biodistribution Rate >= 80% in Lymphoma Patients
NCT01921387 (4) [back to overview]	Progression-free Survival Following Autologous Stem Cell Transplant (ASCT)
NCT01921387 (4) [back to overview]	Maximum-tolerated Dose (MTD) of Yttrium-90-BC8-DOTA
NCT01921387 (4) [back to overview]	Estimated Dose to Tumor Sites Based on the Tumor to Normal Organ Ratios Derived From Dosimetry Estimates Coupled With the Absorbed Dose to Normal Organs Based on the Administered Activity of Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8
NCT01959698 (6) [back to overview]	MTD Defined as the Dose of Carfilzomib Added to Standard R-ICE Chemotherapy Which, if Exceeded, Would Put the Patient at an Undesirable Risk of Medically Unacceptable Dose-limiting Toxicities (Phase I)
NCT01959698 (6) [back to overview]	Overall Response Rate (PR + CR)
NCT01959698 (6) [back to overview]	Overall Survival
NCT01959698 (6) [back to overview]	Progression-free Survival
NCT01959698 (6) [back to overview]	Toxicity of the Addition of Carfilzomib to R-ICE at the MTD, Assessed by the CTEP Version 4.0 of the NCI CTCAE
NCT01959698 (6) [back to overview]	Complete Response Rate According to the International Working Group Response Criteria as Reported by the Revised Cheson Criteria
NCT01979536 (3) [back to overview]	Occurrence of Grade 3+ Non-hematologic Adverse Events
NCT01979536 (3) [back to overview]	Prognostic Significance of Minimal Residual Disease
NCT01979536 (3) [back to overview]	Event Free Survival (EFS)
NCT02017964 (5) [back to overview]	Event-free Survival (EFS)
NCT02017964 (5) [back to overview]	Overall Survival (OS)
NCT02017964 (5) [back to overview]	Progression-free Survival (PFS)
NCT02017964 (5) [back to overview]	Percentage of Patients With Responses at 273 Days
NCT02017964 (5) [back to overview]	Percentage of Patients With Responses at 189 Days
NCT02101853 (4) [back to overview]	Overall Survival (OS) of LR Relapse Patients
NCT02101853 (4) [back to overview]	Overall Survival (OS) of HR and IR Relapse Patients
NCT02101853 (4) [back to overview]	Disease Free Survival (DFS) of Low Risk (LR) Relapse Patients
NCT02101853 (4) [back to overview]	Disease Free Survival (DFS) of High-risk (HR) and Intermediate-risk (IR) Relapse Patients
NCT02112916 (6) [back to overview]	EFS for Very High Risk (VHR) T-ALL Patients Treated With High Risk (HR) Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Become Minimal Residual Disease (MRD) Negative and Those Who Remain MRD Positive at the End of HR Block 3
NCT02112916 (6) [back to overview]	Cumulative Incidence Rates of Isolated Central Nervous System (CNS) Relapse for SR and IR T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no CRT) and Similar Patients on AALL0434 (Receive CRT)
NCT02112916 (6) [back to overview]	Toxicity Rates Associated With Modified Standard Therapy, Including Dexamethasone and Additional Pegaspargase
NCT02112916 (6) [back to overview]	Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients
NCT02112916 (6) [back to overview]	EFS for Very High Risk (VHR) T-LLy Patients Treated With HR Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Have Complete or Partial Remission and Those Who do Not Respond
NCT02112916 (6) [back to overview]	EFS for Standard (SR) and Intermediate Risk (IR) T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no Cranial Radiation Therapy [CRT]) and Similar Patients on AALL0434 (Received CRT)
NCT02166463 (3) [back to overview]	Event Free Survival (EFS), Where Events Include Disease Progression or Relapse, Second Malignancy, or Death
NCT02166463 (3) [back to overview]	Percentages of Patients Experiencing Grade 3+ Peripheral Neuropathy Assessed by Modified Balis Scale
NCT02166463 (3) [back to overview]	Percentages of Patients With Early Response Defined as no Slow Responding Lesions (SRL) and no Progressive Disease (PD) at Any Disease Sites Determined by Positron Emission Tomography (PET) Per Deauville Criteria Through Central Review
NCT02227199 (4) [back to overview]	2 Year Overall Survival
NCT02227199 (4) [back to overview]	2 Year Progression-free Survival
NCT02227199 (4) [back to overview]	Maximum Tolerated Dose of Brentuximab Vedotin That Can be Combined With Ifosfamide, Carboplatin, and Etoposide Chemotherapy
NCT02227199 (4) [back to overview]	Percentage of Patients That Achieve a Complete Remission Following Study Treatment
NCT02306161 (3) [back to overview]	Overall Survival
NCT02306161 (3) [back to overview]	Frequency of Toxicity-events
NCT02306161 (3) [back to overview]	Event-free Survival
NCT02481310 (2) [back to overview]	12-month PFS (Progression Free Survival) of Treatment With Ixazomib in Combination With DA-EPOCH-R (Phase II)
NCT02481310 (2) [back to overview]	To Determine the Recommended Phase II Dose (RP2D) of Ixazomib in Combination With DA-EPOCH-R.
NCT02483000 (3) [back to overview]	Overall Survival
NCT02483000 (3) [back to overview]	Dosimetry of Yttrium Y 90 DOTA-biotin
NCT02483000 (3) [back to overview]	Incidence of Toxicity, Defined According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
NCT02561273 (7) [back to overview]	Overall Survival
NCT02561273 (7) [back to overview]	Progression-free Survival
NCT02561273 (7) [back to overview]	Number of Participants With Adverse Events Graded According to CTC (Phase II)
NCT02561273 (7) [back to overview]	Number of Participants With Adverse Events Graded According to Common Toxicity Criteria (CTC) (Phase I)
NCT02561273 (7) [back to overview]	Complete Response Rate (Phase II)
NCT02561273 (7) [back to overview]	Maximum Tolerated Dose (MTD) of Lenalidomide and CHOEP
NCT02561273 (7) [back to overview]	Overall Response Rate
NCT02797470 (1) [back to overview]	Percentage of Participants Who Achieve a Timely Engraftment
NCT03019640 (2) [back to overview]	Number of Participants Who Survived
NCT03019640 (2) [back to overview]	Treatment-related Mortality Within 30 Days (TRM30)
NCT03023046 (5) [back to overview]	Overall Survival
NCT03023046 (5) [back to overview]	Number of Participants With Complete Measurable Residual Disease (MRD) Response Rate
NCT03023046 (5) [back to overview]	Number of Participants With Morphological Complete Response Rate
NCT03023046 (5) [back to overview]	Number of Participants With Adverse Events
NCT03023046 (5) [back to overview]	Event-free Survival
NCT03113500 (2) [back to overview]	Complete Response (CR) Rate After Cyclophosphamide, Doxorubicin, Etoposide, Prednisone, and Brentuximab Vedotin (CHEP-BV) Induction Therapy
NCT03113500 (2) [back to overview]	Overall Survival at 1 Year
NCT03382561 (3) [back to overview]	Overall Survival (OS)
NCT03382561 (3) [back to overview]	Response Rate
NCT03382561 (3) [back to overview]	Progression-free Survival (PFS)
NCT03532776 (3) [back to overview]	Analysis of Safety Variables Will be Based on All Adverse Events (AE).
NCT03532776 (3) [back to overview]	Number and Percentage of Subjects With Total Disappearance of All Warts Within All Treated Areas.
NCT03532776 (3) [back to overview]	Local Application Site Reaction Scores (Erythema, Dryness, Burning/Stinging, Erosion, Edema, Pain, Itching, and Bleeding) Per Skin Reaction Scale.
NCT03786783 (5) [back to overview]	"Percentage of Participants Who Are Feasibility Failure"
NCT03786783 (5) [back to overview]	Event-free Survival
NCT03786783 (5) [back to overview]	Response Rate
NCT03786783 (5) [back to overview]	Percentage of Participants With Unacceptable Toxicity
NCT03786783 (5) [back to overview]	Overall Survival
NCT04372927 (4) [back to overview]	Frequency and Severity of Pneumonitis
NCT04372927 (4) [back to overview]	Overall Survival (OS)
NCT04372927 (4) [back to overview]	Response Rate
NCT04372927 (4) [back to overview]	Frequency of Adverse Events
NCT04631029 (4) [back to overview]	Number of Participants Experiencing Grade 3 and 4 Adverse Events
NCT04631029 (4) [back to overview]	Number of Participants Who Received 3 or More Cycles of the Combination of Entinostat, Atezolizumab, Carboplatin, and Etoposide
NCT04631029 (4) [back to overview]	Number of Participants With Dose Limiting Toxicities
NCT04631029 (4) [back to overview]	Progression Free Survival (PFS) Rate

Incidence of Second Cancers

Number of patients who developed second primary cancers (NCT00003389)
Timeframe: Assessed every 2 months if patient is < 1 year from study entry, every 3 months for the second year, every 4 months for the third year, every 6 months for years 4 and 5, and yearly for 5 years

Intervention	participants (Number)
Arm A (ABVD)	15
Arm B (Stanford V)	19

Intervention	Participants (Count of Participants)
	6 Months	1 Year	1.5 Years	2 Years	3 Years
Chemoresistant Group	12	8	8	8	8
Chemosensitive Group	36	27	25	25	22
Unknown Chemosensitivity Group	1	0	0	0	0

Intervention	Number of participants (Number)
Arm I (Patients Off-therapy Before Callback-Induction Only)	5
Arm II (RER With CR [ABVE-PC, IFRT])	370
Arm III (RER With CR [ABVE-PC])	380
Arm IV (RER With Less Than CR [ABVE-PC, IFRT])	538
Arm V (RER With PD)	29
Arm VI (SER [DECA, ABVE-PC, IFRT])	105
Arm VII (SER [ABVE-PC, IFRT])	100

Intervention	Probability of survival (Number)
Arm I (Patients Off-therapy Before Callback-Induction Only)	0.93
Arm II (RER With CR [ABVE-PC, IFRT])	0.98
Arm III (RER With CR [ABVE-PC])	0.98
Arm IV (RER With Less Than CR [ABVE-PC, IFRT])	0.98
Arm VI (SER [DECA, ABVE-PC, IFRT])	0.96
Arm VII (SER [ABVE-PC, IFRT])	0.93

Intervention	Probability of EFS at 5 years (Number)
GTR1 Differentiated Histology Supratentorial (Group 1)	0.614
Radiation (Group 2)	0.685
Sub-Total Resection Any Histology or Location (STR) (Group 3)	0.372

Intervention	Probability of OS at 5 years (Number)
GTR1 Differentiated Histology Supratentorial (Group 1)	1
Radiation (Group 2)	0.862
Sub-Total Resection Any Histology or Location (STR) (Group 3)	0.702

Intervention	Participant (Number)
	Local control	Pattern of failure local	Pattern of failure Metastatic	Pattern of failure local & metastatic
GTR1 Differentiated Histology Supratentorial (Group 1)	6	4	0	1
Radiation (Group 2)	217	57	26	7
Sub-Total Resection Any Histology or Location (STR) (Group 3)	29	31	5	4

Intervention	proportion of participants (Number)
PET (Topotecan/Etoposide/Cisplatin/G-CSF)	0.697
PIE (Irinotecan/Cisplatin/Etoposide)	0.576

Intervention	Months (Median)
PET (Topotecan/Etoposide/Cisplatin/G-CSF)	11.9
PIE (Irinotecan/Cisplatin/Etoposide)	11.0

Intervention	participants (Number)
	Incidence of Abdominal Infection	Incidence of Abdominal Pain	Incidence of Acidosis	Activated Partial Thromboplastin Time Prolonged	Incidence of Adrenal Insufficiency	Incidence of Alanine Aminotransferase Increased	Incidence of Allergic Reaction	Incidence of Anemia	Incidence of Anorexia	Incidence of Aspartate Aminotransferase Increased	Incidence of Blood Bilirubin Increased	Incidence of Cardiac Disorders - Other, Specify	Incidence of Catheter Related Infection	Incidence of Colitis	Incidence of Confusion	Incidence of Dehydration	Incidence of Depressed Level of Consciousness	Incidence of Diarrhea	Incidence of Dyspnea	Incidence of Enterocolitis Infectious	Incidence of Esophagitis	Incidence of Febrile Neutropenia	Incidence of Fever	Incidence of Gastrointestinal Disorders - Other, S	Incidence of Generalized Muscle Weakness	Incidence of GGT Increased	Incidence of Hearing Impaired	Incidence of Heart Failure	Incidence of Hyperglycemia	Incidence of Hyperkalemia	Incidence of Hypertension	Incidence of Hypocalcemia	Incidence of Hypoglycemia	Incidence of Hypokalemia	Incidence of Hypomagnesemia	Incidence of Hyponatremia	Incidence of Hypophosphatemia	Incidence of Hypotension	Incidence of Hypoxia	Incidence of Infections and Infestations - Other,	Incidence of INR Increased	Incidence of Left Ventricular Systolic Dysfunction	Incidence of Lung Infection	Incidence of Lymphocyte Count Decreased	Toxicity Associated with Mitotane	Incidence of Mucositis Oral	Incidence of Nausea	Incidence of Neutrophil Count Decreased	Incidence of Obstruction Gastric	Incidence of Pain	Incidence of Peripheral Motor Neuropathy	Incidence of Peripheral Sensory Neuropathy	Incidence of Pharyngitis	Incidence of Platelet Count Decreased	Incidence of Pneumonitis	Incidence of Premature Menopause	Incidence of Rash Maculo-papular	Incidence of Sepsis	Incidence of Skin Infection	Incidence of Sore Throat	Incidence of Upper Respiratory Infection	Incidence of Urinary Tract Infection	Incidence of Vascular Access Complication	Incidence of Ventricular Arrhythmia	Incidence of Vomiting	Incidence of White Blood Cell Decreased	Incidence of Wound Infection
Stratum 3	1	2	1	1	5	2	1	22	7	2	1	2	3	1	1	3	1	1	2	1	2	16	1	2	1	1	6	1	3	3	1	3	1	9	2	7	4	2	3	7	1	2	1	2	4	6	5	20	1	1	1	1	1	20	3	1	1	2	1	1	1	1	2	1	5	16	1

Intervention	Participants (Count of Participants)
	children with ACT - wild type (beta)-catenin	A43 del33bp mutation of (beta)-catenin
All Patients	51	1

Intervention	participants (Number)
	C229R mutation in p53 in Patients from Brazil	C229R mutation in Patients not from Brazil	E180K mutation in p53 in Patients from Brazil	E180K mutation in Patients not from Brazil	G245C mutation in p53 in Patients from Brazil	G245C mutation in Patients not from Brazil	I254T mutation in p53 in Patients from Brazil	I254T mutation in Patients not from Brazil	L265Q mutation in p53 in Patients from Brazil	L265Q mutation in Patients not from Brazil	P47S mutation in p53 in Patients from Brazil	P47S mutation in Patients not from Brazil	Q52fs mutation in p53 in Patients from Brazil	Q52fs mutation in Patients not from Brazil	R158L mutation in Patients from Brazil	R158L mutation in Patients not from Brazil	G245S mutation in Patients from Brazil	G245S mutation in Patients not from Brazil	R213P mutation in p53 in Patients from Brazil	R213P mutation in Patients not from Brazil	R248L mutation in Patients from Brazil	R248L mutation in Patients not from Brazil	R282W mutation in p53 in Patients from Brazil	R282W mutation in p53 in Patients not from Brazil	R283H mutation in p53 in Patients from Brazil	R283H mutation in p53 in Patients not from Brazil	R337H mutation in p53 in Patients from Brazil	R337H mutation in p53 in Patients not from Brazil	R342X mutation in p53 in Patients from Brazil	R342X mutation in p53 in Patients not from Brazil	T125T c375G>A muation in p53 in Pts from Brazil	T125T c375G>A mutation in p53 in pts not from Braz	T125T splice in DBD in pts from Brazil	T125T splice in DBD in pts not from Brazil	wild type p53 in Patients from Brazil	wild type p53 in Patients not from Brazil
All Patients	0	2	0	1	0	1	1	0	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	1	0	31	20	0	0	1	1	1	0	1	1	16

Intervention	Participants (Number)
	Acidosis (metabolic or respiratory)	Arthritis (non-septic)	Calcium, serum-low (hypocalcemia)	Carbon monoxide diffusion capacity (DL(co))	Creatinine	Dehydration	Dyspnea (shortness of breath)	Esophagitis	FEV(1)	Febrile neutropenia	Glucose, serum-high (hyperglycemia)	Hemoglobin	Hemorrhage, Respiratory tract NOS	Hemorrhage, GI - Peritoneal cavity	Hemorrhage, pulmonary/upper respiratory - Lung	Hypotension	Hypoxia	INR (of prothrombin time)	Inf (clin/microbio) w/Gr 3-4 neuts - Nose	Inf (clin/microbio) w/Gr 3-4 neuts - Oral cav-gums	Inf (clin/microbio) w/Gr 3-4 neuts - UTI	Inf (clin/microbio) w/Gr 3-4 neuts - Upper airway	Inf w/normal ANC or Gr 1-2 neutrophils - Blood	Inf w/normal ANC or Gr 1-2 neutrophils - Lung	Leukocytes (total WBC)	Lymphopenia	Muscle weakness, not d/t neuropathy - body/general	Nausea	Neutrophils/granulocytes (ANC/AGC)	Pain - Chest wall	Pain - Chest/thorax NOS	Pain - Head/headache	Pain - Joint	Pain - Neck	Pain - Throat/pharynx/larynx	Platelets	Pneumonitis/pulmonary infiltrates	Potassium, serum-low (hypokalemia)	Pulmonary/Upper Respiratory-Other (Specify)	Rash/desquamation	Rash: dermatitis associated w/radiation	Sodium, serum-low (hyponatremia)	Weight loss
Concurrent Chemotherapy and Radiotherapy	0	0	0	1	1	1	1	2	1	3	1	2	0	0	0	1	0	1	1	1	1	0	1	1	6	2	1	2	10	1	1	1	0	1	1	2	1	3	0	1	1	1	0
Consolidation Therapy With Docetaxel and Bevacizumab.	1	1	1	0	0	0	1	0	0	0	0	2	1	1	1	0	1	0	0	0	0	1	0	0	0	3	1	0	0	0	0	0	1	0	0	0	2	1	1	0	0	0	1

Intervention	Participants (Count of Participants)
	Nutritional Disorders Induction Cycle I	No Nutritional Disorders Induction Cycle I	Nutritional Disorders Induction Cycle II	No Nutritional Disorders Induction Cycle II	Nutritional Disorders Induction Cycle III	No Nutritional Disorders Induction Cycle III	Nutritional Disorders Consolidation Cycle I	No Nutritional Disorders Consolidation Cycle I	Nutritional Disorders Consolidation Cycle II	No Nutritional Disorders Consolidation Cycle II	Nutritional Disorders Consolidation Cycle III	No Nutritional Disorders Consolidation Cycle III
Arm I (Patients Treated Without Methotrexate (MTX))	10	29	13	26	7	32	12	27	9	30	10	29
Arm II (Patients Treated With MTX)	17	21	13	25	12	26	8	30	5	33	5	33

Intervention	percentage of participants (Number)
Arm I (Patients Treated Without Methotrexate (MTX))	97.4
Arm II (Patients Treated With MTX)	97.2

Intervention	scores on a scale (Median)
	Total Quality of Life Score	Intelligence Quotient	Processing Speed Index
Arm I (Patients Treated Without Methotrexate (MTX))	60.5	77.0	82.0
Arm II (Patients Treated With MTX)	56.5	78.5	89.0

Intervention	Participants (Count of Participants)
	GI Tox Induction Cycle I	No GI Tox Induction Cycle I	GI Tox Induction Cycle II	No GI Tox Induction Cycle II	GI Tox Induction Cycle III	No GI Tox Induction Cycle III	GI Tox Consolidation Cycle I	No GI Tox Consolidation Cycle I	GI Tox Consolidation Cycle II	No GI Tox Consolidation Phase II	GI Tox Consolidation Cycle III	No GI Tox Consolidation Cycle III
Arm I (Patients Treated Without Methotrexate (MTX))	8	31	4	35	4	35	11	28	7	32	5	34
Arm II (Patients Treated With MTX)	12	26	10	28	8	30	14	24	10	28	6	32

Intervention	percentage of participants with EFS (Number)
Arm I (Patients Treated Without Methotrexate (MTX))	43.6
Arm II (Patients Treated With MTX)	54.9

Intervention	Probability of EFS at 4 years (Number)
Stage III/IV With LOH 1p and 16q Treated With Regimen M	0.90
Stage IV With Non-lung Disease Treated With Regimen M	0.73

Intervention	percentage of patients progression free (Number)
High Risk - Treated With Alternating R-CODOX-M/R-IVAC	76
Low Risk - Treatment With 3 Cycles of R-CODOX-M	100

Intervention	participants (Number)
	Anemia : Grade 3	Anemia : Grade 4	Neutropenia : Grade 3	Neutropenia : Grade 4	Thrombocytopenia : Grade 3	Thrombocytopenia : Grade 4	Mucositis : Grade 3	Mucositis : Grade 4	Infection : Grade 3	Infection : Grade 4	Elevated Transaminases : Grade 3	Elevated Transaminases : Grade 4	Fever (Neutropenic) : Grade 3	Fever (Neutropenic) : Grade 4	Low Phosphate : Grade 3	Low Phosphate : Grade 4	Sodium Abnormalities : Grade 3	Sodium Abnormalities : Grade 4	Hyperglycemia : Grade 3	Hyperglycemia : Grade 4	Hypoalbuminemia : Grade 3	Hypoalbuminemia : Grade 4	Hypokalemia : Grade 3	Hypokalemia : Grade 4	Cardiac : Grade 3	Cardiac : Grade 4	Diarrhea : Grade 3	Diarrhea : Grade 4	Elevated Creatinine : Grade 3	Elevated Creatinine : Grade 4	Nausea/Vomiting : Grade 3	Nausea/Vomiting : Grade 4	Low Blood Pressure : Grade 3	Low Blood Pressure : Grade 4	Rash : Grade 3	Rash : Grade 4	Edema : Grade 3	Edema : Grade 4	Low Magnesium : Grade 3	Low Magnesium : Grade 4
High Risk - Treated With Alternating R-CODOX-M/R-IVAC	13	1	5	6	1	13	7	3	8	0	6	0	4	0	5	0	4	0	1	5	4	0	1	0	3	0	2	0	2	0	1	0	1	0	1	0	1	0	1	0
Low Risk - Treatment With 3 Cycles of R-CODOX-M	3	0	2	2	1	2	2	0	1	0	2	0	3	0	1	0	2	0	3	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

podophyllotoxin

Description

Related Flora

Cross-References

Synonyms (170)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (6)

Drug Classes (3)

Pathways (1)

Protein Targets (106)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (283)

Molecular Functions (110)

Ceullar Components (75)

Bioassays (1369)

Research

Studies (2,967)

Market Indicators

Research Demand Index: 34.32

Study Types

Clinical Trials (138)

Trial Overview

Trial Outcomes

Incidence of Second Cancers

Failure-free Survival at 5 Years

5-year Overall Survival

Progression Free-survival (PFS)

Engraftment of HLA Identical PBSC Allografts

Non-Relapse Mortality

Overall Survival (OS)

Disease Response Assessed by Modified RECIST Criteria

Event-free Survival

Grade 3 or 4 Non-hematologic Toxicity

Overall Survival

Event-free Survival

Event-free Survival (EFS)

Event-free Survival (EFS)

Overall Survival

Rate of Gross-total or Near-total Resection and Second Surgery After Chemotherapy

Local Control and Patterns of Failure

Proportion of Patients With Objective Response by Solid Tumor Response Criteria (RECIST)

Overall Survival

Duration of Response

Event-free Survival (EFS)

Toxicity as Measured by Common Terminology Criteria for Adverse Events (CTCAE) v3.0

Percentage of Patients With Overall Survival

5-year Overall Survival

2-year Progression-Free Survival (PFS)

Five Year Event-free Survival (EFS)

Complications Associated With Radical Adrenalectomy and RLND

Toxicity Associated With Chemotherapy Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

Molecular Alterations and Embryonal Markers in Children With ACT - A43 del33bp Mutation of (Beta)-Catenin.

Frequency of Tumor Spillage at the Time of Tumor Resection

Frequency of Lymph Node Involvement by Imaging.

Incidence and Type of Germline TP53 Mutations in Non-Brazilian Children and Children From Southern Brazil by Deoxyribonucleic Acid (DNA) Sequencing and Affymetrix Gene Chip Analysis.

Overall Survival

Response Rate (Confirmed or Unconfirmed Partial Response)

Adverse Events

Progression-free Survival

Rates of Nutritional Toxicities

Number of Participants With Chronic Primary Hypothyroidism/Subclinical Compensatory HypothyroidismHypothyroidism/Subclinical Compensatory Hypothyroidism

Number of Participants With Chronic Diabetes Insipidus

Number of Participants With Chronic Low Somatomedin C

Number of Participants With Secondary Malignancies

Percentage of Participants With Any Acute Adverse Events

Median/Range of Patients for Total Quality of Life (QOL) Score, Intelligence Quotient (IQ) and Processing Speed Index (PSI).

Rates of Gastrointestinal Toxicities

Percentage of Participants With Event Free Survival (EFS)

Number of Participants With Chronic Central Hypothyroidism

Intervention	percentage of patients (Number)
	ORR after two cycles of treatment	ORR at completion of treatment
High Risk - Treated With Alternating R-CODOX-M/R-IVAC	100	100
Low Risk - Treatment With 3 Cycles of R-CODOX-M	100	100

Intervention	Participants (Count of Participants)
Treatment (Chemotherapy, Transplant, Filgrastim, Tacrolimus)	0
Velcade Dose Level 2	0
Velcade Dose Level 3	0

Intervention	Participants (Count of Participants)
Velcade Dose Level 1	16
Velcade Dose Level 2	0
Velcade Dose Level 3	0

Intervention	months (Median)
Arm I (Combination Chemotherapy + Sunitinib Maintenance)	9.0
Arm II (Combination Chemotherapy + Placebo Maintenance)	6.9

Intervention	participants (Number)
	Complete Response	Partial Response
Arm I (Combination Chemotherapy + Sunitinib Maintenance)	3	4
Arm II (Combination Chemotherapy + Placebo Maintenance)	0	5

Intervention	percentage of participants (Number)
	Abdominal pain	Acute kidney injury	Alanine aminotransferase increased	Anemia	Anorexia	Apnea	Aspartate aminotransferase increased	Catheter related infection	Dehydration	Depressed level of consciousness	Diarrhea	Encephalopathy	Enterocolitis	Enterocolitis infectious	Esophagitis	Febrile neutropenia	Fever	GGT increased	Gastric hemorrhage	Hearing impaired	Hypermagnesemia	Hypertension	Hypoalbuminemia	Hypocalcemia	Hypoglycemia	Hypokalemia	Hypomagnesemia	Hyponatremia	Hypophosphatemia	Hypotension	Hypoxia	Infections and infestations - Other, specify	Lower gastrointestinal hemorrhage	Lung infection	Lymphocyte count decreased	Mucositis oral	Nausea	Nervous system disorders - Other, specify	Neutrophil count decreased	Oral pain	Pain	Peripheral motor neuropathy	Pharyngeal mucositis	Platelet count decreased	Pneumonitis	Rectal pain	Seizure	Sepsis	Sinus tachycardia	Sinusitis	Skin infection	Upper respiratory infection	Vomiting	White blood cell decreased
Stage 2/3 Patients	0	0	0	0	11.1	0	0	11.1	0	0	5.6	0	0	5.6	0	55.6	11.1	0	0	11.1	5.6	0	0	5.6	0	27.8	5.6	11.1	22.2	0	0	27.8	0	16.7	0	5.6	16.7	0	5.6	0	0	5.6	0	5.6	5.6	0	0	0	0	11.1	0	11.1	11.1	5.6
Stage 4a Patients	5.6	5.6	16.7	0	33.3	0	11.1	0	11.1	0	16.7	0	5.6	11.1	5.6	55.6	0	5.6	5.6	5.6	0	5.6	0	5.6	0	16.7	5.6	0	0	11.1	2.6	33.3	5.6	0	0	27.8	11.1	0	0	5.6	5.6	0	5.6	0	0	5.6	0	11.1	5.6	0	5.6	5.6	22.2	0
Stage 4b Patients	0	0	5.3	5.3	15.8	5.3	5.3	0	10.5	5.3	0	5.3	0	5.3	0	36.8	5.3	0	0	5.3	0	0	5.3	10.5	5.3	21.1	10.5	15.8	10.5	0	0	21.1	0	0	5.3	5.3	5.3	10.5	5.3	0	0	0	0	5.3	0	0	5.3	0	0	0	5.3	0	5.3	5.3

Intervention	qPCR fold expression ratio (Mean)
Arm A (Standard Risk MLL-G)	1.25
Arm B (IR/HR MLL-R Chemotherapy)	7.85
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)	5.83

Intervention	percent probability (Number)
Arm B (IR/HR MLL-R Chemotherapy)	38.89
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)	35.82

Intervention	percent probability (Number)
Arm A (MRD Negative)	86.05
Arm A (MRD Positive)	87.5
Arm B (MRD Negative)	47.37
Arm B (MRD Positive)	22.73
Arm C (MRD Negative)	51.85
Arm C (MRD Positive)	27.03

Intervention	Proportion of cells that are viable (Median)
Arm A (Standard Risk MLL-G)	0.75
Arm B (IR/HR MLL-R Chemotherapy)	0.48
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)	0.47